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Abstract
It has become increasingly evident that low serum levels of testosterone experienced by aging 
males are associated with cardiovascular disease. Clinical trials have shown that testosterone 
replacement therapy (TRT) can improve symptoms of cardiovascular disease and reduce the 
inflammatory burden, evident in the early stages of atherosclerosis. Thus, a potential role of 
testosterone as an anti-inflammatory agent has emerged. The over-recruitment and activation 
of leukocytes characteristic of early atherosclerosis is considered the driving force behind 
atheroma development and is regulated by the concerted activities of several cytokines, 
chemokines and adhesion molecules, expressed by vascular endothelial and smooth muscle 
cells. The chemokines CCL2 and CX3CL1, which influence the migration of these leukocytes to 
sites of inflammation, have been implicated in disease progression. W hether testosterone has 
a modulatory effect on these orchestrating inflammatory molecules remains largely unknown.
The aim of this thesis was to determine whether testosterone influences vascular 
inflammation as part of its beneficial effects on atherosclerosis, using a combined in vitro and 
in vivo approach. Primary human aortic endothelial and smooth muscle cells in vitro were 
investigated for CX3 CL1 and CCL2 expression under pro-inflammatory conditions, as a model of 
vascular inflammation. Androgen treatm ent of these vascular cells, with or without AR 
blockade, was studied to determine potential anti-inflammatory effects. In addition, the 
testicular feminised (Tfm) mouse, which expresses low endogenous testosterone and a non­
functional androgen receptor (AR), was used to assess the in vivo effect of androgen status 
upon atheroma formation, serum lipids and inflammatory mediators, to identify actions of 
testosterone on these pathways.
Findings from this thesis confirmed that CX3CL1 and CCL2 are involved in vascular inflammation 
associated with atherosclerosis evident by the in vitro up-regulation by pro-inflammatory 
cytokines, and also that CX3CL1 was present, along with CX3CR1, in early fatty streaks in the 
aortic root of Tfm mice. A high-cholesterol diet was associated with increased fatty streak 
formation in the aortic root of wildtype mice, an effect that was significantly amplified by the 
low endogenous testosterone and a non-functional AR (in the Tfm mouse). Physiological TRT 
reduced fatty streak formation in the Tfm mouse but did not have significant effects on 
circulating cytokines. No significant modulation of CX3CL1 or CCL2 expression by testosterone 
treatm ent in vitro was observed, although further work is required to definitively confirm this 
finding.
This thesis has demonstrated that physiological concentrations of testosterone can inhibit fatty  
streak formation, via an AR-independent mechanism in Tfm mice, although not through 
systemic or local anti-inflammatory actions. The mechanisms by which TRT may confer 
cardiovascular benefits to men with hypotestosteronemia and cardiovascular risk requires 
further investigation.
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Chapter 1
_____________General Introduction
1.1 Cardiovascular Disease
Cardiovascular disease (CVD) remains the major cause of mortality in the western world, 
accounting for nearly half of all deaths in Europe (48%) and the European Union (42%), and is 
the UK's biggest killer (Rayner et al. 2009). CVD comprises all diseases of the heart and 
circulatory system, but primarily includes coronary heart disease (myocardial infarction, angina, 
heart failure and coronary death), cerebrovascular diseases (stroke, transient ischaemic 
attacks) and peripheral vascular diseases (intermittent claudication, gangrene) (Glaudemans et 
al. 2010). The major underlying cause of CVD is atherosclerosis. In order to improve prognosis 
and provide better therapies for cardiovascular disease, it is critical to develop a greater 
understanding of the basic pathophysiological processes of atherosclerosis.
1.2 Atherosclerosis
Atherosclerosis is a complex disease of the large and medium sized arteries that has a lengthy 
asymptomatic phase of development. Beginning in the first decade of life, although early 
vascular changes are minor, atherosclerosis can progress over time and typically manifests 
clinically in middle and late adulthood or, more often than not, it may regress and disappear 
with time (Hansson and Libby 2006, Hong 2010).
This disease is characterised by the over recruitment of leukocytes and lipid accumulation in 
the vessel wall, leading to a loss of normal vascular function and stenosis, narrowing of the 
arteries. Stenosis interrupts the normal blood flow through the vessel, which can manifest as 
specific clinical complications depending upon the location of the affected vessel (Figure 1.1b). 
Over time, as the accumulation of lipid and immune cells continues, these lesions, known as 
atherosclerotic plaques, mature and take on new characteristics, often becoming vulnerable to 
rupture as a result of aggressive immunological activity. Although clinical complications of 
stenosis occur, the most severe clinical manifestations of
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Figure 1.1; Illustration o f an artery showing stenosis and blockage with associated 
clinical complications. Arteries are made up o f m u ltip le  d istinctive  layers which results in 
a dynam ic responsive tissue (a). As leukocytes and lipid accum ulates in the  vessel w all 
during atherosclerosis, there  is a narrow ing o f the lum en restric ting  blood flow . 
Dependent upon the vascular te rr ito ry  o f the  a therosclero tic  lesion, clinical com plica tions 
occur as a result o f restricted blood flo w  (b). If the  a rte ry becomes to ta lly  occluded by c lo t 
fo rm a tion  at the lesion site, severe and som etim es fata l consequences can ensue (c).
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atherosclerosis arise from plaque rupture, which exposes the thrombotic plaque contents to 
the blood and sudden thrombotic occlusion may ensue (figure 1.2). Depending upon the 
vascular location of the blockage, severe and often fatal clinical complications transpire, such 
as myocardial infarction (M l) and stroke (figure 1.1c). The precise mechanisms that underlie 
this plaque development remain disputed. However, over the past three decades our 
understanding has evolved from early hypotheses based on lipid deposition within the vessel 
wall, to a more complex interplay between the conventional risk factors (obesity, smoking, 
family history, hypertension), inflammation and dysfunction of the vasculature. These pan- 
vascular processes are now focussed on immunological involvement and have established 
atherosclerosis as an inflammatory lipid pathology.
1.2.1 Initiation of inflammatory atherosclerotic events
As excessive atherogenic lipids in the vascular wall influence inflammation, which 
subsequently affects vascular permeability to lipids creating a circular and perpetuating 
situation, the debate over the triggers of atherosclerosis continues.
It is plausible that distal events that alter systemic inflammatory status have the potential to 
modify and activate local inflammatory actions in the artery at the site of atheroma formation. 
Such events may include; increases in circulating lipoprotein particles acting locally on the 
vasculature to affect oxidative status (see following sections), extravascular infection that 
elevates systemic cytokine production and immune activation, hyperglycaemic modification of 
macromolecules associated with diabetes that subsequently cause endothelial activation, 
hypertension-induced alterations of oxidative and inflammatory status, as well as physical 
damage from shear stress in extreme cases, and increases in circulating inflammatory 
cytokines from adipose tissue due to obesity (see Libby 2006 for review). In addition, local 
intravascular infection might also provide a local inflammatory stimulus, as seen with microbial 
agents such as Chlamydia pneumoniae (Kol et al. 1999).
Regardless of which of these preceding events may initiate the inflammation in atherosclerosis, 
the role of lipids and their transformation to immunogenic species by oxidative reactions 
remains central to early athero-inflammatory events.
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D
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Figure 1.2; The stages o f atherosclerosis. A) Leukocyte recru itm en t (predom inantly  
monocytes and T cells) to  the nascent atherosclerotic lesion at sites o f endothelia l 
activations due to  lipid accum ulation. P ro-in flam m atory m ediators expressed w ith in  
the activated vascular wall p rom ote  leukocyte m atu ra tion  and subsequent release o f 
in flam m atory  m ediators such as cytokines, chemokines and adhesion molecules. 
A dditiona l leukocytes are a ttracted  to  the lesion and the fa tty  streak develops (B). 
Fatty streaks develop in to  m ature atherosclerotic plaques as a central necrotic core o f 
lipid and dead cells develops as a result o f in flam m ation-induced apoptosis (C). 
Additiona lly , sm ooth muscle cells m igrate from  the  tunica media to  fo rm  a pro tective  
cap over the plaque through deposition o f strength-giving collagen. W hen th is 
p ro tective  fib rous cap thins, due to  continued aggressive in flam m ation , the plaque is 
prone to  rup ture  exposing its contents to  the circu lating blood. Coagulants in the  blood 
are activated and fo rm  a th rom bus th a t causes m ost o f the acute com plications o f 
atherosclerosis (D). Adapted from  Hansson and Libby (2006).
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1.2.1.1 The role of lipids
Although our knowledge of atherosclerosis has developed beyond early theories that 
suggested only a primary hyperlipidemia, the role of lipids, and particularly cholesterol, 
cannot be ignored as they are implicated in the initiation, development and progression of 
the disease. Abnormalities in lipoprotein profiles are still recognised as the most important 
cause of premature atherosclerosis (Knopp 1999).
1.2.1.1.1 Cholesterol
Cholesterol is a biologically important molecule within the body, acting as a structural 
component in cell membranes and as a precursor to steroid hormones, vitamin D and bile 
acids (Daniels et al. 2009). The majority of the cholesterol needed to maintain a healthy 
status is biosynthesised in the liver. Hence a much smaller proportion is required from  
dietary intake of foods high in saturated fatty acids. This balance is altered with dietary 
intake, with biosynthesis reduced when intake is high and increased when it is low (Jones 
1997). This tight regulatory balance is essential for maintaining health. However, the 
homeostatic mechanisms can be inadequate when dietary cholesterol intake is excessive or 
in pathologies that alter lipid processing.
As cholesterol is water insoluble it is not found free in the blood. Instead it is esterified to 
fatty acids and packaged into lipoprotein particles. There are five main classes of 
lipoproteins, based on size and protein-to-lipid ratio density (the more protein the higher 
the density) (Daniels et al. 2009) (figure 1.3). Dietary cholesterol is packaged into 
chylomicrons in the intestine through the esterification of free cholesterol and the 
synthesis of triglycerides from free fatty acids, amalgamated together with apolipoprotein B 
(apoB) (Daniels et al. 2009). These particles pass into the circulation where they are 
targeted by lipase enzymes which break down chylomicron components to allow the 
redistribution of fatty acids. Very low density lipoproteins (VLDL) are produced by the liver 
from chylomicron remnants and function to distribute triglycerides and cholesterol esters 
to the rest of the body. As they circulate, high density lipoprotein (HDL) and lipoprotein 
lipase enzymes in the capillaries remove triglycerides and alter the VLDL particles to an 
intermediate density lipoprotein (IDL), which is either removed from the plasma by the liver 
or further transformed to a low density lipoprotein (LDL) by continued reduction of fatty  
acids and apolipoproteins (Gunston et al. 2007). LDLs are the main source of cholesterol
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Figure 1.3; Classification o f lipoproteins. The five main classes o f lipoprote ins, 
based on size and p ro te in -to -lip id  ratio  density. D ietary cholesterol is packaged in to  
chylom icrons in the intestine. Lipase activ ity  frees some o f the fa tty  acid content, 
thus increasing the density o f the  partic le and fo rm ing  VLDL. Further lipase activ ity  
occurs at d iffe ren t locations, sequentia lly reducing the lipid conten t o f the particles 
to  fo rm  IDL, LDL then HDL. Cholesterol (red stars), apo lipoprote in  B (keys), 
apolipoprote in  A (y shapes), and m em brane pro te ins (blue dots).
From h ttp ://cm e.m edscape .com /v iew artic le /416521_3
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transport in the circulation and are considered atherogenic due to their propensity to bind 
to connective tissue in the intima of arteries (Mourao and Bracamonte 1984). Conversely, 
HDL presents anti-atherogenic properties due to its ability to negate cholesterol 
accumulation in tissues. HDL is continuously manufactured in the liver and circulates in the 
blood, acting as a scavenger for free cholesterol and cholesteryl esters from chylomicrons 
and VLDL. HDL can also acquire cholesterol from LDL particles in the circulation or tissues, 
before returning to the liver, where reverse cholesterol transport removes cholesterol and 
it is used to synthesise bile acids or it is excreted (Daniels et al. 2009).
LDLs and other lipoproteins can freely enter the artery wall from the plasma, and can be 
taken up by vascular cells via receptor-mediated endocytosis or lipase activity, or can 
remain free in the intima (Goldstein and Brown 1977, Dabagh e ta l. 2009). Equally, they can 
return to the circulation from the tissues, dependent upon circulating concentrations. 
When plasma levels are high (hyperlipidaemia) entry can be greater than exit, and 
lipoproteins accumulate in the vascular wall (Barter 2005). Therefore, the lipid profile of an 
individual may greatly influence susceptibility to atherosclerosis, with particular emphasis 
on the balance between circulating cholesterol-rich LDLs and cholesterol-clearing HDLs. This 
is demonstrated by many cross-sectional and epidemiological studies implicating 
atherogenic dyslipidemia (low HDL-cholesterol, increased triglycerides and non-HDL 
cholesterol, and elevated small dense LDL particle concentrations) with CVD (See Musunuru 
2010).
1.2.1.2 The role of shear stress and oxidative status
Remarkably, atherosclerotic lesions tend to develop in predisposed areas of the vasculature 
that are associated with specific haemodynamic conditions. Physiological laminar shear 
stress is created by the dragging force generated by blood flow over the luminal surface of 
the vascular endothelium (Patel et al. 2000). It is of particular importance for protecting the 
endothelium from abnormal activation and the promotion of atherogenesis. The protective 
effect of laminar shear stress is thought to be due to the release and activity of nitric oxide 
(NO) (Tao et al. 2006, Pan 2009). NO is a potent endogenous vasodilator contributing to the 
maintenance of tone, reactivity and homeostasis of the vasculature, and influences local 
and regional blood flow (Naploi and Ignarro 2001, Forstermann 2010). Importantly, NO also
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decreases endothelial permeability and reduces the flux of lipoproteins into the vessel wall 
(Cardona-Sanclemente and Born 1995).
Synthesis of NO occurs via endothelial nitric oxide synthase (eNOS) or inducible nitric oxide 
synthase (iNOS) which can be regulated by elevations in calcium ion concentration, as a 
result of vascular mechano-chemical sensitive responses to haemodynamics (Jagnandan et 
al. 2005, Napoli et al. 2006). Physiological laminar shear stress increases the abundance of 
eNOS in the vasculature, thus maintaining NO and vascular function (De Nigris et al. 2003). 
However, at locations subjected to oscillating or prolonged low or high shear forces, such as 
near arterial branches, bifurcations and curvatures, NO activity is reduced (Napoli et al.
2006). A reduction in NO synthesis is a major contributing factor to endothelial dysfunction 
(Wever et al. 1998) and reduced eNOS expression has been demonstrated in human 
atherosclerotic lesions (Oemar et al. 1998).
Focal and regional haemodynamic parameters influence endothelial gene expression with 
an increase in pro-inflammatory gene expression in areas of disturbed flow, compared to 
anti-inflammatory gene expression in areas of healthy high shear stress (Davies et al. 2009, 
Boon and Horrevoets 2009). This may be mediated via NO activity, through the regulation 
of transcription factors associated with inflammatory genes and suppression of the 
expression of atherogenic molecules (De Caterina et al. 1995, Shin et al. 1996). Loss of NO 
and subsequent upregulation of these pro-inflammatory genes may result in activation of 
the endothelium. Cultured endothelial cells exposed to oscillatory shear stress mimicking 
arterial blood flow display increased expression of several leukocyte adhesion molecules 
(Dai et al. 2004). Hastings et al. (2007) observed that cultured endothelial cells exposed to 
disturbed flow patterns show increased expression and secretion of the inflammatory 
cytokine IL-8 . Disturbed haemodynamics also increase vascular expression of endothelin-1 
(ET-1), a potent vasoactive peptide, which in turn induces the appearance of adhesion 
molecules and promotes excessive oxidative stress (Grover-Paez and Zavalza-Gomez 2009). 
In addition vascular wall shear stress has the capability to act beyond the endothelium, with 
turbulent flow leading to an increased production of proteoglycan molecules by smooth 
muscle cells (Grover-Paez et al. 2009). Proteoglycans can bind and retain lipoprotein 
particles, facilitating their oxidative modification and subsequent inflammatory events 
(Skalen et al. 2002). The mechanisms by which these inflammatory characteristics evolve
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are not fully understood, but may be caused indirectly due to NO depletion and subsequent 
inflammatory signal pathway activation.
1.2,13 Oxidation of LDL
The cause and effect relationship between endothelial dysfunction and vascular 
dyslipidemia, and therefore the first step that initiates endothelial activation, has not yet 
been identified. The infiltration of LDL, however, is considered a fundamental juncture. 
Once LDL has penetrated the endothelium it is susceptible to modifications by reactive 
molecules present in the vascular wall as a result of normal and pathologically altered 
metabolic function.
Reactive oxygen species (ROS) are naturally occuring oxidants produced through normal 
eukaryotic metabolism. These free and non-free radicals possess potent oxidative ability, 
capable of damaging cellular components including lipids and membranes (Madamanchi et 
al. 2005). Oxygen radicals also possess the capacity to modify unsaturated fatty acid 
residues of triglycerides and phospholipids of LDL, resulting in highly reactive oxidised-LDL 
(oxLDL). The mechanisms by which LDL is oxidised remains unknown, and the modified 
structures of oxLDL are also not yet clear, in part due to the heterogeneous nature of the 
composite mixture of modified particles (Itabe 2009). However transformation of residues 
on LDL molecules are known to alter its structure to form atherogenic neoepitopes, with 
properties that can be recognised by scavenger receptors on macrophages that are capable 
of initiating an immune response (Horkko et al. 2000). As oxLDL is a self-protein, altered in a 
way that is capable of immune interactions and initiation of inflammation, atherosclerosis 
may be considered an autoimmune disease (See Mandal et al. 2005, Blasi 2008). In addition, 
LDL and oxLDL have been shown to increase ROS generation through eNOS uncoupling, 
whereby synthesis of this enzyme is increased but function is altered as a result of 
decreased L-arginine uptake (the eNOS substrate for NO production), and disruption of the 
transcription of NOS ultimately decreases the production of NO (Pritchard et al. 1995, 
Jessup 1996, Vergnani et al. 2000). Cells have evolved a protective mechanism by which 
these oxidants can be enzymatically "mopped-up" by superoxide dismutases (SOD), 
catalase and glutathione peroxidase, which break down oxidised lipid and neutralise their 
proinflammatory effects (Heistad et al. 2008). This homeostatic balance usually sees a 
compensatory increase in levels of SOD in response to heightened metabolic activities and
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oxidative stress (Heistad et al. 2008). However, in pathophysiological conditions, excess 
oxidants can overwhelm the scavenging capacity of these cellular antioxidant systems 
resulting in oxidative damage (Madamanchi et al. 2005).
Alterations in oxidative status, as a result of increased ROS accumulation and subsequent 
oxidative damage, can activate nuclear transcription factors that increase the expression of 
cytokines, chemokines and adhesion molecules involved in atherogenesis within cells of the 
vasculature (Reape and Groot 1999). Vascular cell adhesion molecule-1 (VCAM-1), intra­
cellular adhesion molecule-1 (ICAM-1), E-selectin, and P-selectin are expressed on 
endothelial cells at locations considered to be reflective of disturbed haemodynamics and 
are also upregulated by oxLDL (Reape and Groot 1999, Galkina and Ley 2007). Immune 
recruitment to activated endothelium may primarily be a protective response for oxLDL 
clearance, yet could ultimately initiate inflammation typical of atherosclerosis. Again, this 
vascular activation affects endothelial permeability to macromolecules, and in 
hypercholesterolemia, LDL can diffuse into the intima (Ogunrinade et al. 2002). In addition, 
elevated levels of ROS can induce oxidative damage of DNA leading to arrest of cell growth 
and apoptosis, which in turn is capable of initiating immune responses (Bennett 2001). The 
target of ROS-induced DNA damage in atherosclerotic lesions is unclear. However, ROS is 
capable of provoking toxicity in vascular cells (Li et al. 1997) and macrophage apoptosis 
(Martinet et al. 2001).
ROS are generated in atherosclerotic plaques, particularly by macrophages (Kojda et al. 
1999). Therefore, vascular oxidative stress is exacerbated by elevated atherogenic lipid 
profiles and the activity of recruited immune cells, leading to excessive ROS formation and 
vascular injury/activation. In the presence of hypercholesterolemia this, in turn increases 
LDL influx into the vessel wall, subsequent LDL oxidation and leads to NO inactivation, 
which further accelerates superoxide generation and LDL oxidation, perpetuating 
endothelial dysfunction (Arimura et al. 2001, Chen et al. 2006). The initial cause of 
endothelial injury/activation, lipid accumulation and oxidative damage-modification 
remains unclear. However, it is clear that the combination of these events is capable of 
promoting immune responses.
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1.3 Immune response in atherosclerosis
The initiating events that trigger the arterial inflammation associated with atherosclerosis 
are not completely known. However, as seen above, elevated atherogenic lipids in the 
vessel wall, endothelial dysfunction and modified lipids and proteins due to increased 
oxidative activity, can all result in immunogenic epitopes that can activate and injure the 
endothelium.
1.3.1 Early vascular changes
Activated vascular cells at arterial sites prone to atheroma promote early inflammatory cell 
recruitment, a process that is orchestrated by cytokines, chemokines and adhesion 
molecules.
13.1.1 Cytokines
Cytokines are pleiotropic signalling proteins, important for regulating inflammatory and 
immune responses through autocrine, paracrine and juxtocrine activity. They are regulators 
of innate and adaptive immune responses and can generally be divided into several classes; 
interleukins (IL), tumour necrosis factors (TNF), interferons (IFN), colony stimulating factors 
(CSF), transforming growth factors (TGF) and chemokines (Tedgui and Mallat 2006). Many 
cytokines have the ability to act synergistically in their immunological function and can be 
both pro- and anti-inflammatory.
13.1.2 Chemokines
Chemokines are a family of low molecular weight soluble chemoattractant proteins, 
released at the site of inflammation that act on immune cells and vascular cells in a 
localised manner to regulate several processes involved in inflammation, including 
leukocyte trafficking, apoptosis, proliferation and further cytokine and chemokine synthesis 
(Taub and Oppenheim, Rollins 1997). There are approximately 42 human chemokines that 
can be subdivided into four families (C, CC, CXC and CX3C) based on the number and spacing 
of the first two cysteine residues in a conserved cysteine motif (Bazan et al. 1997, Zlotnik 
and Yoshie 2000). With 20 known chemokine receptors and extensive overlap of ligand- 
receptor recognition, the chemokine system has the capacity to be very specific yet very
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complex (Surmi et al. 2009) (Table 1.1). The orchestration of this chemokine system in 
atherosclerosis is, as yet, not clearly defined. However, many chemokines have been 
identified in human atherosclerotic lesions demonstrating their involvement in the 
pathogenesis of the disease (Reape and Groote 1999, Abi-Younes et al. 2000, Greaves and 
Gordon 2001, Wong et al. 2002a).
As circulating leukocytes come into contact with inflammatory chemokines, released from 
the activated endothelium, receptor-ligand binding occurs and the cells become active. This 
occurs through actin rearrangement and a change in cell shape, enabling movement to the 
inflammatory site via concentration gradient-induced migration (Charo and Taubman 2004). 
The consequence of this receptor activation is not limited to locomotion, as gene 
transcription can take place, leading to other functions such as increased adhesive 
characteristics through the modulation of integrins, selectins and other adhesion molecules 
(Thelen 2001).
In addition, chemokines secreted at sites of inflammation can be immobilised and 
concentrated on the surface of immune and vascular cells via binding to proteoglycans 
(Kuschert et al. 1999). This creates an endothelial milieu favourable to leukocyte adhesion 
and transmigration into the vascular wall, whereby inflammation is perpetuated.
1.3.1.3 Adhesion molecules
Adhesion molecules aid cell-cell communication and are involved in the recruitment of 
immune cells, in conjunction with chemoattractant molecules, which are often co­
expressed. Endothelial cells, under normal circumstances, have a low adhesive capacity for 
leukocytes and platelets. However, in atherosclerosis-prone sites, increased adhesion 
molecule expression occurs with immunological consequence. As an initial response to 
inflammatory stimuli, vascular endothelial cells increase expression of leukocyte adhesion 
molecules such as VCAM-1, ICAM-1, E-selectin, P-selectin and integrins, which are 
considered to be involved in atherogenesis (Sima et al. 2009).
Circulating leukocytes initially tether to the luminal surface of the endothelium via integrin- 
and selectin-mediated binding, either directly or through platelet interactions. This binding 
is transient and not sufficient to firmly capture leukocytes, but can slow their progression
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C chemokines XCL1 Lym photactina /SC M a XCR1XCL2 Ly m p h ota ct i n (3/SC M (3 XCR1
CCL1 1-309 CCR8
CCL2 MCP-1 CCR2
CCL3 MIP-lcc CCR1, CCR5
CCL4 M IP -lp CCR5
CCL5 RANTES CCR6
CCL7 MCP-3 CCR1, CCR2, CCR5
CCL8 MCP-2 CCR3
CCL11 Eotaxin CCR3
CCL13 MCP-4 CCR2, CCR3
CCL14 HCC-1 CCR1
CCL15 HCC-2 CCR1, CCR4
CC chemokines CCL16 HCC-4 CCR1CCL17 TARC CCR4
CCL18 PARC Unknown
CCL19 M l P-3(3/ELC CCR7
CCL20 M IP-3a/LARC CCR6
CCL21 SLC/6Ckine CCR7
CCL22 MDC/STCP-1 CCR4
CCL23 M PIF-1 CCR1
CCL24 MPIF-2 CCR3
CCL25 TECK CCR9
CCL26 Eotaxin-3 CCR3
CCL27 CTACK/ILC CCR10
CCL28 MEC CCR10
CXCL1 GROa CXCR1, CXCR2
CXCL2 GROp CXCR2
CXCL3 GROy CXCR2
CXCL4 PF4 CXCR3B
CXCL5 ENA-78 CXCR2
CXCL6 GCP-2 CXCR1, CXCR2
CXCL7 NAP-2 CXCR2
CXC chemokines CXCL8 IL-8 CXCR1, CXCR2
CXCL9 MIG CXCR3
CXCL10 IP-10 CXCR3
CXCL11 ITAC CXCR3
CXCL12 S D F -la /P CXCR4
CXCL13 BCA-1/BLC CXCR5
CXCL14 BRAK Unknown
CXCL16 - CXCR6
CX3C chemokines CX3CL1 Fractalkine CX3C RI
Table 1.1; Human chemokine families. There are approxim ate ly 42 human chem okines 
th a t are subdivided into fo u r fam ilies based on the  num ber and spacing o f the  firs t tw o  
cysteine residues in a conserved cysteine m otif. 20 known chem okine receptors a llow  
extensive overlap o f ligand-receptor recognition. See M antovani e t al. (2006).
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allowing for further tethering to additional adhesion molecules. This creates a 'rolling' 
effect of the leukocyte along the endothelium and maximises cell-cell communication 
(Figure 1.4). Under normal conditions selectin and integrin interactions are reversible and 
are not sufficient to bind rolling leukocytes. Cytokines and chemokines released from  
endothelial sites of inflammation activate integrins and selectins and result in the firm 
capture of leukocytes (Campbell et al. 1998, W eber 2003). The binding of other up- 
regulated adhesion molecules, due to the close contact of leukocyte rolling, may mediate 
integrin activation or may independently instigate cell arrest. Firm adhesion of leukocytes 
to the endothelium propagates intra-cellular signaling in both leukocytes and endothelial 
cells to facilitate diapedesis of immune cells into the sub-endothelial space (vascular intima), 
independently or via further chemokine signalling (Weber 2003, Ley et al 2007).
1.3.2 Cell types involved in atherosclerosis
The accumulation of inflammatory cells within the artery wall, predominantly monocytes 
and T cells in early plaques, leads to increased local production of cytokines, growth factors 
and chemokines from vascular cells and immune cells. These factors enhance and amplify 
the cascade of inflammatory events that attract and activate further leukocytes to the 
intima, such as mast cells, neutrophils, natural killer cells and rarely B-cells (figure 1.5) 
(Libby eta l. 2002a).
1.3.2.1 Monocytes/macrophages
Monocytes have been identified as the 'crucial force' in driving atherogenesis, and are 
present at all stages of plaque development (Weber et al. 2008). In early plaques, 
macrophages are the predominant inflammatory cells and represent the effector cells of 
the innate immune response (Hansson and Libby 2006).
Circulating monocytes are recruited to sites of inflammation predominantly by chemokines. 
Monocyte chemoattractant protein-1 (MCP1, or CCL2) (Gu et al. 1998, Boring et al. 1998), 
fractalkine (CX3CL1) (Bazan et al. 1997, Guo et al. 2003), and CCL5 (Tacke et al. 2007, 
Combadiere et al. 2008) are considered to act as chemoattractants for monocytes, initiating 
their migration towards the inflammatory site down a concentration gradient and assisting 
in extravasation into the vessel. Monocyte differentiation into macrophages in the vascular 
intima results from stimulation with macrophage colony-stimulating factor (M-CSF),
15
Flow >
I I
DiapedesisTethering I Firm
1 Adhesion
Platelet-m ediated
adhesion
Figure 1.4; Leukocyte migration into the vascular wall. C irculating leukocytes in itia lly  
te th e r to  the  lum inal surface o f the endothe lium  via reversible in tegrin - and selectin- 
m ediated binding, e ithe r d irectly  o r th rough p la te le t in teractions. Leukocytes roll over the 
endothe lium  maxim ising cell-cell com m unication which leads to  firm  adhesion to  
activated integrins and selectins o r add itiona l adhesion molecules. In tra-ce llu la r signalling 
in both leukocytes and endothe lia l cells fac ilita tes diapedesis o f im m une cells in to  the 
sub-endothelia l space. See W eber (2003)
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produced by activated endothelial and smooth muscle cells (Rajavashisth et al. 1990b). In 
addition, M-CSF can induce scavenger receptor expression on macrophages (Clinton et al. 
1992). Scavenger receptors are a fam ily of pattern-recognition receptors, including CD36, 
CD6 8 , CXCR16, lectin-type oxidised low-density lipoprotein receptor-1 (LOX1), scavenger 
receptor-A (SR-A) and SR-B1, which bind proteins recognised as foreign, including modified 
LDL, and internalise them for proteolytic degradation (See Hansson and Libby 2006). These 
receptors may have evolved as a means o f recognising oxidised self-antigens to mediate 
the ir degradation and clearance to avoid autoimmunity (Greaves and Gordon 2008). In 
atherosclerosis, these protective mechanisms may become overwhelmed, leading to 
pathological outcomes. Also implicated in the initial events of immune recognition and 
recruitment are toll-like receptors (TLR), which have a similar function to scavenger 
receptors, but can directly elicit inflammatory responses (Libby e ta l. 2009).
Macrophages bind, via the ir scavenger receptors, engulf and degrade oxLDL particles to 
generate free cholesterol for efflux. However, during hypercholesterolem ia and heightened 
vascular activation associated with atherosclerosis, the clearing of cholesterol is inhibited 
and lipid accumulates within the macrophages forming so-called 'foam cells' due to the ir 
foamy appearance under the microscope (Galis et al. 1995). Additionally, at sites of 
inflammation, macrophages and monocytes are capable of phagocytosis of lipid-laden 
platelets, also causing foam cell formation, and the conversion of monocytes to foam cells 
is inducible by platelet-derived factors (Reviewed in Seigel-Axel et al. 2008). Foam cells are 
the characteristic cells of early 'fatty streak' atherosclerosis (Montecucco and Mach 2009).
Monocytes exhibit heterogeneity, falling into two distinct subsets relating to high and low 
immunological activity, potentially identified by expression o f cell adhesion ligands and 
chemokine receptors which determ ine the ir subsequent role in inflammation (Tacke et al.
2007, Libby et al. 2008). Inflammatory monocytes are CCR2+ and CX3CR1|0 and are thought 
to adhere preferentially to activated endothelium, moving rapidly from the blood to sites of 
inflammation and giving rise to classically activated (M l)  macrophages (Geissmann et al. 
2003, Swirski et al. 2007). In addition, these monocytes express high levels o f P-selectin 
glycoprotein-1 (PSGL-1) that contributes to homing and rolling on the arterial endothelium  
by demonstrating a high capacity for binding the selectin adhesion molecules (An et al.
2008, Shimada 2009). In contrast, the second subset of 'non-classical' monocytes express 
high CX3 CR1 levels but are CCR2 negative. These monocytes, with distinct adhesive
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capabilities, are considered to 'patrol' the luminal side of the endothelium (Woolard and 
Geissman 2010) and are destined to become less inflammatory resident M2 macrophages 
(Geissmann et al. 2003) or dendritic cells (Tacke et al. 2007), potentially involved in 
atherosclerosis. W hether this subset patrols the entire vascular tree, however, is yet to be 
explored (Woolard and Geissman 2010).
Also, circulating monocyte subsets show plasticity and are capable of converting to the 
alternate phenotype depending upon the activating stimuli (Swirski et al. 2007). 
Proatherogenic stimuli, such as dyslipidemia, leads to a profound increase in the expression 
o f proinflammatory subsets o f monocytes, which mature into M l  macrophages in the 
intima and exhibit heightened proinflammatory activity (Geissmann et al. 2003, Schlitt et al. 
2004, Swirski et al. 2007, Tacke et al. 2007). The specific contributions of monocyte and 
macrophage subsets remain largely unknown, however, the ir presence in early lesions is 
clear.
Pro-atherogenic M l  macrophages predominate in athero-development and secrete pro- 
inflammatory cytokine mediators such as IL-1, TNFa and ROS, thereby promoting continued 
immune cell recruitment and accumulation o f lipid within the artery wall (Hansson 2005). 
Several lines of investigation suggest that the initiation of cytokine production from  
macrophages in atherosclerotic sites is most likely elicited by oxLDL (Tedgui 2005). TNFa 
and IL-ip are also secreted by activated and lipid-laden macrophages provoking multiple 
cellular effects within the vasculature that promote atheroma formation (Packard et al. 
2009). In addition, TLR activation leads to the production of cytokines by macrophages. In 
particular, TNFa and IFNy are secreted in high levels from TLR-activated dendritic cells 
(Krutzik et al. 2005). The less inflammatory M2 macrophages may function to modulate 
athero-progression by dampening the inflammatory response through secretion o f anti­
inflammatory mediators such as IL-10 and TGF0 (Gordon 2003) promoting resolution of 
inflammation (Martinez et al. 2009).
Macrophages, foam cells and dendritic cells act as antigen presenting cells (APC) to 
leukocytes of the adaptive immune response. OxLDL is ingested and processed by 
lysosomal degradation resulting in oxLDL-derived epitope delivery and display on the cell 
membrane by major histocompatibility complex (MHC) class I and II molecules (van
19
Puijvelde et al. 2006). This presentation allows for interaction with cells of the adaptive 
immune response (See section 1.3.2.2).
1.3.2.2 T cells
The significant presence of T cells and the ir production of cytokines and other inflammatory 
modulators in atherosclerotic plaques implicate a regulatory role for these adaptive 
immune cells in instructing the more abundant effector cells of the innate immune 
response (Hansson et al. 2000), and thus demonstrate a link between pathways of innate 
and adaptive immunity in early atherosclerosis. Circulating T cells enter the arterial intima 
in the early stages o f atherosclerosis in response to adhesion molecule expression on the 
activated endothelium and local release of chemokines, in a manner similar to monocytes. 
Activated vascular cells and macrophages in the developing plaque produce the T cell 
chemoattractant CCL5 (also known as RANTES (regulated on activation, normal T-cell 
expressed and secreted)) (Mach et al. 1999). In addition, T cells respond to the IFNy- 
inducible chemokines IFNy-inducible protein-10 (IP-10, CXCL10), monokine induced by IFNy 
(MIG, CXCL9) and CXCL11 (also known as IFNy-inducible T cell a-chemoattractant (l-TAC)) 
and adhere to VCAM-1 at sites o f atheroma (Libby 2009).
Most T cells in atherosclerotic lesions are CD4+ T cells, but there are also a small proportion 
of CD8 + cells (Paulsson et al. 2000). Local CD4+ T cell activation occurs due to interaction 
with antigen presenting cells. Naive T cells, with specific oxLDL receptors, bind the MHC 
class M-oxLDL antigen complex on APCs resulting in the proliferation and clonal expansion of 
oxLDL specific T-cells (Stemme et al. 1995). During this T cell-APC interaction, additional 
membrane proteins aid communication between T cells and macrophages, significantly 
CD40-CD40 ligand (CD40L) interactions, which activate both cell types (Libby 2006). Upon 
oxLDL recognition, T cells undergo antigen-dependent activation in which they synthesise 
CD40L. CD40L interacts with CD40 on the macrophage surface activating its effector 
mechanisms, including enhanced cytokine production (IL-1, IL-12, TNF-a) (Phipps 2000). In 
addition, CD40-CD40L interactions are critical for the development of T cell effector 
functions o f proliferation, differentiation and cytokine production (Laman et al. 1996). T cell 
cytokines include TNF-a, IFN-y, IL-4, IL-6 , IL-12, IL-2, (Phipps 2000, Hansson and Libby 2006, 
van Puijvelde et al. 2006). These cytokines, in turn, control further macrophage activation 
including scavenger receptor expression, MHC expression and cytokine production, in
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addition to the ir effects on the vascular wall. This perpetuating active "cross talk" through 
the T h l cytokine repertoire accelerates atherosclerosis (Horkko et al. 2000).
Upon activation, T lymphocytes differentiate into particular subsets, dependent on co­
stimulation from cytokines, growth factors and specific cell-cell interactions, and are 
therefore controlled by the local inflammatory milieu. Most oxLDL reactive CD4+ T cells 
have a T helper 1 (Th l) phenotype (Stemme et al. 1995, Zhou et al. 2001), and 
consequently CD4+ T h l cells are the predominant T cell in lesions, with CD8 + cytotoxic T 
cells detected to a lesser extent (Hosono et al. 2003). The differentiation o f CD4+ T cells 
into T h l, Th2 or regulatory T cell (Treg) subsets is driven by the influence of cytokines. T h l 
cell differentiation is driven by the proinflammatory cytokines IL-18 and IL-12 synergistically 
(Packard et al. 2009), whereas IL-4 induces the Th2 subset (Weirda et al. 2010) and IL-10 
and TGFP provoke regulatory T cells (Tregs) whilst also down-regulating T h l cell production 
(Ait-Oufella e ta l. 2009).
T h l cells are the predominant T cell in atherosclerotic plaques and are the primary source 
of IFNy, although NK cells, and to a lesser extent macrophages, can also produce IFNy 
(Andersson et al. 2010). IFNy potentiates the production of proinflammatory T h l-  
promoting cytokines IL-12 and IL-18 by macrophages and smooth muscle cells, in addition 
to MHC-II expression, increased lipid uptake and increased APC activation (Leon and 
Zuckerman 2005, Hansson and Libby 2006). IFNy may influence foam cell formation through 
the inhibition of scavenger receptor expression, as demonstrated in the THP-1 macrophage 
cell line (Li et al. 1995, Grewal et al. 2001, Wuttge et al. 2004, Wagsater et al. 2004) and 
subsequent decrease of modified LDL uptake (Reiss et al. 2004).
The role of Th2 cells in atherosclerosis is poorly understood though it is generally 
considered that they are anti-atherogenic as they oppose pro-atherogenic T h l 
differentiation and cell response, and produce the anti-inflammatory cytokines IL-4, IL-5, IL- 
10 and IL-13 (Andersson et al. 2010). Mice predisposed to a Th2 response are found to be 
resistant to diet-induced atherosclerosis (Paigen et al. 1985) and elimination of the Th2 
response gives rise to atherosclerosis susceptibility (Huber et al. 2001). Th2 cells, however, 
are rarely detected in mouse atherosclerotic lesions (Mallat et al. 2009).
Tregs are considered to influence the inflammatory progression of atherosclerosis through 
the release of anti-inflammatory cytokines, such as IL-10 and TGF3, and the ir presence in all
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developmental stages o f human plaque formation could explain the smouldering chronic 
inflammatory process that occurs throughout the longstanding course of the disease (de 
Boer et al. 2007).
1.3.2.3 Platelets
There is accumulating evidence for the involvement of platelets in early and late 
atherosclerosis through the ir contribution to endothelial activation, modulation of 
inflammatory responses leading to lesion formation, and subsequent thrombotic 
complications.
Platelets are influenced by circulating lipids. LDL, VLDL and particularly oxLDL can bind to 
specific receptors on platelets, including scavenger receptors SR-B1, CDB6  and LOX-1, 
mediating lipoprotein-platelet interactions (Badimon et al. 2009). The specificity and 
detailed function o f these receptors is a m atter of debate (Seigel-Axel et al. 2008). Platelet 
interactions with native LDL may function as a mechanism of lipoprotein exchange between 
the tissues and the circulation, delivering vital cellular components or facilitating lipid 
clearance. In contrast, oxLDL binding to platelets induces activation, morphological changes 
and promotes hyperaggregation (Tandon e ta l. 1989, Surya and Akkerman 1993, Elisaf et al.
1999). W hether lipoproteins are simply bound to the platelet surface or endocytosed is not 
fully understood.
Activated platelets are prone to adhere to the endothelium, particularly at sites o f 
endothelial dysfunction or activation, where adhesion molecule expression is increased or 
the extracellular matrix is exposed. These mechanisms may initially serve to protect the 
endothelium, by initiating vascular repair through the release of growth factors and the 
attraction of progenitor cells (reviewed in Badimon et al. 2009). There is also evidence that 
platelets adhere to intact endothelium, possibly due to the ir sensitisation by pro- 
inflammatory stimuli and lipoprotein status (Seigel-Axel et al. 2008). Platelets adhere 
following the well-controlled mechanism o f tethering and rolling, initiated by P-selectin- 
PSGL-1 interactions. Tethering further activates platelets, increasing cell-cell 
communication with the endothelium via increased production of cytokines, chemokines 
and adhesion molecules, and ultimately promotes platelet arrest (Lindemann et al. 2007). 
Firm platelet adhesion causes maximal platelet activation, leading to increased 
inflammatory mediator secretion (Lindemann et al. 2007). For example, endothelial CD40
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interactions with CD40Lon platelets induces the secretion o f the chemokines CCL2 and IL- 8  
(CXCL8 ) from endothelial cells, thereby generating chemotactic signals that recruit 
leukocytes (Henn et al. 1998). Additionally, activated platelets secrete IL-ip, a potent 
inflammatory cytokine (see Lindemann et al. 2007). Consequently, these cytokines are able 
to further activate endothelial expression of adhesion molecules ICAM-1, VCAM-1 and P- 
selectin (Lindemann et al. 2007). Therefore, platelets can activate, and be activated by, 
dysfunctional endothelium either directly or indirectly as a consequence of lipoprotein 
interactions (see figure 1 .6 ).
In addition, there is evidence that both resting and activated platelets are capable of 
generating ROS. Due to the ir interactions with lipoproteins, this may augment oxLDL 
formation (See Seigel-Axel et al. 2008). Therefore, although most evidence indicates a 
fundamental role in endothelial activation and leukocyte adhesion, platelets may have 
multiple influences on atheroma development.
1.3.2A Additional leukocytes
As the early fatty streak develops, further cell types, such as mast cells, neutrophils, natural 
killer cells and rare reports o f B cells appear in the plaques as they progress into the mature 
atherosclerotic state, although they remain relatively minor constituents and relatively 
poorly understood with regard to plaque development (Libby and Aikawa 2002). Each of 
these immune cells is capable of exacerbating the inflammatory environment through the 
balance of pro- and anti-infammatory mediators that regulate the magnitude of the 
inflammation in the lesion, though the ir specific contributions and interactions are not 
definitively established (See Packard et al. 2009 for review) (Figure 1.5).
1.3.3 Atherosclerotic plaque progression
The inflammatory events orchestrating the development and progression o f atherosclerosis 
are tightly regulated by the balance between pro- and anti-inflammatory activities. These 
mechanisms originally arise to provide vascular protection, clearing the vessel wall o f toxic 
lipids as well as healing the damaged endothelium, and many of the key immune events in 
early lesions function normally, with the objective of resolving the inflammation (Tabas
2009). Many cytokines and cells have both pro- and anti-inflammatory functions, 
depending upon the local inflammatory milieu.
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Figure 1.6; Platelet activation and adhesion to the endothelium. Platelets are 
influenced by c ircu lating lipids which can prom ote  hyperaggregation. Activated 
plate lets adhere to  the endothe lium  via te the ring  and rolling, in itia ted  by P-selectin- 
PSGL-1 interactions. Tethering and adhesion increases the production o f cytokines (IL- 
13), chemokines (PAF, MIP-1, RANTES), add itiona l adhesion molecules (CD40L) which 
u ltim ate ly  p rom ote  p la te le t arrest and diapedesis. Consequently, these in flam m ato ry  
mechanisms are able to  fu rth e r activate endothe lia l expression o f adhesion m olecules 
I CAM-1, VCAM-1 and P-selectin, and IL-8 and CCL2 secretion. This in tu rn  a ttracts  
fu rth e r leukocytes to  the endothe lium  where they can bind attached p la te le ts o r 
d irectly  to  endothe lia l adhesion molecules (Lindemann e t al. 2007). PAF, p la te le t 
activa ting  fa c to r; TGFfi transfo rm ing g row th  fa c to r-p ; PDGF, p la te le t derived g row th  
fa c to r; RANTES, regu la ted  upon activation norm a l T cell expressed and secreted; MIP-1, 
m acrophage in flam m ato ry  p ro te in -1 ; PF4, p la te le t fac to r-4 .
24
When anti-inflammatory mechanisms are overwhelmed and atheroma formation continues, 
the vascular wall can remodel to compensate and reduce the detriment of growing 
inflammation. The continuous influx o f cells into the arterial intima and the mediators 
secreted by activated leukocytes and vascular cells leads to changes in the structure of the 
vessel converting the early fatty streak into a more complex and advanced lesion. SMC 
proliferate and migrate from the tunica media producing strength-giving collagen which 
adds structural quality to the plaque by creating a fibrous cap over the lesion and decreases 
vulnerability to rupture (Figure 1.2b). This remodelling o f the vascular wall, from leukocyte 
entry to SMC functioning, is thought to be directed by the activity of endogenous proteases, 
matrix metalloproteinases (MMPs), that are capable of degrading all components o f the 
blood vessel wall (Ikeda and Shimada 2003) and are involved in physiological and 
pathological reorganisation o f the vasculature (Galis et al. 2002). The human M M P family 
contains at least 23 members that are classified into subgroups (e.g. collagenases, 
gelatinases, stromelysins and others) based on the ir substrate specificity, although many 
MMPs have overlapping substrate specificities (Johnson 2007). MMPs are produced by 
vascular cells and macrophages as a result o f stimulation by growth factors (epidermal 
growth factor (EGF), platelet-derived growth factor (PDGF) and basic fibroblast growth 
factor (bFGF)) (Dollery et al. 1995, George 2000), cytokines (IL-1, IL-6 , TNF-a) (Galis et al. 
1994b), contact with inflammatory cell ligands (such as CD40L) (Schonbeck et al. 1997) and 
oxLDL (Rajagopalan e ta l. 1996). Normal human arteries do not express active collagenases, 
yet macrophages in human plaque areas demonstrate expression of interstitial collagenases 
M M P-1 and gelatinases M MP-2 and -9 by immunohistochem istry (Galis et al. 1994a, Nikkari 
e ta l. 1995).
The close contact of VSMC w ith adjacent cells and the ir surrounding basement membrane 
are considered to inhibit proliferation (Johnson 2007). In atherosclerosis as MMPs free 
VSMC from these tight physical barriers via extracellular matrix (ECM) decomposition and 
proliferation signals are intensified in addition to the cells ability to traverse through the 
weakened basement membrane to remodel the vasculature. SMC migrate and proliferate 
in response to this ECM liberation and in response to chemokines down concentration 
gradients, to give strength to the expanding vascular wall through the formation of a 
fibrous cap over the lesion (Johnson 2007). In addition, the proteolytic activity o f MMPs can 
release the active form of TGF(3 from inactive complexes, thus promoting anti-inflammatory 
actions in addition to smooth muscle cell survival and collagen synthesis (Karsdal et al. 2002,
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Maeda et al.2002, Yu et al. 2000). Studies on M M P knockout mice reveal that the ir role in 
atherosclerosis is complex as some MMPs support lesion growth and destabilisation while 
others suppress growth and promote lesion stability, partly due to the ir overlapping 
substrates and differential control of enzymatic activity by cytokines and growth factors 
(Johnson et al. 2005, Johnson et al. 2006). Therefore, the nature of M M P activity is 
influenced by the stage of lesion development and its associated inflammatory 
environment, as well as the vascular location (Johnson et al. 2006).
The proteolytic activity of MMPs is regulated by tissue inhibitors of metalloproteinases 
(TIMPs), which reversibly inhibit enzymatic activity by binding to the catalytic domain o f the 
enzyme to form inactive complexes (Fassina et al. 2000). Four mammalian TIMPs (TIMP-1, - 
2, -3, and -4) have been characterised which can be synthesised by vascular cells and 
immune cells, often in conjunction with M M P production, thus maintaining the balance 
between matrix synthesis and degradation, under normal physiological conditions (Johnson
2007). Gene transcription of TIMP-1 and -3 can be upregulated by several growth factors 
and the cytokines IL-1 and TNFa (see Johnson 2007). Conversely, TIMP-2 is considered to be 
unregulated (Fassina et al. 2000), although TGF|3 and TNFa have been shown to down- 
regulate TIMP-2 levels (Stetler-Stevenson et al. 1989). Thus inflammatory mediators 
involved in atherosclerosis can influence M MP activity and expression o f the ir tissue 
inhibitors to influence the structure of the plaque.
Vascular remodelling can create stenosis, often w ith clinical complications of restricted 
blood flow. Although it is not considered fatal and is not necessarily related to negative CVD 
outcomes, luminal stenosis can further alter laminar blood flow, leading to the 
complications of oxidative stress and endothelial dysfunction, thus potentiating 
atherosclerosis (Kinlay et al. 2002). More recently it has been demonstrated that 
atherosclerotic arteries compensate by outward enlargement (diffuse atherosclerosis) to 
maintain lumen diameter, rather than as previously suggested by distension on the luminal 
side of the artery, which may obstruct the blood flow (focal atherosclerosis) (Galis and 
Khatri 2002). This 'positive remodelling', whereby lumen size is not affected by plaque 
growth due to the expansion o f the external elastic membrane, often has no clinical 
symptoms. With this recent knowledge it has become apparent that relatively small 
plaques, identified by ultrasound, may only be the tip of the atherosclerotic 'iceburg' (Libby 
and Theroux 2005).
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In addition to remodelling, prolonged exposure to pro-inflammatory cytokines along with 
increased lipids and an elevated oxidative status in plaque regions contribute to apoptosis 
of lesion cells including macrophages (Seimon and Tabas 2008), SMC (Stoneman and 
Bennett 2004) and endothelial cells (Choy et al. 2001). This increased cell death can result 
in the build up of a necrotic core w ithin the plaque (Figure 1.2c). Increased cell death w ithin 
the lesion, particularly of SMC, significantly weakens the plaque and consequently 
susceptibility to rupture is increased (Chandrasekar et al. 2006, Mallat et al. 2001c).
1.3.4 Plaque rupture
As the plaque develops and fatty streaks are converted to more advanced lesions, the 
inflammatory milieu alters and the immune response progresses leading to a change in the 
structure and vulnerability of the plaque due to continued leukocyte influx and retarded 
inflammatory cell egress.
Failure of macrophage egress leads to prolonged production of MMPs by foam cells in the 
lesion (Tabas et al. 2009). The activity of MMPs can evade normal control without 
alteration in regulatory TIMPs expression and can lead to detrimental vascular 
modifications resulting in excessive ECM destruction (Galis et al. 2002, Ikeda et al. 2003, 
Cho and Reidy 2002). This deprives VSMC from matrix-dependent and cell-cell and cell- 
matrix survival signals, leading to apoptosis and the formation of a necrotic core in the 
developing lesion (llic et al. 1998, Almeida et al. 2000). In addition, the processing of pro- 
TNFa to its active form from the surface of TNFa-expressing cells by numerous MMPs, may 
lead to apoptosis of neighbouring cells, as TNFa can act as a death ligand signal dependent 
upon coregulatory stimulation from other inflammatory pathways (see Johnson 2007 and 
Van Herreweghe et al. 2010).
The switch to a selective recruitment of T h l cells represents an important point towards 
disruptive events destabilising the plaque, including increased cytokine-mediated cell death 
and decreased proliferation (Glaudemans et al. 2010). IFNy strongly inhibits the production 
o f interstitial collagens by VSMC (Amento et al. 1991). IFNy can also inhibit the proliferation 
o f SMC, thereby reducing the stability of the plaque (Hansson et al. 1989a). Through 
paracrine and autocrine mechanisms, TNFa can induce apoptosis of SMC (Boyle et al. 2003) 
and it is proposed that endothelial cell apoptosis might be a major determ inant o f plaque 
rupture (Durand et al. 2004). Thus, the aggressive inflammatory profile w ithin vulnerable
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plaque sites promotes increased breakdown and decreased synthesis of collagen, yielding a 
doubly negative consequence for plaque stability. Coupled with increased cell death, 
degradation of the protective structural components of the lesion results in plaque rupture 
and the exposure of thrombotic factors to reactive clotting agents in the blood. Thrombus 
ensues, with the potential to totally occlude the vessel with detrimental consequence 
(Figure 1.2d).
The most vulnerable plaques are those w ith low positive remodelling, increased 
concentration of inflammatory cells and relatively large necrotic core thickness (Bui 2009). 
The thinning of the fibrous cap renders the plaque susceptible to physical disruption. These 
lesions are often less advanced rapidly growing lesions with only a moderate stenosis. In 
fact, angiographic studies reveal that the majority of acute myocardial infarcts occur in 
vessels with stenosis o f less than 70% (Falk et al. 1995), and a relatively small amount of 
stenosis in an artery, which may appear normal, may still give rise to acute fatal thrombosis 
(Libby 2001a). Thus, vascular remodelling may initially be protective and compensate for 
the inflammation at the plaque site, maintaining integrity of the blood vessel wall even 
when stenosis occurs. It is when this remodelling does not occur, is no longer effective, or 
has developed beyond protective-compensatory processes, that rupture or acute coronary 
consequences manifest. It may therefore be concluded that the quality rather than quantity 
of the plaque is paramount and stability has a greater importance for acute thrombotic  
pathologies.
Although not fully elucidated, it is clear that plaque composition is critical to future clinical 
events and that immunological mediators, namely cytokines, chemokines and adhesion 
molecules, orchestrate and define this composition through multiple functions. The 
presence of immune cells in the atherosclerotic plaque has been demonstrated as a major 
contributing factor for lesion progression at all stages of atheroma development through to 
plaque rupture (See Yilmaz et al. 2007). Therefore, mediators that promote leukocyte 
recruitment and accumulation at atherosclerotic lesion sites are central to all stages of 
disease progression.
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1.4 Role of the monocyte chemoattractant CCL2 
in atherosclerosis
CCL2 has been strongly linked with atherosclerosis as its target specificity makes it a key 
candidate for the signal that attracts monocytes to the activated artery wall in lesion 
development (Coll et al. 2007).
CCL2 is a low molecular weight C-C or p-chemokine that is secreted by endothelial cells 
(Rollins et al. 1990), SMC (Valente et al. 1988), monocyte/macrophages (Yoshimura et al. 
1989a), and fibroblasts (Strieter et al. 1999b) in response to inflammatory stimuli. Pro- 
inflammatory cytokines IL-ip, TNFa, IFNy and altered haemodynamic forces have been 
shown to induce endothelial CCL2 expression and secretion (Rollins et al. 1990, Sica et al. 
1990, Shyy et al. 1994, Cybulsky and Gimbrone 1991, Gimbrone et al. 1997), and PDGF and 
IL-ip  can induce CCL2 expression in VSMC (Taubman et al. 1992, Lim et al. 2009). Walch et 
al. (2006) demonstrated that IL-4 was capable of inducing the genes encoding CCL2 in the 
vascular endothelium, through in vitro experiments using HUVEC. Chen and colleagues 
(2004a) have demonstrated that TNFa enhances ROS-mediated CCL2 expression in human 
aortic endothelial cells (HAEC) and human dermal microvascular endothelial cells (HMEC). 
Additionally, oxLDL and oxVLDL induced significant increases in CCL2 mRNA and protein in 
aortic endothelial cells (Yu et al. 1998) and vascular endothelial and SMC exposed to 
minimally modified lipids express elevated levels of CCL2 in culture (Cushing et al. 1990). 
Rollins et al. (1990) have demonstrated that human vascular endothelial cells express little 
CCL2 under normal culture conditions, although this expression is markedly induced by pro- 
inflammatory cytokines. These data therefore suggest that CCL2 is upregulated in pro- 
atherogenic conditions.
1.4.1 CCR2
The actions of CCL2 are mediated through cell surface receptors and although it binds to 
CCR2, CCR1 and CCR9, signal transduction only appears to occur via CCR2 at physiological 
concentrations of the ligand (Charo et al. 1994, Nibbs et al. 1997, Neote et al. 1993). CCR2 
is a 7 transmembrane-spanning GTP-binding protein-coupled receptor (Charo et al. 1994)
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and exists in two highly homologous isoforms in humans, CCR2A and CCR2B (Wong et al.
1997).
CCR2 is expressed on circulating leukocytes, primarily monocytes but also basophils, NK 
cells, dendritic cells and certain subsets o f T cells (Charo et al. 1994, Mackay 1996, Sozzani 
et al. 1997, Nieto et al. 1998, Ochensberger et al. 1999, Sica et al. 1997). The recruitment of 
monocytes and the ir migration to sites o f inflammation may be regulated by a number of 
different signalling molecules, but CCL2 is considered the most important and appears to be 
responsible for the ir migration into the intima at sites of lesion formation in early 
atherosclerosis (Gu et al. 1998, Boring et al. 1998, Coll et al. 2007). Han et al (1998) 
demonstrated that THP-1 monocytes displayed chemotactic activity toward CCL2, with 
chemotactic activities increasing in correlation with CCR2 expression level. Similarly, 
Tangirala et al. (1997) showed decreased chemotactic activity o f THP-1 monocytes 
following down-regulation of CCL2 gene expression. W eber et al. (1999) also reported that 
Mono Mac 6  cells migrated across a HUVEC layer towards CCL2, and that these monocytes 
demonstrated a 45% higher surface expression of CCR2 than non-migrating cells.
In addition to chemotaxis, CCL2-CCR2 binding promotes monocyte adhesion to the 
inflamed endothelium under conditions o f physiological shear stress by increasing the 
activation of (32-integrin (Gerszten et al. 1999, Luscinskas et al. 2000, Maus et al. 2002). 
Similarly, CCL2 stimulation of CCR2+ THP-1 and isolated human monocytes leads to an 
increased expression of CX3CR1 protein on the cell surface and subsequently increased the ir 
adhesion to immobilised CX3 CL1 (Green e ta l. 2006).
In addition, experimental evidence from HUVEC indicates that endothelial cells are capable 
of CCR2 expression, although at lower levels than monocytes, responding to CCL2 through 
chemotaxis, which suggests a potential role in revascularisation and angiogenesis 
associated with advanced plaque development (Salcedo et al. 2000, W eber et al. 1999a). 
Furthermore, CCR2 has been identified on human VSMC where it may influence 
proliferation and migration associated with atherosclerotic vascular remodelling (Hayes et 
al. 1998, Viedt et al. 2002).
A finely tuned network of cytokines, chemokines and cell-cell communication regulates 
CCR2 expression in distinct cellular systems. Han et al. (1998) discovered that isolated 
human monocytes and THP-1 cells treated with oxLDL decreased the ir expression of CCR2
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whereas native LDL induces rapid expression of CCR2 mRNA and protein. This suggests that 
CCL2 may primarily be involved in monocyte extravasation into the intima and only plays a 
minor role in subsequent events within the lesion where oxLDL would be at higher 
concentrations. However, W eber et al. (1999b) also noted that oxLDL counteracts a TNFa- 
induced down-regulation o f CCR2 in monocytes and actually increases CCR2 mRNA and 
protein expression, contradictory to earlier findings, suggesting that the down-regulatory 
actions of cytokines may be modified by a pro-atherogenic milieu. The transformation of 
monocytes to a less CCL2-responsive state via down-regulation of CCR2 expression is 
regulated by certain pro-inflammatory cytokines such as TNFa (Rollins et al. 1990, Tangirala 
et al. 1997, W eber et al. 1999a). Therefore, any subsequent egress from the intima, as 
monocyte/macrophages traverse the endothelium from basal to apical direction, is 
considered to be regulated by chemokines or soluble factors other than CCL2, as CCR2 
expression is reduced by the growing pro-inflammatory conditions in the lesion (Randolph 
e ta l. 1996).
1.4.2 Role of CCL2 in atherosclerosis
Experimental and clinical data provide evidence that CCL2 and CCR2 play a pivotal role in 
early stages o f atherosclerosis.
1.4.2.1 Evidence from animal studies
There are numerous animal studies that implicate the involvement of CCL2 in 
atherosclerosis. Atherosclerosis-prone LDL receptor knockout mice deficient in CCL2 display 
83% less lipid deposition throughout the ir aortas, with lesions of a reduced size and with 
less macrophage infiltration when compared to wildtype CCR2 genotype controls (Gu et al.
1998). Comparable results were observed in ApoE-/- mice genetically manipulated to be 
CCR2 deficient (Boring et al. 1998, Dawson et al. 1999)
Indeed, CCR2 knock-out mice display a phenotype similar to that of CCL2 deficient mice 
whereby significant defects in the recruitment of monocytes to sites of inflammation occur 
(Boring et al. 1997, Kurihara et al. 1997, Kuzeil et al. 1997). Furthermore, Gosling et al. 
(1999) showed that CCL2 deficiency reduced susceptibility to atherosclerosis in mice 
overexpressing apoB, the primary apolipoprotein in LDL. Furthermore, the overexpression 
o f CCL2 in apoE deficient trangenic mice accelerates atherosclerosis by increasing the
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number of macrophages in artery lesions (Aiello et al. 1999). In addition, blockade of CCL2- 
CCR2 interaction, through gene therapy, in atherosclerosis-prone mice was seen to inhibit 
the formation o f fatty streak lesions and limit the progression o f pre-existing plaques, 
without affecting serum lipid concentrations (see Coll et al. 2007). Although, Schecter et al. 
(2004) demonstrated CCL2 activation of SMC isolated from CCR2-/- animals, suggesting that 
a different receptor may be important in mediating some of the CCL2 effects.
1.4.2.2 Evidence from clinical studies
Evidence for the role of CCL2 in CVD is accumulating. CCL2 has been shown to be associated 
with acute coronary syndromes (Kervinen et al. 2004), subclinical atherosclerosis as 
measured by coronary risk factors (Deo et al. 2004), and obesity (Ohman and Eitzman 2009, 
Kim et al. 2006a). Additionally, CAD patients assessed for circulating CCL2 levels showed 
significantly higher concentrations than those of controls (Martinovic et al. 2005, Herder et 
al. 2006), and in CAD patients with the additional presence of PAD (Hoogeveen et al. 2005). 
Plasma CCL2 is elevated in patients after severe acute M l (Parissis et al. 2002, Kobusiak- 
Prokopowicz et al. 2007) and was positively associated with frequency of its occurrence (de 
Lemos et al. 20073). Higher CCL2 concentrations in the serum and/or plasma of HIV and 
renal insufficiency patients were associated with increased carotid IMT measures (Alonzo- 
Villaverde et al. 2004, Coll et al. 2006, Iwai et al. 2006, Pawlak et al. 2006). Furthermore, 
higher CCL2 values were seen in the serum of stroke patients compared to healthy controls 
(Arakelyan et al. 2005). These data on circulating CCL2 levels correlate w ith findings 
showing that CCL2 is upregulated in human atherosclerotic plaques (Nelken et al. 1991, Yla- 
Herttualla et al. 1991), a potentially more reliable measure of localised CCL2 activity.
In addition, peripheral blood mononuclear cells (PBMCs) from patients with CAD 
spontaneously secrete more CCL2 than PBMCs from healthy controls, and release greater 
amounts when stimulated with oxLDL (Breland et al. 2008, Oliveira et al. 2009). Okumoto et 
al. (2009) showed a positive correlation between CCR2 expression on circulating monocytes 
and serum CCL2 w ith carotid intima-media thickness and cardio-ankle vascular index, as 
measures of atherosclerotic indices, in chronic haemodialysis patients.
In contrast, a recent study failed to demonstrate a relationship between serum CCL2 and 
acute coronary syndrome outcomes in patients recovering from M l (Korybalska et al. 2010). 
A similar lack of correlation has also been documented between circulating CCL2 and
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coronary heart disease (CHD) atherosclerotic burden assessed with the Framingham risk 
score (Mosedale et al. 2005), and for M l following a multivariate analysis o f a large cohort 
from the Framingham study (McDermott et al. 2005).
These contrasting data reveal the difficulty o f clinical studies and in the comparison of 
results from different investigations where different spectrums of the same disease are 
assessed. However, the majority of the evidence suggests a role for CCL2 in the progression 
of atherosclerosis. It is not yet clearly established whether it may be an independent risk 
factor for athero-development.
1.5 Role of the novel chemokine fractalkine in 
atherosclerosis
The importance of chemokines and adhesion molecules as the orchestrating inflammatory 
mediators in atherosclerosis has also led to a significant amount o f focus on the novel 
chemokine, fractalkine (CX3CL1). This is due to its proposed dual structure and function as 
both an adhesion molecule and chemoattractant.
Synthesised as a 50-70kDa precursor, CX3CL1 is processed and glycosylated to a mature 
lOOkDa species (Garton et al. 2001). The extracellular chemokine domain o f CX3CL1 
comprises a novel arrangement of cysteine residues (CysXaaXaaXaaCys), classifying it as the 
only member of its chemokine subfamily (CX3C) (Bazan et al. 1997). Extending from the 
CX3C motif is a mucin-like stalk which acts as an efficient presentation molecule for the bio­
effector chemokine domain situated on the distal end of the molecule (Imai et al. 1997). A 
transmembrane domain and an intracellular domain follow to anchor CX3CL1 to the cell 
membrane (Figure 1.7). CX3CL1 is expressed by vascular endothelial and SMC, w ith 
expression amplified by pro-inflammatory cytokines TNFa (Ahn et al. 2004, Ollivier et al. 
2003, Lesnik et al. 2003), IFNy (Bazan et al. 1997, Imaizumi et al. 2000, Ollivier et al. 2003, 
Lesnik et al. 2003), IL-1, IL- 6  (Bazan et al. 1997, Garcia et al. 2000) as well as oxLDL (Barlic et 
al. 2007), whilst anti-inflammatory cytokines IL-4 and IL-13 inhibit CX3CL1 expression 
(Fraticelli et al. 2001). In addition, CX3CL1 expression has been detected in dendritic cells 
(Papadopoulos et al. 1999) and macrophages (Greaves and Gordon 2001), although to a 
lesser extent.
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Figure 1.7; Schematic structure o f CX3CL1. CX3CL1 is a large pro te in  o f 373 
am ino acids conta in ing m ultip le  domains and is s tructura lly  d iffe ren t from  
o the r chemokines. Beginning w ith  the predicted signal peptide, it contains an 
N-term inal chem okine dom ain (residues 1-76) w ith  the unique 3-residue 
insertion between cysteines (CX3C), m ucin-like stalk (residues 77-317), 
transm em brane dom ain (residues 318-336) and in trace llu la r dom ain (residues 
337-373). Adapted from  Umehara et al. (2004)
The chemokine region of CX3CL1 can be enzymatically cleaved from its membrane anchor 
to release the bio-effector domain as a soluble 85-95kDa fragment. This enables processes 
beyond the cell surface to occur and establishes a dual existence of CX3CL1 as a cell- 
associated molecule and a shed protein. A Disintigrin and Metalloprotease-17 (ADAM-17) is 
a member of a fam ily of multidomain, type I transmembrane proteins containing a zinc- 
dependent catalytic domain, a disintegrin domain, a transmembrane domain and a 
cytoplasmic tail (Tsou et al. 2001). ADAM-17 is synthesised as an inactive pro-form, or 
zymogen, that is cleaved intracellularly by the proteolytic enzyme furin, or a furin-type pro­
protein convertase, to yield a mature active enzyme that is translocated to the membrane 
surface (Moss et al. 1997, Schlondorff et al. 2000). It is only this mature active form of 
ADAM-17 that is expressed on the cell surface (Doedens and Black 2000, Schlondorff et al.
2 0 0 0 ) and its enzymatic activities act only on substrates expressed on the same cell (Itai et 
al. 2001). Rapid inducible cleavage of CX3CL1 is considered to be via ADAM-17 (Garton et al. 
2001, Hundhausen et al. 2003, Tsou et al. 2001). Previous studies have demonstrated that 
ADAM-17 mediates this inducible cleavage of CX3 CL1 following phorbol 12-myristate 13- 
acetate (PMA) stimulation, an effect that was not observed in cells isolated from ADAM-17 
knockout mice or when M MP activity was blocked (Chapman et al. 2000b, Garton et al. 
2001, Tsou et al. 2001). In cells deficient of ADAM-17, unstimulated CX3CL1 cleavage 
remained, suggesting that an alternate protein was responsible for constitutive shedding 
(Tsou et al. 2001). Constitutive CX3CL1 cleavage at proximal membrane regions is thought 
to be mediated by ADAM-10, which has high sequence homology to ADAM-17. 
Hundhausen et al. (2003) have reported an enhanced constitutive cleavage of CX3CL1 in a 
primate fibroblast cell line (COS-7) overexpressing ADAM-10. Additionally, murine ADAM- 
10-deficient fibroblasts display markedly reduced constitutive cleavage of CX3CL1 
(Hundhausen et al. 2003). Inhibiting the activity of ADAM-10 in HUVEC and a human 
endothelial cell line, EVC304, led to an increased adhesion of a CX3CRl-expressing murine 
pre-B cell line (Schwarz et al. 2010).
The catalytic activity o f ADAM enzymes is regulated by endogenous TIMPs. TIMPs are a 
fam ily of proteins made up of four structurally similar members, TIMP-1, -2, -3, and -4, 
which bind with varying affinity to MMPs and inhibit the ir activity via noncovalent 
interactions (Crocker et al. 2004, Gomis-Ruth et al. 1997). The expression o f TIMPs has 
been shown to be down-regulated by pro-inflammatory cytokines TNFa and IL-ip in cardiac 
and endothelial cells, suggesting that the activity of ADAMs may be enhanced during
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inflammation (Singh et al. 2005, Li et al. 2004, Bugno et al. 1999). TIMP-3 has been found to 
be the endogenous inhibitor of ADAM-17 (Amour et al. 1998). ADAM-10 activity has been 
shown, in vitro, to be inhibited by TIMP-1 and TIMP-3 (Amour et al. 2000).
Proteomic and functional investigations have recently revealed that M M P2 and cathepsin S 
are also capable of cleaving CX3CL1 (Dean 2007, Clark et al. 2007). However, as broad 
spectrum metalloproteinase inhibitors are capable of blocking constitutive and inducible 
CX3 CL1 shedding (Chapman et al. 2000b, Garton et al. 2001, Hundhausen et al. 2003), the 
role of cathepsin S may be limited.
Remarkably, Schulte et al. (2007) illustrated further cleavage of CX3CL1 after initial 
chemokine domain shedding, by ADAM proteases, although the function of the resulting 
liberated intracellular fragment was not determ ined. A potential role as an intracellular 
signal molecule was proposed, due to its comparable activity with the type - 1  surface 
molecules Notch and E-cadherin (Reiss et al. 2006). However rapid enzymatic degradation 
may more likely occur in the cytoplasm.
In the basal state, approximately half of the CX3CL1 is located on the membrane of 
endothelial cells and human embryonic kidney (HEK) cells, with the majority remaining in a 
separate punctuate juxtanuclear compartment (Liu et al. 2005, Hermand et al. 2008). The 
latter was suggested to act as an internal storage site for CX3CL1, allowing recycling of the 
protein to the membrane upon pro-inflammatory stimuli or down-regulating surface 
expression via stimulation of endocytosis. This permits an additional level of functional 
regulation beyond transcription and translation, whereby the CX3 CL1 could be rapidly 
mobilised to increase surface expression upon stimulation. Huang et al. (2009) suggest that 
the endocytosis of CX3CL1 is a protective mechanism against proteolytic cleavage from the 
plasma membrane by endogenous sheddases, since inhibition of this intracellular trafficking 
resulted in extensive cleavage and release of soluble chemokine. This idea is consistent w ith 
the cell surface expression pattern of active ADAM-17 and ADAM-10 (Doedens and Black 
2000, Schlondorff et al. 2000). Taken together, these findings suggest that the equilibrium  
of CX3CLI between the membrane-bound molecule and its cleaved soluble form will greatly 
influence its function, either in adhesion or chemoattraction.
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1.5.1 CXsCRl
Unlike other chemokines, CX3CL1 interacts exclusively with a single receptor and therefore 
cells expressing the CX3CL1 receptor (CX3CR1) are indisputably targets for CX3CL1 (Imai et ol. 
1997, Bazan et al. 1997). CX3CL1 exerts both its chemotactic and adhesive effects through 
the CX3CLI receptor (CX3CR1) (Combadiere et al. 1998). As a seven transmembrane 
spanning structure, CX3CR1 binds the signal peptide domain of CX3CL1 w ith high affinity, 
activating intracellular pathways o f inflammation and directly mediating cell adhesion, 
when the chemokine is anchored to the cell membrane, or cell migration, when the 
chemokine is shed (Imai et al. 1997).
CX3CRI expression has been demonstrated on many different cell types associated with 
atherosclerosis both in vivo and in vitro, including monocytes, macrophages, T cells, NK cells, 
dendritic cells, and vascular smooth muscle cells. CX3CR1 activation leads to distinct 
functions within these cells dependent upon cell type, location and ligand position (e.g. cell- 
bound or shed) (Imai et al. 1997, Combadiere et al. 1998).
1.5.2 Functions of soluble CX3 CLI
Following its shedding from the cell surface, soluble CX3CL1 is free to recruit cells expressing 
CX3CRI, enabling them to m igrate along concentration gradients to the site of inflammation, 
where they can exert the ir effects. Previous studies have demonstrated that soluble CX3CL1 
exhibits chemotactic activity for monocytes, NK cells, T-cells and dendritic cells expressing 
CX3 CRI (Bazan et al. 1997, Guo et al. 2003).
Similar to other chemotactic factors, soluble CX3CL1 can also adhere to glycosaminoglycans 
(GAGs) on the luminal surface of endothelial cells creating a stationary and localised 
chemoattractant gradient drawing leukocytes to inflammatory sites (Surmi et al. 2009). 
HEK293 cells transfected to express high concentrations o f CX3CR1 demonstrate 
chemotactic responses to soluble CX3CL1, migrating across concentration gradients 
(Combadiere et al. 1998). Similarly, Imai et al. (1997) revealed the chemotactic activity of 
subsets o f isolated lymphocytes (particularly CD4+) and, although to a lesser extent, 
monocytes in response to soluble CX3CL1. Moreover, human monocyte-derived 
macrophages and murine bone marrow-derived macrophages displayed effective 
chemotaxis towards apoptotic CX3CLl-secreting B cells in culture, w ith CX3CR1 deficiency
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reducing this migration (Truman et al. 2008). Almost all NK cells express CX3CR1 and 
particular subsets demonstrate m igratory responses to soluble CX3CL1 and enhanced 
cytolytic function against target cells, contributing to the endothelial injury (Fong et al. 
2000, Yoneda et al. 2000).
The expression of CX3CR1, however, does not always determ ine the m igratory activity of 
leukocytes to CX3CL1, as only a percentage of the cell types identified with the receptor 
respond to soluble CX3CL1 (Imai et al. 1997). CX3CL1 acts as a potent chemoattractant for 
NK cells, T-cells and dendritic cells, but exerts a poor effect on monocyte migration in vitro 
(Vitale et al. 2004). Rather, the chemoattraction of monocytes is considered to be largely 
due to CCL2, w ith CX3CL1 functioning primarily as an adhesion molecule (Umehara et al. 
2001).
Chapman et al. (2000a) argued that CX3 CL1 cleavage from the cell membrane represents a 
term inating event to down-regulate the adhesive properties of the molecule rather than 
liberate a chemotactic molecule. This was supported by blocking the activity o f ADAM-17 
and ADAM-10 which led to increased adhesion, but blocked transmigration (Schwarz et al.
2010). In addition, soluble CX3CL1 has been found to prevent the chemoattractant effects 
of CCL2 on monocyte trafficking (Vitale et al. 2004), block the adhesion of NK cells to the 
endothelium (see McDermott et al. 2001) and reduce the adhesive properties of CX3CR1- 
expressing cells to the endothelium and aortic SMC in vitro by blocking the receptor (Imai et 
al. 1997, Chapman et al. 2000b, Ollivier et al. 2003).
In addition to CX3CRl-dependent leukocyte recruitment, VSMC express the receptor and 
may also function through CX3 CL1 to influence lesion development. SMC CX3 CR1 expression 
is considered to be involved in vascular remodelling and a ligand-induced proliferation and 
migration in response to CX3CL1 has been demonstrated (Perros et al. 2007, Lucas et al. 
2003, Chandrasekar et al. 2003).
Thus, the cleavage of CX3CL1 from the cell membrane plays a role in atherosclerosis acting 
on cells which express CX3CR1. However, the mechanisms are not fully elucidated and may 
depend on other influencing factors at the site of atherogenesis.
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1.5.3 Adhesive functions of CX3 CLI
Bazan and colleagues (1997) first demonstrated that monocytes and T cells which express 
CX3CRI adhere to monolayers of CX3CLl-expressing HEK293 cells under static conditions in 
culture. THP-1 cells have also been shown to adhere to CX3CLl-expressing ECV304 cells in 
culture (Hundhausen et al. 2003). This adhesive interaction of CX3CL1-CX3CR1 has been 
shown to be independent of additional cell-cell adhesion molecule contact. Transfected 
HEK293 cells expressing CX3CR1 adhered to CX3CLl-coated slides and endothelial cells 
under flow conditions, with no effect of inhibiting receptor intracellular signals and 
therefore upregulation of alternate adhesion molecules (Haskell et al. 1999). Also, K562 
myelogenous leukaemia cells, which do not express selectins, adhered to immobilised 
CX3CL1 underflow  conditions (Fong e ta l. 1998).
Recently, Hermand et al. (2008) reported that clustering of CX3 CL1 on the cell membrane is 
essential for adhesive potency, similar to integrin adhesion requirements and comparable 
to PSGL-1 dimerisation (Wehrle-Haller and Imhof 2003, Snapp et al. 1998). This molecular 
aggregation is critically dependent upon the transmembrane domain o f the protein.
Cell bound or soluble CX3CL1 may also upregulate additional cell adhesion molecules, as G- 
protein coupled CX3CR1 signalling has been demonstrated (Charo e ta l. 2004, Cambien e ta l. 
2001, Thelen et al. 2001) and ligand-stimulation of CX3CRl-expressing endothelial cells 
results in an upregulation of ICAM-1 (Yang et al. 2007). Furthermore, G-protein mediated 
mechanisms o f CX3CR1 enhance integrin binding avidity for its ligand and further facilitate 
adhesion and prolonged cell arrest at the endothelium, as well as activating cell signal 
cascades that facilitate diapedesis (Goda et al. 2000). In addition, cell adhesion is enhanced 
by co-immobilisation of CX3CL1 w ith integrin ligands allowing for multiple concurrent 
binding interactions (Umehara et al. 2 0 0 1 ).
Membrane-bound CX3CL1 has been shown to enhance activation, degranulation and 
adhesive properties of platelets (Schafer et al. 2004). Platelets expressing CX3CR1 
accumulate at the inflamed endothelium as an essential mechanism of CX3CLl-induced 
leukocyte adhesion under arterial shear conditions. This interaction leads to platelet 
activation and upregulation of P-selectin, further creating an inflammatory site capable of 
slowing and adhering leukocytes to the luminal surface of the vessel (Schulz et al. 2007). 
Pre-treatment of platelets from rats with CX3CL1 heightened the ir adhesive properties,
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increasing P-selectin surface expression and enhancing adhesion to collagen and fibrinogen 
(Schafer e ta l. 2004).
SMC expression of CX3 CL1 may serve to retain CX3 CR1+ leukocytes in the subendothelial 
space of arteries in a similar manner suggested for ICAM-1 and VCAM-1 (Doran et al. 2008). 
This allows the infiltration and anchoring o f leukocytes beyond the endothelium and into 
smooth muscle layers of the vasculature, typical of vascular remodelling in plaque 
development.
1.5.4 Additional properties of CX3 CLI
In addition to the functions documented above, CX3CL1 may have a number of other 
properties. CX3CL1 has been demonstrated to have anti-apoptotic and proliferative effects 
on SMC (White et al. 2009, Perros et al. 2007). Both these mechanisms may contribute to 
the morphology of the atherosclerotic plaque, ultimately influencing stability and/or 
vulnerability to rupture. Therefore, CX3CL1 appears to act beyond the recruitment of 
inflammatory cells at the endothelium. VSMC express CX3 CR1 in addition to CX3 CL1 
production, allowing a potential self-regulatory signalling loop for the control o f SMC 
function at sites o f atherosclerosis.
CX3CRI is expressed on both CD8 + and CD4+ subsets o f T lymphocytes and preferentially in 
T h l compared to Th2 cells (Foussat et al. 2000, Fraticelli et al. 2001). As CX3CL1 is induced 
in endothelial cells by cytokines produced by T h l cells, such as IFNy and TNFa, and T h l cells 
express CX3CR1, an amplifying inflammatory circuit exists to perpetuate pro-inflammatory 
cytokine and chemokine release in athero-development. Additionally, a dose-dependent 
differential regulation of cytokine secretion was observed in macrophages stimulated with  
CX3CLI (M izutani et al. 2007).
Landsman et al (2009) suggest a role for CX3 CL1-CX3CR1 interactions in the transmission of 
essential survival signals in monocytes and foam cells, preventing induced cell death and 
therefore maintaining the presence of activated immune cells continuing the pro- 
inflammatory milieu. Also, foam cell death in early disease stages has been shown to 
correlate w ith decreased atherogenesis (Tabas 2005). CX3CLl-induced monocyte survival 
may also be potentially atheroprotective as macrophage apoptosis in late stages of
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atherosclerosis contributes to the destabilising lipid-rich necrotic core w ithin advanced 
plaques (Jaffer et al. 2006).
Taken together, this functional data supports a role for CX3CL1 in the vascular inflammation 
associated with atherosclerosis, although the underlying mechanisms remain unclear.
1.5.5 Role of CX3CLI in atherosclerosis
Experimental and clinical data provide evidence that the novel chemokine CX3CL1 and its 
receptor CX3CR1 play an important role in the inflammation associated with early stages of 
atherosclerosis.
1.5.5.1 Evidence from animal studies
Compelling evidence for a role of CX3CL1 in atherosclerosis has arisen from experimental 
animal models of atherosclerosis. Significant reductions in atherosclerotic lesion formation  
of high-cholesterol diet-fed apoE-/- mice, where the gene encoding CX3CR1 was lacking 
(Lesnik et al. 200S). Similar results were reported by Combadiere et al. (2003). Teupser et al. 
(2004) found a reduction in brachiocephalic artery atherosclerosis in apoE-/- CX3CL1-/- mice 
compared to controls, although no difference was apparent in aortic root lesions. In 
addition, when combined with CCR2 deficiency, CX3CL1-/- apoE-/- mice displayed 
dramatically reduced macrophage accumulation in the artery wall and the subsequent 
development of atherosclerosis (Saedrup et al. 2007). These mechanisms may function 
through the proposed survival signal induction by CX3 CL1-CX3CR1 interactions in foam cells, 
plaque macrophages and monocytes, a mechanism not observed in CX3CR1 deficient mice 
(Landsman et al. 2009).
1.5.5.2 Evidence from clinical studies
Evidence for the role of CX3CL1 in atherosclerosis, and its in vivo significance in plaque 
progression and clinical CVD consequences, has only recently become a focus o f interest. 
Expressional, functional and epidemiological data has revealed a significant, yet undefined, 
role for CX3CL1 and its receptor in atherosclerosis (Greaves and Gordon 2001, Fong et al. 
1998, Harrison et al. 2001, McDermott et al. 2001, Moatti et al. 2001, Lesnik et al. 2003).
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Clinical evidence for a role for CX3CL1 in atherosclerosis is apparent from human genetic 
investigations of non-functional CX3CL1-CX3CR1 systems. Two naturally occurring single 
nucleotide polymorphisms have been detected in the region encoding the CX3 CR1, resulting 
in a dysfunctional receptor directly affecting ligand recognition and significantly decreasing 
CX3CL1 binding capacity (Faure et al. 2000, M oatti et al. 2001, McDermott et al. 2003, 
Daoudi e ta l. 2004). The majority o f data from these population-based retrospective studies 
identify an associated decreased risk of atherosclerosis when the mutated non-functional 
CX3CR1 allele is present. The prevalence of CX3CR1 polymorphisms was of a lower 
frequency in CAD patients diagnosed via angiography (Apostolakis et al. 2007a), and within 
similar patient cohorts, a mutated allele resulted in a protective effect on the occurrence of 
acute coronary events (Niessner et al. 2005, M oatti et al. 2001). These results were 
supported by a recent study in a Chinese population assessed for carotid atherosclerosis 
(Zhao et al. 2010). McDermott et al. (2001) also conclude that patients expressing a CX3CR1 
polymorphism have a reduced risk of atherosclerosis as a consequence of improved 
endothelial function, a finding that was independent of established CAD risk factors 
(McDermott et al. 2003, Hattori et al. 2005).
However, no replicable associations were observed between CX3CR1 polymorphisms and 
carotid artery IMT (Debette et al. 2009), ischaemic cerebrovascular disease (Hattori et al.
2005), CAD (Niessner et al. 2005) and acute coronary syndrome (Apostolakis et al. 2007a, 
Niessner et al. 2005). These disparities may depend on the specific polymorphic mutation 
and subsequent receptor functioning, in addition to the distinct clinical manifestations of 
the CVD investigated. The exact functional effect of the mutated alleles is unclear 
(Apostolakis et al. 2009). Also, the power needed in particular investigations to predict 
negative correlation may reduce the sensitivity to detect subtle differences between 
disease and control groups. In addition, the concept of redundancy is well recognised in 
chemokine and chemokine receptor systems, therefore alternative chemokines or 
receptors may substitute for the mutation in particular situations, abrogating any decrease 
in inflammation (Umehara 2 0 0 1 ).
Immunohistochemical studies demonstrate CX3CL1 expression in human atherosclerotic 
coronary arteries but not in normal arteries, whereas its receptor, CX3 CR1, is expressed 
throughout the vessel (Wong et al. 2002a). Patel et al. (2008) also detected CX3 CR1+ cells in 
the abdominal aortas of patients with AAA where there was a thickening o f the vessels.
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Lucas and colleagues (2003) also demonstrated receptor and ligand presence in human 
coronary artery atherosclerotic plaques, with a positive correlation between the number of 
CX3CLl-expressing cells and CX3CR1+ cells in the lesion. In addition, high levels of CX3CL1 
mRNA have been observed in some human vessels with advanced atherosclerotic lesions, 
emphasising the upregulated expression of CX3CL1 in atherogenesis (Wong et al. 2002a, 
Greaves and Gordon 2001).
Also, when comparing peripheral blood mononuclear cells (PBMC) o f angiographically 
evaluated CAD patients with healthy counterparts, a higher number of CX3CR1+ monocytic 
cells were observed (Apostolakis et al. 2009). This finding was similar to an earlier study in 
which isolated PBMC from patients with AAA demonstrated higher percentages o f CX3CRI+ 
NK cells and T cells (Patel et al. 2008). The fact that atherosclerotic patients express 
increased vascular CX3CL1 and more CX3CR1 on peripheral blood monocytes supports the 
proposed importance of CX3CL1 in atherogenesis.
Thus, C X 3C LI unequivocally has a role in inflammatory processes typical o f atherosclerosis, 
yet to date it is still uncertain at what stage of pathogenesis this chemokine is involved and 
the mechanisms underlying its activation, its subsequent activity and clinical relevance all 
remain uncertain.
1.6 CCL2 and CX3CLI interactions
The complex array of chemokines involved in atherosclerosis have the potential to interact 
w ith each other through multiple mechanisms that influence disease progression. 
Therefore, the relationship between CCL2 and CX3CL1, two of the major inflammatory 
mediators in athero-development, is considered.
Classical monocytes (CCR2+ and CX3CRI10) are dependent upon both CCR2 and CX3CL1 for 
trafficking and entry into plaques, and combined inhibition of these pathways markedly 
reduced monocyte/macrophage accumulation in the atherosclerotic lesions of apoE 
knockout mice (Combadiere et al. 2008). The trafficking mechanisms o f CCR2' CX3C R lhl 
monocytes are so far unknown.
Saedrup et al. (2007) provide evidence for CX3CL1 in the direct recruitment and/or capture 
of CCR2-deficient monocytes, suggesting independent roles for CCR2 and CX3 CL1. Tacke et
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al. (2007), however, demonstrated that CCR2' CX3CRlhl monocytes enter plaques in a CCR2- 
and CX3CRl-independent manner and instead use CCR5, albeit less efficiently and less 
frequently than classical monocyte trafficking. In addition, CCR2+ CX3CRl'° monocytes were 
also shown to express and utilise CCR5 for trafficking, suggesting that multiple chemokines 
act in concert to control the migration of specific leukocyte populations, though the extent 
to which each individually contributes in vivo remains elusive. The combined inhibition of 
CCL2, CX3CR1 and CCR5 resulted in a 90% reduction in lesion size in atherosclerosis-prone 
mice (Combadiere et al. 2008). This reduction was associated with fewer circulating 
monocytes and this was considered to be at least partly due to a decrease in monocytosis 
from the bone marrow, and therefore a potential systemic anti-inflammatory effect 
upstream from plaque formation. W hether these receptors function independently, 
sequentially or synergistically remains to be fully understood.
The importance of CCL2 activity in CX3CLl-mediated adhesion o f PBMCs to the endothelium  
was supported by Green et al. (2006) who demonstrated that CCL2 upregulates CX3CR1 
expression by PBMCs and THP-1 monocytes via a CCR2-mediated p38 MAP kinase pathway, 
thus increasing adhesion to immobilised CX3CL1. The authors suggested that in vivo CX3CL1 
and CCL2 act concurrently and sequentially and highlighted the possibility that CCL2 
potentiates the functional inflammatory activities of CX3CL1. CCL2 enhancement of 
monocyte adhesion to CX3 CL1 may act to retain monocytes in the vascular wall on activated 
SMC and different monocytes may thus be recruited to different locations (Barlic et al.
2006).
These data suggest a complex interplay between CCL2, CX3CL1 and the ir receptors in the 
chemoattraction, adhesion and transendothelial migration of monocytes into the 
vasculature, which can be independent of classic adhesion cascades, but are often 
cooperative and complementary. Although the mechanisms are not completely elucidated, 
the expression o f CCL2 and CX3CL1 at sites o f inflammation, such as atherosclerotic plaques, 
may differentially regulate the migration of monocyte subsets into the vascular wall. As 
monocytes/macrophages are considered the most abundant inflammatory cells in 
atherosclerotic lesions that participate in all stages of pathology, therapeutic mechanisms 
that target the disruption of the ir recruitment may be of clinical benefit.
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1.7 Testosterone
Testosterone is the predominant sex hormone in males and is an anabolic steroid hormone 
belonging to the androgen group. Derived from cholesterol as its starting material, 
testosterone is synthesised from the precursatory substances dehydroepiandrosterone 
(DHEA) and androstenodione (see figure 1.8). This takes place primarily in Leydig cells in the 
testes of males, and to a lesser extent in the ovaries o f females, with a small amount also 
produced in the adrenal glands (Rang et al. 1999). This process is regulated by the 
hypothalamic-adrenal-gonadal axis, with luteinizing hormone (LH) released from the 
pituitary following gonadotropin releasing hormone (GnRH) stimulation, stimulating the 
synthesis and release of testosterone from the testes (Rang et al. 1999). Most circulating 
testosterone is transported to target tissues via the circulation, either as free testosterone 
or bound to specific plasma proteins (sex hormone binding globulin (SHBG)) (6 8 %) or 
weakly bound to albumin (30%). Only 1-2% of testosterone is free/unbound (Vermeulen 
and Verdonck 1968, Dunn et al. 1981), with SHBG holding much of the body's circulating 
testosterone inactive in the blood until target tissue activities lead to its release. The 
primary role of androgens is in the development of primary and secondary sexual 
characteristics, directing sexual differentiation, development and maintenance of the male 
phenotype (Silverthorn 1998).
Testosterone can act via four possible pathways (figure 1.9). The direct pathway involves 
the binding of testosterone to cytoplasmic androgen receptors (AR), following free diffusion 
across the target cell membrane. The AR is held in an inactive state in the cytoplasm by 
chaperone proteins, (heat shock proteins (HSP)) (Pratt and Toft 1997, Defranco 2000). Upon 
testosterone binding, ARs dissociate from the ir HSP and undergo a conformational change 
that results in tight homodimer formation with a neighbouring activated AR and the 
exposure of the ir nuclear targeting signal domains and DNA binding sites. This active 
homodimer traffics to the nucleus where it binds to specific androgen response elements 
(ARE) located in the DNA of target genes and acts directly as a transcription factor (see Liu 
et al. 2003 for review). The second pathway is termed the amplification pathway, due to 
the conversion of testosterone to its more potent metabolite dihydrotestosterone (DHT). 
Testosterone is converted to DHT in the cytoplasm by two enzymes, type 1 and type 2 5a- 
reductase (Rommerts 2004). DHT potentiates the effects of testosterone action as it binds
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Figure 1.9; Testosterone signalling pathways. Testosterone (T) can free ly  d iffuse 
across the  ta rge t cell m em brane 1) The d irect pathway involves the  binding o f 
testosterone to  cytoplasm ic androgen receptors (AR). 2) The am p lifica tion  pathw ay 
sees the conversion o f testosterone to  its m ore p o ten t m etabo lite  DHT (D) by 50- 
reductase. The AR is held in an inactive state in the cytoplasm  by heat shock pro te ins 
(HSP). Active AR hom odim ers tra ffic  to  the nucleus w here they bind to  androgen 
response elem ents (ARE). 3) The d iversifica tion pathway sees the  conversion o f 
testosterone to  estradio l (E) by aromatase. Oestrogen binds to  the oestrogen recepto r 
(ER) which targets oestrogen response e lem ents (ERE) in DNA. 4) Testosterone may 
also act via nongenomic pathways th rough the  invo lvem ent o f a hypothe tica l non- 
classical m em brane-associated steroid receptor.
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to the AR w ith higher affinity and has a slower dissociation rate from the receptor complex, 
amplifying the effects o f testosterone more than two-fo ld. The third pathway of action is 
called the diversification pathway as testosterone is converted and acts upon oestrogen 
receptors, often producing different outcomes to those of the AR. Testosterone is 
converted to 17(3-estradiol by the enzymatic activity of aromatase located in the cytoplasm 
of cells (Rommerts 2004).
In addition to these genomic pathways, there is evidence to suggest that a forth pathway 
exists whereby testosterone may also act via nongenomic mechanisms through the 
involvement of a hypothetical non-classical membrane-associated steroid receptor. These 
actions are mainly characterised by only a short delay of action and lack of susceptibility to 
inhibitors of transcription and protein synthesis (Heinlein and Chang 2002). Testosterone 
may exert these nongenomic effects in part by binding to a G-protein coupled receptor 
specific for the SHBG-testosterone complex, which, in turn, initiates a cAMP-mediated non- 
transcriptional pathway rapidly affecting intracellular calcium concentrations (Rosner et al. 
1992, Benten et al. 1999). Calcium fluctuations are subsequently involved in the activation 
of intracellular signalling, ultimately influencing specific target proteins and cellular 
responses (Alberts et al. 1994).
1.7.1 Role of Androgens in CVD
Gender differences in mortality and morbidity relating to CVD have long been apparent, 
w ith men being more than twice as likely to suffer from coronary heart disease as women 
of a similar age (Lerner et al. 1986, Rayner et al. 1998), a fact that remains consistent across 
various ethnic and social groups (Malkin et al. 2003a). The differences in gender-related risk 
are thought to be associated with sex hormones (Malkin et al. 2003a). It was originally 
proposed that oestrogens have protective mechanisms in the development of 
atherosclerosis. This was supported by evidence that post-menopausal women 
demonstrate an increased risk of atherosclerosis, similar to that of age-related males, after 
a post-menopausal catch-up time of around 1 0  years when the female steroid declines 
(Malkin et al. 2003b). Further to this, androgens were considered to be detrimental to 
cardiovascular health, due to the adverse effects seen in cases of anabolic steroid over-use 
and abuse (See van Amsterdam et al. 2010 for review).
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However, the marked gender difference observed in CVD risk is no longer thought to be 
due to testosterone or male gender per se. In fact it is more likely that low testosterone 
levels associated with aging and related comorbidities are directly linked with 
cardiovascular pathology and atherosclerosis. The age-related decline in testosterone 
observed in males is complex, surpassing a simple decrease in synthesis in the Leydig cells 
(Midzak et al. 2009). Stimulated to produce testosterone by luteinizing hormone, the Leydig 
cells in the testis may develop reduced responsiveness to this hormonal feedback circuit 
over time as a result of accumulatory intrinsic and extrinsic factors, not completely 
elucidated, resulting in lower circulating testosterone levels (For review see M idzak et al. 
2009). It is becoming increasingly evident, however, that this age-related androgen decline 
is associated with emerging pathophysiologies o f multiple diseases, in particular diseases of 
cardiovascular and metabolic consequence (Lunenfeld and Nieschlag 2007).
Several epidemiological studies have found a negative association between testosterone 
levels and CVD outcomes (Makinen et al. 2005, English et al. 2000c, Vikan et al. 2009). In 
the Rotterdam study, elderly men in the highest tertile of endogenous testosterone levels 
had a risk reduction o f 60-80% of severe aortic atherosclerosis after adjusting for age and 
cardiovascular risk factors (Hak et al. 2002). Akishita et al. (2009) has recently replicated 
such findings in a Japanese population of 171 m iddle-aged men. Carotid IMT, as an 
indicator o f general atherosclerosis, was also found to be associated with low total 
testosterone measures in large elderly male populations (Svartberg et al. 2006, Mu ller et al. 
2004). This correlation was also shown in men w ith obesity and type 2 diabetes (De Pergola 
et al. 2003, Fukui et al. 2003). Another recent population-based study in a cohort of 1954 
men advocated an association between low serum testosterone levels and increased 
mortality during a 7.2 year follow-up, after controlling for cardiovascular risk factors (Haring 
et al. 2010). This study did not adjust associations for age however, which may be indicative 
of testosterone levels and other compounding influences rather than a direct testosterone 
association. Male CAD patients have lower testosterone levels than men w ith normal 
coronary angiograms of the same age, although this correlation was with free and 
bioavailable testosterone but not total testosterone (English et al. 2000c). Furthermore, 
Pugh et al. (2000) reported that in a cohort of 831 male CAD patients, hypogonadism had a 
prevalence of greater than 20 percent. In contrast, two recent studies found no association 
between testosterone and abdominal aortic calcification as a measure of sub-clinical 
atherosclerosis, highlighting the complexity o f potential endocrine influences on CVD
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(Michos et al. 2008, Post et al. 2007). These investigations highlight that differences in 
reports may be attributed to the large divergence in study design, the array of associated 
risk factors used to adjust the results, differences in patient populations, and disparity in 
the vascular location of clinical measurement.
Androgen deprivation therapy (ADT), often used for the treatm ent of prostate cancer, has 
revealed further evidence for the protective role of testosterone in maintaining 
cardiovascular health. Men suffering from prostate cancer and receiving ADT experience 
shorter time to M l compared to age matched controls (D'Amico et al. 2007), express 20% 
higher risk of serious cardiovascular morbidity than similar men not receiving ADT (Saigal et 
al. 2007), and demonstrate increased risk of death from CVD (Keating et al. 2006, Tsai et al.
2007). A recent meta-analysis of studies over the last 20 years found an overall increase in 
risk for cardiovascular pathologies in male prostate cancer patients undergoing ADT, 
supporting the negative implications o f low testosterone (Shahani et al. 2008).
It is also now becoming apparent that testosterone replacement can potentially improve 
cardiovascular symptoms and health outcomes dependent upon the physiological setting 
(See Jones and Saad 2009, Bain 2010 for review). The administration o f testosterone has 
long since been shown to alleviate symptoms of angina in men and women (Lesser et al. 
1946, English et al. 2000b), improve cardiac output (Pugh et al. 2003), and has been 
demonstrated to be useful for treating chronic heart failure (Malkin et al. 2006b, Pugh et al. 
2004). TRT in hypogonadal men w ith ischaemic heart disease led to a delay in time to 
ischaemia and reduced cholesterol and TNFa levels (Malkin et al. 2004b), with male CAD 
patients demonstrating similar ischaemic improvements following TRT (Rosano et al. 1999, 
Webb et al. 1999). Additionally, a direct link has been made between long-term  
testosterone treatm ent and a significant reduction in carotid IMT as an indicator of vascular 
damage in overweight middle-aged men (Zitzmann e ta l. 2008).
Aromatase gene expression has been detected in the endothelium and smooth muscle of 
vascular tissue (Harada et al. 1999, Murakami et al. 2001) and the protective effects of 
testosterone have been suggested to be due to its localised conversion to estradiol by 
aromatase (Nathan et al. 2001). The presence of oestrogen receptors in vascular cells 
supports this notion, with expression in atherosclerotic vessels being reduced relative to 
normal arteries (Kim-Schulze et al. 1996). Additionally, both type 1 and type 2 5 a-reductase
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have been identified in vascular tissue suggesting a potential modulatory role of vascular 
tissues in the conversion o f testosterone to DHT as a further potential mechanism of 
androgen action (Eicheler et al. 1994, Fujimoto et al. 1994).
The relationship between androgens and CVD risk factors is therefore now well established, 
with the general consensus that low testosterone bestows negative outcomes. Low 
testosterone has recently been regarded as an independent risk factor for CVD (Maggio et 
al. 2009). However, the underlying mechanisms by which testosterone exerts these 
observed cardiovascular benefits is complex and has not been completely delineated.
1.7.1.1 Effects of androgens on lipids
Androgens have extensive anabolic actions in many tissues and organs, and, of particular 
relevance, on lipid metabolism. Although not completely elucidated, testosterone has 
effects on circulating lipid profiles that may influence atherosclerotic risk (Jones and Saad 
2009).
Many epidemiological studies have confirmed a direct correlation between obesity (more 
accurately visceral obesity) and CVD (Maison et al. 2001, Casaneuva et al. 2009, and See 
Despres et al. 2009 for review) w ith the role of low testosterone as a concomitant factor 
(Goncharov et al. 2009, and see Stanworth et al. 2009 for review). Zumoff et al. (1990) 
found that free testosterone and non-SHBG-bound testosterone are decreased in obese 
men in proportion to the degree of obesity. More recently, decreased levels o f total and 
free testosterone were associated with obesity in the Massachusetts Male Aging Study 
(Derby et al. 2006).
As previously mentioned (section 1.2.1.1), the balance of circulating lipids contributes to 
the risk o f atherosclerosis, with a disruption o f this balance associated with plaque 
development. Low levels of testosterone have been associated with an atherogenic 
lipoprotein profile, characterised by high LDL and triglyceride levels (Wu and von 
Eckardstein 2003), and a negative correlation between serum levels of testosterone and 
total and LDL-cholesterol has been observed in cross-sectional studies (Barrett-Conner et al. 
1988, Barrett-Conner et al. 1992, Haffner et al. 1993, Simon et al. 1997, Barud et al. 2002). 
In contrast to this, Khaw et al. (2007) reported that LDL levels were increased in patients in 
the upper quartile of endogenous testosterone levels compared to the lower quartile. The
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authors also reported a positive association of HDL with testosterone level, an observation 
demonstrated in other observational and cross-sectional studies (Simon et al 1997, van 
Pottelbergh et al. 2003). A few  cross-sectional studies, however, have found no association 
between serum lipid measurements and endogenous testosterone (Kiel et al. 1989, Denti et 
al. 2 0 0 0 ).
Patients undergoing ADT demonstrate increased total cholesterol and LDL cholesterol 
(Dockery et al. 2003, Nishiyama et al. 2005, Braga-basaria et al. 2006, Yannucci et al. 2006, 
Smith et al. 2008), elevated triglycerides and reduced HDL cholesterol (Haffner et al. 1993), 
or all of these indicators of atherogenic lipid profiles (Haidar et al. 2007) when compared to 
baseline or controls.
In contrast, the majority o f data from studies investigating TRT in hypogonadal and 
eugonadal men show improvements in lipid and lipoprotein profiles (Table 1.2). However, 
discrepancies and conflicts in the data indicate the complexity of the relationships and 
underlying interactions. The dose of androgen administration may play a central role in the 
efficacy of cardiovascular benefits. Specifically, supraphysiologiccal doses o f exogenous 
androgen administered to healthy eugonadal men generally results in significant reductions 
in HDL and elevations in LDL (Hurley et al. 1984, Thompson et al. 1989, Bhasin et al. 1996, 
Singh et al. 2003). Alternatively, physiological replacement in men w ith low endogenous 
testosterone yields favourable, or neutral, lipid profiles. Differences in study design, doses 
and formulations of androgens used, route of administration, duration of treatm ent and 
follow-up, and/or methods o f analysis may explain the variability in the results.
Dyslipidaemia, altered body fat distribution to visceral areas and resulting obesity can, in 
turn, also influence androgen levels, making it difficult to invoke a cause-and-effect 
relationship between low levels of testosterone and negative metabolic outcomes. For 
instance, it has been demonstrated that adipose tissue exhibits high concentrations of 
aromatase capable of converting testosterone to estradiol, not only reducing bioavailable 
testosterone, but also shifting the androgen-oestrogen balance in males (Hammoud et al.
2006). An increased conversion of androstenedione to oestrone by aromatase in body fat 
and muscle supports this (Schneider et al. 1979). To further exacerbate this sex hormone 
imbalance, an oestrogen-mediated reduction in luteinizing hormone represses stimulation
52
<D rsi
CD 00
u M M X.u, till
00
8* 8 n e e
S i  3 a a a- a a & .yj  p , p , p,
I s *  *
A o .2 a £ 2 f  ij 9 cinS 5 h g «<*. C <N O  r-.•S « i" c•o — n  —ss a « ?i
ru cu
CUD f0
53
of the testis to produce testosterone (Vermeulen et al. 1993). In addition, adipose tissue 
has been shown to express several steroidogenic and steroid-inactivating enzymes (Blouin 
et al. 2008). This circular relationship further demonstrates a link between lipids, 
testosterone and atherosclerosis, although the causality of the relationship is not yet 
known and cannot be unravelled by epidemiological studies.
Therefore, it may be concluded that androgen deficiency is associated with negative lipid 
profiles and that this detrimental alteration can be somewhat ameliorated by replacing 
testosterone to physiological levels in men.
1.7.1.2 Effects of Androgens on vascular function
The AR is expressed ubiquitously in cells o f the vasculature. Testosterone exhibits direct 
vasodilatory effects on vascular smooth muscle (Jones et al. 2003) with the mechanism of 
action thought to be androgen receptor-independent via calcium channel blockade and/or 
potassium channel opening (Ding and Stallone 2001, Jones et al. 2003), or increased release 
of endothelium-derived NO (See M iller and Mulvagh 2007). This is supported by the fact 
that acute vasodilatory actions of testosterone in rat coronary arteries and thoracic aortae 
of mice were not abolished by the androgen receptor blocker flutamide, suggesting a non- 
classical AR-mediated mechanism (Jones et al. 2004, Channer and Jones 2003). The 
maintenance of vascular tone is important in atheroprotection, where reduced vasodilatory 
responses and enhanced vasoconstriction further restrict haemodynamic flow through 
atherosclerotic vessels with stenosis, exacerbating clinical symptoms and perpetuating 
atherogenesis through vascular dysfunction. As previously described (section 1.2.1.2), 
dysfunctional vascular reactivity that influences vessel shear stress, can significantly alter 
metabolic processes in cells of the vessel wall leading to elevated oxidative status. 
Testosterone may, therefore, alleviate haemodynamic symptoms of atherosclerosis and 
improve atherosclerotic outcomes associated with disturbed flow patterns.
Recent evidence showed that low levels of testosterone are related to increased oxidative 
stress and a reduced antioxidant capacity in men, potentially as a mechanism o f disturbed 
flow due to loss of vascular reactivity, and that TRT was capable of reversing this status 
(Mancini et al. 2008). The negative correlation between testosterone and hypertension has 
also been demonstrated (Barrett-connor ef al. 1988, Phillips e ta l. 1993, Simon e ta l. 1997,). 
This is further supported by the evidence that patients with prostate cancer undergoing
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ADT experience arterial stiffness, as measured by pulse-wave analysis in the radial artery 
(Smith et al. 2001).
The vascular system is a target for direct androgen action and beneficial effects o f TRT on 
symptoms of angina (Maggio et al. 2009), blood pressure (Khaw et al. 1988), and erectile 
dysfunction (Corona et al. 2008a) may be due to vasodilatory actions of testosterone. Men 
w ith CHD show enhanced vasoreactivity following testosterone treatm ent (Webb et al. 
1999, Kang et al. 2002). Low testosterone levels in men are associated with erectile 
dysfunction possibly as a result o f impaired penile blood flow due to diminished
vasoreactivity (Yassin et al. 2008, Corona et al. 2009) and it is suggested that erectile
dysfunction and atherosclerosis are often closely related pathologies. In concordance w ith 
this, testosterone has been reported to display both acute and chronic vasodilatory effects 
upon various vascular beds (Manolakou et al. 2009), and testosterone improves cardiac 
output in patients with angina after exercise (Jaffe 1977) and myocardial ischemia in CAD 
patients (Webb et al. 1999, Rosano et al. 1999). Both chronic exposure to physiological 
testosterone therapy (Kang et al. 2002) and acute exposure to supraphysiological doses of 
testosterone (Ong et al. 2000) are reported to increase flow-mediated brachial artery
vasodilation, and occurs as a result of increased NO release from the endothelium in
responses to changes in shear stress in men w ith CAD.
However, studies regarding the vasoreactive effects of testosterone are contradictory, with 
several reports assigning vasoconstrictive properties to testosterone. These actions have 
been proposed to be mediated via direct ion channel inhibition or activation, or indirectly 
by stimulating various vasoconstriction pathways (Kumai et al. 1995, Reckelhoff et al. 2000) 
or inhibiting other vasodilators (Masuda et al. 1991, Ceballos et al. 1999) from studies 
performed in rats. Kienitz and Quinkler (2008) attribute these discordant findings to the 
mode of administration o f androgens, suggesting that a decrease in vascular tone seems to 
follow acute exposure to supraphysiological doses, whereas the long-term net effect of 
physiological androgens appears to be vasoconstrictive, w ith some dependence on prior 
exposure, or pre-treatment, of the vascular cells. The importance of age, as a factor leading 
to diminished vasoreactivity is also emphasised, although is not thought to be mediated 
through a decline in endothelial orVSMCfunction (English e ta l. 2000a).
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1.7.1.3 Effects of Androgens on inflammation
With the reported benefits of testosterone in CVD and the inflammatory nature of 
atherosclerosis, several clinical studies investigating the association between androgen 
levels and immune function/inflammation have emerged.
1.7.1.3.1 Effects of androgens on cytokines
The potential benefit of testosterone in reducing inflammatory cytokines has been 
demonstrated in several observational clinical studies. It has been suggested that plasma 
cytokine levels correlate negatively with androgen levels in men (Yesilova et al. 2000) and 
women (Christodoulakos et al. 2007). Yang et al. (2005) confirmed a significant inverse 
correlation between serum testosterone levels and IL-6 , slCAM-1 and C-reactive protein 
(CRP, a non-specific acute-phase reactant and marker of inflammation). Indeed, elderly 
hypogonadal men also exhibit raised serum levels of TNFa and IL- 6  (Khosla et al. 2002). An 
inverse relationship was seen between serum IL-ip and endogenous testosterone in CAD 
patients, with the increase in IL-lp significantly related to disease severity in a stepwise 
manner (Pugh et al. 2003, Nettleship et al. 2007b). No association was observed for TNFa, 
IL- 6  and IL-10, although IL-10 was implicated in disease progression. Such observations 
suggest that the underlying testosterone status may modulate cytokine production in men 
w ith CAD.
TRT studies have further implicated immunomodulatory actions of androgens in 
hypogonadal men w ith cardiovascular symptoms, showing a significant reduction in TNFa 
and an elevation of circulating anti-inflammatory IL-10 (Malkin et al. 2004a, Malkin et al. 
2004b). Additionally, PBMC isolated from androgen deficient men w ith type II diabetes 
showed a reduction or complete abrogation of ex vivo IL-6 , IL-ip and TNFa production 
when treated with testosterone (Corrales et al. 2006). Testosterone also inhibits the 
production o f proinflammatory cytokines such as IL-6 , IL-lp and TNF-a in a range of cell 
types including human endothelial cells (Hatakeyama et al. 2002) and human monocytes 
(Kanda et al. 1996) and testosterone can stimulate the production of anti-inflammatory  
cytokines such as IL-10 from lymphocytes (Liva and Voskuhl 2001).
Testosterone may influence circulating cytokine profiles and consequential inflammation 
indirectly through its proposed action on lipids, as adipose tissue is considered to act as an 
endocrine organ secreting numerous inflammatory factors (see Traish et al. 2009). As
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androgens play a critical role in regulating body fat distribution via mechanisms influencing 
adipogenesis, fatty acid synthesis and lipolysis (Blouin et al. 2005, Blouin et al. 2008), the 
shift towards increased visceral obesity, and therefore increased adipose tissue body 
content, seen w ith aging, may result from this age related testosterone decline in men. This, 
in turn, may increase inflammatory reactivity through adipose cytokine secretion and the 
promotion o f favourable conditions for the development of atherosclerosis, diabetes, and 
metabolic syndrome. TNFa is expressed by adipocytes and stromovascular cells within 
adipose tissue (Fain et al. 2004), although this may result in localised effects rather than 
systemic inflammatory actions as circulating levels are low and TNFa receptors are 
expressed by adipocytes (Ruan and Lodish 2003). Additionally, IL- 6  and IL- 6  receptors are 
expressed in adipocytes and adipose tissue matrix (Fain et al. 2004), with high levels 
detectable in the circulation allowing for a potential systemic inflammatory influence. In 
fact, plasma IL- 6  concentrations are considered to predict diabetes and CVD (Fernandez- 
Real e ta l. 2003).
In addition, atherogenic circulating lipids contribute to oxidative stress and endothelial 
dysfunction, promoting increased local cytokines, chemokines and adhesion molecules 
indicative of early inflammatory atherogenesis. By influencing lipid metabolism, 
testosterone may indirectly ameliorate vascular inflammation through local and systemic 
cytokine modulation. Furthermore, the antioxidant properties o f testosterone are thought 
to be due to its conversion to oestrogen by aromatase and its ability to increase the activity 
of antioxidant enzymes (such as SOD) in the vascular wall, although the exact mechanisms 
remain unknown (Massafra e ta l. 2000).
1.7.1.3.2 Effects of androgens on leukocytes
Anti-inflammatory mechanisms of androgens have been long recognised with the majority 
o f the evidence suggesting that the ir actions are mediated, at least in part, by a suppressive 
effect on pro-inflammatory cytokine activation and corresponding up-regulation o f anti­
inflammatory cytokines (Pugh et al. 2002).To a lesser extent and only more recently, 
androgenic effects on immune cell behaviour are becoming apparent w ith particular 
reference to the predominant plaque leukocytes, macrophages and T cells.
Corcoran and colleagues (2010) have recently shown that both physiological and 
supraphysiological concentrations of testosterone reduced the expression and secretion of
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TNFa and IL-ip in monocyte-derived macrophages obtained from a CHD age-relevant 
population. No effects were observed on IL- 6  and CRP expression. In addition, androgen 
deprivation increases T cell levels and enhances stimulatory proliferative response 
suggesting that testosterone may have a suppressive effect on T cell inflammatory response 
and therefore reduce the prom inent T h l cytokines relevant to plaque development (Roden 
et al. 2004). Moreover, isolated mouse CD4+ T cells increased anti-inflammatory IL-10 
production following treatm ent w ith DHT (Liva and Voskuhl. 2001). In contrast, through the 
study o f AR knockout mice (ARKO), Lai et al. (2009) demonstrated that signalling through 
the AR enhanced TNFa and CCR2 expression in isolated macrophages. This elevated 
inflammatory response, however, was related to cutaneous wound healing and may be a 
condition and tissue specific response.
The accumulation o f cholesterol in macrophages and the subsequent formation o f foam  
cells as a prominent early feature of fatty streak formation is influenced by androgens. A 
recent report by Qui and colleagues (2010) demonstrated that DHT significantly reduced 
high-cholesterol diet-induced foam cell formation in the proximal descending aorta of male 
New Zealand white rabbits. This was accompanied by a decreased expression of lectin-like 
oxLDL receptor-1 (LOX-1) in these cells. The same group also showed that in cultured 
macrophages the induction of foam cell formation by oxLDL was inhibited by DHT, an effect 
that was only observed in macrophages isolated from male w ild-type mice but not in male 
AR-null mice (Qui et al. 2010). Primary human monocyte-derived macrophages treated with 
testosterone displayed a dose-dependent upregulation of SR-BI (Langer at al. 2002). Due to 
the SR-BI role in association o f ApoA containing lipid molecules, primarily HDL, to the 
macrophage membrane and assists in the transfer of cholesterol to the lipoprotein 
molecule, upregulation of SR-BI consequently, increased cholesterol efflux (Langer at al. 
2002). Similarly, Orekhov et al. (2009) demonstrated that DHT inhibited cholesterol 
accumulation in both male and female primary cultured monocyte-derived macrophages 
and suggested the mechanism was via stimulation of cholesterol efflux rather than 
inhibition of LDL uptake, although SR-BI was not investigated.
In summary, it is clear that androgens modulate vessel wall function and that a loss of 
vasoreactivity may result in negative vascular changes and endothelial damage, precursory 
and contributory to the inflammatory development of atherosclerotic lesion formation. 
Specific actions of testosterone on inflammation as a key factor of athero-development are
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apparent yet complex and not completely understood. Further investigations are required 
to explian the nature and underlying mechanisms o f this influence on immunomodulation 
and its potential actions on atherogenesis.
1.1.8 Hypothesis and aims of this thesis
The overall aim of the study was to investigate the inflammatory response seen in early 
atherosclerosis to address the hypothesis that testosterone has beneficial effects on 
atherosclerosis through anti-inflammatory actions. In particular, determ ining the effect of 
testosterone on two key immunological mediators implicated in atherosclerosis, CCL2 and 
CX3CLI, and investigating the role of the androgen receptor in potential testosterone- 
mediated effects.
A combined in vitro and in vivo approach was taken w ith the following objectives:
•  To optimise a cell culture model of CX3CL1 and CCL2 pro-inflammatory vascular 
upregulation, and determ ine the effects o f testosterone on the modulation o f these 
inflammatory mediators.
•  To investigate the role of the AR in in vitro vascular cell inflammation
•  To determ ine the role of TRT on fatty streak formation in an animal model of low 
testosterone and diet-induced atherosclerosis.
•  To investigate the role of the AR in lipid streak development and 
atherosclerotic risk factors and inflammatory mediators
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CHAPTER 2
In vitro investigation of the role of 
testosterone on pro-inflammatory 
chemokine upregulation in aortic 
___________________ vascular cells
2.1 Introduction
The inflammatory process of leukocyte migration into the vascular wall of arteries in the 
development of atherosclerotic lesions directly involves endothelial and smooth muscle cells. 
These vascular cells are both the source and the target of many of the inflammatory mediators 
whose concerted activities orchestrate the pathology o f the disease.
2.1.1 Cytokine regulation of inflammatory mediators
The recruited cells in vascular inflammation at atherosclerotic sites are predominantly 
monocyte/macrophages and T cells, which initiate and co-ordinate early inflammatory events 
through the release of multiple cytokines. Two of the major cytokines secreted by activated T 
cells and macrophages are TNFa and IFNy, which have been repeatedly implicated in 
atherosclerosis (Hansson et al. 1989b, Barath et al. 1990, Rus et al 1991, Tipping and Hancock 
1993, Ridker et al. 2000a, 2005, Skoog et al. 2002). In addition, these cytokines have been 
shown to a lter endothelial permeability to favour leukocyte transmigration (Wojciak-Stothard 
et al. 1998). Therefore, TNFa and IFNy have pivotal roles in promoting the atherosclerotic 
process. Mice lacking TNFa have been shown to have reduced atherosclerosis (Branen et al. 
2004;), and mice deficient in IFNy or its receptor also demonstrate retarded atheroma 
formation (Gupta et al. 1997, Buono et al. 2003).
2.1.1.1 TNFa
The pro-inflammatory cytokine TNFa is secreted by activated and lipid-laden macrophages and 
exists in two forms; a transmembrane protein and a mature soluble protein (Packard et al. 
2009). Cleaved from the cell membrane by ADAM-17, TNFa signals through e ither of its two  
receptors (TNFR1, TNFR2) to mediate numerous inflammatory processes depending on the cell
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type and stimuli. TNF binding to its receptor (TNFR) recruits associated proteins; TNF Receptor 
Associated Death Domain (TRADD), TNF Receptor Associated Factors (TRAFs), and Receptor 
Interacting Protein (RIP1), to converge at the cytoplasmic tail of TNFR and form an activated 
complex which represents the molecular link between several possible signalling pathways 
(Hauer et al. 2005). Once TRAFs are activated, they in turn interact w ith specific members of 
other second messenger signal pathways, of particular interest, the m itogen-activated protein 
kinase kinase kinase (MAPKKK or MAP3K) group. Specific MAPKKKs have the ability to activate 
inhibitory-KB kinase complexes (IKKs) which in turn phosphorylate inhibitory-kappa-B (IkB) 
proteins targeting them for proteolytic degradation. The degradation of IkB proteins, which 
hold NFkB inactive in the cytoplasm, exposes nuclear localisation signals and allows NFkB 
activation and translocation to the nucleus, where it is known to upregulate many 
proinflammatory molecules (Ghosh and Baltimore 1990, Van der Heiden et ol. 2010)(Figure 
2 .1).
2.1.12 IFNy
IFN-y is a type-ll class of interferon involved in inflammatory processes and is considered to 
have a key role in the progression of atherosclerosis. Secreted by T-cells and NK cells following 
synergistic activation by IL-12 and IL-18, IFNy becomes biologically active as a homodimer and 
acts upon cells of the immune system and vasculature that express the IFNy receptor (IFN-yR) 
(Umehara et al. 2004). The binding of IFNy to IFN-yR l and IFN-yR2 subunits results in receptor 
clustering at the cell membrane to form an active intracellular receptor complex. IFN-yR l is 
constitutively associated with Janus Kinase-1 (JAK1) and IFN-yR2 with JAK2. On ligand-induced 
dimerisation, JAK2 rapidly phosphorylates itself and the corresponding JAK1 on intracellular 
regions of IFN-yR l, which further activates both kinases (Kohlhuber et al. 1997). JAK1 
phosphorylates the specific tyrosine residue 440 on IFN-yR l to reveal a docking site for the 
subsequent kinase in this signalling pathway, signal transducer and activator o f transcription - 1  
(STAT1) (Mahboubi and Pober 2002). Inactive cytoplasmic STAT1 is recruited to IFN-yRl upon 
activation o f the receptor kinase complex and binds temporarily to its docking site where it is 
phosphorylated by JAK2 on tyrosine residues. Adjacent phosphorylated STAT1 molecules 
homo- or hetero-dimerise to become active and disassociate from the receptor complex. 
Translocation to the nucleus follows, where STAT1 binds to specific y-activated sequence (GAS) 
elements to induce gene transcription (See Kotenko and Pestka 2000 for review)(Figure 2.2). 
Several IFNy-inducible chemokines have been observed in human atherosclerotic coronary 
arteries (Ranjbaran et al. 2007) and IFNy stimulation of vascular cells has been shown to 
enhance adhesion molecule expression (Couffinhal e ta l. 1994, Kota et al. 2005).
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Figure 2.1; Schematic representation o f NFkB signalling. 1) Specific MAPKKKs have 
the  ab ility  to  in teract and stim ulate  inh ib itory-kappa-B kinase complexes (IKKs) 
leading to  th e ir assembly as an activating complex. Made up o f tw o  catalytic 
subunits, IKKoc and IKKp, and a structura l com ponent, NEMO/IKKy/IKKAP, IKKs exist 
in the cytoplasm. NFkB is held inactive in the cytoplasm by inh ib itory-kappa-B  (IkB). 
2) Activated IKKs phosphorylate IkB on tw o  conserved serine residues in the  N- 
te rm ina l domain. 3) This leads to  the po lyub iqu itina tion  o f IkB pro te ins by a 
ub iqu itin  ligase E3 complex, subsequently targeting  them  fo r degradation by the 
26S proteasome (4). 5) Degradation o f the  IkB pro te in  exposes NFkB nuclear 
localization signal on the NFkB molecule thus a llow ing its transloca tion  to  the  
nucleus and subsequent association w ith  kB binding sites in the  p rom o te r regions o f 
specific genes.
k B  b in d in g  s ite s
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Figure 2.2; Schematic representation ofJAK/STATsignalling. The binding o f IFN-y to  IFN- 
y R l and IFN-yR2 subunits results in receptor clustering at the cell m em brane to  fo rm  an 
active in trace llu la r receptor complex. IFN-yRl is constitu tive ly  associated w ith  Janus 
Kinase-1 (JAK1) and IFN-yR2 w ith  JAK2. On ligand-induced d im erisation, JAK2 rap id ly 
phosphorylates itse lf and the  corresponding JAK1 on in trace llu la r regions o f IFN-yR l 
which fu rth e r activates both kinases. JAK1 fu rth e r phosphorylates the  specific tyros ine  
residue 440 on IFN-yRl to  reveal a docking site fo r the subsequent kinase in th is  signalling 
pathway, signal transducer and activa tor o f transcrip tion -1  (STAT1). Inactive cytoplasm ic 
STAT1 is recruited to  IFN-yRl upon activation o f the  receptor kinase com plex and binds 
tem pora rily  to  its docking site where it is phosphorylated by JAK2 on tyros ine  residues. 
Adjacent phosphorylated STAT molecules hom o- o r hetero-d im erise to  become active 
and disassociate from  the receptor complex. Translocation to  the nucleus fo llow s w here 
STAT moleculess bind to  specific y-activated sequence (GAS) e lem ents to  induce gene 
transcrip tion  (See Kotenko e t al. 2000 fo r review).
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IL-18
IL-18 is a pleiotropic proinflammatory cytokine whose role in atherogenesis is only recently 
starting to be uncovered. M l patients have notably higher levels of IL-18 than patients with 
stable angina or healthy controls (Seta et al. 2000, Mallat et al.2001a, Mallat et al. 2002, Narins 
et al. 2004), and IL-18 has been shown to be elevated in heart failure patients (Naito et al. 
2002), suggesting a role in plaque instability. IL-18 was demonstrated as an independent risk 
factor for cardiovascular death in a cohort of CAD patients (Blankenberg et al. 2002).
Produced as a biologically inactive precursor protein (Pro-IL-18) primarily by activated 
monocyte/macrophage cells, IL-18 is cleaved from its 24kD precursor to an 18kD active 
molecule by caspase-1 (Ma llat et al. 2001a). Also known as Interferon-gamma inducing factor 
(IGIF), IL-18 induces the production o f IFNy in T cells. NK cells, subsets o f macrophages, and 
more recently VSMC and endothelial cells have been identified as possessing the 
heterodimeric IL-18 receptor (IL-18R) complex and express IFNy when stimulated with 
recombinant IL-18 in vitro (Sahar et al. 2005). IL-18 augments the production of various other 
mediators involved in atherosclerosis in cells expressing its receptor. IL-ip, IL-8 , IL-6 , CCL2, 
TNFa and several adhesion molecules are induced directly by IL-18 (Puren et al. 1998, Vidal- 
Vanaclocha et al. 2000, Gerdes et al. 2002). Additionally, IL-18 has been directly linked to 
vascular remodelling through its possible activation o f tyrosine kinase pathways and 
transcription factors implicated in SMC proliferation and migration (Sahar et al. 2005). 
Therefore, IL-18 is a relatively new mediator in the atherosclerosis story, with potential 
inflammatory actions in atherogenesis which warrant further investigation.
Upon IL-18 binding to IL-18Ra, IL-18R(3 is recruited to form a high-affinity complex at the cell 
membrane which induces second messenger signalling pathways similar to those of other 
cytokines (Gracie et al. 2003). Initially, IL-lR-associated kinase (IRAK) is recruited to the 
complex and is subsequently activated and autophosphorylated leading to its dissociation from  
the receptor (Wesche et al. 1997, Adachi et al. 1998, Kanakaraj et al. 1999). IRAK can then 
interact w ith TRAF6  and once activated, as with TNFa signalling, can in turn interact w ith 
specific members o f other second messenger signalling pathways ultimately leading to IkB 
degradation and NFkB activation (See Gracie e ta l. 2003).
2.1.2 Chemokines
Activated vascular cells express a number of chemokines that influence the recru itment of 
leukocytes to the vessel wall. However, several lines of evidence support the notion that CCL2-
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CCR2 and CX3CL1-CX3CR1 are the primary chemokine-receptor pairs that drive atherosclerotic 
lesion formation (See section 1.6).
2.1.2.1 CX3CLI
The expression of fractalkine has been repeatedly shown in vascular endothelial cells in vitro, 
and can be amplified upon stimulation with inflammatory cytokines; TNFa (Ahn et al. 2004), 
IFNy (Bazan et ol. 1997, Imaizumi et al. 2000), IL-1, IL- 6  (Bazan et al. 1997, Garcia et al. 2000) 
and oxLDL (Barlic et al. 2007). Endothelial cells express little CX3CL1 mRNA constitutively but a 
marked increase is observed following activation with inflammatory stimuli, TNFa or IL-ip  
(Bazan et al. 1997). Anti-inflammatory cytokines IL-4 and IL-13 inhibit induction of CX3 CL1 by 
TNFa and IFNy, lending support to the role of CX3 CL1 in inflammatory processes (Fraticelli et 
al. 2001). In addition to endothelial expression of CX3CL1, VSMC synthesise and release CX3CL1 
in response to pro-inflammatory cytokines (Ollivier et al. 2003). Aortic SMC grown in culture 
synthesise and express CX3CL1 in response to proinflammatory cytokines, leading to increased 
adhesion and chemoattraction o f CX3CR1+ leukocytes (Ollivier et al. 2003, Lesnik et al. 2003). 
Patel et al. (2008) also demonstrated a TNFa-induced upregulation of CX3CL1 expression in 
human saphenous vein endothelial and SMC in relation to AAA.
The intracellular signal transduction preceding the upregulation of CX3CL1 is a lot less clear, but 
is considered to be mainly via NFkB signalling pathways (Ahn et al. 2004). Garcia et al. (2000) 
demonstrated a central role for NFkB pathways in the activation of endothelial cells by 
inflammatory molecules or vascular injury. The human CX3CL1 gene is located on chromosome 
16 and there are binding sites for both NFkB and STAT in the promoter region o f the gene 
(Nom iyama et al. 1998). Therefore, inflammatory molecules known to activate NFkB, such as 
TNFa, and STAT, such as IFNy, may therefore lead to increased expression of chemokines such 
as CX3CL1.
2.1.2.2 CCL2
Rollins et al (1990) demonstrated that human vascular endothelial cells express little CCL2 
under normal culture conditions, and that expression is markedly induced by pro-inflammatory 
cytokines IL-lp and TNFa, and to a lesser extent by IFNy. Another study reported that TNFa 
induced CCL2 expression in human pulmonary artery endothelial cells (HPAEC) and that this 
expression was essential for firm adhesion of monocytes under conditions of physiological flow  
(Maus et al. 2002). This was in agreement w ith an earlier study (Kukreti et al. 1997), in which 
the mechanisms o f firm adhesion were considered to be mediated via CCL2 activation o f 
integrins on monocytes. In HUVEC, CCL2 has been demonstrated to be up-regulated by TNFa,
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IL-lp, (Strieter et al. 1989a, Sica et al. 1990, Cybulsky et al. 1991). Taubman et al. (1992) and 
Lim et al (2009) have also described the upregulation o f CCL2 mRNA and secreted protein in IL- 
lp -  and platelet derived growth factor (PDGF)-stimulated HASMC respectively.
The underlying signalling pathways leading to CCL2 gene transcription are complex and not 
fully understood. However, it appears that two NFkB binding sites, located near the 
transcription initiation site, are critical elements in CCL2 induction, in response to 
proinflammatory cytokines such as IL-ip and TNFa (Ueda et al. 1994; Ping et al. 1996; Ueda et 
al. 1997). Furthermore, Chen et al. (2004) indicated that TNFa-stimulated CCL2 production is 
dually regulated by activator protein-1 (AP-1) and NFkB pathways in rat VSMC. A lternate 
pathways are also implicated, that do not require NFkB activation (Lim et al. 2009). Valente et 
al. (1998) identified GAS elements at the promoter site of CCL2 that resemble the binding site 
for STAT transcription factors, and demonstrated that STAT1 was primarily involved in IFNy up­
regulation of CCL2. The authors also noted that this gene induction was influenced by other 
complex regulatory factors, adding a multifaceted level of control to CCL2 transcription.
2.1.3 Testosterone as an anti-inflammatory agent
Testosterone is considered to be immunosuppressive and there are several in vitro studies to 
support this. Testosterone inhibits the production o f proinflammatory cytokines such as IL-6 , 
IL-lp and TNFa in a range of human, mouse and rat monocytes (Li et al. 1993, Kanda et al. 
1996, D'Agostino et al. 1999), fibroblasts (Gornstein et al. 1999) and osteoblasts (Hofbauer et 
al. 1999). In addition, testosterone can stimulate the production o f anti-inflammatory 
cytokines such as IL-10 in lymphocytes (Liva and Voskuhl 2001), and murine macrophages 
(D'Agostino et al. 1999). Also, activation o f the AR influences the expression o f chemokine 
receptors CXCR4 and CCR1, and subsequent chemokine responses, in prostate cancer cells 
(Akashi et al. 2006). Conversely, testosterone has also been seen to increase TNFa expression 
in a monocytic cell line (Zhu et al. 2009).
Testosterone is thought to modulate SMC through the upregulation of proliferation-associated 
genes and through possible inhibition of pro-inflammatory cytokines, decreasing apoptosis and 
promoting proliferation (Williams et al. 2002, Nakamura et al. 2006). Proliferation o f SMC has 
been suggested to be a result of conversion of testosterone to DHT (Fujimoto et al. 1994). 
While this proliferation adds to the vascular remodelling associated with atherosclerosis, 
potential athero-protective effects are plausible, since SMC impart strength to the vascular 
wall and promote fibrous cap formation, reducing the likelihood of thrombotic episodes. 
However, testosterone enhances human vascular endothelial cell apoptosis when
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administrated at physiological levels in culture (Ling et al. 2002), whereas oestrogen inhibits 
TNFa- and oxLDL-induced apoptosis (Florian et al. 2007).
This data, along with the previously discussed anti-inflammatory effects o f TRT in clinical 
studies (see section 1.7.1.3), supports the proposed role of testosterone in the modulation of 
inflammatory mediators, although the underlying mechanisms remain relatively unknown. Sex 
steroid hormones have specifically been shown to demonstrate the ability to modulate the 
expression of adhesion molecules (Table 2.1), and to a lesser extent chemokines (Table 2.2), on 
vascular cells allowing a direct involvement in early atherogenesis. The results from such 
studies are, however, inconsistent.
2.1.3.1 Effects of testosterone on adhesion molecules
TNFa induced VCAM-1 expression in HAEC was inhibited by testosterone treatm ent suggesting 
that the male androgen plays an important role in the prevention o f atherogenesis 
(Hatakeyama et al. 2002). This study additionally described an inhibition of NFkB activation, 
not only as a potential mechanism for decreased VCAM-1 expression, but also as a prospective 
modulator of several other inflammatory gene targets known to be activated by NFkB. The 
promoter regions of the genes encoding ICAM-1, VCAM-1 and E-selectin all contain at least 
one kB site required for cytokine gene activation (Neish et al. 1992, Kaszubska et al. 1993, Hou 
et al. 1994, Read et al. 1994). It is suggested that the influence of androgens on NFkB may be 
via inhibition of NFkB nuclear translocation, as a result of decreased IKK and consequent IkB 
activity, rather than a direct action on NFkB (Death et al. 2004). Norata et al. (2006) furthered  
this notion by elegantly demonstrating a decreased inflammatory response to TNFa and LPS in 
human endothelial cells when treated with DHT. This included a reduction in adhesion 
molecule VCAM-1 and ICAM-1 expression and cytokines IL-6 , CCL2, and TNFa release, amongst 
other inflammatory markers. Again, the mode of action was proposed to be via inhibition of 
NFkB activity. Although this study was performed in HUVEC, and therefore may not be 
reflective of the behaviour o f other endothelial cell types, the inhibition of VCAM-1 expression 
supports the findings of the previous investigation using HAEC (Hatakeyama et al. 2002). In 
addition to testosterone's interaction with NFkB, preliminary data has proposed that DHT and 
IFNy can modulate each other's signalling via an interaction at the transcriptional level, 
suggesting that androgens may down-regulate IFN-induced genes (Bettoun et al. 2005).
Contradictory to the proposed athero-protective role of testosterone, several studies have 
demonstrated that cytokine-stimulated upregulation of adhesion molecules is increased in
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Table 2.1; Summary o f in vitro studies investigating hormone modulation o f vascular cell 
adhesion molecule expression under pro-inflam m atory conditions. Expression was e ithe r 
up-regulated ( 'V ), dow n-regula ted (v|/), o r no t a ltered (<->) as a resu lt o f horm one 
trea tm en t. BAEC, bovine aortic  endothe lia l cells; HAEC, human aortic  endothe lia l cells; 
HUVEC, human um bilical vein endothe lia l cells; HSVEC, human saphenous vein endothe lia l 
cells; RASMC, rat aortic sm ooth muscle cells; AR, androgen receptor; ER, Oestrogen 
receptor; LPS, lipopolysaccharide; Nl, not investigated.
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Table2.2; Summary o f in vitro studies investigating hormone modulation o f vascular cell 
chemokine expression under pro-inflam m atory conditions. Expression was e ith e r up- 
regulated (1s), dow n- regulated (1/), o r not a ltered (<-») as a result o f horm one trea tm en t. 
BAEC, bovine aortic endothe lia l cells; HAEC, human aortic  endothe lia l cells; HUVEC, human 
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aortic sm ooth muscle cells; AR, androgen receptor; ER, Oestrogen receptor; LPS, 
lipopolysaccharide; Nl, not investigated.
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cultured endothelial cells upon treatm ent w ith androgens (McCrohon et al. 1999, Zhang et al. 
2002; Death et al. 2004). Through direct AR antagonism, Zhang et al. (2002) completely 
abrogated the androgen enhancement of TNFa-induced E-selectin and VCAM-1 up-regulation, 
indicating that testosterone functions through the AR to modulate adhesion molecule 
expression. In support of this, McCrohon et al. (1999) reported that DHT increased the 
expression of VCAM-1 in HUVEC without cytokine influence, and that this effect was 
antagonised by blockade of AR. Zhang et al. (2002), however, observed no effect of 
testosterone. This may be due to the higher affinity binding of DHT to the AR. There is no 
direct evidence for existence of androgen response elements on VCAM-1 gene promoter 
regions, and the enhanced expression observed was not believed to be due to an up­
regulation of cytokine receptors, suggesting other signalling pathways that may direct these 
pro-atherogenic actions of androgens. Death and colleagues (2004) support the role of the AR 
in the enhancement of pro-inflammatory cytokine-stimulated expression o f adhesion 
molecules. Treatment of HUVEC w ith DHT and IL-lp, significantly increased VCAM-1 
expression, and this was blocked by AR antagonism with hydroxyflutamide. The authors 
further demonstrated that DHT increased VCAM-1 promoter activity via NFkB activation, 
although not via direct interactions between AR and NFkB. Instead, DHT was demonstrated to 
decrease the level of IkB protein through heightened degradation, thus activating NFkB and 
subsequent VCAM-1 expression. In addition, 27 genes related to atherosclerotic functions, 
including adhesion and inflammation, have been found to be up-regulated in monocytes 
isolated from males treated with DHT (Ng et al. 2003). The same genes were not altered in 
female donors following the same treatm ent, indicating that androgen actions may be gender 
specific.
The attenuating effects of testosterone on adhesion molecule up-regulation in cultured 
vascular endothelial cells have been proposed to be due to conversion o f testosterone to 
estradiol and to act via the ER rather than the AR (Mukherjee et al. 2002). Mukherjee et al. 
(2002) showed that testosterone could attenuate TNFa-induced VCAM-1 upregulation in 
HUVEC, an action that was abolished by both ER antagonism and aromatase inhibition. This 
study utilised HUVEC of female origin and may not be directly comparable to investigations 
with male endothelial cells. In parallel, another study has reported that 17p-estradiol can 
inhibit IL-l-induced ICAM-1, VCAM-1 and E-selectin expression in HUVEC isolated from a 
female foetus (Caulin-GIaser et al. 1996;). Xing e ta l. (2007) reported that 17p-estradiol inhibits 
mRNA expression of ICAM-1, VCAM-1, P-selectin and CCL2 in rat aortic SMC, and further 
described that this effect was attenuated by ERp blockade. Additionally, Nakagami et al. (2010) 
have recently demonstrated that 17P-estradiol inhibits lipoprotein-a (Lp-a; an atherogenic
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lipoprotein) induced expression o f VCAM-1, ICAM-1, and E-selectin in bovine aortic endothelial 
cells; and IL-ip, TNFa and CCL2 in macrophages differentiated from THP-1 cells. Simoncini et 
al. (2000) also showed that 17P-estradiol inhibited expression of VCAM-1 when induced by 
LPS, IL - la  or TNFa. The authors considered this effect to be due to 17p-estradiol influence on 
NFkB. Furthermore, ER has also been shown to inhibit NFkB activity in several cell lines (see 
Kalaitzidis and Gilmore 2005). The ER is considered to directly bind subunits of NFkB in vitro 
and inhibit transcriptional activity, possibly by preventing DNA binding or by inhibiting 
essential coactivator protein association (Stein and Yang 1995). However ER-NFkB complexes 
have not been reported. 17P-estradiol has been suggested to influence NFkB activities 
indirectly through the stabilisation of IkB, via inhibition of IKK (Simoncini et al. 2000).
Contradictory to these reports, Aziz et al. (1996) demonstrated that 17p-estradiol enhanced 
the expression o f E-selectin after TNFa stimulation, and supported similar findings from a 
previous study where VCAM-1 and ICAM-1 were additionally upregulated, promoting 
leukocyte adherence (Cid et al. 1994;). Both these investigations reported a lack of oestrogen 
modulation on adhesion molecule expression following IL-lp stimulation, whereas Zhang et al. 
(2002) reported that estradiol enhanced TNFa-induced mRNA and surface expression of E- 
selectin and VCAM-1. The effect was completely abrogated by pre-incubating the cells with the 
oestrogen antagonist tamoxifen.
Therefore, it is apparent that sex hormones are capable of inducing both pro- and anti­
inflammatory effects. The mechanisms underlying these effects remain to be clarified, but may 
be via the co-regulation of inflammatory genes by either direct androgen or oestrogen 
response e lement activation or by "cross-talking" to other signalling molecules. The outcome 
of such signalling may rely on multiple other concurrent pathways dependent upon present 
cellular status and may be influenced by cell phenotype. This level o f complexity in regulation 
may account for conflicting reports in the data, and demonstrate that further research in this 
area is required (see Kalaitzidis and Gilmore 2005).
2.13.2 Effects of testosterone on chemokines
Testosterone has been shown to increase CCL2 expression in a monocyte cell line and this was 
thought to be a result o f NFkB activation (Zhu et al. 2009). Yamada et al. (1996) found no 
effect of testosterone on monocyte migration in vitro. Norata et al. (2006) demonstrated that 
DHT could inhibit a LPS-induced upregulation o f CCL2 in HUVEC, an effect that was abolished 
by AR antagonism. The authors additionally reported that the upregulatory effects o f TNFa on 
CCL2 expression were partially, but significantly, inhibited by DHT treatm ent, an effect that
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was not significantly altered by AR blockade. This may suggest that the observed anti­
inflammatory effects of DHT occur via AR and non-AR mediated pathways, depending on the 
inflammatory stimuli. Moreover, Norata et al. (2010) recently extended this theory by 
demonstrating that DHT can reduce TNFa-induced CCL2 expression in HUVEC via conversion to 
5a-androstane-3P,17p-diol (3p-adiol) and subsequent activation o f ER. While DHT is non- 
aromatisable, 3J3-adiol is a product of DHT metabolism by 3-hydroxysteroid dehydrogenase 
enzymes, present in endothelial cells, and is a molecule unable to bind to the AR, but has high 
affinity for ER (Weilhua et al. 2002, Guerini et al. 2005). This supports the idea that androgenic 
anti-inflammatory actions are mediated via ER activation. Indeed, 17(3-estradiol inhibits CCL2 
expression in VSMC (Jiang et al. 2010) and fibroblasts (Kovacs et al. 1996), and inhibits 
monocyte migration towards CCL2 (Yamada et al. 1996). Xing et al. (2007) have shown a direct 
inhibitory effect of 17(3-estradiol on TNFa-induced expression of CCL2 in rat aortic SMC. 
Through subsequent receptor antagonism, the authors demonstrate that the mechanisms 
controlling this chemokine suppression are directed through ER(3. In addition, this study also 
described the down-regulation of cytokine-induced neutrophil chemoattractant (CINC)-2P, a 
member of the CXC chemokine family. In rats, this chemokine is considered to act in a similar 
manner to human IL- 8  in the potent chemoattraction of neutrophils. Moreover, blocking CINC- 
2 activity reduced the chemotactic activity of differentiated myeloid leukaemia HL-60 cells to 
the same extent as 17(3-estradiol, but did not completely ablate the activity, partially inhibiting 
the migration of neutrophils (Xing et al. 2007). Data from this study, therefore, implicates a 
role for oestrogens, and potentially testosterone via aromatisation to 17P-estradiol, in the 
recruitment of inflammatory immune cells to the vascular wall. In contrast, however, Norata et 
al (2010) found no effect of 17P-estradiol on TNFa-induced CCL2 expression.
2.13.3 Molecular mechanisms underlying the anti­
inflammatory actions of testosterone
NFkB and AR both act at the transcriptional level and have been experimentally found to be 
antagonistic to one another (McKay and Cidlowski 1999), limiting gene expression to relative 
nuclear presence of either factor. Keller et al. (1996) showed that DHT repressed activation of 
the IL- 6  promotor via the AR partly by elevating IkB and consequently inhibiting NFkB 
translocation. As the AR and NFkB are mutual antagonists the ir interaction and influence on 
function can be bidirectional, with inflammatory agents that activate NFkB interfering with 
normal androgen signalling as well as AR interrupting NFkB inflammatory transcription. If this 
is the case, prolonged exposure of vascular cells to the inflammatory activation o f NFkB 
associated with atherosclerosis may reduce or alter the protective effects o f testosterone. In
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addition, physical interactions of NFkB subunits and promoter regions of the AR gene have 
been observed (Supakar et al. 1995), suggesting a possible feedback loop whereby 
inflammatory activities in cells promote increased androgen sensitivity through increased 
receptor synthesis, and thereby possible anti-inflammatory regulatory consequences. The in 
vivo significance of these interactions, however, remains to be established.
2.1.4 Summary
Androgens are capable of modulating the inflammatory response associated with 
atherosclerosis through specific affects on chemokines and adhesion molecules, and this is 
demonstrable in cell culture models. The extent of this modulation and the supposed pro- or 
anti-inflammatory actions present differently in different cell types, at different 
concentrations, for different treatm ent periods, when used in combination with different 
inflammatory stimulants and dependent upon the target investigated. Also, it is not clear 
whether testosterone functions through the AR (either directly or following conversion to 
DHT), or through the ER (following aromatization to estradiol or conversion to 3p-adiol), or via 
non-classical receptor-mediated mechanisms. This highlights the complexity of interactions 
between sex hormones and inflammation. Though the mode of action may be via multiple 
divergent signalling pathways that are not yet completely understood, the role of NFkB and 
STAT may be important, as these transcription factors are activated by pro-atherogenic 
cytokines, such as TNFa and IFNy, and show potential interaction with AR and ER. 
Experimental observations regarding the role of testosterone in adhesion molecule and 
chemokine expression suggest that testosterone may influence the recru itment of 
inflammatory cells to the vascular wall in atherosclerosis. The conflicting data from these 
studies, however, highlights the requirement for further investigations to elucidate the precise 
underlying cellular mechanisms. W hether testosterone has a modulatory effect on chemokine 
expression, and in particular the central chemokines CX3CL1 and CCL2, in human aortic 
vascular cells has not previously been investigated.
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2.1.5 Hypothesis and aims of the in vitro study
The aim of the in vitro study was to use a primary vascular cell culture model to address the 
hypothesis that testosterone down-regulates the proinflammatory upregulation of the key 
chemokines CX3CL1 and CCL2 in aortic vascular cells.
Aims
1. To characterise and establish a cell culture model o f CX3CL1 and CCL2 pro- 
inflammatory vascular upregulation in primary human aortic endothelial and smooth 
muscle cells.
2. To identify the effect of pro-inflammatory cytokine treatm ent on the expression and 
shedding o f the novel chemokine CX3CL1 in HASMC and HAEC, and to investigate the 
underlying control mechanisms of CX3CL1 shedding.
3. To identify the effect of pro-inflammatory cytokine treatm ent on the expression of 
CCL2 in HASMC and HAEC.
4. To investigate the effects of androgen treatm ent on the expression of CX3CL1 and CCL2 
in HASMC and HAEC under normal and pro-inflammatory conditions, and investigate 
the role of the androgen receptor in potential testosterone-mediated effects.
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2.2 Methods
2.2.1 Cell culture
All cell culture procedures were carried out under sterile conditions in a laminar flow hood 
using sterile equipment.
2.2.1.1 Human aortic vascular cells
Human aortic smooth muscle cells (HASMC) and human aortic endothelial cells (HAEC) were 
obtained from Cascade Biologies™, UK. Cells were in the tertiary stage of culture after 
isolation from a 16 year old and a 15 year old male donor respectively. These adherent primary 
cell cultures were grown at 37°C in a 5% C0 2/95%  air atmosphere in low serum medium in cell 
culture flasks (Fisher Scientific, UK). HAECs were cultured in Medium-200 (Cascade Biologies, 
UK), a basal culture medium, supplemented with low serum growth supplement (LSGS; 
containing 2% v/v  foetal bovine serum (FBS); hydrocortisone lpg /m l; human epidermal growth 
factor lOng/ml; basic fibroblast growth factor 3ng/m l; and heparin 10pg/ml; Cascade Biologies, 
UK). HASMCs were cultured in Medium-231 (Cascade Biologies, UK) supplemented with 
smooth muscle growth supplement (SMGS; containing 5% v/v FBS; recombinant human basic 
fibroblast growth factor 3ng/m l, recombinant human epidermal growth factor lOng/m l, and 
insulin 5pg/m l). Media were changed approximately every 48 hours and all vascular cell 
culture experiments were performed using cells up to a maximum passage number of 1 0  to 
avoid dedifferentiation.
2.2.1.2 THP-1 cells
THP-l cells are a human monocytic leukaemia cell line derived from the peripheral blood of a 1 
year old male w ith acute monocytic leukaemia. THP-1 cells are w idely used as an appropriate 
model o f human blood monocytes, as they express many distinct monocytic markers and 
characteristics, which are maintained over time in culture (Tsuchiya et al. 1980). These cells 
were used in the study as a positive control for specific gene and protein targets.
THP-1 cells, originally obtained from the European collection of cell cultures (ECACC, UK), were 
cultured in RPMI 1640 (GIBCO*) media with 2m M glutamine, 10% foetal calf serum (FCS) and 
2m M penicillin/streptomycin (GIBCO*). Media were changed approximately every 48 hours. 
The passage number of this cell line was unknown.
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2.2.13 DuCaP cells
DuCaP (dura m ater cancer of the prostate) cells are an adherent prostate cancer cell line, 
established from a dura m ater metastasis xenograft in severe combined immunodeficient mice 
(SCID) originating from a patient w ith castration resistant prostate cancer (Lee et al. 2001). 
DuCaPs express elevated levels of the wild type AR gene and are often deemed appropriate for 
testing agents targeting AR or androgen metabolism (Pfeiffer et al. 2010).
The DuCaP cell line was a kind donation from Dr. Ken Pienta (University o f Michigan, Ml, USA). 
These cells were included in the study to test the delivery of androgens to cells in culture. 
DuCaP cells were cultured in RPMI 1640 (GIBCO*) media with 2mM glutamine, 5% FCS and 
2m M penicillin/streptomycin (GIBCO*). Media were changed approximately every 48 hours. 
The passage number of this cell line was unknown. Prior to experimental investigation, cells 
were transferred to charcoal-stripped media fo ra  period of 48 hours.
2.2.1.3.1 Preparation of charcoal-stripped media
Treatment of FCS w ith charcoal stripping removes any unknown lipid-related elements in the 
sera, such as hormones, without affecting the amino acid, glucose and salt content. In brief, 
FCS was incubated with dextran-coated charcoal (Sigma-Aldich, UK) for 30 min in a w ater bath 
at 55°C w ith periodical shaking. A fter centrifugation (20,000 x g for 20 min) the supernatant 
was treated with sulphatase (Sigma-Aldrich, UK) (2 U/m l of serum) for 2 hours at 37°C in a 
water bath. Incubation with dextran-coated charcoal and centrifugation was repeated, and the 
resulting supernatant was filtered through a 0.2pm filter (Fisher, UK) and added to RPMI media 
in place of untreated FCS.
2.2.2 Subculture of cells
At 70-90% confluence medium was removed from the culture flasks and cells were washed 
twice w ith phosphate buffered saline (PBS (GIBCO*)). lm l/25cm 2 of trypsin/EDTA solution 
(0.5% trypsin and 0.53nM EDTA (GIBCO*, UK) was applied to the cells (HAEC, HASMC and 
DuCaPs) and incubated at room temperature for 3 minutes. The flask was tapped gently to 
dislodge cells from the surface and an equal amount o f complete (serum-containing) medium  
added to neutralise the trypsin/EDTA. The cell suspension was removed to sterile tubes and 
centrifuged for 5 minutes at 200 x g. A fter removing the supernatant the cells were  
resuspended in 1 ml of fresh medium, 2 0 pl o f this cell suspension was added to 2 0 pl of trypan 
blue solution (0.4% trypan blue prepared in 0.81% sodium chloride and 0.06% potassium 
phosphate (Sigma-Aldrich, UK)) and incubated for 5 minutes. Using a haemocytometer, cell
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viability was determ ined by counting cells that excluded the blue stain (i.e. dead, non-viable 
cells stain blue). By calculating the ratio of blue to normal cells, the percentage viability was 
obtained. Viable cells were then further diluted to working densities and used in the 
experimental procedures, subcultured or cryopreserved. For THP-1 cell subculture, the same 
procedure was followed with the omission of the trypsinisation step.
2.2.3 Cryopreservation of cells
Cells were removed from the culture flasks as in section 2.2.2, and resuspended in 1ml o f FCS 
(GIBCO*, UK). Using a haemocytometer, cells were counted, then further diluted within the 
range of 2 x l0 6-1 0 x l0 6 cells/ml with freezing medium (final concentration of 10% DMSO 
(Sigma-Aldrich, UK), 90% FBS). 1ml of cell suspension was aliquoted per cryovial (NALGENE*, 
UK) and stored at -80°C in a Cryo 1°C freezing container (NALGENE*, UK) for 4 hours or 
overnight in order to gradually lower the temperature by l°C /m inute for maximal cell 
preservation. Frozen cell suspensions were then transferred to liquid nitrogen storage.
2.2.3.1 Initiation of cryopreserved cells
A cryovial o f cells was removed from liquid nitrogen storage and thawed at 37°C for 
approximately 5 minutes or until contents thawed. The vial was wiped with 70% ethanol and 
the cell suspension was pipetted up and down to disperse the cells. Cells were then 
transferred to an appropriate number of culture flasks in order to obtain an optimal seeding 
density o f approximately 1 .25xl04, estimated from previous freezing densities assuming near 
maximal preservation, in a volume of medium equivalent to lm l/5c m 2. Following inoculation, 
the flasks were swirled to distribute the cells evenly and then cultured for a m inimum of 24 
hours before media change or subculture.
2.2.4 Testing for the presence of mycoplasma in cell cultures
Mycoplasma is a genus of bacteria that is commonly recognised as a contaminant of 
mammalian cell cultures. Due to the ir extremely small size the contam ination is not readily 
apparent and infection may not kill or stop cells from dividing, but the ir effects can be w ide 
ranging and can potentially invalidate experimental procedures. Mycoplasmal infection can 
extensively influence cell growth, morphology, metabolism and the functional activity o f the 
cell, ultimately decreasing viability (Hay et al. 1989, Rottem and Yogev 2000). The importance 
of routine testing for mycoplasma in cell culture procedures is therefore paramount for 
experimental validity.
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The EZ-PCR mycoplasma test kit (Geneflow, UK) was used in the present study. This kit uses 
PCR to specifically amplify a conserved, mycoplasma-specific ribosomal RNA gene region using 
optimised primers. The primer set allows for sensitive and specific detection of various 
mycoplasma species in cell culture supernatants. PCR-amplified DNA fragments are verified by 
electrophoresis to confirm the presence or absence of mycoplasmal infection.
M ethod
lm l o f cell culture supernatant was transferred to a 1.5ml Eppendorf tube and centrifuged at 
250 x g for 5 minutes to pellet the cellular debris. The supernatant was then transferred to a 
sterile tube and further centrifuged at 20,000 x g for 10 minutes to pellet any mycoplasma. The 
supernatant was carefully aspirated and the pellet was resuspended in 50pl of buffer solution 
(Geneflow, UK) and mixed thoroughly by pipetting. The sample was heated to 95°C for 3 
minutes on a heating block and then allowed to cool. 5pl of the sample was added to a PCR 
tube and mixed with 35pl of nuclease-free water (Sigma-Aldrich, UK) and 10pl of reaction mix 
(Geneflow, UK). A positive control test reaction was also prepared by adding lp l of positive 
temp late control to 39pl of nuclease-free water and 10pl of reaction mix. Tubes were placed 
into a thermal cycler (MWG Biotech, UK) and subjected to the following conditions;
94°C 30 seconds
94°C 30 seconds ■—
60°C 120 seconds I 35 cycles
72°C 60 seconds |
94°C 30 seconds
60°C 120 seconds
72°C 5 minutes
20pl of the resulting PCR product was placed on a 2% agarose gel pre-stained with ethidium  
bromide (Sigma-Aldrich, UK). To form the agarose gel, lg  of agarose (Bioline, UK) was dissolved 
in 50ml TBE buffer (89m M Tris-HCI pH 7.8, 89m M  borate and 2m M  EDTA) with 2pl ethidium  
bromide. Loading dye (Promega, UK) was diluted 1:1 with each sample and 8 pl o f the sample 
was loaded onto the gel. A lOObp ladder (VWR International Ltd., UK) was also loaded onto the 
gel to allow for DNA band sizing. Using TBE as the buffer, the gel was run at 100V for 30 
minutes. Mycoplasma primer sets produce a PCR product o f 270bp, where mycoplasma DNA is 
present. Gels were visualised using a UVP Bioimaging system (Bio-Rad, UK) and images 
obtained with Labworks 4 software.
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2.2.5 Experimental conditions for testing the effects of 
cytokines on CX3CLI and CCL2 expression in human aortic 
vascular ceils
Cells were seeded into 6  well plates, 96 well plates and chamber slides (NUNC™), at an initial 
density of 1x10s cells/ml in complete medium, equivalent to lm l/5c m 2. Cells were cultured at 
37°C for 24h prior to treatm ent, then washed twice w ith PBS and incubated for a further 24 
hours in serum free media.
Cells were treated with recombinant human cytokines TNFa, IFNy and IL-18, alone or in 
combination. TNFa and IFNy (Peprotech, UK) were initially reconstituted in sterile w ater and 
PBS respectively, to working aliquots of lOOpg/ml and stored at -20°C. Recombinant human IL- 
18 (R&D Systems, UK) was directly aliquoted at 50pg/m l and stored at -80°C. All cytokines 
were further diluted in serum-free medium to working concentrations of 1, 10, and lOOng/ml 
alone or in combination. Cells were incubated for 2-4h for gene expression analysis, 2-48h for 
protein expression analysis, with the cytokines alone or in combination and then the 
supernatant and cell lysates collected. Serum-free medium was used as a control and all 
treatments were performed in duplicate w ith experiments repeated at least three times for 
each condition.
2.2.6 Experimental conditions for testing the effects of 
androgens on CX3 CLI and CCL2 expression in human aortic 
vascular cells
Testosterone or DHT (Sigma-Aldrich, UK) was dissolved in ethanol (Fisher Scientific, UK) at an 
initial dilution of lOOmg/ml and stored at 4°C until used. The androgen solution was further 
diluted in serum-free medium to working concentrations, via an intermediary 1 : 1 0 0 0  dilution 
in ethanol. Cells were seeded as above and were cultured for 24h prior to treatm ent, then 
washed twice w ith PBS and incubated for a further 24h in serum free media. Cells were then 
incubated with the androgen at working concentrations o f 1, 10, 100 and lOOOnM for 2-48h, 
either prior to cytokine treatm ent or w ith the cytokines. Ethanol, at a volume equal to that of 
the diluted working solution of testosterone or DHT, was used as the vehicle control.
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2.2.6.1 Experimental conditions for testing the effects of 
androgen receptor blockade
Flutamide is a non-steroidal anti-androgen that inhibits the actions of testosterone and DHT by 
binding to and blocking the AR (llliescu et al. 2003). Flutamide (Sigma-Aldrich, UK) was 
dissolved in ethanol (Fisher Scientific, UK) at an initial concentration o f lOOmg/ml and stored 
at 4°C until used. The solution was further diluted in serum-free medium to working 
concentrations, via an intermediary 1:1000 dilution in ethanol. Cells were incubated with 
flutamide at working concentrations of 1, 10, 100 and lOOOnM for 2-48h along with the 
androgen treatments. Ethanol, at a volume equal to that of the diluted working solution of 
flutamide, was used as the vehicle control.
2.2.7 Investigating the effects of cell treatments on cell
proliferation
2.2.7.1 Bromodeoxyuridine (BrdU) assay
To determ ine and quantify the effects of various mediators on cell proliferation, ELISAs that 
target markers of proliferative activity can be employed. BrdU is a pyrimidine analogue that is 
incorporated into newly synthesised cellular DNA o f proliferating cells in place of the 
nucleoside thym idine as they replicate and divide (Gratzner 1982; Alison 1995). BrdU can then 
be measured by antibody detection. An anti-BrdU antibody, which specifically binds BrdU that 
has been incorporated into the DNA of proliferating cells, conjugated to a peroxidase (POD) 
enzyme, which converts the substrate tetramethylbenzidine (TMB) to a coloured product, was 
utilised. Resulting colour change is directly correlated to the amount of BrdU present and thus 
the amount of DNA synthesised in proliferating cells.
M eth od
Cells were seeded onto 96-well plates at known densities (0 .5x l0 4 -  1x10s cells/ml) and 
cultured in 200pl o f serum-containing media for 24h. After this period the media were 
removed and replaced with serum-free media, and cells were incubated for a further 24h. Cells 
were finally incubated in the presence or absence of the cytokines/androgens, in triplicate, as 
outlined above. The BrdU cell proliferation ELISA kit (Roche, UK) contained all solutions other 
than the stop solution (1M H2S04 ; Fisher Scientific, UK). BrdU labelling solution was added 
directly to the test wells at a dilution of 1 : 1 0  (e.g. 2 0 pl added to 180pl of medium) and 
incubated for 4h at 37°C in 5% C 0 2/95%  air atmosphere. The labelling medium was removed 
by aspiration and wells were left to air dry for 5-10m in. 200pl of FixDenat solution was added
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to the wells for 30 minutes at room temperature to fix the cells and denature the DNA. 
FixDenat solution was removed by aspiration and blotting onto a clean paper towel. 100pl of 
mouse anti-BrdU-POD antibody working solution was added to the cells and left to incubate 
for 90m in at room temperature. Antibody conjugate was then removed by aspiration and 
blotting, followed by 3 washes with 300|il/we ll o f wash solution. The plate was blotted again 
after the final wash step to ensure complete removal of liquid. lOOpI of TMB substrate solution 
was added to the wells and incubated at room temperature for approximately 30min or until 
sufficient colour developed. Stop solution (1M H2S04) was added at 25pl/we ll, the plate 
tapped to mix thoroughly and the optical density determ ined at 450nm within 5min of the 
stop solution being added using a Labsystems Victor II Wallac MULTISKAN-MS plate reader 
(Perkin Elmer, UK). Blank controls were performed in duplicate to provide information about 
the non-specific binding of BrdU and the anti-BrdU-POD conjugate to the plate. These control 
wells contained no cells but underwent the same assay procedure as the test wells. Optical 
density readings for blank control wells were subtracted from those for all test wells. In 
addition, a background control was performed in duplicate, to account for non-specific binding 
o f the anti-BrdU-POD conjugate to the cells, and underwent the same procedure but w ith the 
omission of the BrdU label.
2.2.7.2 Quantification of cell protein using the bicinchoninic
acid assay (BCA)
The BCA assay is a method for determ ining the total protein content in a solution. Cu2+ ions 
from cupric sulphate can be reduced to Cu+ by the peptide bonds in protein. The amount of 
Cu2+ reduced is proportional to the amount of protein present in a solution. Molecules of 
bicinchoninic acid then chelate w ith each Cu+ ion, form ing a purple-coloured product that can 
absorb light at a wavelength of 570nm. Samples can be quantified by comparing them to 
standard protein solutions of known concentrations (Walker et al. 1994). Total protein was 
measured to account for potential differences in cell number that may result from different 
treatments.
M ethod
Bovine serum albumin (BSA) fraction V (Fisher Scientific, UK) was serially diluted from a 
50mg/m l stock solution in PBS (GIBCO*) over a range of Opg/ml - 5000pg/m l to obtain a 
standard curve. 2 0 pl of standards were pipetted in triplicate along with 2 0 pl o f samples in 
duplicate onto a 96-well plate. This was immediately followed by the addition of 200pl of BCA 
working solution (4% Copper sulphate solution (Sigma-Aldrich, UK) diluted 1:50 in BCA solution 
(Sigma-Aldrich, UK)) to all the wells, and incubation at room temperature for 30m in.
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Absorbance was read at 570nm using a Labsystems Victor II Wallac MULTISKAN-MS plate 
reader (Perkin Elmer, UK) and sample protein concentrations were calculated from the 
standard curve using Microsoft Office Excel (Microsoft, USA).
2.2.8 Investigation of protein expression in human aortic 
vascular cells by immunocytochemistry
Immunocytochem istry is a sensitive and versatile technique which uses antibody affinity and 
selectivity to detect a single epitope, mainly proteins, in its cellular location. The architecture 
of the cell, and therefore the target proteins (antigens), require fixation before detection. This 
is accomplished by use of a fixative which cross-links protein molecules and changes the 
chemical properties o f the tissue or cell constituents to preserve morphology. This process, 
however, can impact on the ability of antibodies to specifically bind to the ir target, as the 
three-dimensional protein conformation can be altered and proteins can even be cleaved from  
the cell (Fritschy 2008). Fixatives can also be used to permeablise the cells to allow the 
detection of intracellular antigens. Antibodies raised against specific antigens are incubated 
with the cells to allow antigen-antibody binding to occur. Unbound antibody is removed by 
washing and the bound antibody is detected either directly, if the primary antibody is labelled, 
or indirectly, using labelled secondary antibodies directed against the primary antibody (Figure 
2.3). Indirect immuno-labelling has the ability to amplify the signal, as multiple secondary 
antibody molecules can bind to a single epitope-bound primary antibody. Antibodies can be 
enzyme-labelled, requiring the addition of a substrate for local colour change, or fluorophor- 
labelled, requiring specific wavelength excitation for fluorescence emission. To reduce 
background and non-specific staining, and to minimise conformational protein alterations and 
epitope masking, the immunocytochemical conditions need to be optimised for each specific 
cell type and antibody.
In this thesis, indirect immunofluorescence was used for immunocytochem ical analysis, 
whereby epifluorescence microscopy detects the light signal em itted by a fluorochrome bound 
to the secondary antibody.
M ethod
The methods o f fixation, blocking, antibody dilution, incubation period and counterstaining 
were optimised to provide the strongest specific antigen staining with the lowest non-specific 
binding for each cell type and antibody. Once this was established, the procedure was utilised 
for all immunostaining (See Table 2.3).
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Figure 2.3; Schematic representation of immunocytochemical detection of 
antigens on cells or tissue. Antigens can be detected directly (A) w ith  the use o f a 
conjugated antibody directed against the target antigen, or indirectly (B and C) w ith  
the use o f a second conjugated antibody directed against the primary antibody. 
Antibodies can be conjugated to  fluorescent molecules (A and B) or enzymes (C) 
tha t react w ith  a substrate to  create a colour change. The use o f a secondary 
antibody amplifies the signal generated due to the binding o f m ultip le  conjugated 
antibodies to  a single primary antibody.
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Primary
Antibody
Target
Supplier Isotype/
species
Fixative Block Dilution Secondary
Antibody
CX3CLI R&D
(MAB3651)
IgGi (ms, 
m onoclonal)
Acetone (1 :2 5 -1 :4 0 0 )
1 : 1 0 0
Rb x Ms 488
(1 :4 0 0 -1 :8 0 0 )
1:400
CX3CRI Santa Cruz 
(sc-30030)
IgG (rb, 
polyclonal)
Acetone 5%
BSA
(1 :2 5 -1 :4 0 0 )
1:50
Gt x Rb 568
(1 :4 0 0 -1 :8 0 0 )
1:400
ADAM-17 Santa-Cruz
(sc-25782)
IgG (rb, 
polyclonal)
Acetone
4%PFA
5%
Serum
(1 :2 5 -1 :4 0 0 )
1:50
Gt x Rb 568
(1 :4 0 0 -1 :8 0 0 )
1:800
ADAM-10 abCam
(ab l997 )
IgG (rb, 
polyclonal)
Acetone
4%PFA
5%
Serum
(1 :2 5 -1 :4 0 0 )
1:50
Gt x Rb 568
(1 :4 0 0 -1 :8 0 0 )
1:800
AR abCam
(ab2742)
IgG (rt, 
m onoclonal)
Acetone 5%
BSA
(1 :2 5 -1 :4 0 0 )
1:25
Gt x Rt FITC
(1 :2 0 0 -1 :4 0 0 )
1:400
a-Actin Sigma-
Aldrich
(A2547)
lgG2A (ms, 
m onoclonal)
Acetone (1 :2 5 -1 :4 0 0 )
1 : 2 0 0
Rb x Ms 488
(1 :4 0 0 -1 :8 0 0 )
1:800
vWF Dako
(M0616)
IgGi (ms, 
m onoclonal)
Acetone (1 :2 5 -1 :4 0 0 )
1:400
Rb x Ms 488
(1 :8 0 0 -1 :1 0 0 0 )
1:800
a-Tubulin Sigma-
Aldrich
(T5168)
IgGi (ms, 
m onoclonal)
Acetone (1 :2 5 -1 :4 0 0 )
1:400
Rb x Ms 488
(1 :8 0 0 -1 :1 0 0 0 )
1:800
Table 2.3; Antibodies used fo r  immunocytochemistry. Summary o f the antibod ies used 
fo r  ta rge t p ro te in  detection in human aortic  vascular cells fo llow ing  op tim isa tion  o f 
methods. The fixative, block and d ilu tions o f prim ary and secondary antibod ies w ere 
selected to  produce the  highest am oun t o f specific staining w h ils t reducing, or 
p re fe ren tia lly  e lim inating, non-specific binding. The range o f an tibody d ilu tions  tested  
is shown, w ith  the selected op tim um  d ilu tion  in bold. AR, androgen receptor; vWF, von 
W illebrand Factor; ms, mouse; rb, rabb it; rt, ra t; gt, goat; x, a n ti (e.g. ra b b it a n ti­
mouse).
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Cells were seeded onto chamber slides at a density of 1x10s cells/ml in a volume of medium 
equivalent to lm l/5cm 2and cultured with or w ithout test reagents as appropriate. Media was 
aspirated carefully and cells were washed twice in PBS before fixation. For THP-1 cells, the 
suspended cell line was centrifuged (200 x g for 5 mins) to pellet the cells, washed by 
resuspending in 5ml of PBS and the centrifugation repeated. The cell pellet was resuspended 
in 1ml o f PBS and cells counted using a haemocytometer. Cell concentration was adjusted, 
ranging from lx lO 3 - l x l0 5cells/ml, and 200pl of cell suspension was loaded into a cytospin 
tunnel assembled with a microscope slide. The cytospin assembly was then spun at 200 x g for 
3 minutes in a Shandon cytospin centrifuge (Thermo Scientific, UK) to propel the cells onto the 
slide, the slide removed from the assembly and cells fixed by the appropriate optimised 
method.
Potential non-specific binding of the antibody was blocked using the appropriate optimised 
blocking method (See Table 2.3). Primary antibodies specific to the cellular targets were used 
for detection at the optimised dilutions in PBS. The primary antibody was applied to the cells 
and incubated overnight at 4°C. Cells were then washed 3 times for 5 minutes with PBS 
containing 0.05% Tween 20 (PBS-T) (Sigma-Aldrich, UK). Primary antibody binding was 
visualized by incubation with a secondary antibody reactive to the species of the primary 
antibody, at the optimised dilutions in PBS, for 1 hour at room temperature whilst protected 
from light. Cells were subsequently washed with PBS-T, as before, to remove any unbound 
antibody. Nuclei were stained using Vectashield mounting medium containing 4',6-Diamidino- 
2-phenyindole (DAPI) (Vector Labs Inc, UK) and covered with coverslips which were sealed at 
the edges with nail varnish to prevent cell drying. Negative controls, lacking the primary 
antibody, were included to determ ine non-specific binding of the secondary antibodies. The 
exclusion o f both primary and secondary antibodies was initially used to determ ine cellular 
autofluorescence and establish whether Sudan black blocking was necessary. Cells were 
exam ined and images captured using a Zeiss 510 laser scanning confocal microscope (Carl Zeiss 
Ltd, UK).
2.2.8.1 Confocal laser scanning microscopy (CLSM).
Confocal laser scanning microscopy (CLSM) is a valuable technique in biomedical science for 
imaging tissues or cells which have been labelled with one or more fluorescent probes. 
Samples are excited or illuminated by a multi-wavelength laser or multiple lasers capable of 
excitation at several wavelengths. Due to a series of mirrors and filters only light em itted from  
a specific focal plane reaches the detector and all other signal is filtered out (Figure 2.4). With  
such specific focus, image information is maximally resolute w ith reduced background
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Figure 2.4; Schematic diagram o f the optical pathw ay and principal components in a 
confocal laser scanning microscope. The laser beam passes th rough  a ligh t source 
pinhole aperture  and is reflected by a d ichrom atic  m irro r tow ards the  m icroscope 
objective. The objective focuses the  laser beam to  a chosen focal plane w ith in  the  
specimen th a t becomes confocal w ith  the  pinhole apertures o f the  ligh t source and 
de tecto r (Claxton 2005). By re-focussing the  objective, an a lterna te  focal plane can be 
investigated. Light em itted  from  focal planes above or below  the region o f in te res t (or 
objective  focal plane), th a t would  norm ally in te rfe re  w ith  the  reso lu tion o f structures in 
focus, is obstructed and excluded from  detection  as it is unable to  pass th rough  the  
d e tec to r p inhole aperture. Focussed ligh t th a t passes th rough the  d e te c to r p inhole 
aperture  is collected by a p ho tom u ltip lie r de tecto r, which produces a signal th a t is 
d irectly  p roportiona l to  the brightness o f the light. This signal is fina lly  converted  to  
create an image d irectly  processed by the  associated com pute r and displayed as a high- 
reso lu tion image representative o f the objective  focal slice.
From w w w .o lym pusconfoca l.com /theory/LS C M Intro .pd f
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fluorescence and improved signal-to-noise at the chosen depth (Sandison and Webb 1994). 
This scanned fluorescence detection at specific depths throughout the tissue allows for an 
optical sectioning, which uses light rather than physical means to serially section the specimen 
further w ith sequential image acquisition at each step, or slice (Paddock 2000). By acquiring, 
collating and processing these multiple scanned images of focal sections throughout the 
specimen at known intervals, a three-dimensional representation of the sample can be 
constructed to provide detailed structural information.
M ethod
Processed cells mounted on chamber slides were stored at 4°C in the dark until image analysis 
on the confocal microscope. Microscope settings were optimised for each target antibody to 
maximise fluorescence detection while minimising background and maintaining image 
resolution. Once these parameters were established the settings were re-applied to all 
samples and negative controls to ensure consistent and reliable image reproduction.
2.2.9 Investigation of CX3CLI and CCL2 expression in human 
aortic vascular cells using Enzyme-Linked Immuno-Sorbant Assay 
(ELISA)
Enzyme-Linked Immuno-Sorbant Assay (ELISA) is a technique used to detect a specific antigen 
or antibody in a sample. Sandwich ELISAs employ two antibodies specific to different epitopes 
of the antigen, w ith the first capturing and immobilising the antigen (capture antibody), and 
the second form ing a complex by binding multiple different epitope of the same antigen 
(detection antibody) and thus amplifying the reaction and increasing the sensitivity o f the 
assay. The detection antibody is biotinylated and when streptavidin-horseraddish peroxidise 
(HRP) is added, it binds to biotin on the detection antibody. Finally, a peroxidase substrate is 
added allowing enzymatic conversion to take place which results in a colour change 
proportional to the amount of starting antigen in the sample. This colour change is detectable 
by spectrophotometry and can be quantified using a standard curve of known antigen 
concentrations. All steps are followed by a thorough washing process to remove any proteins 
or antibodies that are not specifically bound (Figure 2.5). The major advantages of a sandwich 
ELISA is specificity, allowing the use of crude or impure samples with relative precision, and it's 
quantitative capacity.
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Figure 2.5; Schematic representation of the principles of an enzyme-linked 
immunosorbant assay (ELISA), a) Initially an analyte-specific primary antibody is coated 
onto the wells o f a 96-well plate, followed by washing and blocking, b) Standards, samples 
and controls are added and incubated on the plate to  allow the target molecule to  bind to 
the immobilised capture antibody. Aspiration and wash steps fo llow , c) A b iotinylated 
detection antibody is added which binds to  a second epitope on the analyte. This form s a 
capture antibody-analyte-detection antibody 'sandwich' complex. Unbound antibody is 
removed by washing, d) Streptavidin-HRP is added, which binds to  biotin on the detection 
antibody, and this is followed by washing, e) TMB, a peroxidase substrate, is added to  the 
wells and is converted to  a blue coloured reaction product by HRP in proportion to  the 
amount o f bound analyte, f) Finally, H2S04 is added to  stop the reaction and tu rn  the 
reaction product yellow. The product is quantified by spectrophotom etry.
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2 .2 .9.1 Preparation of cell samples for ELISA
Cells were seeded onto 6  well plates as described in 2.2.5 and subjected to cytokine and/or 
androgen treatments. The supernatants were collected, centrifuged to pellet debris, removed 
to a fresh tube and stored at -80°C until analysis. Cells were lysed and the protein extracted 
using 500pl/we ll of CelLytic-m buffer (Sigma-Aldrich, UK) containing 10% protease inhibitor 
cocktail (Sigma-Aldrich, UK) at 4°C for 15min with gentle agitation. All cellular material was 
removed from the plate surface by cell scraping and then mixed into a homogenous solution 
by repeated pipetting. The lysates were centrifuged at 12,000 x g to pellet cellular debris and 
the resulting protein-containing supernatants were then stored at -80°C until analysis.
2 .2 .9 .2  Investigation of CX3CLI expression in human aortic 
vascular cells by ELISA
A DuoSet® ELISA development kit (R&D Systems, UK) specific for the CX3CL1 chemokine 
domain was used, according to the manufacturer's instructions, to determ ine the 
concentration of human CX3CL1 concentrations in the cell supernatants and lysates. In brief, 
mouse anti-human CX3CL1 capture antibody was diluted to a working concentration of 4pg/m l 
in PBS (137m M  NaCI, 2.7m M KCI, 8.1m M  Na2 HP04 ,1 .5 m M  KH2 P04, pH 7.2-7.4, 0.2pm filtered) 
and a 96 well plate was coated with lOOpl/well, sealed and incubated overnight at room 
temperature. Each well was then aspirated and washed 3 times with 300p l/we ll wash buffer 
(PBS + 0.05% Tween® 20 (Sigma-Aldrich, UK)). After the last wash, any remaining liquid was 
removed by blotting against a clean paper towel. Plates were blocked by the addition of 
300p l/we ll of reagent diluent (1% BSA (Fisher Scientific, UK) in PBS) and incubated at room 
temperature for a minimum of lh . The aspiration and wash step was repeated. CX3 CL1 
standards were prepared by dilution of the recombinant human CX3CL1 stock solution 
(240ng/ml) in reagent diluent, to produce a range of 0-20ng/m l. This was after initially testing 
for CX3CLI recovery from standards diluted in celLytic or culture medium as appropriate. 
lOOpl/well of sample or standard was added to the plate in duplicate, sealed and incubated for 
2h at room temperature. The wells were aspirated and washed before lOOpl/well o f detection 
antibody (biotinylated mouse anti-human CX3CL1), diluted to a working concentration of 
500ng/m l in reagent diluent, was added to each well and incubated for 2h at room 
temperature. Subsequently, the aspiration and wash steps were repeated, followed by the 
addition of 100p l/we ll of streptavidin-HRP diluted in reagent diluent 1:100. The plate was then 
covered and incubated in the dark for 20m in. The aspiration/wash step was repeated and 
lOOpl/well o f substrate solution (1:1 mixture of colour reagent A (H20 2) and colour reagent B 
(tetramethylbenzidine; TMB)) were added to the plate and incubated for 20m in at room
temperature in the dark. 50pl of stop solution (1M H2S04) was subsequently added to all wells 
and the optical density of each well was determ ined immediately using a Labsystems Victor II 
Wallac MULTISKAN-MS plate reader (Perkin Elmer, UK) at 450nm. Wavelength correction was 
applied at 570nm to correct for optical imperfections in the plate. Unknown CX3CL1 
concentrations were calculated from a standard curve of known CX3CL1 concentrations using 
Microsoft Office Excel.
2.2.93 Investigation of CCL2 expression in human aortic
vascular cells by ELISA
The human CCL2 ELISA development kit (R&D Systems, UK) employs the same methods and 
principles as the human CX3CL1 ELISA (see above), but utilises mouse anti-human CCL2 and 
biotinylated goat anti-human CCL2 as the capture and detection antibody pair respectively. 
This was used to detect CCL2 in cell supernatants and lysates o f human aortic vascular cells 
following the same procedures as in 2.2.9.2.
2.2.10 Investigation of surface protein expression in human
aortic smooth muscle cells using flow cytometry
Flow cytometry is a laser-based technology that allows the rapid measurement of individual 
particles based on the ir light-scattering, fluorescent and other optical properties. Scattering 
and emission data can be used to simultaneously examine a variety of biochemical, biophysical 
and molecular aspects o f a particle (Jaroszeski and Radcliff 1999). Most often the particles 
analysed are individual cells. The flow cytometer is composed of four closely related systems. 
The fluidics system orders the sample into a stream of single particles by creating a drag effect 
from faster flowing sheaf fluid surrounding the sample, which passes through a narrowing 
central chamber. This hydrodynamically focuses the sample suspension into a very thin sample 
stream (Nolan and Yang 2007) (Figure 2.6a). Once in single cell flow, the sample passes 
through an illumination system, where each individual particle is interrogated by one or more 
beams of light. The resulting light-scattering and fluorescence is directed by multiple optical 
filters to the appropriate photomultiplier detector tubes and then converted to electrical 
signal by the optical and electronics system (Figure 2.6c). These electronic signals can be 
processed and stored by the computer control system and provide information about the 
particles properties (Radcliff and Jaroszeski 1998). Partially diffracted light is collected by the 
forward scatter detector (FSC) as a measure of relative cell size. Light that is reflected or 
refracted is collected by the side scatter detector (SSC) and relates to the complexity of the 
cell. FCS and SSC are unique for every cell type and the combination of these parameters can
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Figure 2.6; Schematic representation of flow cytometry analysis. Samples o f cell 
suspensions are drawn into the flow  cytom eter and the drag effect o f the fast flow ing sheath 
fluid surrounding the samples creates a single stream o f cells (A). Light tha t is scattered in 
the forward direction (FSC) is diffracted light related to  surface area and provides 
inform ation o f the cell or particle size. Light scattered at approximately 90° to  the excitation 
light beam is reflected and refracted light, known as the side scatter (SSC) and provides 
inform ation related to  granular content and complexity o f the cell or particle (B). Samples 
are interrogated by light and lasers to  ascertain cellular inform ation. The d iffe ren t signals 
em itted are filtered and reflected to  appropriate detectors (FL1-4) which relay the signal to  a 
computer where data is analysed (C). Adapted from
http ://w w w .abdserotec.com /support/in troduction_to_flow _cytom etry-685.htm l
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be used to differentiate cell types and distinguish between live cells and cellular debris. 
Fluorescence measurements at different wavelengths, dependent on the fluorochrome 
selected, are distinguished by separate detectors and provide information about specific 
cellular molecules typically identified by fluorescent conjugated antibodies.
The resulting flow cytometry data is graphically presented with interpretation reliant on 
processing the data within histograms and dot plots. The technique of gating or drawing 
regions around populations on dual parameter plots allows the exclusion of particles that may 
interfere w ith analysis and the focussed exam ination o f populations o f interest. This increases 
the specificity but also increases the extent of user-defined parameters and requires stringent 
standardisation between experiments for reliable and comparable results (Herzenberg et al. 
2006).
2.2.10.1 Optimisation of cell retrieval from culture for flow  
cytometry
To maximise cell viability and minimise cell surface disruptions, the method of cell removal of 
adherent cells from culture flasks to produce a single cell suspension for flow cytometry was 
investigated.
M eth od
Cells were seeded at an initial density of lx lO 5 cells/ml into culture flasks (25cm2) in complete 
medium equivalent to lm l/5cm 2. Cells were incubated for 24h prior to treatm ent, then 
washed twice w ith PBS and incubated for a further 24h in serum-free media containing 
lOng/m l TNFa plus IFNy to induce CX3CL1 expression. Four different methods were used to 
remove cells from culture flasks; addition of 3m l 0.5% trypsin/0.2% EDTA (GIBCO®) for 5m in at 
room temperature, 3ml non-enzymatic cell dissociation solution (Sigma-Aldrich, UK) at room 
temperature until cells were dislodged, 3ml non-enzymatic cell dissociation solution at 37°C 
until cells were dislodged, or cell scraping. Samples were then analysed for CX3CL1 expression 
by flow cytometry and the suitability of each removal method was assessed based upon cell 
viability and the preservation o f cell surface CX3CL1 expression.
2.2.10.2 Flow cytometry method
3ml of complete media was added to cells removed from culture flasks enzymatically or cells 
were gently scraped from the flask surface whilst still in growth medium. The resulting cell 
suspension was dispensed into a sterile tube and centrifuged at 208 x g for 5m in to pellet the 
cells. The cells were resuspended in 1ml of PBS containing 1% FCS (GIBCO®, UK) and cells were
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counted using a haemocytometer. The cell suspension was divided into appropriate tubes at a 
concentration o f 1 x 106 cells per tube and 1ml o f PBS/FBS was added to each tube. Cells were 
centrifuged for 5m in at 208 x g and the resulting supernatant discarded. Cell pellets were 
resuspended in 50pl of PBS/FCS and 5pl of previously titrated conjugated antibody (anti­
human CX3CL1 Phycoerythrin MAb IgGi, anti-human ADAM17 Fluorescein MAb IgGi; R&D 
Systems, UK) or isotype control (Mouse IgGi Phycoerythrin Isotype Control, Mouse IgGi 
Fluorescein Isotype Control; R8 iD Systems, UK) was added. Samples were mixed thoroughly 
and incubated at 4°C for lh . To remove any unbound antibody, 1ml of PBS/FBS was added to 
each tube, mixed and centrifuged at 208 x g for 5min. Supernatant was removed and the 
resulting pellet was resuspended in 300pl of PBS/FBS. Directly before samples were analysed, 
25pl of propidium iodide (lOOpg/ml in PBS; Sigma-Aldrich, UK) was added to the cell 
suspension and mixed thoroughly. All samples were analysed on a FACS Calibur flow cytometer 
and data processed using Cell Quest Pro software (Becton Dickinson, UK). 10,000 events were 
measured per sample and the mean fluorescence index (MFI) was calculated by subtracting 
the geometric mean fluorescence of isotype controls from geometric mean fluorescence of 
samples.
2.2.11 Molecular investigation of gene expression in human 
aortic vascular cells using semi-quantitative real-time reverse 
transcription polymerase chain reaction (qRT-PCR)
Reverse transcription polymerase chain reaction (RT-PCR) is an improvement on the classical 
PCR reaction, in which specific sequences of DNA are amplified through thermocycling. If the 
gene of interest is present in a sample, then the primers anneal to the ir corresponding 
sequence and amplification takes place in an exponential manner as the thermocycling 
conditions, or cycle, are repeated to allow millions of copies of the target DNA to be 
synthesised (Templeton 1992). RT-PCR measures target gene expression in mRNA samples and 
first requires the reverse transcription of mRNA to a complementary DNA (cDNA) sequence. 
This is achieved by the enzyme reverse transcriptase which elongates and copies the single­
strand RNA using deoxynucleotide triphosphates (dNTPs), at primer initiated sites, to make 
long single-stranded cDNA sequences o f the entire length of RNA. Once cDNA templates have 
been synthesised the conventional PCR reaction can be utilised, whereby primers designed to 
sit at 3' and 5' ends of a specific DNA sequence initiate DNA polymerase activity to copy the 
target sequence into double-stranded DNA. The double-stranded DNA product from this 
reaction undergoes many repeats (cycles) of the thermocycling conditions; heating to 
denature the hydrogen bonds of the alpha-DNA helix thus separating the strands, and cooling
to anneal primers and encourage polymerisation, allowing millions of copies of target DNA to 
be synthesised exponentially. The amplified product of known length (amplicon), denoted by 
the distance between the primers on the target sequence of the gene, is produced and can be 
measured and sem i-quantified by agarose gel electrophoresis. This analysis is subject to 
considerable variability due to the precision of the agarose gel in resolving band size and the 
quantification of ethidium bromide fluorescence imaging. In addition, the end-point data 
collection allows inclusion of variations in enzyme kinetics between each reaction, or tube 
(http://www.appliedbiosystems.com/absite/us/en/home/applicationstechnolo gies/real-time- 
pcr/real-time-pcr-vs-traditional-pcr.printable.htm l). These differences begin to appear in the 
linear phase of amplification and present most clearly at the plateaux phase towards the end 
o f the repeated cyclings (or run) as reagents are being consumed and kinetics vary. Replicates 
of the same sample will behave differently and express variable end-point results due to these 
factors (Figure 2.7).
Real-time RT-PCR, as the name suggests, measures amplification cycle by cycle in real-time. By 
quantifying PCR product while the reaction is in the exponential phase of amplification and 
where there is an exact doubling of product every cycle, the precision o f the analysis is greatly 
enhanced. The real-time RT-PCR assay measures fluorescent signal produced during each cycle 
of the PCR reaction by either intercalation of a fluorogenic dye into double-stranded DNA 
(SYBR Green), or the separation of a fluorescent molecule from its adjacent signal quenching 
molecule (TaqMan®, Molecular beacons, Scorpions®) (Wong et ol. 2005). As more of the 
amplicon is produced the fluorescence intensifies. Individual reactions are characterised by the 
PCR cycle at which the fluorescence first increases above a background or threshold level 
(Cycle threshold; Ct), which is usually ten times the standard deviation of the baseline 
measurement (Wong et al. 2005). The increase in fluorescent signal and the point at which it 
crosses the specified threshold is proportional to the amount of starting DNA target, thus 
allowing quantification of target molecules. As real-time PCR collects data during the 
exponential phase, which is the most constant and reproducible phase of PCR amplification, 
increased accuracy in the calculation of relative abundance of the target molecules is 
perm itted and the high degree of variability generated by measuring the PCR end product is 
eliminated (Figure 2.7).
2.2.11.1 RNA Extraction
Total RNA can be isolated from cells or tissue directly and rapidly through the use of organic 
and aqueous solvent separation. TRI® reagent (Sigma-Aldrich, UK) combines phenol and 
guanidine thiocyanate in a monophasic solution to rapidly inhibit RNase activity, slowing and
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Figure 2.7; qRT-PCR amplification plot. Real-time PCR measures fluorescence 
at the exponential phase o f amplification, increasing accuracy and reliability 
and reducing the inter-reaction variability of end-point measurement. Repeats 
of the same sample possess only a small amount o f variability at the 
exponential phase, but this presents as large differences by the end o f the 
amplification.
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preventing RNA degradation. The add ition  o f ch lo ro fo rm  enables the phasic separation o f 
pro te in , DNA and RNA sim ultaneously in to  aqueous and organic layers. Once separated, RNA 
can be precip ita ted  and washed to  yield RNA suitable fo r dow nstream  applications such as 
qRT-PCR.
M ethod
RNA was extracted from  cu ltured cells using TRI® reagent according to  the m anufacturer's 
instructions. In brief, 200|il o r 400^1 o f TRI® reagent was added d irectly  onto  24-well and 6- 
w ell cu lture  plates respectively to  lyse the cells, d isrupting and solubilising ce llu lar 
com ponents. The resulting so lu tion was repeatedly p ipetted , transfe rred  to  a tube  and 
vortexed to  ensure com plete ce llu lar d isrup tion. C hloroform  (Sigma-Aldrich, UK) was added, 
equ iva lent to  lOOpil per 1ml o f TRI® reagent, and samples were vortex mixed then a llowed to  
stand fo r  5 m inutes at room  tem pera ture . Samples were centrifuged at 12,000 x g fo r  15min at 
4°C to  separate pro te in , DNA and RNA in to  th ree  layers. The upper aqueous layer conta in ing 
RNA was removed to  a clean 1.5m l tube, then  500|il o f isopropanol per ml o f TRI® reagent 
added, vortex m ixed briefly, le ft to  stand at room  tem pera tu re  fo r 5m in and centrifuged at 
12,000 x g fo r lO m in  at 4°C. The supernatant was discarded and the precip ita ted  RNA pelle t 
was washed by adding 1ml o f 75% ethanol, vo rtex m ixed and centrifuged at 12,000 x g fo r 
5m in at 4°C. The supernatant was discarded and the resulting RNA pelle t was b rie fly  a ir dried 
and solubilised in 10-50pl o f d ie thy lpyrocarbonate  (DEPC)-treated w ater (Sigma-Aldrich, UK).
2.2.11.2 Quantification of RNA
It is advantageous to  use approxim ate ly  the same am ount o f RNA when com paring d iffe re n t 
samples to  m inim ise varia tions in reverse transcrip tion  kinetics and u ltim a te ly  cDNA product; 
there fo re , accurate RNA quantifica tion  is beneficial.
The NanoDrop® ND1000 (Labtech In te rnationa l Ltd, UK) is a fu ll-spectrum  UV/VIS 
spectrophotom ete r capable o f measuring nucleic acid concentra tions and sample p u rity  in 
small sample volumes (as low  as lp il). Using surface tension, an aqueous sample fo rm s a 
colum n between the  tw o  fib re  optic-con ta in ing  pedestals. Light is passed th rough  the  sample 
and absorbance measured at d ifference wavelengths fo r the appropria te  concentra tion  and 
purity  analysis (Gallagher 2008). Measured at 260 and 280nm , the  nucleic acid concen tra tion  is 
calculated using a slightly m odified  Beer-Lambert equation;
c=(A*e)/b
c ,  is  n u c le ic  a c id  c o n c e n tr a t io n
A . is  a b s o r b a n c e  in  AU
e ,  i s  w a v e le n g th - d e p e n d e n t  e x tin c tio n
c o e ff ic ie n t in n g -c m /p l
b . i s  p a th le n g th  in c m
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This predicts a linear change in absorbance w ith concentration. Sample concentrations are 
calculated automatically with the NanoDrop® software and are represented as ng/pl. The ratio 
of sample absorbance at 260 and 280nm provides an indication of the RNA purity (acceptable 
at approximately ~2.0±0.4). Acceptable ranges may be established for individual studies. The 
ratio of sample absorbance at 260 and 230nm is a secondary measure of nucleic acid purity 
and may indicate the presence of co-purified contaminantes (accepted as 'pure' at 
approximately ~ 1 .8 -2 .2 ) (http://w w w .b io . davidson.edu/projects/gcat/protocols/ 
NanoDrop_tip.pdf).
M eth od
lp l of sample or blank was pipetted onto the lower measurement pedestal. The upper 
measurement pedestal was lowered and brought into contact with the sample, which was 
analysed as described above. Samples were wiped clear from the measurement pedestals 
between each analysis. DEPC-treated water was used as a blank control measurement to 
calibrate the NanoDrop.
2.2.11.3 Determination of RNA Integrity
Assessment of RNA integrity is an additional control to minimise non-specific sample variations 
and unrepresentative expression profiles of target genes. Where moderately degraded RNA 
samples may still result in reasonable and comparable RT-PCR when normalised to reference 
genes, the use of high quality RNA will provide the most accurate and reliable down-stream  
analysis reflective of a sample's natural state (Fleige and Pfaffl 2006) and reduce any potential 
gene-specific differential degradation of individual mRNAs, that would ultimately affect 
analysis (Bustin et al. 2005).
RNA integrity can be assessed by agarose gel electrophoresis. The gel is stained with ethidium  
bromide, and the presence of two sharp bands denoting 28S and 18S rRNA components in the 
gel are used as an indicator of RNA integrity. The brightness of the 28S and 18S bands under 
UV light should possess an intensity ratio of approximately 2:1 respectively (Sambrook and 
Russel 2001).
M ethod
2pl o f the extracted RNA sample was mixed with 2pl loading buffer (Promega, UK) and loaded 
onto a 1% agarose gel pre-stained with ethidium bromide. To form the agarose gel, lg  of 
agarose (Bioline, UK) was dissolved in 50ml TBE buffer (89m M Tris-HCI pH 7.8, 89m M  borate 
and 2m M  EDTA) with 2pl ethiduim bromide (lOm g/m l). Using TBE as the buffer, the gel was
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run fo r 30 m inutes at lOOv and the resulting gel was visualised on a UVP Bioimaging system 
using LabWorks 4 softw are (Bio-Rad, UK).
2.2.11 A cDNA Synthesis
Accurate and precise quantifica tion  o f RNA targets relies on the  perform ance o f the  reverse 
transcrip tion  reaction and subsequent conversion to  cDNA. The prim ing m ethod fo r  cDNA 
synthesis can vary dependent upon the characteristics o f the sample and dow n-stream  
application, w ith  advantages and disadvantages to  each th a t have to  be considered before 
selection (Bustin and M ue lle r 2005, Bustin et al. 2009).
Random prim ers (or random  hexamers) anneal to  the  RNA tem p la te  at m u ltip le  locations and 
produce more than one cDNA ta rge t per original mRNA tem pla te . Random hexamers 
transcribe the  entire  RNA sequence producing cDNA th a t covers the w ho le  transcrip t and is a 
useful prim ing m ethod, when several d iffe ren t amplicons need to  be analysed from  a small 
am ount o f RNA. Based on this, random  prim ers were selected as the prim ing  m ethod fo r  cDNA 
synthesis in th is study.
RNA is reverse transcribed in to  cDNA by the  enzyme reverse transcriptase (RT). In itia ted  by the  
binding o f the p rim er, RT elongates the sequence using dNTPs to  produce a com p lem entary  
sequence.
M ethod
RNA was d ilu ted  in DEPC-treated w a te r (Sigma-Aldrich) to  give a concentra tion  o f lp g  in lO pI 
in a PCR tube. To each tube the reaction com ponents from  the high capacity cDNA synthesis 
k it (Applied Biosystems, UK) w ere added (2pl reverse transcrip tion  buffer, 0.8pl dNTPs mix, 2pl 
random  primers, lp l  RT enzyme, and 4.2pl nuclease-free w ater) to  give a fina l vo lum e o f 20pl. 
The samples were then loaded in to  a therm ocycler and run on the  fo llow ing  single cycle;
25 37 85 4
lO m in 120min 5sec Hold
A m inus RT contro l reaction was utilised to  investigate genom ic DNA contam ination  fo r  each 
cell type o r experim ental procedure used. In th is reaction all com ponents were included o th e r
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than the RT enzyme. The lack o f amplification in these samples in the subsequent qRT-PCR 
analysis indicated no contamination from genomic DNA.
2.2.11.5 qRT-PCR using TaqMan® methodology
TaqMan sequence detection chemistry has three levels o f specificity for targeting a gene of 
interest. In addition to forward and reverse primers, an oligonucleotide probe designed to 
target a specific sequence that lies within the amplified target sequence, or amplicon, of the 
primers provides an extra level o f specificity compared to standard PCR and non-specific dye 
intercalation methodologies (Bustin et al. 2005). This greatly reduces the chance of mis- 
priming events leading to the amplification o f alternate sequences to the target, and 
eliminates the possibility of primer-dimer formation (where primers bind with themselves) 
resulting in fluorescence emission.
The oligonucleotide probe contains a high-energy fluorescent reporter dye on the 5; end and a 
subsequent low-energy quencher dye on the 3' end. The fluorescence of the reporter dye is 
greatly reduced by the proximity o f the quencher through a process known as fluorescence 
resonance energy transfer (FRET) through space (Livak et al. 1995). If the target sequence is 
present in the DNA sample, then the probe anneals downstream from one of the primer 
binding sites. As amplification takes place, the nuclease activity at the 5 1 end of the Taq DNA 
polymerase cleaves the probe as the primers extend. This separates the reporter dye from the 
quencher, and fluorescence signal is em itted when excited. The probe is eventually removed 
from the target strand and the full amplicon sequence synthesised (Figure 2.8). This process 
continues with each cycle resulting in an increase in fluorescence intensity relative to the 
amount of amplicon produced as increasing amounts of probe are cleaved. The cycle at which 
the fluorescence intensity increases above the threshold (Ct) is proportional to the initial 
abundance of the target sequence (or gene) (Bustin et al. 2005).
M eth od
TaqMan primer probes (see Appendix 1 for product detail) were purchased as pre-designed, 
pre-optimised assays intended to cross exon-exon boundaries in the target gene sequence to 
ensure that only DNA transcribed from mRNA was amplified (Sandhu and Acharya 2005).
For each gene target lp l of sample or controls (no RT controls and no temp late controls) were 
carefully pipetted in triplicate into 384-well or 46-well PCR plates (Applied Biosystems, UK) on 
ice. This was followed by 4.2pl o f DEPC-treated water (Sigma-Aldrich, UK), 4pl o f TaqMan® 
Universal PCR mastermix (Applied Biosystems, UK) and lp l o f the target-specific primer-probe 
mix (Applied Biosystems, UK). Plates were covered with an adhesive film, centrifuged to
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Figure 2.8; Schematic representation o f the qRT-PCR TaqMan chemistry. A)
Sequence-specific forward and reverse primers and oligonucleotide probe hybridise 
to  the target DNA template. As amplification takes place, the nuclease activ ity at 
the 51 end o f the Taq DNA polymerase cleaves the probe as the primers extend (B 
and C). This separates the reporter dye (R) from  the quencher (Q), and fluorescence 
signal is increased. D) The probe is eventually removed from  the target strand and 
the fu ll amplicon sequence synthesised.
Adapted from ; www3.appliedbiosystems.com/AB_Home/applications 
technologies/Real-TimePCR/TaqManvsSYBRGreenChemistries/index.htm
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ensure that all solutions were collected at the bottom of the wells then analysed using either 
the 7900HT PCR system or StepOne™ real-time PCR system (Applied Biosystems, UK) for 384- 
well and 46-well plates respectively using the following cycle;
40 cycles
95°C 95°C
10 mins
60°C
50°C 1 min
2 mins
Stage 2Stage 1 Stage 3
The universal PCR mastermix contained a passive reference fluorescence dye, ROX™, which the 
reporter dye is normalised to during analysis to control for fluctuations in reaction 
concentrations or volumes caused by pipetting errors. No template controls (NTC) were 
included for each target on each plate to detect PCR contam ination or determ ine any 
unintended amplification.
2.2.11.6 Selection of endogenous control reference genes
Accurate normalisation of gene expression is essential for the reliable quantification and 
comparison of gene expression studies. In order to measure variations in the levels of a target 
gene's mRNA across a range of samples, expression values must be represented relative to the 
expression of endogenous control genes, or reference genes (often referred to as 
housekeeping genes) (Vandesomple et al. 2002). Reference genes are presumed to be 
continually expressed as they produce proteins necessary for basal cellular function. Ideally 
this expression should not only be continuous but also unaffected by experimental conditions, 
creating an internally stable reference. By normalising to an endogenously consistent 
reference gene expression, variations in total RNA quantity and quality, enzymatic efficiencies 
and differences between cells or tissues can be accounted for and controlled for in order to 
identify real gene-specific variation (Vandesomple et al. 2002, Bustin et al. 2005, Fleige and 
Pfaffl 2006). However, all genes are regulated to some extent and are not all expressed 
independently of experimental conditions (Bustin et al. 2005). It is therefore necessary to 
thoroughly validate the use of reference genes for each tissue or cell type and for all 
experimental treatments as the selection of appropriate controls affects the validity of the 
results (Thellin e ta l. 1999).
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To validate the presumed stability o f a particular reference gene, it is necessary to normalise 
its own expression, to control for the previously mentioned nonspecific variations, creating a 
circular problem (Vandesomple et al. 2002). GeNorm (Primer Design Ltd, UK) is an algorithm- 
based computer program that uses a pair-wise comparison to rank the expression profile of 
each reference gene against that of all other reference genes to elicit an expression ratio 
across experimental conditions. Stepwise exclusion of the lowest ranked genes reveals 
candidate reference genes demonstrating the most stable expression ratio relative to each 
other and identifies them as appropriate reference genes suitable for the experimental 
procedure (Vandesomple et al. 2002). It has been suggested that between three and five 
reference genes should be used for qRT-PCR investigation (Vandesomple et al. 2002). However 
this is impractical and costly for high throughput, low budget investigations (Barber et al. 
2005). Therefore, GeNorm suggests the number of reference genes needed for accurate 
normalisation, based upon the relative stability of the highest ranked expression ratio 
combinations at an acceptable degree of variation which can be user-specified.
An additional consideration when selecting suitable reference genes is the relative abundance 
of that gene. Genes o f low abundance, and therefore high Ct values, unavoidably give rise to 
poorer precision and decrease the capabilities of qRT-PCR to detect small-fold changes. By 
selecting reference genes that are stable and suitably abundant, accuracies o f normalisation 
are improved (Thellin et al. 1999, Bustin et al. 2005).
M ethod
Six commonly used reference genes (RPL13A, p-actin, p-2 microglobulin, GAPDH, HRPT1 and 
SDHA) were tested for the ir stability across the experimental conditions in the investigation. To 
avoid co-regulation biases during reference gene selection, genes with unrelated functions 
were chosen (Table 2.4). Following qRT-PCR, reference genes with high Ct values or no 
amplification were excluded as unsuitable. The remaining reference genes were analysed using 
GeNorm software (Primer Design Ltd, UK) to determ ine the most stable genes within each 
experimental condition. Prior to input into the geNorm program, Ct values for each target 
were transformed to quantities relative to the highest expression of that target gene across 
the investigated sample conditions. This was achieved by subtracting the lowest Ct value from 
all Ct values for the given reference gene. The quantities were then converted to linear form to 
account for the logarithmic nature of the PCR reaction (Livak et al. 2001);
2"(sample Ct - lowest Ct sample)
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Gene
Symbol
Accession
number
Gene name Function Aliases
G A P D H N M _ 0 0 2 0 4 6 G ly c e ra ld e h y d e -3 -
p h o s p h a te
d e h y d ro g e n a s e
E n zym e in v o lv e d  in 
glycolysis an d  
g lu c o n eo g en es is
G 3P D
G A PD
M G C 8 8 6 8 5
R PL13A N M _ 0 1 2 4 2 3 R ib o so m al p ro te in  
L13a
S tru c tu ra l c o m p o n e n t o f  
th e  la rg e  60S  r ib o s o m a l 
s u b u n it
ACTB N M _ 0 0 1 1 0 1 B e ta -a c t in  (P -a c tin ) C y to s k e le ta l s tru c tu ra l  
p ro te in
PS1TP5BP1
BACTIN
B 2 M N M _ 0 0 4 0 4 8 B e ta -2 -m ic ro g lo b u lin B e ta -c h a in  o f  m a jo r  
h is to c o m p a tib ility  
c o m p le x  class 1 m o le c u le s
HPRT1 N M _ 0 0 0 1 9 4 H y p o x a n th in e  g u a n in e  
p h o s p h o r ib o s y l 
tra n s fe ra s e  1
In v o lv e d  in m e ta b o lic  
sa lvag e o f  p u r in e s  in 
m a m m a ls
HGPRT
HPRT
SD HA N M _ 0 0 4 1 6 8 S u cc in a te  
d e h y d ro g e n a s e  
co m p le x , s u b u n it A
E lec tro n  tra n s p o r te r  in 
th e  c itric  ac id  cycle in 
m ito c h o n d r ia
FP
SDH2
SDHF
Table 2.4; Summary o f reference genes tested fo r  qRT-PCR analysis. Six genes w ere 
investigated fo r su itab ility  as endogenous contro ls fo r  subsequent qRT-PCR analysis. 
The reference genes investigated w ere selected to  have unrelated functions to  
m inim ise co-regulation biases.
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The highest relative quantities for each gene were therefore set to one. These raw reference 
gene quantities were then inserted into the geNorm software, which calculates the relatively 
'most stable' gene expression and suggests a potential number of reference genes required for 
accurate normalisation.
2.2.11.7 Determination of Primer Efficiencies
With optimal amplification efficiency (100%) there is a doubling of PCR product with every 
cycle during the exponential phase of PCR amplification (Livak et al. 2001). The relative 
quantification method relies on the efficiencies o f the primers used to be approximately equal 
and optimally as close to 1 0 0 % as possible.
A two-fold serial dilution of the temp late cDNA ranging from 1:1 to 1:32 in DEPC-treated water 
was created to assess primer efficiencies. A plot of Ct values for all target and reference genes 
against log dilution factor was constructed. A linear trendline was applied, with the slope of 
the line used to calculate the percentage efficiency of each primer.
Efficiencyx = io (‘1/slope) - 1
Linear correlation with R2 values >0.95 were demonstrated, indicating that the Ct values 
acceptably matched the trendline fitted. Exponential primer efficiencies between the ranges of 
90-110% were accepted and considered to demonstrate acceptable comparability of 
amplification kinetics efficiency for investigated genes.
2.2.11.8 Validation of primer targets by electrophoresis
Products amplified by TaqMan primers in the real-time RT-PCR analysis for each target were 
further validated by visualisation on an agarose gel. Products should yield a single band, 
indicating that only one specific sequence has been amplified, at a known size
M ethod
8 pl of real-time RT-PCR product for each target was mixed with 2pl o f 5x loading dye 
(Promega, UK) and run on a 2.5% agarose gel at 100V for 30m in. Bands were visualised using a 
UVP bioimaging system (BioRad, UK) and compared to expected band sizes as indicated from  
primer probe assays (Applied Biosystems, UK).
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2.2.11.9 Relative quantification analysis of qRT-PCR data
Triplicate Ct values from the same sample were averaged to give a representative value and 
account for inter-assay variability. Mean Ct values of all sample targets were first normalised 
to the expression o f the appropriate reference gene Ct to determ ine the ACt value;
ACt = Ct target -  Ct reference
For sem i-quantitative analysis of mRNA expression, the Ct values for target genes in 
experimental conditions were represented relative to the ir expression in control conditions. 
The control conditions, or calibrator sample, would therefore be the 'normal', 'untreated' or 
'zero' sample. An average ACt of control samples from each repeat of the experiment was 
taken as the ACt calibrator value for which all other individual ACt values were normalised, 
including individual control ACts. This allowed for between-experiment variation to be 
accounted for in control samples. Test samples were presented as relative fold-change from 
control. This relative quantification was calculated as AACt;
AACt = ACt sample - ACt calibrator
This data was then converted to linear form to account for the exponential nature of the PCR 
reaction;
2 -AACt
The 2'AACt value for calibrator control samples is approximately 1, and data is represented as 
fold-change from this calibrator control value (Livak et al. 2001).
2"AACt values of repeated experiments were presented as mean ± SEM and statistical differences 
between experimental groups were determ ined using the non-parametric Kruskal-Wallis test 
followed by Dunn's post hoc test.
2.2.12 Statistical Analysis
Data is presented as mean ± SEM unless otherwise stated. Experimental groups were assessed 
for normality by D'Agostino and Pearson omnibus normality test where eight or more 
individual values were applicable for each group. Where sample numbers were below eight, a 
Kolmogorov-Smirnov (KS) was applied to test goodness-of-fit o f the sample population to a 
theoretical normal distribution that represents the typical 'bell-shaped' curve. W here sample 
numbers were too small (<6 ) to be graphically represented as the 'bell-shaped' curve on a
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frequency distribution plot and subsequent KS test, non-parametric tests were employed (Zar 
2010).
In addition, normally distributed samples were tested for equal variance w ithin the groups as 
parametric tests assume this attribute w ithin the data. Bartlett's test o f homogeneity of 
variance was used to assess this. Data o f unequal variance or non-normal distribution was 
transformed by logarithm, square root, or negative reciprocal and data retested for normality 
and variance. If the transformed data then met these requirements, parametric tests were 
applied to assess significant differences between sample means. Where three or more samples 
were compared a one-way ANOVA followed by Tukey's post hoc was used to establish the 
significance of any differences. For two group comparisons a student's t test was used. If the 
transformed data remained non-normal, of unequal variance, or sample size was considered 
too small for parametric analyses, a non-parametric Kruskal-Wallis test was applied to the 
original data for multiple groups, followed by Dunn's post hoc test. For two group comparisons 
a Mann Whitney U test was used. Significance was accepted at P<0.05 (Zar 2010).
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2.3 Results
2.3.1 Cell culture characterisation
Primary HASMC and HAEC proliferated at differential rates, with endothelial cells exhibiting a 
much longer doubling time (approx 48h and 96h respectively)(Figure 2.9). In addition, while 
SMC were relatively robust with regard to the stresses o f subculture, recovering within hours 
of trypsin dislodgement and splitting, endothelial cells required a longer period of time to 
return to a steady proliferative state (approximately overnight). Endothelial cells continued to 
proliferate for only 3-4 passages after removal from liquid nitrogen and after two freeze-thaw  
cycles. HASMC, in contrast, retained a steady state of proliferation after many passages and 
withstood multiple freeze-thaw cycles, maintaining comparable doubling times beyond 
passage 12. Cells were used experimentally below passage 10, for both cell types, to ensure 
phenotypic consistency. The growth patterns of the cells restricted the number of 
experiments, due to the difficulty in obtaining sufficient numbers o f endothelial cells for 
experimental procedures. For this reason, most of the preliminary investigations were carried 
out on HASMC, w ith endothelial cells utilised for the principal experiments where possible, 
dependent on cell numbers.
Within the cell passage limits, cell morphology remained consistent for both cell types, with  
characteristic phenotype markers diffusely expressed when investigated by 
immunocytochem istry at early and late passages. HASMC expressed smooth muscle a-actin, 
but were negative for von Willebrand Factor (vWF), an exclusive endothelial protein, while 
tubulin staining demonstrated the cytoskeletal substructure of the cells (Figure 2.10). HAEC, as 
expected, were positive for vWF and negative for a-actin, although a low level of non-specific 
staining could be seen (Figure 2.10). This may be the result of potential cross-reactivity 
between alternate and common actin isoforms of the cytoskeleton, which share a high 
percentage of sequence homology, even at the variable N-term inus region where the antibody 
was directed (Skalli e ta l. 1986). Again, tubulin staining highlighted the cytoskeletal structure of 
endothelial cells comparable w ith that of smooth muscle cells (Figure 2.10).
Analysis o f cell culture supernatants for mycoplasma infection demonstrated negative results 
for all cells used in this investigation. HASMC and HAEC were tested routinely at intervals 
throughout the duration of the investigation. THP-1 cells and DuCAPs were tested once prior 
to experimentation, due to the short time-frame of use in the project, but also showed no 
mycoplasma was present in the cultures. Figure 2.11 shows a representative agarose gel of
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resulting PCR products from the mycoplasma test.
2.3.2 Optimisation of cytokine treatments
HASMC were treated with TNFa, IFNy or IL-18, either alone or in combination, and at a range 
of concentrations from 0-100ng/m l. ELISA of the cell culture supernatants, as a measure of 
cleaved CX3 CL1, demonstrated that combination o f TNFa w ith IFNy produced the largest effect 
on CX3CLI upregulation (Figure 2.12). TNFa alone had no significant effect on cleaved CX3CL1 
expression, and a similar finding was seen w ith IL-18. IFNy alone increased CX3CL1 expression 
in a dose-dependent manner, reaching significance at lOOng/ml. When SMC were co-treated 
with TNFa and IFNy, expression of CX3CL1 was significantly upregulated, in a dose-dependent 
manner. These two cytokines seemed to act synergistically, as the magnitude of CX3CL1 
expression was more than additive compared to the effect of these factors alone. When IL-18 
was combined with e ither IFNy or TNFa plus IFNy, no additional increase in CX3 CL1 expression 
was observed, (Figure 2.12). The combination o f TNFa w ith IFNy was therefore selected as an 
appropriate cytokine treatm ent to induce detectable and significant CX3CL1 upregulation.
A time course of expression o f cleaved (measured in supernatants) and cell-bound (measured 
in cell lysates) CX3CL1 was measured by ELISA. Cleaved CX3CL1 expression increased with time  
in response to TNFa plus IFNy treatm ent of cells, at both lOng/m l and lOOng/ml, with the 
largest effect seen at 24 and 48h (Figure 2.13). Increased expression o f cleaved CX3CL1 was 
first detected at the 16h time point, indicating a lag between cytokine-induced upregulation 
and subsequent enzymatic cleavage. Cell-bound CX3 CL1 expression was increased more rapidly 
in response to these cytokines, with detectable increases observed as early as 2 h post­
treatm ent. Expression peaked at between 8  and 16h then steadily started to decrease from  
24h, in a dose-dependent manner, returning almost to basal expression levels by 48h at both 
concentrations of cytokine stimulations (Figure 2.13b). Controls, in which there was no 
cytokine treatm ent, showed very little cleaved and cell-bound CX3 CL1 expression over time. 
Taking into consideration the increases in both cleaved and cell-bound CX3CL1 expression, an 
incubation time of 24h was chosen for the cytokine stimulations for all subsequent 
experiments.
2.3.3 Optimisation of Flow Cytometry
In this study flow cytometry was used to measure protein expression in live cells. Therefore, 
the methods for removal of adherent cells from the culture surface were compared to 
ascertain the optimal procedure for maximal cell viability, whilst maintaining the cells'
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Figure 2.11: Agarose gel electrophoresis o f mycoplasma PCR products. Cells were 
tested fo r mycoplasma contam ination. Following PCR and 1% agarose gel 
electrophoresis, the  absence o f a band at 285bp in cell cu lture  supernatants indicated 
th a t all cell cultures were negative fo r the  presence o f mycoplasma.
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B. Cell Lysates
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Figure 2.13 Investigation o f CX3CL1 protein expression over time in HASMC 
following cytokine treatm ent measured by ELISA. Cleaved (supernatant) CX3CL1 
expression increased sign ificantly from  16h compared to  contro l (A). Cell bound 
(lysate) CX3CL1 expression increased m ore rapid ly fo llow ing  cytokine trea tm en t, 
peaking at 16h before fa lling  back to  basal levels by 48h (B). n=3 *P<0.05/ **P<0.01/ 
***P <0.001 vs control (Ong) Kruskal-Wallis n=3.
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structural integrity. Cell viability was maintained above 90% when cells were removed by 
trypsin or 37°C cell dissociation solution methods, with trypsin displaying slightly superior 
viability (94.97% and 93.75% respectively). Removal o f cells by room temperature cell 
dissociation solution resulted in a lower cell viability, potentially due to the extended period 
required for complete removal from the surface which was approximately 45 minutes. Cell 
scraping produced the lowest cell viability most likely due to the severe physical detachment 
of this method (Figure 2.14). CX3CL1 expression was induced by lOng/m l TNFa plus IFNy 
treatm ent for 24 hours and then cell-surface expression was measured in cells removed by all 
methods. Although trypsin removal maintained cell viability, it appeared to cleave CX3 CL1 from 
the cell surface, and low expression was observed (Figure 2.15). This was also apparent for the 
few viable cells analysed following removal by cell scraping. Removal of cells by the cell 
dissociation solution at room temperature resulted in a retention o f slightly more CX3CL1 on 
the cell surface, but this was still greatly reduced compared to cells removed by the 37°C cell 
dissociation solution method (Figure 2.15). Thus, the latter method was selected as the 
removal method for all cells in subsequent experimental procedures.
2.3.4 Optimisation of qRT-PCR
Integrity of the RNA isolated from the cells was assessed by agarose gel electrophoresis. The 
presence of two sharp bands, denoting 28S and 18S rRNA components, with an intensity ratio 
of approximately 2:1 respectively (Fleige and Pfaffl 2006) was observed, indicating acceptable 
RNA integrity for the majority of samples (Figure 2.16). Where no bands, a single band, blurred 
bands or bands o f the wrong size were detected, the final wash steps of the RNA extraction 
process were repeated and samples analysed again, otherwise these samples were not 
included in subsequent analysis.
2.3.4.1 Selection of endogenous reference gene controls
Six reference genes (RPL13A, (3-actin, (3-2 microglobulin, GAPDH, HRPT1 and SDHA) were 
tested for the ir stability across the experimental conditions and suitability for the qRT-PCR 
investigation. HRPT1 and SDHA were excluded from further analysis, due to low expression or 
unexpected product characteristics upon agarose gel analysis (data not shown). The remaining 
reference genes were tested under all experimental conditions. GeNorm established RPL13A 
and GAPDH to be the most relatively stable genes expressed in HASMC and HAEC. For all 
subsequent qRT-PCR experiments target gene expression was normalised to these two  
reference genes.
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Figure 2.14; Flow cytometry analysis o f HASMC viability following different methods 
o f cell retrieval from  culture. A) The gated area marked R1 in the  do t plots indicates 
cells th a t are negative fo r p ropid ium  iodide (PI), measured on the X axis, and th e re fo re  
corresponds to  viable cells. The percentage o f gated cells shifts considerably w ith  the  
m ethod o f removal. B) The histograms correspond to  the  percentage o f the to ta l cells 
gated in the  PI negative region. n=2
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Figure 2.15; Flow cytometry analysis o f HASMC expression o f CX3CL1 follow ing different 
methods o f cell retrieval. (A) Histogram p lo t dem onstrating the d ifference in fluorescence 
(measured on FL2-H), corresponding to  anti-CX3CLl PE conjugated an tibody binding, fo r 
the  d iffe ren t m ethods o f cell removal. (B) The mean fluorescence index (MFI) o f CX3CL1 
staining dem onstrates the effects o f the  d iffe ren t removal m ethods on cell surface 
expression. CX3CL1 appears to  be cleaved from  cells during the  cell rem oval process. 
Removal o f cells by the  cell dissociation so lu tion at 37°C retains the  m ost cell surface 
CX3CL1 staining. n = l.
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Figure 2.16; Representative agarose gel electrophoresis of RNA samples extracted from 
HASMC. Each lane represents a separate sample, w ith good quality RNA indicated by two  
clear bands (denoting 28S and 18S rRNA components) at an approximate ratio of 2:1.
2.3A.2 Primer efficiencies
Primer efficiencies of all target genes and reference control genes were considered acceptable, 
as they were w ithin the 100±10% range (Figure 2.17 and 2.18), apart from the CX3CR1 gene, 
which was undetectable. Primer products were in the expected range of the ir predicted 
amplicon sizes, and demonstrated a single product when analysed by agarose gel 
electrophoresis (Figure 2.19).
2.3.5 Analysis of CX3CLI expression following cytokine treatment 
of human aortic vascular cells
23.3.1 Analysis of CX3CLI expression by ELISA
Both HASMC and HAEC demonstrated a dose-dependent increase in cleaved (measured in 
cultured supernatants) and cell-bound (measured in cell lysates) CX3CL1 expression following 
cytokine treatm ent, when measured by ELISA. All increases were significant at both lOng/ml 
and lOOng/ml TNFa plus IFNy treatments (P<0.05 ANOVA, n=6 ), and were similar in magnitude 
in SMC (Figure 2.20) and endothelial cells (Figure 2.21). This upregulation of CX3 CLI expression 
upon cytokine treatm ent was not due to effects on cell proliferation, as no significant 
differences were observed in DNA synthesis (BrdU ELISA) and total protein content (BCA assay) 
respectively following cytokine treatm ent (Figure 2.22 and 2.23 respectively).
2.3.5.2 Analysis of CX3CLI expression by flow cytometry
The dose-dependent increase in expression o f cell-bound CX3CL1 following cytokine treatm ent 
observed by ELISA, was replicated by flow cytometry analysis o f HASMC. Cell-bound CX3CL1 
was increased at 1, 10 and lOOng/ml TNFa + IFNy in these cells and significantly increased at 
lOOng/ml (P<0.05 Kruskal Wallis, n=3) (Figure 2.24). Though a substantial difference was 
observed, significance was not demonstrated at the lOng/ml treatm ent. Concurrent 
measurement of cell viability by propidium iodide uptake revealed no significant differences 
between the treatm ent conditions (Data not shown).
2.3.3.3 Analysis ofCXsCLl expression by immunocytochemistry
The increase in CX3CL1 expression following cytokine treatm ent was demonstrated visually in 
HASMC and HAEC by immunocytochemistry. Under basal conditions, with no cytokine 
treatm ent, CX3 CL1 was found to be located diffusely in the cytoplasm and on the cell 
membrane in a similar manner in both cell types (Figure 2.25). The intensity of CX3 CL1 staining 
increased in cells treated with lOOng/ml TNFa plus IFNy for 24 hours, with cellular location
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Figure 2.17; Primer efficiency plots fo r TaqMan qRT-PCR targets. As the tem p la te  s ta rting  
quan tity  is reduced by half th rough serial d ilu tion , approxim ate ly one cycle d iffe rence is 
observed. W hen th is is p lo tted  against Log d ilu tion  fac to r a linear slope o f the  Ct values is 
approxim ate ly -3.32, where th is value equals 100% efficiency.
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Gene Target % Efficiency
G APDH 109.88
RPL13A 96.63
B2M 90.85
C X 3CL1 106.78
CCL2 94.95
A D A M 17 96.25
A D A M 10 100.94
AR 95.59
TIMP1 95.49
T IM P 3 105.89
Figure 2.18; Calculated prim er efficiencies fo r TaqMan qRT-PCR targets. Calculated 
prim er efficiencies from  slope values fall in the range o f 100 ± 10%.
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Figure 2.19; Agarose gel electrophoresis o f prim er products from  qRT-PCR 
amplification. HASMC samples were run on a 2.5% agarose gel fo llo w in g  qRT-PCR 
am plifica tion  and amplicon sizes were compared to  a 25bp m arker. A single p roduct was 
detectable fo r all targets, o the r than CX3CR1 where no product was observed. The 
arrowed line indicates the resulting m igration angle due to  im perfections in the  gel, or 
equ ipm ent. Band size comparisons were used to  account fo r this.
121
HASMC
m  20
Lysate
Supernatant
0 10 100
TNF + IFN n g /m l
Figure 2.20; CX3CL1 expression in HASMC determined by ELISA. A dose-dependent 
increase in cleaved (supernatant) and cell-associated (lysate) CX3CL1 pro te in  was seen 
a fte r a 24h incubation w ith  TNFa + IFNy. *P<0.05, **P<0.01, ***P<0.001vs Ong/ml 
ANOVA n=6.
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Figure 2.21; CX3CL1 expression in HAEC determined by ELISA. A dose-dependent 
increase in cleaved (supernatant) and cell-associated (lysate) CX3CL1 p ro te in  was seen 
a fte r a 24h incubation w ith  TNFa + IFNy. *P<0.05, **P<0.01, ***P <0.001 vs Ong/ml 
ANOVA n=6.
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Figure 2.22; DNA synthesis in HASMC as measured by BrdU proliferation ELISA 
following cytokine treatments. No significant effects were observed fo r all trea tm en ts  
in serum -free media. 10% serum media was used as a positive contro l. ***P <0.001  vs 
Control, ANOVA, n=6
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Figure 2.23; Total protein content o f HASMC and HAEC as measured by BCA 
following cytokine treatments. No significant changes were observed fo llo w in g  
experim ental trea tm en ts  when compared to  untreated contro l (Ong). Kruskal-Wallis 
n=3.
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Figure 2.24; Flow cytometry analysis o f cell surface CX3CL1 expression in HASMC 
following cytokine treatm ent. Cells dem onstrated a dose-dependent response to  
TNFa + IFNy trea tm en t. (A). As cytokine concentra tion  increased, the histogram  
traces sh ifted to  the  right on the  x-axis (FL2-H) ind icating increased fluorescence due 
to  antibody binding (B). The mean fluorescence index (MFI) represents the  am ount o f 
positive staining normalised to  isotype contro l. Colours in bar chart (B) correspond to  
lines in histogram  (A). *P<0.05 vs Ong/ml, Kruskal-Wallis, n=3.
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remaining consistent. Intensity o f staining was not quantified, and was used only as a visual 
representation. The intensity of smooth muscle cell CX3CL1 staining appeared greater than 
that of endothelial cells, in contrast to the expression detected by ELISA.
23.5.4 Analysis ofCXsCLl mRNA expression by qRT-PCR
Expression of CX3CL1 mRNA increased following cytokine treatm ent in both HASMC and HAEC, 
in a dose-dependent manner (Figure 2.26). Fold changes were of a large magnitude, but due to 
the variability o f the data and the small sample sizes (n=3), significance was only demonstrated 
at lOOng/ml TNFa plus IFNy for SMC and endothelial cells alike (p<0.05, p<0.01 respectively, 
Kruskal Wallis). The cytokine induced increase in mRNA expression was substantially greater in 
HASMC compared to HAEC, with fold change in expression demonstrated as thousand-fold 
opposed to hundred-fold, indicating a lOx greater magnitude in HASMC.
In summary, CX3CL1 expression was significantly and dose-dependently increased in HASMC 
and HAEC by treatm ent w ith TNFa + IFNy, at both the protein and mRNA level. The magnitude 
of increase in expression was different between the different cell types, although this was 
technique dependent (Table 2.5).
2.3.6 Expression of ADAM-10 and -17 in human vascular cells
Since experiments indicated a significant increase in shedding of CX3CL1 into the supernatant 
following cytokine treatm ent of vascular cells, the expression of ADAM-10 and ADAM-17, 
known sheddases for CX3CL1 (Garton et al. 2001, Tsou et al. 2001, Hundhausen et al. 2003), 
were investigated.
2.3.6.1 Analysis of ADAM-10 and -17 expression by 
immunocytochemistry
Immunocytochemical investigation demonstrated that ADAM-10 and ADAM-17 were 
constitutively expressed on the cell membrane and in the cytoplasm of HASMC (Figure 2.27). 
When fixed with 4% PFA, the staining patterns o f both ADAM-17 and ADAM-10 was 
membraneous and represented the cell-bound, and therefore active, fraction o f these 
enzymes. Following acetone fixation and permeablisation, both ADAM-17 and ADAM-10 were 
also found to localise in perinuclear compartments (Figure 2.27).
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A  8 0 0 0
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TN F + IFN (n g /m l)
B 7 0 0
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Figure 2.26; qRT-PCR analysis o f CX3CL1 mRNA expression in human aortic vascular 
cells following cytokine treatm ent. Both HASMC (A) and HAEC (B) dem onstra ted  a 
dose-dependent increase in CX3CL1 mRNA expression fo llow ing  TNFa + IFNy 
trea tm en ts  relative to  contro l. HASMC showed a 10-fold greater upregula tion than 
HAEC. 2"AACt is representative o f fo ld-change from  contro l. *P<0.05, **P<0.01 vs 
Ong/mlKruskal-Wallis, n=3.
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H A S M C H A E C
Cytok ines  
T N Fa+ IFN y (n g /m l)
1 1 0 1 0 0 1 1 0 1 0 0
ELISA Supernatant Nl Nl
* * *
t
* * *
Lysate Nl t *
*  * *
t Nl
* * * * * *
t
ICC Nl Nl t Nl Nl t
qRT-PCR t t t * t t yK **t
Flow Cytom etry t t Nl Nl Nl
Table 2.5; Summary o f cytokine-induced CX3CL1 expression in human aortic vascular 
cells. C X 3C LI was consistently upregulated by p ro in flam m atory  cytokines TNFa and 
IFNy in both HASMCand HAEC. *P<0.05, **P<0.01, ***P <0.001; NI=not investigated
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2.3.6.2 Analysis of AD AM I 7 expression by flow cytometry
The expression of cell-surface ADAM-17 appeared to be marginally, but not significantly, 
upregulated in a dose-dependent manner by treatm ent of HASMC w ith TNFa plus IFNy, when 
assessed by flow cytometry and MFI analysed(Figure 2.28b). Histogram plots revealed no 
significant modulation of ADAM-17 surface expression by cytokine treatm ent (Figure 2.28a).
2.3.6.3 Analysis of ADAM-10 and -17 expression by qRT-PCR
Expression o f ADAM-10 and ADAM-17 mRNA was not significantly altered by cytokine 
treatm ent in vascular endothelial or SMC (Figure 2.29). Some fluctuations did occur, with slight 
increases for ADAM-17 expression in HASMC at 10 and lOOng/ml, but these did not reach 
significance. The endogenous inhibitors of ADAM-17 and ADAM-10, TIMP-3 and TIMP-1, were 
also not significantly modulated at the mRNA level in HAEC and HASMC when these cells were 
treated with the pro-inflammatory cytokines TNFa plus IFNy. A slight decrease in TIMP-3 
mRNA expression was observed but this did not reach significance (Figure 2.29).
In summary, ADAM-17 and ADAM-10 (the enzymes responsible for CX3CL1 shedding) are 
expressed by aortic vascular cells, along with the ir tissue inhibitors TIMP-3 and TIMP-1. 
Although ADAM-17 expression appeared to be slightly increased by TNFa + IFNy, significance 
was not demonstrated and the magnitude of the increases was small. In addition, no changes 
in TIMP-3 or TIMP-1 expression were observed following cytokine treatm ent.
2.3.7 Expression of CX3CRI in human aortic vascular cells
To determ ine whether CX3CL1 can act in an autocrine manner on aortic vascular cells, the 
expression o f its receptor was investigated.
2.3.7.1 Analysis of CX3CRI mRNA expression by qRT-PCR
CX3CRI mRNA was undetectable by qRT-PCR in both HASMC and HAEC under basal conditions 
and following treatm ent w ith inflammatory cytokine (0-100ng/m l TNFa + IFNy). To determ ine 
the specificity o f the primer-probe used, THP-1 cells were assessed for CX3 CR1 expression as a 
positive control. CX3CR1 mRNA was expressed in this cell line, confirming the specificity of the 
primers (Figure 2.30b). In addition, CX3CR1 mRNA expression in THP-1 cells was down- 
regulated following treatm ent w ith 10 and lOOng/ml TNFa plus IFNy for 2 hours (Figure 2.30c).
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Figure 2.28; Flow cytometry analysis o f cell surface ADAM-17 expression in HASMC 
following cytokine treatm ent. A dose-dependent increase in ADAM-17 is apparent 
fo llow ing  TNFa + IFNy trea tm en t, although changes w ere not s ign ificantly d iffe re n t from  
contro l, which can be seen from  the small m agnitude o f the Y axis scale (B) and the  lack o f 
m ovem ent in cell traces on the histogram (A). Colours in bar chart (B) correspond to  lines 
in histogram  (A). Kruskal-Wallis n=3.
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Figure 2.29 qRT-PCR analysis o f ADAM-17, -10 and their corresponding tissue 
inhibitors, TIMP-1 and TIMP-3, in aortic vascular cells following cytokine 
treatm ent. No significant changes in mRNA expression occurred fo llow ing  2h 
TNFa + IFNv trea tm en t. Kruskal-Wallis n=3.
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Figure 2.30; CX3CR1 expression in THP-1 cells. (A) CX3CR1 prote in  expression was 
confirm ed by im m unocytochem istry  in THP-1 cells when aggregated as a resu lt o f 
cytospinning, and when isolated (n= l). Staining appeared to  be localised to  the  cell 
mem brane. A negative contro l w ith  the omission o f the prim ary antibody revealed no 
non-specific b inding o f the secondary antibody. Nuclei were countersta ined w ith  
DAPI (Blue). (B) CX3CR1 mRNA was detected in THP-1 cells by qRT-PCR as 
dem onstrated by trip lica te  am plifica tion curves. B2M was used as the  reference 
gene. CX3CR1 mRNA expression was down regulated fo llow ing  trea tm en t o f cells w ith  
TNFa + IFNy (C). n=2.
CX3CR1
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2.3.7.2 Analysis of CX3CRI expression by immunocytochemistry
Contrary to qRT-PCR findings, the CX3CR1 protein was detected in HASMC and HAEC by 
immunocytochem istry (Figure 2.31). The receptor appeared punctuate throughout the cell in 
HASMC, and clustered in a perinuclear location in HAEC.
THP-1 cells were used as a positive control for CX3CR1 immunofluorescent staining. As these 
cells were a suspension cell line, a small volume of cells was cytospun onto glass slides before 
immunostaining. This was performed at high and low cell density, to rule out non-specific 
binding to aggregated cells, and to demonstrate universal cell staining. THP-1 cells appeared 
immuno-positive for CX3CR1 staining, which was localised on the cell membrane of both 
clustered and isolated cells, suggesting specificity of the antibodies (Figure 2.30a).
In summary, CX3CR1 protein was expressed on the surface of aortic vascular cells, but the 
mRNA was not detected by qRT-PCR. This disparity did not appear to be due to non-specific 
activity o f the antibodies used in immunocytochemistry or lack o f specificity o f primer-probes 
used in qRT-PCR.
2.3.8 CCL2 expression in human aortic vascular cells
Since CCL2 has been implicated in monocyte recruitment to atherosclerotic lesions, its 
expression was investigated in the cell model used in this project.
2.3.8.1 Analysis ofCCL2 expression by ELISA
The CCL2 protein was expressed in both HASMC and HAEC as measured by ELISA. HAEC- 
associated and secreted CCL2 was increased following 24h cytokine treatm ent, in a dose- 
dependent manner, as was cell-associated CCL2 in HASMC. This upregulation was significant at 
10 and lOOng/ml TNFa + IFNy (P<0.001, ANOVA, n=3). No significant changes were observed 
for secreted CCL2 in HASMC. A similar magnitude of expression was exhibited for both cell 
types (Figure 2.32).
2.3.8.2 Analysis ofCCL2 mRNA expression by qRT-PCR
qRT-PCR demonstrated a dose-dependent upregulation of CCL2 mRNA expression in vascular 
cells following cytokine treatm ent (Figure 2.33). The increase was similar between the two cell 
types, and appeared to plateau at lOng/ml. Increases were significant for HAEC at 10 and 
lOOng/ml (P<0.05, Kruskal Wallis, n=3) and at lOOng/ml for HASMC (P<0.05, Kruskal Wallis, 
n=3). In summary, vascular aortic endothelial and smooth muscle cells express CCL2 at the 
protein and mRNA level, and this expression is upregulated by proinflammatory cytokines.
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HASMC
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Figure 2.31; Immunocytochem ical analysis of CX3CR1 expression in human 
aortic vascular cells. Both HASMC and HAEC dem onstrate  im m uno-positive  
sta ining fo r CX3CR1. The receptor expression appeared punctuate  th rough  the 
cytoplasm o f HASMC and partia lly  clustered around the  nucleus o f HAEC 
fo llow ing  actetone fixa tion  and perm eablisation. Negative contro ls w ith  the 
omission o f the  prim ary antibody revealed no non-specific b inding o f the 
secondary antibody. Nuclei were countersta ined w ith  DAPI (Blue).
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Figure 2.32; ELISA analysis o f CCL2 expression in human aortic vascular cells follow ing  
cytokine treatm ent. Cellular (lysate) CCL2 was upregulated in HASMC. Secreted 
(supernatant) HASMC CCL2 was not s ign ificantly a ltered due to  high basal expression 
(A). Cellular and secreted CCL2 were sign ificantly upregulated fo llow ing  TNFa + IFNy 
trea tm en t in HAEC (B). ***P <0.001/ ANOVA, n=6
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Figure 2.33; qRT-PCR analysis o f CCL2 mRNA expression in human aortic  
vascular cells following cytokine treatm ent. Both HASMC (A) and HAEC (B) 
dem onstrated a dose-dependent upregula tion o f CCL2 mRNA fo llow ing  2h 
TNFa + IFNy trea tm en t. *P<0.05, Kruskal-Wallis n=3.
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2.3.9 Investigation of androgen modulation of cytokine-induced 
CX3CLI expression in vascular cells
In order to determ ine any potential modulatory effect of androgens in inflammation, the effect 
of testosterone and DHT on cytokine-induced CX3CL1 expression was investigated.
2.3.9.1 Effect of androgens on CX3CLI expression: analysis by 
ELISA
Testosterone and DHT showed no significant or reproducible modulation of CX3CL1 expression 
induced by 10 or lOOng TNFa plus IFNy stimulation in HASMC, as measured by ELISA. No 
effects were seen when the androgens were applied for either 2h (data not shown, n=3), 24h 
prior to the 24h cytokine treatm ent, or concurrently with the cytokines for 8 h (n= 6  and n=2 
respectively; see figure 2.34 and 2.35). Similarly in HAEC there was a lack o f androgen 
modulation of CX3CL1 expression in supernatants and lysates, after 24h DHT treatm ent 
followed by the addition of lOng/m l TNFa plus IFNy for 24h (n=6 ; figure 2.36). Androgens did 
not affect cell proliferation, as no significant differences were observed in DNA synthesis 
(measured by BrdU ELISA) or total protein content (measured by BCA assay) respectively, 
following testosterone or DHT treatm ent (Figure 2.37 and 2.28 respectively).
2.3.9.2 Effect of androgens on CX3CLI expression: analysis by 
qRT-PCR
Androgens, similarly, did not affect the cytokine-induced CX3CL1 mRNA expression, as 
measured by qRT-PCR. Expression of CX3CL1 mRNA was not significantly modulated in HASMC 
following 24h of lOnM  androgen treatm ent and 2h of lOng/m l cytokine stimulation, although 
testosterone did appear to slightly down-regulate cytokine-induced CX3CL1 mRNA expression 
(n=3; see figure 2.39).
Androgen modulation was investigated further in vascular cells cultured in complete medium
(containing serum), to test whether the presence of growth factors is needed for androgens to
exert a modulatory action on inflammation, as suggested by Orio (2002) and Bakin (2003). To
exclude the possibility of androgens present in the serum causing an effect, experiments were
performed in the presence and absence of the antiandrogen flutamide alone, or in
combination with e ither testosterone or DHT. As measured by qRT-PCR, no significant effects
or trends were seen in the expression of CX3CL1 in vascular cells following 24h treatm ent w ith
testosterone or DHT, with or w ithout flutamide (n=3; see figures 2.40 and 2.41). When a
subsequent 2h lOng/m l cytokine stimulation was applied after the 24h androgen treatm ent,
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Figure 2.34; ELISA analysis o f CX3CL1 expression in HASMC following  
cytokine and 24h androgen treatm ent. Cell-associated (lysate) and secreted 
(supernatant) 24h 10 o r lOOng/ml cytokine-induced CX3CL1 expression was 
not a ltered by 24h p re -trea tm ent w ith  testosterone or DHT. Kruskal-Wallis 
n=6
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Figure 2.35; ELISA analysis o f CX3CL1 expression in HASMC following 8h 
cytokine and androgen co-treatment. Cell-associated (lysate) and secreted 
(supernatant) 8 h lO ng/m l cytokine-induced CX3CL1 expression was not 
a ltered by 8 h co -trea tm en t w ith  testosterone or DHT. Kruskal-Wallis n=2
139
HAEC
V e h ic le lO n M lO O n M
lO n g /m l TN F + IFN
Figure 2.36; ELISA analysis o f CX3CL1 expression in HAEC following cytokine 
and 24h androgen treatm ent. Cell-associated (lysate) and secreted 
(supernatant, s/n) 24h cytokine-induced CX3CL1 expression was not a ltered by 
24h p re -trea tm ent w ith  DHT. Kruskal-Wallis n=6
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Figure 2.37; DNA synthesis in HASMC as measured by BrdU proliferation  
ELISA following androgen treatments. No significant effects were observed 
for all treatments in serum-free media. 10% serum media was used as a 
positive control. ***P <0.001  vs vehicle, ANOVA, n=6
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Figure 2.38; Total protein content o f HASMC and HAEC samples as 
measured by BCA following androgen treatments. No significant changes 
were observed following experimental treatments when compared to 
untreated vehicle (Ong). Kruskal-W allis n=3.
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Figure 2.39; qRT-PCR analysis o f CX3CL1 mRNA expression in HASMC following  
cytokine and androgen trea tm en t 24hr androgen and 2hr cytokine trea tm en t 
dem onstrated CX3CL1 expression appeared m arginally but not sign ificantly 
reduced by testosterone trea tm en t. No e ffect was o f DHT was observed. Kruskal- 
Wallis n=3.
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Figure 2.40; qRT-PCR analysis o f CX3CL1 mRNA expression in HASMC follow ing  
androgen treatm ent and AR blockade. No significant e ffects or trends w ere seen in 
the expression o f CX3CL1 in vascular cells fo llow ing  24h trea tm en t w ith  testosterone 
(A) or DHT (B); w ith  o r w ith o u t flu tam ide  (F100=Flutamide lOOnM, F1000=Flutam ide 
lOOOnM). Kruskal-Wallis n=3.
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Figure 2.41; qRT-PCR analysis of CX3 CL1 mRNA expression in HAEC following androgen 
treatm ent and AR blockade. No significant e ffects o r trends were seen in the  expression 
o f CX3CL1 in vascular cells fo llow ing  24h trea tm en t w ith  testosterone (h) o r DHT (i), w ith  
o r w ith o u t flu tam ide  (F100=Flutamide lOOnM, F1000=Flutamide lOOOnM). Kruskal-Wallis 
n=3.
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CX3CL1 mRNA expression in HASMC appeared to be physiologically, although not statistically, 
down-regulated in a dose-dependent manner by testosterone. This trend was not altered by 
AR antagonism (n=3; figure 2.42). However, no effect was seen w ith DHT treatm ent under the 
same experimental conditions (n=3; figure 2.42). In agreement w ith this, in HAEC DHT did not 
modulate cytokine-induced CX3CL1 upregulation (n=3; figure 2.43), whereas a slight 
physiological, but not statistically significant, reduction due to testosterone was observed, 
particularly at the higher concentration of lOOng/ml TNFa plus IFNy (n=3; figure 2.43). This 
down-regulation was abolished by co-treatment w ith lOOOnM flutamide, suggesting an AR- 
mediated response.
2.3.10 Investigation of androgen modulation of cytokine-
induced CCL2 expression in vascular cells
In order to further study a potential modulatory effect of androgens in inflammation, the 
effect of testosterone and DHT on cytokine-induced CCL2 expression was investigated.
2.3.10.1 Effect of androgens on CCL2 expression: analysis by 
ELISA
As cytokine-induced CX3CL1 protein expression in vascular cells was not modulated by 
androgens when cells were incubated in lOnM to 2pM for 24h prior to 24h TNFa plus IFNy 
treatm ent, in this experiment only supraphysiological doses of testosterone were used to test 
for an effect on CCL2 expression in HASMC. Pre-treatment w ith 0.1 and lO pM  testosterone 
produced no significant effect on cytokine-induced CCL2 expression, measured in both the cell 
supernatants and lysates (n=2; see figure 2.44).
2.3.10.2 Effect of androgens on CCL2 expression: analysis by 
qRT-PCR
Expression of CCL2 mRNA in vascular cells was similarly not significantly modulated by 24h
treatm ent w ith testosterone or DHT, either w ith or w ithout flutamide in serum containing
media. However, lOOnM testosterone treatm ent did appear to reduce CCL2 mRNA expression
in HAEC, both w ith and without AR antagonism (n=3; see figures 2.45 and 2.46). As with
CX3CL1 mRNA expression, when a subsequent 2h lOng/m l cytokine stimulation was applied
a fter the 24h androgen treatments, expression o f CCL2 mRNA in HAEC appeared
physiologically, although not statistically, down-regulated by testosterone, particularly at
lOnM concentrations. Again this trend was abrogated by AR antagonism, suggesting an AR-
mediated response (n=3; figure 2.47). However, no effect was seen w ith DHT treatm ent under
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Figure 2.42; qRT-PCR analysis o f CX3CL1 mRNA expression in HASMC 
follow ing cytokine and androgen treatm ent with AR blockade. TNFa plus 
IFNy-induced CX3CL1 expression appeared m arginally but no t s ign ificantly 
reduced by testosterone trea tm en t, an e ffect th a t was not a ltered by 
blocking the  AR w ith  lOOOnM flu tam ide  (F1000) (A). No e ffect was 
observed w ith  DFIT trea tm en t (B). Kruskal-Wallis n=3.
145
0
1
fM
CX 3 C L I
V e h ic le  1 10
T e s to s te ro n e  (n M )  
lO n g /m l T N F + IF N
100
F0
F 1 0 0 0
4 5 0  t
CX3 CL1
V e h ic le 1 I 10 
D H T  (n M )  
lO n g /m l T N F + IF N
FO
F 1 0 0 0
Figure 2.43; qRT-PCR analysis o f CX3CL1 mRNA expression in HAEC 
following cytokine and androgen treatm ent with AR blockade. TNFa plus 
IFNy-induced CX3CL1 expression appeared m arginally but not s ign ificantly 
reduced by testosterone trea tm en t, an e ffect th a t was abrogated by 
blocking the AR w ith  lOOOnM flu tam ide  (F1000) (A). No e ffec t was 
observed w ith  DHT trea tm en t (B). Kruskal-Wallis n=3.
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Figure 2.44; ELISA analysis o f CCL2 expression in HASMC following cytokine 
and androgen treatm ent. Cell-associated (lysate) and secreted (supernatant, 
s/n) 24h cytokine-induced CCL2 expression was not a ltered by 24h pre­
trea tm en t w ith  DHT. Kruskal-Wallis n=2
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Figure 2.45; qRT-PCR analysis o f CCL2 mRNA expression in HASMC follow ing androgen 
treatm ent and AR blockade. No significant e ffects or trends were seen in the  
expression o f CCL2 in vascular cells fo llow ing  24h tre a tm e n t w ith  testoste rone  (A) or 
DHT (B), w ith  or w ith o u t flu tam ide  (F100=Flutamide lOOnM, F1000=Flutam ide 
lOOOnM). Kruskal-Wallis n=3.
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Figure 2.46; qRT-PCR analysis o f CCL2 mRNA expression in HAEC following androgen 
treatm ent and AR blockade. No significant effects or trends were seen in the 
expression o f CCL2 in HAEC fo llow ing  24h trea tm en t w ith  testosterone (m) o r DHT (n), 
w ith  or w ith o u t flu tam ide . Kruskal-Wallis n=3.
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the same experimental conditions (n=3; figure 2.47), and there was no effect of testosterone 
or DHT on HASMC cytokine-induced CCL2 upregulation (n=3; see figure 2.48).
2.3.11 Androgen delivery test
To test androgen action on vascular cells, AR mRNA was assessed in HASMC and HAEC 
following testosterone or DHT treatm ent. No modulation was observed and only low copy 
numbers of the AR gene were expressed (n=3; see figure 2.49).
AR expression was confirmed in the human vascular cells by immunocytochemistry. AR 
staining was demonstrated at low levels in the cytoplasm and the perinuclear regions of 
HASMC. HAEC displayed a similar pattern of staining, but with increased AR staining in the 
perinuclear region. Negative controls, with the omission o f the primary antibody, showed no 
staining, ruling out potential non-specific binding of the secondary antibody (Figure 2.50).
To investigate whether this lack o f effect on vascular cells was due to a failure to deliver the 
androgens to the cells, the prostate cancer cell line DuCAPs (Figure 2.51) was utilised, since 
these cells are known for the ir androgenic response due to amplified AR expression (Saramaki 
et al. 2008). DHT (n=3) and testosterone (n= l) were shown to down-regulate AR expression in 
DuCAPs in a dose-dependent manner following 24h treatm ent (Figure 2.51). This down- 
regulation was not statistically significant, due to the variability of data and lack o f power 
associated with qRT-PCR experiments. However, the physiological effect was clearly evident. 
This confirmed that androgens were being delivered to the cells in this experimental system. 
The pronounced effect of androgens seen in DuCAPs compared to the vascular cells maybe 
due to the greatly increased copy number of AR mRNA observed relative to GAPDH in these 
cells, potentially translating to an increased AR protein expression and activity relative to the 
vascular cells (Figure 2.52).
2.3.12 Summary
The cytokine (TNFa + IFNy)-induced upregulation o f CX3 CL1 in aortic vascular cells in this model 
was not significantly modulated by testosterone or DHT treatm ent. Slight modulations in 
expression were observed, particularly following testosterone treatm ent, and mostly showed a 
down-regulation with AR antagonism differentially regulating any such modulations 
dependent upon cell type, treatm ent duration and whether testosterone or DHT was used. 
However, the majority of the different culture conditions investigated demonstrated no 
androgenic effects and where slight trends were apparent significance was lacking. Similar 
inconsistent results were seen for the modulation of cytokine-induced CCL2 upregulation.
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Figure 2.47; qRT-PCR analysis o f CCL2 mRNA expression in HAEC 
following cytokine and androgen treatm ent wityh AR blockade. TNFa 
plus IFNy-induced CCL2 expression appeared m arginally bu t no t 
sign ificantly reduced by testosterone trea tm en t, an e ffect th a t was 
abrogated by blocking the AR w ith  lOOOnM flu tam ide  (F1000) (A). No 
e ffect was seen w ith  DFiT trea tm en t (B). Kruskal-Wallis n=3.
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Figure 2.48; qRT-PCR analysis o f CCL2 mRNA expression in HASMC follow ing  
cytokine and androgen treatm ent with AR blockade. 2hr cytokine-induced CCL2 
expression was not significantly a ltered by 24hr p re -trea tm ent w ith  testoste rone  
(A) or DHT (B) trea tm en t, w ith  or w ith o u t AR blockade (lOOOnM flu tam ide ; 
F1000). Kruskal-Wallis n=3.
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Figure 2.49; qRT-PCR analysis o f AR mRNA expression in HASMC following  
cytokine and androgen trea tm en t  24hr androgen tre a tm e n t fo llow ed  by 2hr 
cytokine s tim u la tion  dem onstrated no e ffect on AR expression. Kruskal-Wallis n=3.
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Figure 2.50; Immunocytochemical analysis o f androgen receptor expression in human 
aortic vascular cells. Both HASMC and HAEC display positive im m unofluo rescen t 
staining fo r the AR. The AR appears to  be located in the  cytoplasm and the  nuclear 
regions o f the cells fo llow ing  acetone fixa tion  and perm eablisation. Negative contro ls 
w ith  the omission o f the prim ary antibody revealed no non-specific b inding o f the 
secondary antibody. Nuclei were countersta ined w ith  DAPI (Blue).
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■  T e s to s te ro n e
O n M  V e h ic le  O . ln M  I n M  lO n M  lO O n M
Figure 2.51; qRT-PCR analysis o f androgen receptor mRNA expression in 
DuCaP cells following androgen trea tm en t DHT dose-dependently decreases 
AR expression in DuCAP cells (n=3). The same pattern  is seen w ith  testosterone 
tre a tm e n t (n= l).
M DUCAPs
■  H A S M C
■  HAEC
DUCAPs H A S M C HAEC
2.973909151 0.002041509 0.000631
Figure 2.52; qRT-PCR relative expression o f androgen receptor mRNA in 
DuCaP cells and human aortic vascular cells. The relative copy num ber o f 
AR mRNA normalised to  GAPDH, as measured by 2"ACt, was greater in the 
DuCaPs. *P<0.05vs DuCaPs, n=3, Kruskal-Wallis.
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2.4 Discussion
2.4.1 Optimisation of cytokine treatments
The main aim of the in vitro studies was to establish an inducible pro-inflammatory cell culture 
environment for both HAEC and HASMC as a model of vascular CX3CL1 and CCL2 upregulation, 
whereby expression could be reliably measured and the impact o f testosterone on the 
inflammatory response assessed.
In this study, IFNy treatm ent of HASMC brought about an increase in CX3CL1 protein 
expression in the cell culture supernatants, whereas TNFa and IL-18 had no effect. This is in 
contrast to previous research which has demonstrated on several occasions that TNFa 
stimulation o f vascular cells leads to the upregulation and expression o f CX3CL1 (Chapman et 
al. 2000, Garcia et al. 2000, Ludwig et al. 2002, Lesnik et al. 2003, Ollivier et al. 2003, Ahn et ol. 
2004). In particular, Ollivier et al. (2003) investigated the expression o f CX3CL1 in HASMC 
following TNFa stimulation. Following 4 hours exposure to TNFa (0.1-20ng/m l), added to the 
culture medium, CX3CL1 cell protein (measured via ELISA and flow cytometry) and mRNA 
(measured via qRT-PCR) was significantly upregulated. It is possible that the different results 
found in the present study are a result o f measuring just cleaved CX3CL1 in the culture 
supernatant. In the study by Ollivier et al. (2003) it was reported that CX3CL1 released into the 
culture supernatant made up a maximum of just 30% o f the CX3CL1 expressed, and taken w ith 
the proposition that cell-bound CX3CL1 can be recycled from the membrane to regulate 
surface expression (Huang et al. 2009, Liu et al. 2004), measurement of shed CX3CL1 alone may 
not be an adequate measure. The detection of CX3CL1 in culture supernatants may be more 
reflective of the activity of its endogenous sheddases rather than CX3CL1 expression per se.
The present study does however support previous findings where IFNy increased CX3CL1 
expression in vascular endothelial cells (Bazan et al. 1997, Imaizumi et al. 2000) and in vascular 
SMC (Ludwig et al 2002, Ollivier et al. 2003, Lesnik et al. 2003) in a dose dependent manner. 
Again, the measurement of cleaved CX3CL1 may represent sheddase function, as well as an 
increase in CX3CL1 expression.
IL-18 had no effect on CX3CL1 expression in HASMC in the present study, when applied alone 
or in combination with TNFa, IFNy or TNFa and IFNy together. As IL-18 augments the 
production of various other mediators, such as IFNy, IL-ip, IL-8 , IL-6 , MCP-1, TNFa, and several 
adhesion molecules (Puren et al. 1998, Vidal-Vanaclocha et al. 2000, Gerdes et al. 2002), as
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well as playing a role in SMC proliferation and migration (Sahar et al. 2005), it is possible that 
this cytokine may produce it's proatherogenic effects via interaction with, and regulation of, 
other mediators rather than having a direct action on CX3CL1 expression.
The combination of TNFa and IFNy dose-dependently upregulated shed CX3CL1 expression in 
HASMC in a manner that was more than additive compared to the effects observed from single 
cytokine treatments. This would suggest that TNFa and IFNy act in synergy to increase CX3CL1 
expression. TNFa and IFNy are known to cooperate w ith each other in the upregulation of 
various genes (Paludan 2000). The synergistic induction of CX3CL1 by TNFa and IFNy has been 
reported previously in vascular endothelial cells (Matsumiya et al. 2010), and in cultured 
astrocytes (Yoshida et al. 2001). Matsumiya et al. (2010) recently attempted to characterise 
these mechanisms. The authors reported regulation at a post-transcriptional level, with TNFa 
stabilising the CX3 CL1 mRNA expressed in response to IFNy. This would allow for increased 
translation and protein assembly of CX3CL1, therefore elevating the levels of expression. This 
theory is supported by the findings of the present study, as TNFa stimulation alone resulted in 
no increase in CX3 CL1 expression, whereas IFNy generated a modest upregulation, which was 
enhanced by combined stimulation with TNFa. Additionally, a combined stimulation with TNFa 
and IFNy has previously been shown to increase in vitro CX3CL1 expression in HASMC, 
measured by ELISA, flow cytometry and qRT-PCR (Ludwig et al. 2002, Ollivier et al. 2003, Lesnik 
et al. 2003).
Investigation of this TNFa and IFNy-induced CX3CL1 upregulation over time revealed that
cleaved CX3CL1 increased with the duration o f cytokine stimulation, first detected at 8  hours
post-stimulation and then rising to maximal levels by 48 hours. Cell-associated CX3CL1 was
increased rapidly, as early as 2  hours post-stimulation, and displayed maximal expression
between 8  and 24 hours post-stimulation, before returning almost to basal levels by 48 hours.
This time-course of cell-associated CX3CL1 expression in HASMC is reflective of the expression
seen in HUVEC, whereby detection of full-length CX3CL1 is observed at 6  hours post TNFa
treatm ent (25ng/m l), reaching maximal concentrations at 12 hours, before returning towards
basal levels by 24 hours (Chapman et al. 2000). These authors additionally reported a TNFa-
induced increase in expression of CX3CL1 mRNA at 2 hours, peaking between 6  and 12 hours,
before falling at 24 hours post stimulation. Therefore, the decline in cell-associated CX3CL1
described may be due to down-regulation of the cytokine-induced gene expression and
surface shedding. This is possible as soluble CX3 CL1 in culture supernatants rose
correspondingly. Chapman et al. (2000) also demonstrated a time-dependent increase of
soluble CX3CLI in the culture media beginning at 12 hours post stimulation and increasing at
24 hours. As with the present study, this may not be reflective of increased production and
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cleavage of CX3CL1; but may result from CX3CL1 accumulation in the cell culture supernatants 
over the time course of the experiment. Ollivier et al. (2003) also demonstrated an increase in 
CX3CL1 mRNA expression in HASMC following TNFa plus IFNy treatm ent, detectable at 2 hours 
post stimulation, peaking at 8 h and falling by 16h. Additionally, Yoshida et al. (2001) 
demonstrated an almost identical time course profile of CX3 CL1 expression in the cell lysates 
and culture medium of astrocytes following a combined stimulation with TNFa and IFNy, as 
seen in the present investigation. Thus, the response does not appear to be cell type-specific 
and the mechanism may be common to a number of cell types.
The time course of detection o f both cell-associated and soluble CX3CL1 in the present study 
supports the previous hypothesis that full-length CX3CL1 is produced by vascular cells and 
directed to the membrane before it's release by a cleavage event (Bazan et al. 1997). W hether 
this cleavage in vivo serves to release CX3CL1 as a chemoattractant, or whether it represents a 
term inating event to cellular expression remains controversial, and may depend on cell type, 
vascular location and additional inflammatory influences (Chapman et al. 2000, Ludwig et al. 
2007).
In the present study there was a rapid induction (<2 hours) of CX3CL1 protein expression in 
HASMC lysates which may indicate liberation from intracellular pools, as de novo protein 
synthesis characteristically requires a longer time period (Liu et al. 2005). Similar rapid protein 
detection has been observed in human fibroblasts and endothelial cells for the expression of 
CCL2 (Streiter et al. 1989b) and CX3CR1 in monocytes (Green et al. 2006). However, the 
majority of CX3CL1 protein measured in the cell lysates by ELISA in the present study was 
observed between 8  and 24 hours post cytokine treatm ent, which is more likely to be 
representative of gene upregulation and subsequent protein synthesis.
2.4.2 Analysis of CX3 CLI expression following cytokine treatment 
of human aortic vascular cells
In the present study the dose-dependent increase in expression of cell-bound CX3 CL1 following 
pro-inflammatory cytokine treatm ent observed by ELISA and qRT-PCR in HASMC and HAEC, 
and flow cytometric analysis o f HASMC, clearly indicate a role for this novel chemokine in 
vascular inflammation. Although substantial increases in expression were observed, indicating 
a physiological relevance, statistical significance was not always demonstrated, possibly due to 
low sample numbers and the subsequent use of non-parametric statistical analysis. In contrast 
to the expression of CX3 CL1 detected by ELISA, but in parallel with qRT-PCR data, the intensity 
of smooth muscle cell CX3CL1 staining appeared greater than that of endothelial cells, as
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analysed by immunocytochemistry. The fluorescence intensity was not quantified, however, so 
definitive conclusions cannot be drawn. Mixed reports exist as to the expression patterns of 
CX3CL1 in vascular cells. Hansson and Libby (2006) describe that CX3CL1 is preferentially 
expressed by smooth muscle cells, however, the major source of CX3CL1 production in the 
arteries o f CVD risk vessels has been considered to be from the endothelial cells (Perros et al.
2007). CX3 CL1 may have differential expression and function in cells dependent upon vascular 
location and current inflammatory status.
As stated in the previous section, the dose-dependent increases in CX3CL1 expression seen in 
the present study have been reported previously in HASMC following TNFa and IFNy 
stimulation (Ludwig et al. 2002, Ollivier et al. 2003, Lesnik et al. 2003). The mechanism by 
which this upregulation occurs is not fully elucidated, however NFkB and STAT signalling 
pathways may be involved. The human CX3CL1 gene is located on chromosome 16 and there 
are binding sites for both NFkB and STAT in the promoter region of the gene (Nom iyama et al. 
1998). TNFa and IFNy receptor activation results in NFkB and STAT activity respectively, and is 
therefore capable of promoting CX3CL1 gene transcription (Kotenko et al. 2000, Van der 
Heiden e ta l. 2010).
To control for potential effects of cytokine treatments on proliferation and cell number, which
might affect the interpretation of the expressional results comparative to control conditions,
BrdU and BCA assays were employed. The upregulation o f CX3CL1 protein and mRNA
expression resulting from cytokine treatm ent was not considered to be a result o f increased
proliferation or cell number and was therefore a true reflection o f CX3CL1 synthesis. There was
no significant effect of cytokine treatments on cell proliferation in HASMC as measured by
BrdU assay. In parallel, the measurement of cell viability by propidium iodide uptake and
subsequent flow cytometric analysis, revealed no significant differences between the cytokine
treatm ent conditions in HASMC. Total protein from HASMC and HAEC samples was not altered
between experimental conditions, as measured by BCA assay, supporting the proliferation and
viability data. Therefore the samples were able to be directly compared. In contrast to this
data, previous research has demonstrated both proliferative and apoptotic actions of TNFa
and IFNy in vascular cells. Yu et al (2009) reported a TNFa-induced apoptosis in bovine carotid
artery endothelial cells, a mechanism that was also observed in human vascular endothelial
cells (Chandra et al. 2003, Ramana et al. 2004). Dimmeler et al. (1999) provided evidence that
apoptosis of vascular endothelial cells is due to the post translational modification of anti-
apoptotic proteins sensitising the cells to cell death signals. Opposing results were observed
for the effects of TNFa signalling in VSMC isolated from rat aorta (OuYang et al. 2002) and
human vessels (Lee et al. 2005, Rajesh et al. 2008), as cell proliferation was reported post-
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stimulation. These data suggest a cell type-specific action o f TNFa. In contrast to these actions 
of TNFa, IFNy has been reported to elicit pro-apoptotic effects in VSMC (Rosner et al. 2006, Bai 
et al. 2008). However, taken out of context of the atherosclerotic milieu at any given time in 
lesion development, isolated cytokine stimulations may not be fully representative of in vivo 
mechanisms, as additional apoptotic and/or survival signals may influence the fate of the 
vascular cells. These previous studies investigated the effects of single cytokine treatments, to 
elucidate the mechanisms o f cell proliferation and apoptosis, as opposed to the combined 
stimulation used in the present study. It is plausible that in HASMC proliferation signals 
induced by TNFa (OuYang et al. 2002, Lee et al. 2005, Rajesh et al. 2008) are combined with  
apoptotic signals induced by IFNy (Rosner et al. 2006, Bai et al. 2008) resulting in signal 
suppression and ultimately no overall effect on cell survival or growth. For the purpose of this 
study it was important to consider the effects of cytokine treatments on cell proliferation or 
apoptosis, as this may have biased the analysis. Since no effect was observed, it was 
considered that any subsequent effects o f cytokine treatm ent were due to direct effects on 
target expression.
In summary, human aortic vascular cell expression of CX3CL1 is significantly, and reproducibly, 
upregulated by the combination of proinflammatory cytokines TNFa and IFNy in a dose- 
dependent manner. Thus, in the present study these experimental conditions were used as a 
suitable in vitro model of chemokine upregulation in aortic vascular cells.
2.4.3 Expression of ADAM-10 and ADAM-17 in human vascular 
cells
ADAM-10 and ADAM-17, and the ir tissue inhibitors TIMP-1 and TIMP-3, regulate the cleavage 
of CX3CL1 from the surface of cells and therefore direct the functioning of this chemokine. 
Expression o f these mediators was assessed in relation to the demonstrated cytokine-induced 
CX3CL1 upregulation.
In the present study qRT-PCR and flow cytometry data suggest that the cytokine-induced 
increase in cleaved CX3CL1 in aortic vascular cells is not a result of increased expression of 
ADAM-17 or ADAM-10, or decreased expression o f the ir tissue inhibitors TIMP-1 and TIMP-3. 
As ADAM-10 is involved in the constitutive cleavage of CX3CL1 (Hundhausen et al. 2003), it may 
be expected that the expression of this enzyme would not alter following stimulation. Previous 
studies have demonstrated that ADAM-17 mediates the inducible cleavage of CX3CL1 following 
PMA stimulation (Chapman et al. 2000a, Garton et al. 2001, Tsou et al. 2001). These studies 
demonstrated increased ADAM-17 activity via increased concentrations o f soluble CX3CL1 in
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culture supernatant, but did not investigate expression of the ADAM enzymes, or the ir tissue 
inhibitors, or, therefore, the mechanisms by which increased cleavage occurs. Doedens and 
Black (2000) demonstrated a down-regulation o f PMA-induced ADAM-17 cell surface 
expression on monocytes in culture. This was partially due to internalisation of the enzyme, 
followed by degradation. ADAM-17 has also been reported to be associated with cholesterol- 
rich subcellular membrane microdomains, termed lipid rafts (Tellier et al. 2006). It is possible 
that this pool of ADAM-17 may cycle to the membrane to increase catalytic activity, rather 
than increasing gene transcription and subsequent protein expression. Comparable to the 
present study and supporting this idea, Schlondorff et al. (2000) reported that endogenous 
ADAM-17 localises predominantly in a perinuclear location, with at least some detected on the 
cell surface in COS-7 cells, an SV40 transformed kidney cell line from the African green 
monkey. Additionally, this distribution was not detectably altered by PMA stimulation. 
However, Huang et al. (2009) showed ADAM-17 and ADAM-10 expression predominantly on 
the cell surface in ECV-304 cells, a cell line originating from HUVEC. ADAM-17 expression was 
maintained on the surface of neutrophils following activation and induction of apoptosis 
(Walcheck et al. 2006). These differences may exist as functional disparities between different 
cell types in the regulation o f cell surface cleavage of substrates. Additionally, the specificity of 
the antibodies used to localise the ADAM-17 protein may influence the findings, as specific 
targeting of the mature form of ADAM-17 may provide alternative staining patterns to 
antibodies directed against the pro-form or both. The antibody used in the present study 
however, mapped within an extracellular domain and would therefore bind both mature and 
pro-forms. However, no effect of cytokine stimulation on surface expression o f ADAM-17 was 
demonstrated in the current study by flow cytometry, suggesting that translocation between 
subcellular compartments and the cell surface does not regulate the shedding of CX3CL1 in 
HASMC.
ADAM-17 is additionally involved in the cleavage of some 50 transmembrane proteins 
including TNFa, TGFa, p75 TNF receptor, L-selectin and p-amyloid precursor protein (see 
Schlondorff et al. 2000). Similarly, ADAM-10 has high sequence homology to ADAM-17 and is 
implicated in the cleavage of many of the same substrate molecules (Hundhausen et al. 2003). 
Multiple substrate targets for these enzymes means that control of CX3CL1 shedding at a level 
other than ADAM-17 or ADAM-10 expression would bestow greater specificity to the shedding 
of this substrate and the consequential cellular effects.
A down-regulation of TIMP-3 mRNA and protein has been reported in cardiac endothelial cells
following TNFa and IL-ip treatm ent, suggesting that pro-inflammatory cytokines may increase
ADAMs activity, and thus CX3 CL1 shedding, by decreasing endogenous inhibitors of catalytic
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activity (Singh e ta l. 2005). The present study, however, demonstrated no modulation of either 
TIMP-3 or TIMP-1 mRNA expression, implicating that increased CX3CL1 shedding as a result of 
TNFa and IFNy stimulation acts via an alternate mechanism.
A lack of cytokine regulation of ADAM-10, ADAM-17 and the ir tissue inhibitors in the presence 
of increased CX3CL1 shedding may imply that additional enzymes could be responsible for 
ectodomain cleavage. Proteom ic and functional investigations have recently revealed that 
MMP2 and cathepsin S are capable of cleaving CX3 CL1 (Dean et al. 2007, Clark et aL 2007). 
However, as broad spectrum metalloproteinase inhibitors are capable of blocking constitutive 
and inducible CX3CL1 shedding (Chapman et al. 2000a, Garton et al. 2001, Hundhausen et al. 
2003), the role of cathepsin S may be limited. Indeed, Bourd-Boittin et al. (2009) have also 
demonstrated that CX3CL1 shedding in hepatic stellate cells is primarily due to the activity of 
M MP-2, whereas ADAM-10 and ADAM-17 only partially contribute to this cleavage. W hether 
the mechanisms of CX3CL1 shedding are universal, or are differentially regulated in different 
tissues or cells, has not been investigated. Further investigation into the expression of these 
potential CX3CL1 sheddases, in correspondence w ith cytokine-induced soluble CX3CL1 
expression by the vascular cells, would be useful to elaborate the mechanisms influencing the 
cleavage of this novel chemokine in atherosclerosis.
2.4.4 Expression of CX3 CRI in human aortic vascular cells
While the functional roles remain relatively unexplored, CX3CR1 expression on SMC is 
becoming apparent and may play a part in atherogenesis.
Contrary to the qRT-PCR findings in the present study, where no CX3CR1 mRNA was identified, 
the CX3CR1 protein was found to be expressed in HASMC and HAEC by immunocytochem istry. 
CX3CR1 expression has been demonstrated on SMC in atherosclerotic plaque regions o f human 
coronary arteries (Lucas 2003) and pulmonary arteries of rats (Perros et al. 2007). Additionally, 
it has been shown that primary rat pulmonary artery SMC (Perros et al. 2007) and rat aortic 
SMC (Chandrasekar et al. 2003) proliferate in response to CX3CL1 in culture, while W h ite et al. 
(2010) report a similar anti-apoptotic and proliferative effect of CX3CL1 on primary human 
coronary artery SMC. Neither of these studies reported a migratory effect of CX3CL1 on SMC, 
although this was demonstrated in the earlier study by Lucas et al. (2003). This suggests that 
CX3CR1 is present on vascular SMC and that CX3 CL1 has a role in atherosclerosis beyond 
leukocyte attraction and adhesion. The critical balance of SMC apoptosis and proliferation that 
determ ines both plaque stability and vessel stenosis, and potentially the m igration of SMC 
from the tunica media, may be mediated through CX3CR1 interactions.
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Previous research on endothelial cell expression of CX3CR1 is limited. Crola Da Silva et al. 
(2009) investigated a range of endothelial cell lines for the expression o f CX3CR1, including two  
microvascular endothelial types. Human microvascular skin and brain endothelial cells 
displayed mRNA for CX3CR1. A subset of vascular endothelial cells isolated from rat synovial 
tissue in a model o f arthritis (Ruth et al. 2001) and human dermal microvascular cells (Volin et 
al. 2001) have additionally been shown to express CX3CR1. Of particular relevance, Ryu et al. 
(2008) support the hypothesis that vascular endothelial cells express CX3CR1. The authors 
reported that HAEC constitutively express CX3CR1 and that mRNA expression is upregulated 
following CX3 CL1 stimulation. This allows for an autocrine action of CX3CL1 on endothelial cells 
and is thought to influence angiogenic activities (Ryu et al. 2008).
In the present study, the conflicting data from qRT-PCR and immunocytochemical studies does 
not allow for clear conclusions to be drawn as to whether CX3CR1 is expressed on HASMC and 
HAEC. The immunostaining results may need to be treated with caution, especially since high 
background staining and slight staining in the negative control wells occurred, as this may 
result from non-specific binding of the secondary antibody, which in turn may limit the 
reliability of the positive staining. Isotype controls would further validate the specificity of the 
primary antibody. The pitfalls o f immunostaining techniques are reviewed extensively 
elsewhere (Lorincz and Nusser 2008, Fritschy 2008). The technique relies heavily on the 
specificity of the antibodies used to recognise the target antigens. In practice however, IgGs 
often unpredictably bind with low affinity to numerous, mostly undefined, cell and tissue 
constituents, giving rise to non-specific signals (Fritschy 2008). Therefore, setting the threshold 
between background and specific staining is vital, yet principally arbitrary. THP-1 monocytic 
cells were used as a positive control to validate antibody specificity and aid the determ ination 
o f background staining, in an attem pt to reduce the technical limitations. The use of isotype 
control antibodies and/or blocking the primary antibody prior to staining with soluble peptide, 
would also have been useful, and would be important controls for future studies.
In terms o f the reliability of the qRT-PCR data, validation o f the CX3CR1 primer-probes used via
target detection in THP-1 monocytes confirmed the reliability of the procedure. The
correlation between mRNA and protein expression is not always invariant, and Gygi et al.
(1999) described how mRNA is an insufficient predictor o f protein expression. Post-
transcriptional mechanisms controlling the translation rate of the proteins, the half lives of
specific mRNAs or proteins, and the intracellular location and molecular association o f the
protein products may all contribute to the disparity between mRNA and protein quantification
(See Gygi et al. 1999). Intracellular storage of CX3 CR1 has been proposed in monocytes, with
rapidly induced translocation to the membrane allowing a post-transcriptional level of control
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of CX3CRI expression and potentially negating the need for steady-state or inducible mRNA 
activity (See Green et al. 2006). Immunocytochemical analysis in the present study may 
support this theory, as CX3CR1 appeared punctuate through the cytoplasm of HASMC and 
predominantly in a perinuclear location in HAEC. Additional investigations using flow  
cytometry or western blotting analysis would add the necessary extra data to determ ine and 
validate the expression pattern of this receptor in, and on, vascular cells.
CX3CRI expression in THP-1 cells was down-regulated by cytokine stimulation, suggesting a 
negative inflammatory feedback loop. Similarly, W eber et al. (1999b) induced a down- 
regulation o f CCR2 mRNA and surface expression in isolated blood monocytes and Mono Mac 
6  cells through TNFa stimulation, suggesting that proinflammatory cytokines can reduce 
chemokine receptor expression. This down-regulation of CX3CR1 may represent a switch in 
monocyte subset to the more inflammatory CCL2+ CX3CRI10 type (Swirski et al. 2007). 
Alternately, a reduction in CX3CR1 expression may limit the binding of monocytes to CX3CL1- 
expressing vascular cells, allowing for movement into, within and out o f the vessel as these 
innate leukocytes patrol the inflamed vasculature. THP-1 cells are an immortalised cancer cell 
line and are therefore limited in the ir relation to typical human monocytes. Further studies 
using isolated PBMCs would be advantageous for future investigations.
2.4.5 CCL2 expression in human aortic vascular cells
As with CX3CLI expression, CCL2 was constitutively expressed in HASMC and HAEC. Expression 
was dose-dependently increased at the mRNA and protein level, following treatm ent w ith 
TNFa plus IFNy, indicating a role for CCL2 in vascular inflammation. The lack o f statistical 
significance of the data, for what appeared physiological alterations in mRNA expression, may 
be due to the low sample numbers and the conservative nature of the non-parametric 
statistics used to assess the differences.
Rollins et al. (1990) reported that HUVEC express little CCL2 under standard culture conditions, 
and that significantly higher levels can be induced by treatm ent of the cells with TNFa and, to a 
lesser extent, IFNy. TNFa treatm ent increased the expression of CCL2 in primary human 
pulmonary artery endothelial cells (Maus et al. 2002) and in HUVEC there was an increased 
expression in response to injury (Weber et al. 1999a), lending further support for a role of 
CCL2 in vascular injury and inflammation. Additionally, Norata et al. (2010) have recently 
published that CCL2 mRNA is expressed basally in HUVEC and upregulated following incubation 
with TNFa, supporting earlier work by the same group (Norata et al. 2006). CCL2 released from 
the endothelium acts as a chemoattractant, locally recruiting circulating monocytes and also
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promoting monocytosis from bone marrow. Thus, CCL2 has local and distant effects on 
inflammatory mechanisms, many o f which are typical of atheroma formation (see Combadiere 
e ta l. 2008).
CCL2 expression has been demonstrated in VSMC, w ith expression increased by LPS (Jiang et 
al. 2010) and IL-ip stimulation (Lim et al. 2009), indicating a role in pro-inflammatory 
processes in the vessel wall. SMC expression of CCL2 may facilitate the gradient-assisted 
diapedesis and migration of monocytes into the subendothelial space. Additionally, SMC also 
express CCR2 and can modulate the ir own function through autocrine mechanisms that 
promote proliferation and migration (Hayes et al. 1998). Within the vessel wall, SMC CCL2 
secretion may act in a paracrine manner to further promote SMC migration to particular 
plaque areas, enabling the vascular remodelling characteristic o f athero-development (Hayes 
et al. 1998).
High basal expression of CCL2 in the culture supernatant of HASMC could potentially be due to 
a lack o f cell-cell contact communication between cells in culture, creating a cellular 
environment conducive to inflammation. Therefore, survival signals from cell-cell integrin 
signalling, which can activate intracellular kinases, and extracellular fibronectin signals may be 
reduced as a result o f non-confluent cultures (llic et al. 1998, Stoneman and Bennett 2004). 
However, as both cell-associated and secreted CCL2 data displayed comparable expression 
patterns in HAEC, and were similar to the upregulation demonstrated for CX3 CL1 expression, 
the high basal levels may simply be an erroneous result. The dose-dependent increases in CCL2 
mRNA were reflected at the protein level in HAEC and in the previous CX3CL1 expression data, 
thus supporting this idea. Secreted CCL2 in culture supernatants may be expected to follow the 
same pattern, as CX3CL1 and CCL2 appear co-ordinately regulated in response to TNFa and 
IFNy. Increasing the sample numbers of this investigation may clarify this ambiguity.
It has been suggested that multiple chemokines operate in concert to control the m igration of 
inflammatory subsets o f monocytes in inflammation (Tacke et al. 2007). The present study 
supports this notion, as inflammatory cytokines upregulate CX3CL1 and CCL2 in similar 
concentration-dependent patterns in HASMC and HAEC. The higher expression o f CX3CL1 may 
be representative of the low receptor expression on inflammatory monocyte subsets, 
considered to actively infiltrate inflamed tissue such as at sites o f atheroma development, 
therefore requiring higher CX3 CL1 concentrations to induce migration (Geissmann et al. 2003, 
Combadiere et al. 2008). The specific contributions of individual chemokines and the ir cognate 
receptors are not completely understood.
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2.4.6 Investigation of androgen modulation of cytokine-induced 
CX3 CLI and CCL2 expression in vascular cells
No significant effects of testosterone or DHT treatm ent on CX3CL1 and CCL2 expression were 
observed in the present study, suggesting that androgens do not modulate the expression of 
these chemokines in this in vitro model o f chemokine regulation. To ensure that this was not a 
result of inactive androgens or due to lack of ARs, control experiments were performed.
AR expression was investigated in HASMC as a positive control to confirm that androgen 
delivery was successful in the treatm ent conditions. AR mRNA expression has been previously 
demonstrated to be upregulated by 24 hour testosterone treatm ent in VSMC, w ith protein 
expression only partially inhibited by androgen antagonism (Ma et al. 2005a, Ma et al. 2005b). 
However, a 10 m inute exposure of vascular SMC to testosterone resulted in a transient down- 
regulation of AR protein (Ma et al. 2005a). These studies highlight the role of androgens in 
modulating the ir own receptor expression. In the present study, no effect on constitutive AR 
mRNA was observed, making it difficult to establish conclusive evidence that the lack of 
androgen modulation on CX3CL1 and CCL2 was a physiological phenomenon and not simply a 
result of lack o f androgen delivery to the cells. The further investigation o f DuCaP AR mRNA 
expression following identical androgen treatm ent procedures revealed a dose-dependent 
decrease w ith both DHT and testosterone, indicating successful androgen delivery to the cells. 
Although not definitively investigated, the effect may have been due to the greatly enhanced 
AR expression in the prostatic cancer cell line compared to vascular cells, whereby the effect 
on AR expression is mediated through the AR. This, therefore, suggests that the lack o f 
significant effects of androgens on CX3CL1 and CCL2 expression in the present study are not 
due to a lack o f androgen exposure.
Norata et al. (2006) have previously shown a significant decline in TNFa-induced and IL-6 - 
induced CCL2 mRNA expression in HUVEC following a lh  pre-treatment w ith DHT. This decline 
was partially reduced by AR antagonism. The same group later demonstrated that the same 
pro-inflammatory upregulation was not significantly altered by 17p-estradiol, although it 
appeared physiologically reduced (Norata et al. 2010). This would suggest that potential anti­
inflammatory effects o f testosterone on CCL2 expression may function through both AR and ER 
actions. While the present study demonstrated a slight, but non-significant, decrease in TNFa 
plus IFNy-induced CCL2 upregulation in HASMC following testosterone treatm ent, this effect 
was abrogated by blockade of the AR. Similar effects were seen in the mRNA expression data 
obtained for testosterone modulation of cytokine induced-CX3CLl regulation in HAEC in the
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current investigation. This supports the study by Hatakeyama et al. (2002), who have shown, 
w ith qRT-PCR analysis in HAEC, that a testosterone reduction of TNFa-upregulated VCAM-1 
mRNA expression was dependent on AR function, as co-incubation with cyproterone acetate, a 
steroidal antiandrogen, abolished the effect.
Mukherjee et al. (2001) also demonstrated that TNFa-induced VCAM-1 mRNA and protein 
expression was reduced by testosterone, but not by DHT, suggesting that testosterone may act 
through an AR-independent mechanism. Although the study did not look at the effects of 
blocking the AR, inhibition o f aromatase completely abrogated the testosterone reduction of 
VCAM-1 expression, thus indicating that conversion to estradiol and subsequent ER activation 
may be the mode of this anti-inflammatory action of testosterone. Caulin-Glaser et al. (1995), 
provide data supporting this mechanism, since they reported that 17p-estradiol also reduced 
IL-l-stimulated upregulation of ICAM-1, VCAM-1 and E-selectin in HUVEC. These two studies 
however used HUVEC from umbilical cord of female foetuses, and therefore may not be 
reflective of steroid actions in cells of male origin as used in the present study.
The lack of a significant modulation of CX3CL1 and CCL2 at the mRNA level by testosterone may 
not be reflective of membrane protein expression and function. Lui et al. (2005) introduced 
the concept that CX3CL1 can be stored in intracellular pools and demonstrated that the 
equilibrium o f trafficking between subcellular compartments and the cell membrane adds an 
additional level of functional control to CX3CL1 expression beyond genetic regulation (Huang et 
al. 2009). Additionally, it is considered that the functional adhesiveness o f CX3CL1 requires 
molecular aggregation at the cell surface, increasing its avidity for CX3CR1 (Hermand et al.
2008). This may take place through oligomerisation during self-assembly leading to molecular 
clustering. Taken together, it is therefore possible that rather than influencing CX3CL1 gene 
upregulation (as measured by qRT-PCR) or whole cell protein concentrations (as measured by 
ELISA of cell lysates), that testosterone may influence either cell surface abundance or 
functional adhesiveness of this chemokine through actions on endosomal storage or focal 
membrane distribution. Flow cytometry and confocal immunocytochemical analysis would 
provide further insight to this hypothesis and detailed investigations into the mechanisms and 
signalling pathways involved would be required for definitive conclusions.
Taken together, the slight modifications o f cytokine-induced CX3 CL1 upregulation and AR 
antagonism suggest that testosterone may function through AR-dependent mechanisms in 
HAEC and AR-independent mechanisms in HASMC. This conclusion is tentative however, as 
DHT, which primarily signals only through AR and with a higher affinity than testosterone, had 
no effect on CX3CL1 expression in the present study.
166
No effect of androgen treatm ent on BrdU incorporation and total protein, as measures of 
proliferation and cell death affecting final cell numbers at time of sample collection, was 
detected in the present study, suggesting that any effect or lack of effect in subsequent target 
expression was not due to these factors. Ma et al. (2005b) also reported that testosterone did 
not affect DNA synthesis and cell number. Contrary to this, testosterone has been found to 
increase proliferation in human umbilical cord smooth muscle cells and HASMC, by inducing a 
gene known to be involved in proliferation (Nakamura et al. 2006). This supports work by 
Fujimoto et al. (1994) who suggested that androgens may directly accelerate atherosclerosis 
by stimulation o f vascular SMC proliferation. Alternatively, testosterone has been suggested to 
enhance apoptotic damage resulting from serum deprivation in HUVEC (Ling et al. 2002). Also, 
vascular SMC proliferation has been shown to be inhibited by 17[3-estradiol (Morey et al. 1997) 
and dehydroepiandrosterone (Williams et al. 2002). Opposing findings o f investigations o f 
endothelial cells revealed that oestrogens protect from apoptotic damage (Alvarez et al. 1997, 
Spyridopoulos et al. 1997, Florian et al. 2007). Taken together, this data suggests that sex 
steroid hormones can influence proliferative and apoptotic mechanisms in vascular cells.
The lack of effect of androgen treatments on proliferation in the present study is potentially 
due to the serum-deprived culture conditions, whereby growth factors (that would be present 
in the serum) are absent. This is supported by the significant increase in BrdU incorporation 
seen w ith cells incubated with 10% serum as a positive control. However, when cell treatments 
were carried out in serum-containing medium, again no androgen modulation of CX3 CL1 or 
CCL2 expression was observed, although these conditions were not assessed for any effects on 
proliferation or protein synthesis. Therefore, it is possible that any down-regulatory effects of 
androgen treatm ent may be balanced by an increase in cell proliferation. This scenario is 
unlikely however, as reference gene expression in qRT-PCR analysis accounts for increases in 
overall synthesis and displays target expression data relative to this.
To investigate whether the presence of growth factors is necessary for androgens to exert a
modulatory action on inflammation, as suggested by Orio et al. (2002) and Bakin et al. (2003),
media containing serum was used in additional experiments. Blockade of the AR w ith
flutamide ruled out any effect of low-dose androgens that may have been present in the
serum in the medium, on CX3CL1 and CCL2 expression. This did not, however, eliminate
potential effects through the ER or of any oestrogens present in the serum. Comparison of
mRNA data between serum-containing and serum-free media conditions revealed consistent
cytokine expression levels, suggesting that the presence of serum in the media had no
modulatory effect on chemokine expression. The removal o f hormones from the serum by
charcoal-stripping would allow for the benefits of serum factors present in the media while
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eliminating potential steroid influence, and would therefore be useful in future work. The use 
of phenol red as a pH indicator in culture media is standard practice, but may attribute  
methodological limitations to the present study. At concentrations found in tissue culture 
media, phenol red is considered to possess significant oestrogenic activity due to its structural 
resemblance to certain non-steroidal oestrogens (Berthois et al. 1986). This creates unwanted 
ambiguity as to the stimulatory state of the cells studied and the potential to create misleading 
results. However, as the same lack of modulation of CX3 CL1 and CCL2 mRNA expression was 
observed in HAEC, where phenol red-free media was used, the potential influence of this 
chemical may be limited in the present study. To rule out any confounding factors, it would be 
beneficial to use phenol red-free media for any further work.
The lack o f effect of testosterone or DHT on TNFa and IFNy-induced CX3CL1 or CCL2 mRNA 
expression in the current study could be due to its inability to affect the greatly elevated 
expression of these molecules caused by the combined cytokine stimulation used. At low 
cytokine concentrations (ln g /m l TNFa plus IFNy) large increases in mRNA were detected 
(between 80 to >1000 fold change for CX3CL1, and approximately 15-fold difference for CCL2). 
As STAT-1 and NFkB transcription factors are thought to bind DNA independently (Ohmori et 
al. 1997), and due to the bidirectional enhancement of these factors on gene expression (e.g. 
IFNy enhances NFkB transcription, and TNFa enhances STAT-1 activation), greatly elevated 
transcription may occur. Additionally, the synergy of TNFa-induced NFkB and IFNy-activated 
STAT-1 may be, at least in part, due to physical interactions form ing a complex that binds with 
higher avidity to the recognition sites, than the transcription factors individually (Paludan 
2000). In this particular cell model, with cytokine concentrations causing greatly elevated 
upregulatory activation, it may be possible that androgen effects may not be sufficient to 
modulate these synergistically-enhanced mechanisms. All previous investigations into steroid 
modulation of inflammatory molecules have utilised single cytokine stimulations (see Tables
2.1 and 2.2). Repeating the present study with IFNy alone may unmask a detectable androgen 
modulation.
Although DHT was used to investigate the effects of AR activity on inflammatory mediators, as
it is non-aromatable to 17p-estradiol, it has recently been suggested that some of the effects
of testosterone and DHT may be attributed to alternate metabolites capable of activating the
ER. Norata et al. (2010) demonstrated that 5a-androstane-3p,17(3-diol (3(3-adiol), a metabo lite
resulting from the catabolism o f DHT by the enzyme 3-hydroxysteroid dehydrogenase, reduces
TNFa- and LPS-induced inflammatory responses including expression of ICAM-1, VCAM-1 and
CCL2. These effects were inhibited or abolished by blocking the ER, in particular ERp. This
suggests that testosterone metabolites, other than those generated through aromatisation,
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could exert a series of biological effects, which mediate ER activation and potential anti­
inflammatory effects. As the conversion between DHT and 3(3-adiol occurs almost ubiquitously 
(Norata et al. 2010) it is reasonable to propose that any effects, or lack of effects, of 
testosterone or DHT may be influenced by activity o f the ir metabolites, as the existence of 
ligand-selective pathways of ER and AR compensate and contribute to the cellular response. It 
would therefore be desirable in future investigations to inhibit both AR and ER activity, in 
addition to the inhibition of metabolic enzymes in the steroidogenesis pathway, in order to 
delineate the role of potential underlying mechanisms and influencing factors.
Several previous investigations o f vascular cell cultures have also failed to demonstrate an 
effect of androgens on particular inflammatory adhesion molecules, such as ICAM-1 
(McCrohon et al. 1999, Zhang et al. 2002), E-selectin (McCrohon et al. 1999, Norata et al. 
2006), PECAM-1 (Norata et al. 2006) and VCAM-1 (Aziz and Wakefield 1995). Many other 
studies have reported conflicting results regarding androgen modulation, and the effect seems 
to be dependent upon the sex steroid used, the cell type studied, the inflammatory target 
measured, the pro-inflammatory stimulus, the duration of incubations and the method of 
analysis (see Table 2.1).
The anti-inflammatory actions o f testosterone and its reported protective effect on 
atherogenesis demonstrated in vivo, may function through the modulation o f leukocytes. 
Specifically, androgen modulation of macrophages has been shown in vitro w ith DHT reducing 
LOX-1 expression and subsequent foam cell formation (Qui et al. 2010). Additionally, the 
upregulation o f SR-BI and consequential increase in cholesterol efflux (Langer et al. 2002) and 
the reduced expression pro-inflammatory cytokines TNFa and IL-lp (Corcoran et al. 2010) in 
cultured human monocyte-derived macrophages in response to testosterone treatm ent, 
suggests that androgens may act on plaque monocyte/macrophages rather than vascular cells 
to modulate athero-inflammation. Therefore, the lack of androgen modulation on the 
expression o f pro-inflammatory mediators observed in the present study may disprove the 
current hypothesis, yet does not discount the role of potential anti-inflammatory actions of 
testosterone in atheroma formation.
2.4.7 General considerations
The implications of the results from cell culture studies, where investigators fail to identify the 
gender or hormonal status of the original donor studied, may be limited although it is accepted 
that this is often beyond the control of the investigator. The gender origin of cells used in such 
studies will influence hormone receptor expression and therefore the responsiveness o f the
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cells to particular steroid treatments. This, therefore, makes it difficult to compare data across 
different studies. As the donors o f vascular cells in the present study were relatively young (15 
and 16 years old) males, the ir prior hormone exposure may be variable, dependent upon the 
individual's rate of sexual maturation. With this consideration, it may be useful to establish a 
cell culture model of hypogonadism in which cells are propagated and maintained in DHT- or 
testosterone-containing media, with deprivation of the androgen prior to the experimental 
procedure. This would standardise prior exposure, and potentially the responsiveness o f the 
cells, while creating a situation more closely paralleled with the age-related androgen decline 
observed in men.
Cell culture models use isolated components (cells) of relevant tissues to investigate specific 
mechanisms, limiting the relevance to the in vivo situation. In the present study, it may be 
possible that androgens exert the ir atheroprotective and anti-inflammatory effects through 
actions on vessel wall vasodilation and subsequent improvements in vascular dysfunction (See 
Channer et al. 2003 and W ever et al. 1998). Therefore, androgen actions may not be 
demonstrable in isolated cells. In addition, the multiple cytokines, chemokines and enzymes 
which make up the complex milieu at sites of atheroma formation seen in vivo are difficult to 
recreate in vitro. Although in vitro investigations do allow some insight into potential pathways 
and enables the ir manipulation to assess specific functioning, these may not be reflective of 
the in vivo inflammation associated with atherosclerosis.
Another consideration in the present study is that agents used in culture may be degraded 
over the duration of the experiment, particularly in lengthy incubations, resulting in a lower 
exposure of the cells overtim e than nominally proposed. It should also be acknowledged that 
inconsistencies exist between the concentrations of agents required to produce effects in vitro 
and in vivo, particularly with the difficulties in estimating local cytokine concentrations.
2.4.8 Summary
The present study was successful in establishing a cell culture model of pro-inflammatory 
cytokine upregulation of CX3CL1 and CCL2. Androgens had no significant modulating effects on 
the expression of these molecules, and where slight trends were observed these effects were 
not consistent across cell type, androgen treatm ent and receptor function. Although this may 
be due to the limitations o f the cell culture model and the greatly enhanced cell 
responsiveness to cytokine treatments masking any subtle androgen modulation, thorough 
investigation indicates that testosterone does not have anti-inflammatory actions on CX3 CL1
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and CCL2 expression in vascular cells. It is considered that testosterones anti-inflammatory 
mechanisms may act on monocytes/macrophages to confer atheroprotection.
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CHAPTER 3
In vivo investigation of the effects of
testosterone in early 
__________________ atherosclerosis
3.1 Introduction
3.1.1 Animal models of atherosclerosis
Animal studies have become invaluable in atherosclerosis research due to the difficulties in 
obtaining human tissue samples, particularly in a sequential manner, which has restricted 
investigations to cross-sectional studies on tissues acquired from cadavers or end-point 
corrective surgery. The recent advancement in non-invasive imaging modalities has offered 
new possibilities to overcome such limitations, and as technology and techniques improve the 
value of these investigations may add clinical relevance and become more influential in 
research. However, as human lesions develop over years to decades, whereas small animal 
atherogenesis can be induced over much shorter periods, most existing evidence from  
atherosclerosis studies is derived from the use of animal models and currently this remains an 
important tool.
3.1.1.2 Mouse models of atherosclerosis
Many animal models have been used over the years, but due to handling difficulties, large 
animal breeding expenses, breeding time and rate of plaque development, murine models 
have become the de facto  model for in vivo atherosclerosis studies (Catanozi et al. 2009). 
Much of the recent advancement in knowledge of atherogenesis has come from murine 
models in which atherosclerosis can be induced by genetic and/or dietary intervention over 
relatively short periods of time (Tannock et al. 2010). As a species, the mouse is markedly 
resistant to atherosclerosis, necessitating inducing susceptibility via genetic manipulation and 
dietary intervention. Amongst the inbred strains, C57BL/6 mice have been determ ined as the 
strain most susceptible to diet-induced atherosclerosis, although even this was limited to small 
lesions in the aortic root, and this strain is therefore the strain o f choice for producing 
genetically manipulated models (Daugherty 2002). The relative ease in which the mouse
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genome can be altered to over-express or delete specific genes o f interest has allowed for the 
creation of atherosclerosis-susceptible strains of mice valuable in the investigation of the 
mechanisms of the stages o f disease development (Daugherty 2002).
The most extensively characterised genetically-manipulated strains of mice used in 
atherosclerosis research are the apolipoprotein E (apoE) and LDL receptor (LDLr) deficient 
animals. ApoE plays a key protective role in atherosclerosis by facilitating hepatic uptake of 
lipoproteins and stimulating cholesterol efflux from macrophages, thus maintaining overall 
plasma cholesterol homeostasis (Greenow et al. 2005). In a similar way, the LDLr is essential 
for clearance of circulating lipoproteins in the liver and uptake into macrophages in peripheral 
tissue. Therefore, lesion development in animals that lack these regulatory protective 
molecules is accelerated and is further exacerbated by feeding on a high-cholesterol, high-fat 
diet (Daugherty and Ratteri 2005). By combining these manipulations with deletion or up­
regulation o f a gene of interest, the direct testing of the role of certain proteins in 
atherosclerosis can be investigated.
3.1.2 Testosterone therapy in animal models of 
atherosclerosis
Several studies have reported the beneficial effects of hormone supplementation on 
atherosclerotic parameters in animal models, often in relation to castration, orchidectomy and 
ovariectomy. One early report identified a reduction in cholesterol accumulation in the aorta 
of orchidectomised male rabbits fed a pro-atherogenic diet and administered bi-weekly intra­
muscular injections of testosterone, compared to placebo treated animals (Larsen et al. 1993). 
Comparable to these findings, Bruck et al. (1997) demonstrated gender-specific anti­
atherogenic effects o f testosterone and estradiol in orchidectomised male and fema le rabbits 
fed a high fat, high cholesterol diet. Testosterone administration significantly attenuated  
atheroma formation in male rabbits but not females, in which an increase in plaque size was 
observed. Equally, no protective effect of estradiol was seen in male rabbits, although 
atheroma formation was significantly inhibited in females. Interestingly, this study also 
demonstrated that a simultaneous administration o f both testosterone and estradiol to both 
sexes resulted in a reduction in atherosclerosis (Bruck et al. 1997).
Alexandersen et al. (1999) found that castration per se resulted in an increase of aortic 
atherosclerosis in male cholesterol-fed rabbits, with the increase markedly inhibited following 
TRT compared to placebo. Intra-muscular injection of testosterone showed the highest degree 
of atherosclerotic inhibition in this study, potentially due to increased circulating levels over
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time when compared to oral administration. The mode of testosterone action was thought to 
be via its conversion to estradiol and subsequent ER activity, although this was extrapolated 
purely on the basis that lower ER expression was present in the aortas of treated animals, 
possibly due to down-regulation as a result of chronic oestrogen exposure from testosterone 
aromatisation (Alexandersen et al. 1999). In a recent model of balloon injury, whereby balloon 
catheter over-inflation induced moderate or severe vascular damage in the coronary artery of 
male swine, neointima plaque formation was increased in castrated animals compared to 
controls (Tharp et al. 2009). This effect was attenuated by testosterone replacement in 
castrated animals and neointima formation was seen to be inversely related to testosterone 
concentration.
Contrary to these results, Aydilek and Aksakal (2005) demonstrated that intramuscular 
injection of testosterone in male New Zealand wh ite rabbits exacerbated atherogenic lipid 
profiles, increasing total cholesterol (TC):HDL-cholesterol (HDL-C) ratio and decreasing HDL- 
C:LDL-C. This may be due to elevated testosterone concentrations as a result o f supplementing 
otherwise healthy males. Castrated males in this study, however, displayed mildly improved 
lipid profiles compared to controls and significantly favourable HDL-C:LDL-C and TC:HDL-C 
compared to testosterone-injected rabbits, although TC alone was greatly elevated. 
Testosterone treatm ent also lead to an increase in LDL-C and detrimental lipid ratios in rhesus 
monkeys (Tyagi et al. 1999).
3.1.2.1 Testosterone therapy in mouse models of
atherosclerosis
Testosterone therapy has also been studied in mouse models of atherosclerosis, and sub- 
dermal testosterone administration to castrated male apoE deficient mice decreased total 
serum and LDL-cholesterol following high-fat, high-cholesterol feeding (Elhage et al. 1997). 
These lipid lowering effects were reflected in a decrease in fatty streak formation.
Male and female apoE-/- mice receiving either testosterone or DHT via subdermal implant 
demonstrated differential effects on lesion size depending on the vascular territory (McRobb 
et al. 2009). DHT significantly reduced plaque area in the innominate artery of males and 
females compared to same-gender controls, as did testosterone in females. Both testosterone 
and DHT, however, increased lesion calcification, as a feature of advanced arterial plaques, in 
both sexes in the same vascular location. Testosterone and DHT reduced aortic sinus lesion 
area in females, but had no effect in males, whereas testosterone elevated calcification in both 
genders in this vascular bed. Although these results may suggest that androgens are capable of
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increasing lesion calcification, this may be due to the heightened dosage. Androgens appear to 
be generally protective of lesion growth even at supraphysiological concentrations, but 
because they are supraphysiological levels, they may also present some concurrent 
detrimental effects (i.e. the calcification) (McRobb et al. 2009). It is possible that physiological 
concentrations of testosterone supplementation may not have these additional detrimental 
actions and bestow a primarily protective action.
Nathan et al. (2001) suggest that testosterone inhibits atherogenesis via it's conversion to 
estradiol by aromatase. In this study, orchidectomised LDLr knockout male mice on a high 
cholesterol diet had a greater extent of early lesion formation compared to mice receiving 
testosterone supplementation. This inhibitory effect of testosterone on plaque development 
was similar to that seen w ith estradiol administration in the same model. It was demonstrated 
that mice supplemented with testosterone and an aromatase inhibitor simultaneously 
developed increased lesion formation compared to those administered testosterone alone, 
and to a similar degree as untreated high-cholesterol diet fed mice. Conversion to 17-p- 
estradiol was implicated as the sole mechanism of action of testosterone in reducing lesion 
formation, and interestingly, the extent of lesion development appeared to be inversely 
correlated with plasma oestrogen measurements, suggesting that the protective effects of 
testosterone are, at least in part, due to aromatisation of testosterone to estradiol and actions 
via the ER (Nathan et al. 2001).
The idea of oestrogenic protection is supported by the reduction in lesion area observed in 
both male and female apoE deficient mice receiving 17p-estradiol treatm ent (Bourassa et al. 
1996), and also the suggestion that ERa may be a key target in the atheroprotective effect of 
oestrogens in LDLr knockout mice (Billon-Gales et al. 2009). Additionally, treatm ent of 17P- 
estradiol significantly reduces the incidence and severity o f angiotensin ll-induced 
atherosclerosis in male apoE -/-  mice, an effect believed to be associated with the down- 
regulation of NFxB-related inflammatory mediators in the aorta (Martin-McNulty et al. 2003). 
17P-estradiol replacement also attenuated the negative vascular remodelling observed in 
ovariectomised female lipoprotein-a (Lp-a) transgenic mice (Nakagam i et al. 2010).
Contrary to these studies that attribute a beneficial effect of testosterone preventing 
atheroma formation, two reports demonstrate a negative action of androgens. Following 
suppression of testosterone by administration of gonadotropin releasing hormone (GnRH), 
aortic sinus and ascending aorta atheroma formation in male mice was decreased, whilst 
testosterone treatm ent led to an increase in lesion size (von Dehn et al. 2001). Also, despite 
not using TRT, Villablanca et al. (2004) conclude from the ir ERa knockout model that it is
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specifically this receptor that mediates susceptibility to early atherosclerosis in a testosterone- 
dependent manner. ERa w ild-type male mice developed increased lesion size, number of 
lesions, more advanced lesions, and at a faster rate than ERa knockout mice, an effect that 
was eliminated by castration. Thus the actual effects of the AR and TRT on atheroma requires 
further investigation.
3.1.2.1.1 The Testicular Feminised Mouse
The murine equivalent of human complete androgen insensitivity syndrome (cAIS) was first 
described in the 1970s and named the Tfm mouse (Lyon et al. 1970). The Tfm mouse has 
developed a mutation that results in affected animals exhibiting an X-linked, single base-pair 
deletion in the gene encoding the classical androgen receptor (Charest et al. 1991). A 
frameshift mutation in the mRNA encoding the AR occurs as result o f this mutation, leading to 
a stop codon in the am ino-term inal region. Therefore, upon translation premature term ination 
of AR protein synthesis occurs and a truncated receptor is produced that lacks both DNA- and 
steroid-binding domains (He et al. 1991). As such, Tfm mice are rendered completely androgen 
insensitive and express a phenotype that is outwardly female. In addition, the Tfm mouse has 
a reduced level of circulating testosterone, due to a deficiency of the enzyme 17a hydroxylase 
in the Leydig cells of the testis, a key enzyme in steroidogenesis (Murphy et al. 1991, Le 
Goascogne et al. 1993). The reduced activity o f 17a hydroxylase is thought to be due to the 
intra-abdominal location of the testes and the absence of androgen action in utero (Murphy 
and O'Shaughnessy 1991). This additionally leads to elevated luteinising hormone (LH) 
production, as the negative long loop feedback mechanism o f testosterone in the activation of 
pituitary AR is absent, activating mechanisms for increased testosterone production. As this 
negative feedback cannot occur due to AR dysfunction and low testosterone levels, circulating 
levels of LH are elevated, however due to the lack of 17a hydroxylase, circulating testosterone 
remains reduced (Murphy and O'Shaughnessy 1991).
Nettleship et al. (2007a) investigated the influence of the AR in atheroprotection in Tfm mice. 
When fed a high-fat, high-cholesterol diet, Tfm mice display a significant increase in aortic root 
lipid deposition compared to littermates, suggesting that testosterone and/or AR has an 
atheroprotective effect. Physiological testosterone administration prevented fatty streak 
formation when compared to untreated Tfm's and castrated littermate controls. Aromatase 
inhibition and ERa antagonism only moderately, but not completely, attenuated this response, 
and therefore the beneficial effects of testosterone were concluded to be independent of the 
AR and only partly due to ER actions via aromatase conversion. The protective actions of 
testosterone were considered to act, at least in part, via non-classical receptor mechanisms.
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The AR-independent component of these atheroprotective effects were suggested to be due 
to testosterone-mediated improvements in endothelial function and vascular reactivity 
previously suggested by Jones et al. (2003). The distinct underlying mechanisms were not fully 
elucidated. This study did not investigate the potential modulation o f TRT on inflammation, 
and to the best o f my knowledge, there are no mouse models of atherosclerosis which 
investigate the relationship of these parameters.
3.1.3 Summary
Testosterone therapy is implicated as beneficial in preventing the development of 
atherosclerosis in animal models, with the mouse being the preferred species o f investigation. 
The underlying mechanisms o f these actions o f testosterone remain unclear, w ith the AR, ER 
and alternative pathways all potential pathways for athero-modulation. With treatm ent 
outcome being dependent upon dosage, formulation, route of administration, vascular 
territory, genotype and gender, the potential athero-protective effects of testosterone require 
further investigation and the Tfm mouse provides a suitable model for investigating the effects 
o f AR and testosterone function in atherosclerosis.
3.1.4 Hypothesis and aims of the in vivo study
The aim of the in vivo study was to use a mouse model of androgen insensitivity to address the 
hypothesis that TRT reduces diet-induced early atheroma formation in the Tfm mouse through 
anti-inflammatory actions and via AR-independent mechanisms.
Aims
1. To investigate the effects of low endogenous testosterone and a non-functional AR on 
atherosclerotic and inflammatory parameters using the Tfm mouse model.
2. To investigate the effects of high-cholesterol diet on these atherosclerotic and 
inflammatory parameters and the role of low endogenous testosterone and non­
functional AR on such effects.
3. To investigate the effect of testosterone replacement on atherosclerotic and 
inflammatory parameters in the Tfm mouse fed a high-cholesterol diet.
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3.2 Methods
3.2.1 The Testicular Feminised Mouse
The Tfm mouse originates from the C57BL/6 strain which has developed a mutation in the 
gene encoding the classical androgen receptor and a deficiency of the enzyme 17a hydroxylase 
(Charest et al. 1991, Murphy and O'Shaughnessy 1991, Le Goascogne et al. 1993). As such, Tfm 
mice express a non-functional AR and reduced levels of circulating testosterone, and 
consequently are phenotypically female. Therefore, Tfm mouse is considered a suitable model 
for investigating the effects of AR in testosterone function.
3.2.2 Animal Husbandry
The inherited mutation in the AR of Tfm mice is X-linked, resulting in only one quarter of the 
progeny of a breeding pair being affected. Two breeding schemes were employed in the 
present study, using mice of specified genotype. The mice were identified by inherent coat 
colour markers and gender phenotype (Figure 3.1). Tfm mice (XTfmY males) exhibit a dark 
agouti coat colour and have a female phenotype. Unaffected littermate males (XB|0Y or x Ta33HY) 
have a male phenotype and have either light coloured coats (XB|0Y) or dark agouti coats, with 
bald patches behind the ears and dark patches around the eyes (XTa33HY). Carrier females 
(XTfmX) have light fur and exhibit prominent transverse stripes or have dark fur w ith irregular 
patches, whereas non-carrier females (XTa33HX or XBl0X) have both the stripes and the light 
coloured patches (see figure 3.1).
The breeding colony of Tfm mice (strain C57BL/6J-A) used in this study was derived from  
frozen embryos obtained from the Medical Research Council genome project (MRC Harwell, 
UK). Mice were bred in sterile barrier conditions at The University o f Sheffield Field 
Laboratories and XTfmY and male littermate controls (XBl0Y or x Ta33HY) were transferred to the 
holding room upon weaning ( 6  weeks old), where they were maintained for the duration o f 
the experiment. Non-carrier females and carrier females not required for breeding were 
sacrificed via a UK Home Office-approved schedule 1 method once weaned. All animals used 
for the experimental procedures were maintained in cages containing up to 3 animals, on a 
twelve-hour light/dark cycle in a temperature (between 19 and 23°C) and hum idity controlled 
(55 ± 10%) environment. All procedures were carried out under the jurisdiction o f UK Home 
Office personal and project licences (project licence number 40/3165, personal licence number 
60/11754), governed by the Animals Scientific Procedures Act 1986.
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3.2.3 Experimental treatments
Animals were randomly assigned to specific diet and treatment groups after weaning until 
desired group numbers were reached.
Strain Diet Treatm ent Abbreviation
Normal chow diet No treatment XY ND
XY Littermate No treatment XY DHigh-cholesterol diet 10|il intra-muscular XYSsaline injection
Normal chow diet No treatment Tfm ND
No treatment Tfm D
Testicular fem inised 
mouse High-cholesterol diet
10|il intra-muscular 
saline injection Tfm S
lOpil intra-muscular 
sustanonlOO® 
injection
Tfm T
3.2.3.1 Promotion of atheroma formation
At age 8 weeks, Tfm and littermate controls were placed on a diet containing 42% butterfat 
and 1.25% cholesterol, along with 0.5% cholate, which is required for cholesterol absorption in 
the mouse (Special Diet Services, UK), for a period of 28 weeks, ad lib itum . Prior to receiving 
this high-cholesterol diet, animals received a normal chow diet. Control mice received normal 
chow diet for the duration of the study.
3.2.3.2 Testosterone treatment
Mice that underwent testosterone or saline treatment received this via intramuscular 
injections. The hind leg of the mouse was held so to immobilise the quadriceps and the 
injection site shaved with a hair trimmer, previously cleaned with hibitane (SSL International 
Pic, UK). The shaven area was then gently wiped clean using a 1:200 dilution of hibitane. A 
sterile 0.3mL 30G needle (BD, UK) was introduced at a right angle to the skin surface into the 
centre of the muscle mass and lOpL of either Sustanon® 100 (20mg/mL testosterone 
propionate, 40mg/mL testosterone phenylpropionate, 40mg/mL testosterone isocaproate; 
equivalent to 74mg per mL testosterone) or physiological saline was injected. Animals were 
then returned to cages. Mice were injected once fortnightly, from 7 weeks of age, alternating 
the leg injected to minimise discomfort or irritation.
Animals were carefully monitored for the duration of the study and were weighed on a weekly 
basis.
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3 .2 .4  Sry g e n d e r d e te rm in a t io n  o f  a n im a ls
Sry (sex determ ining region Y) gene is a locus located on the Y chromosome. The Sry protein is 
a testis-specific transcription factor that promotes several genes leading to the formation of 
the testis and subsequent sexual differentiation and development in males (Sekido 2010). This 
phenotypic differentiation and male development is driven by the production and secretion of 
testosterone. Tfm mice are phenotypically female, as they possess a non-functional AR and 
express only low levels of testosterone, both elements necessary for male differentiation 
(Murphy et al. 1991), but they remain genetically male. Female mice lack the Sry gene, 
whereas males express the Sry gene regardless o f the ir phenotype. Therefore, testing for the 
presence or absence of the Sry gene is very useful in the molecular assessment of mice with 
abnormal sexual differentiation.
The following methods were carried out in conjunction with BioServ UK Ltd, part o f the 
University of Sheffield.
3.2.4.1 DNA isolation and collection
Ear clips were taken from Tfm mice and XY littermate controls and stored in autoclaved 
Eppendorf tubes overnight at 4°C, prior to analysis. 100pl of lysis buffer (lOng/m l Proteinase K, 
1% sodium dodecyl sulphate (SDS), 50m M  ethylenediaminetetraacetic acid (EDTA)) was added 
to the tube to cover the tissue, followed by a 30-60min incubation at 55°C, with repeated 
interm ittent agitation, until the tissue was completely degraded. Phenol chloroform separation 
buffer (Sigma-Aldrich, UK) was added to the lysed tissue suspension at 2:1 volume:volume 
(200pl), briefly vortexed to mix, then centrifuged at 15.7 x g for lOmins at room temperature. 
After centrifugation, the suspension separated out into 3 layers; an upper aqueous layer 
containing DNA/RNA, a lower organic layer containing protein, and a small intermediate layer 
containing debris. The DNA-containing upper aqueous layer was transferred to a fresh 
autoclaved tube and mixed with an equal volume (lOOpI) of phenol chloroform separation 
buffer and then vortexed and centrifuged as before. The upper aqueous layer was transferred 
to a fresh autoclaved Eppendorf tube. To precipitate and clean the DNA, two volumes (approx 
llO p I) of 100% ethanol was added to the tube and mixed by gentle inversion, so as to not 
shear the DNA. Samples were centrifuged at 15.7 x g for 5mins. The DNA formed a small, not 
always visible, pellet on the bottom and side of the tube. The supernatant was carefully 
removed and the pellet was allowed to air dry for 3-5mins. The DNA was resuspended in 30pl 
of ultrapure diethylpyrocarbonate (DEPC)-treated water (Sigma-Aldrich, UK) w ith repeat
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p ipe tting  to  mix. Samples were heated to  65°C fo r lOm ins to  denature any rem aining rem nants 
o f proteinase K. Finally sample tem pera ture  was reduced to  4°C by storage at -20°C fo r 5 mins.
3.2A.2 PCR gene amplification
A PCR buffer conta in ing lOx m aster m ix (2pl), 2m M  MgCI2 (0.8pl o f 50m M ), 200pM  dNTPs 
(0.16pl o f lOOmM dNTPs mix conta in ing 25m M  o f each dNTP), 1.5 units Taq polymerase (0.3pl 
o f 5 u n it/p l), fo rw ard  and reverse prim ers fo r Sry and a reference gene TagE (0.4pl), was made 
up to  15pl w ith  u ltrapure  DEPC trea ted  w ater (10.14pl). Primer sequences and the selection o f 
the  reference gene were pre-designed and optim ised by BioServ UK, Ltd.
Sry (forward) TGTT CAG CCCT ACAG CCACAT G
Sry (reverse) CCACT CCT CT GTG AC ACTTT AG CC
TagE (forward) GGAGGAGAGAGACCCCGTGAAA
TagE (reverse) ACACGAAGTGACGCCCATCCGT
lp l  o f mouse ear c ip extracted DNA was mixed w ith  4pl o f u ltrapure  DEPC trea ted  w a te r and 
added to  the PCR buffe r m ix to  give a final vo lum e o f 20pl. The samples, along w ith  a negative 
contro l (contain ing no DNA) and a positive contro l (a previously run sample expressing the  Sry 
gene) were am plified  in a Techne Touchgene Gradient therm ocycler (Krackeler Scientific Inc., 
USA) under the fo llow ing  reaction conditions; 30 cycles at 94°C fo r 30s, 60°C fo r 30s and 72°C 
fo r lm in , and 1 cycle at 72°C fo r 5mins and 4°C hold.
To determ ine PCR products, the am plified DNA was run on a 2% agarose gel conta in ing 
e th id ium  brom ide. 5 |il o f 2x loading dye (brom ophenol blue) was added to  5pl o f the  am plified 
DNA and lOpil o f th is m ixture  was loaded into individual wells o f the agarose gel along w ith  a 
lOObp DNA ladder (Sigma-Aldrich, UK) and the gel run at 150v fo r Ih . A m p lifica tion  products 
w ere visualised under UV light to  ascertain the  presence or absence o f the  Sry gene product at 
340bp. The housekeeping gene product at 450bp indicated a successful PCR am p lifica tion  and 
acted as an in ternal contro l fo r the m ethod.
3.2.5 Collection of animal tissues
At the end o f the trea tm en t period (36 weeks old) mice were killed by cervical d is location, a 
Home Office approved Schedule 1 technique.
All samples collected from  the  mice a fte r th is po in t w ere labelled num erically, corresponding
to  the individual animals. Details o f the experim ental procedures th a t each anim al underw en t
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were not revealed until all sample analysis was complete, so that the investigator was blind to 
the test groups throughout sample processing.
3.2.5.1 Serum Collection
Following cervical dislocation, a mid-line sternotomy was performed, the diaphragm was slit 
open and the thoracic aorta severed. Whole blood for serum measurements was collected 
from the chest cavity using a 2ml syringe (BD, UK), collected into 1.5ml Eppendorf tubes and 
allowed to clot for a m inimum o f 30 minutes at room temperature. Whole blood was then 
centrifuged at 0 . 8  x g for 1 0  minutes at room temperature and the serum removed and frozen 
in 60pl aliquots at -80°C, until analysis. All analyses were carried out on non-pooled serum, and 
samples underwent only one freeze-thaw cycle to maintain sample integrity.
3.2.5.2 Tissue collection
Following mid-line sternotomy and removal of whole blood from the chest cavity, the rib cage 
was opened and the lungs dissected clear. The heart, w ith the thoracic aorta attached, was 
carefully dissected free from the adventitia. The basal half of the ventricles was cut on a plane 
parallel with a plane formed by drawing a line between the tips of the atria, and the tissue 
removed. Dissection at this angle resulted in a final tissue orientation that allowed true cross- 
sections of the aortic root to be obtained, by compensating for the angle at which the aorta 
leaves the heart. The ascending aorta was then removed and any extraneous tissue was 
trimmed, taking care not to remove any tissue from the heart or aorta. The heart was perfused 
with PBS to remove any blood clots. The upper half of the heart, w ith the aortic root and initial 
section o f the aortic arch still attached, was placed in a PVC cryogenic tissue mould measuring 
13mm x 5mm (Fisher Scientific, UK) and embedded in optimum cutting tem perature (OCT) 
compound (Bright Cryo-M-Bed; Bright Instrument Company Ltd., UK), with the aorta centred 
and facing upwards. Hearts were then frozen in liquid nitrogen cooled isopentane (Sigma- 
Aldrich, UK) and stored at -80°C until cryosectioning (Figure 3.2).
3.2.5.3 Cryosectioning
The aortic sinus was used to assess atherosclerotic plaque development as it has characteristic 
landmarks enabling reproducible location and identification of the aorta between animals 
(Paigen et al. 1987). In addition, the aortic sinus is the site most prone to atherosclerosis 
development in C57BL/6J mice (Paigen et al. 1987), and fatty streak formation has been 
previously demonstrated in the aortic root o f Tfm mice fed on a high cholesterol diet 
(Nettleship et al. 2007a). Furthermore, lesions in this area have been shown to correlate w ith
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later development of more advanced atherosclerotic lesions in the entire aorta, thus making it 
a good model o f early atherosclerosis (Tangirala et al. 1995).
Method
OCT embedded mouse hearts were removed from -80°C storage and left at -20°C for 30 
minutes to equilibrate to this temperature. Starting at the apex and moving towards the base 
of the heart, transverse sections were taken through the tissue using a Leica CM1850 UV 
cryostat at -16 to -18°C. Unstained sections were examined on an Olympus CH2 microscope to 
check for aortic positioning and sections were discarded until the valve leaflets became visible 
in the aorta. Once the appropriate region was located, 8 pm sections through the aortic sinus 
(approximately 50 per mouse) were collected onto polysine charged slides (Thermo Scientific, 
UK) until the 3-valve cusps or the characteristic architecture of the aortic wall disappeared. 
Slides were stored at -80°C for later lipid and immunohistochemical analysis.
3.2.6 Measurement of serum testosterone via ELISA
In order to measure serum total testosterone levels in the mice a solid-phase competitive 
ELISA was used. In this assay microtitre wells were pre-coated with an antibody directed 
against a unique antigenic site on the testosterone molecule. The principle of the assay is that 
endogenous testosterone in the serum samples competed with a testosterone-horseradish 
peroxidase enzyme conjugate for binding to the antibody-coated well. After washing o ff 
unbound testosterone, the addition of a substrate solution resulted in a colour change that is 
inversely proportional to the amount of testosterone in the sample.
All reagents and multiwell plates contained in the testosterone ELISA kit (DRG Diagnostics, 
Germany) were allowed to equilibrate to room temperature, following 4°C storage. 25pl of 
testosterone standards (0, 0.2, 0.5, 1, 2, 6 , and 16 ng/ml) and test serum were dispensed into 
the appropriate wells in duplicate, followed by the addition of 2 0 0 pl o f enzyme conjugate to 
each well. The plate was mixed for 10 seconds on a plate shaker and allowed to incubate at 
room temperature for 60 minutes. Following incubation, the wells were emptied by inversion 
and 400pl/we ll of wash solution was added. The wash solution was emptied from all wells and 
the plate was blotted onto clean absorbent paper to ensure complete removal o f residual 
droplets. This wash procedure was repeated 3 times. The substrate solution (200pl) was then  
added to each well and the plate incubated at room temperature for 15 m inutes before the 
addition of lOOpI of stop solution (0.5M  H2S04) to term inate the enzymatic reaction. The 
absorbance of the well contents was determ ined using a Wallac multiscan plate reader (Perkin 
Elmer, UK) at 450±10nm within 5 minutes o f stop solution addition. Serum testosterone
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concentrations were calculated from the standard curve in ng/ml using Microsoft Excel 
(Microsoft, USA) and converted into the more w idely applied SI units (nmol/L) via 
multiplication by the known testosterone conversion factor 3.467 (http://www.soc- 
bdr.org/rds/authors/unit_tables_conversions_and_genetic_dictionaries_e5196/index_en.htm l 
)•
3.2.7 Measurement of serum estradiol via ELISA
Estradiol (170-estradiol) is the most potent naturally occurring oestrogen and is primarily 
produced by the female ovaries and the placenta, and to a lesser extent by the adrenals and 
testes in males (Hess et al. 1997). A solid-phase competitive ELISA was used to measure 
estradiol levels in mouse serum. M icrotitre wells were pre-coated with a polyclonal antibody 
directed against an antigenic site on the estradiol molecule. Endogenous estradiol in the serum 
samples competed with an estradiol-horseradish peroxidase enzyme conjugate for binding to 
the antibody coated well. The addition of a substrate solution resulted in a colour change 
inversely proportional to the amount of estradiol in the sample.
All reagents and multiwell plates contained in the estradiol ELISA kit (Demeditec Diagnostics, 
Germany) were allowed to equilibrate to room temperature, following 4°C storage. lOOpI o f 
estradiol standards (0, 3, 10, 50, and 200pg/ml) and serum samples were dispensed into the 
duplicate wells, followed by the addition of 200pl o f enzyme conjugate to each well. The plate 
was mixed for 10 seconds on a plate shaker and incubated at room temperature for 4h. 
Following incubation, the wells were emptied by inversion and 400pl of wash solution was 
added to each well. The wash solution was emptied from all wells and the plate was blotted 
onto clean absorbent paper to ensure complete removal o f residual droplets. This wash 
procedure was repeated 3 times. The substrate solution (200pl) was then added to each well 
and the plate incubated at room temperature for 30 minutes before addition of lOOpI o f stop 
solution (0.5M  H2S04) to term inate the enzymatic reaction. The absorbance was determ ined  
using a multiscan plate reader as for testosterone ELISA. Serum concentrations of estradiol 
were converted to SI units (nmol/L) via multiplication by the known estradiol conversion factor 
3.671 (http://www.soc-bdr.org/rds/authors/unit_tables_conversions_and_genetic_diction 
aries /e5196/index_en.htm l).
3.2.8 Measurement of serum lipids
Total cholesterol (TC), high-density lipoprotein-cholesterol (HDL-C) and triglycerides (TRIG) 
were measured using a VITR0S®5, 1 FS high capacity chemistry system (Orthoclinical
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Diagnostics, UK) with parallel processing at the Department of Clinical Chemistry, Sheffield 
Children's Hospital. The VITROS® chemistry technology is performed on the MicroSlide, an 
entire integrated test environment on a thin piece of layered film.
Mouse serum was thawed at 4°C and diluted two-fold with 7% BSA (VITROS®). A minimum of 
70pl o f sample was transferred to a loading cup and placed in a rack in the VITROS®5, 1 FS 
analyser. All three lipid measurements were obtained from each sample and values were 
adjusted for dilution factors. The principles underlying the three measurements are outlined 
below.
3.2.8.1 Cholesterol
5.5pl o f sample was automatically transferred to the microslide for the enzymatic reaction to 
occur. The sample is evenly distributed on the MicroSlide due to the spreading layer containing 
Triton X-100, which aids the dissociation of the cholesterol and cholesterol esters from  
lipoprotein complexes. Cholesterol ester hydrolase, in the underlying layer, catalyses the 
hydrolysis o f cholesterol esters to form cholesterol and fatty acids. Free cholesterol is then 
oxidised, form ing cholestenone and hydrogen peroxide. Hydrogen peroxide can finally oxidise 
a leuco dye in the presence of peroxidase, also present in the reagent layer, to generate a 
coloured dye (Allain et al. 1974). The colorimetric density o f the dye that is formed is 
measured by reflectance spectrophotometry and is proportional to the cholesterol 
concentration (figure 3.3).
3.2.8.2 Triglyceride
5.5pl of sample was automatically transferred to the microslide and is evenly distributed due 
to the spreading layer containing Triton X-100, which aids in the dissociation o f triglycerides 
from the lipoprotein complexes. The triglyceride molecules are hydrolysed by lipase in the 
spreading layer to generate glycerol and fatty acids. Glycerol diffuses into the underlying 
reagent layer where it is phosphorylated by glycerol kinase, to L-a-glycerophosphate, in the 
presence of ATP and MgCI2. L-a-glycerophosphate is then oxidised to dihydroxyacetone 
phosphate and hydrogen peroxide by L-a-glycerophosphate oxidase, present in the reagent 
layer. Hydrogen peroxide can finally oxidise a leuco dye in the presence of peroxidase, to 
generate a coloured dye (Spayd et al. 1978). The colorimetric density of the dye that is formed 
is measured by reflectance spectrophotometry and is proportional to the starting triglyceride 
concentration (figure 3.4).
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ACholesterol
1. Upper slide mount
2. Spreading layer (BaS04) 
-Triton X-100
3. Reagent layer
-buffer, pH 6.25
- cholesterol ester hydrolase
- cholesterol oxidase
- peroxidase 
-ieucodye
4. Support layer
5. Lower slide mount
B
Sample
4
lipoprotein
TX100
cholesterol + cholesterol esters + proteins
Cho lestero l ester hydrolase
cholesterol esters + H ,0 --------------------- ► cholesterol + fa tty acids
cholesterol + On
H20 2 + leuco dye
Cho lestero l oxidase
Peroxidase
cholestenone + H20 2
dye + 2H20
Figure 3.3; Total cholesterol measurement by the VITROS* chemistry system. The VITROS 
CHOL slide is a m ultilayered, analytical e lem ent coated on a polyester support. The entire  
integrated test environm ent, w ith  specific test reagents, is contained on a th in  piece o f 
layered film  (A), where all reactions take place (B). The final measurable co lour change is 
p roportiona l to  the  am ount o f cholesterol in the sample and is detected by reflectance 
spectrophotom etry.
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ATriglyceride
1.
2 .
3.
4.
5.
Upper slide mount 
Spreading layer (T I02)
-Triton X-100
- Lipase
Reagent layer
-buffer, pH 8.0 
-giycerol kinase 
-ATP
- L-a-glycerophosphate oxidase 
-peroxidase
-leuco dye
Support layer 
Lower slide mount
B
Sample
lipoprote in  
trig lycerides + H20
glycerol + ATP
L-a-glycerophosphate + 0 2
T X 100
Lipase
G lycero l Kinase + M gC I2
L -a -g lycero l-phosphate  ox idase
trig lycerides + proteins 
glycerol + fa tty  acids 
L-a-glycerophosphate + ADP
-* dihydroxyacetone phosphate + H2 0 2
H2 0 2 + leuco dye
Perox idase
-► dye + 2H20
Figure 3.4; Triglyceride measurement by the VITROS chemistry system. The VITROS 
TRIG slide is a m ultilayered, analytical e lem ent coated on a polyester support. The entire  
in tegrated test environm ent, w ith  specific tes t reagents, is contained on a th in  piece o f 
layered film  (A), w here all reactions take place (B). The final measurable co lour change is 
p roportiona l to  the  am ount o f trig lyceride in the sample and is detected by reflectance 
spectrophotom etry.
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3.2.8.3 High density lipoprotein cholesterol (HDL-C)
lOpl of sample was automatically transferred to the microslide to measure serum HDL-C. The 
sample is evenly distributed by the spreading layer and non-HDL is precipitated using 
phosphotungstic acid (PTA) and magnesium chloride contained in this layer. Emulgen B- 6 6  is a 
surfactant in the spreading layer that aids the selective dissociation of cholesterol and 
cholesterol ester from the HDL lipoprotein complexes in the sample. Cholesterol ester 
hydrolase in the underlying layer catalyses the hydrolysis of HDL-derived cholesterol esters to 
cholesterol and fatty acids. Free cholesterol is then oxidised forming cholestenone and 
hydrogen peroxide which can finally oxidise a leuco dye in the presence of peroxidase, to 
generate a coloured dye (Burstein et al. 1970, Allain et al. 1974). The colourmetric density of 
the dye that is formed is measured by reflectance spectrophotometry and is proportional to 
the HDL concentration of the sample (figure 3.5).
3.2.8A Low density lipoprotein cholesterol (LDL-C)
The concentration of serum LDL-C was calculated from the total cholesterol, HDL-C and 
Triglyceride measurements using the Friedewald equation (Friedewald et al. 1972). As very low 
density lipoprotein (VLDL) carries the majority o f the circulating triglycerides, VLDL-C can be 
estimated from the measured total triglycerides divided by 2.2 (See Warnick et al. 1990, 
Obineche et al. 2001). LDL-C is then calculated as:
LDL-C = TC - (measured HDLC + estimated VLDLC).
3.2.9 Quantification of fatty streak formation using oil red 0 
staining
Oil red O (ORO) staining is a histological technique utilised for the detection and localisation o f 
lipids in pathological tissue. ORO is a lysochrome (fat soluble dye) capable of staining 
unsaturated hydrophobic lipids, such as cholesterol and triglycerides. It can be solubilised in 
solvent to produce a histological stain. Since lysochromes stain by preferential solubility, lipids 
will take up the dye and appear deep red, whilst phospholipids appear pink. By counterstaining 
with haematoxylin, lipids can be assessed at a cytological and structural level within the tissue. 
Haematoxylin is a commonly used stain to demonstrate general tissue architecture. 
Preferentially colouring acidic components of the cell blue, haematoxylin is a base that stains 
the nucleus and regions of the cytoplasm containing DNA or RNA. In the present study ORO 
was used for the detection and measurement of lipid deposition within the aortic root of 
previously frozen heart sections.
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AdHDL
1. Upper slide mount
2. Spreading layer (BaS04)
- Emulgen B-66
- Phosphotungstic acid
- Magnesium chloride
3. Reagent layer 
-buffer, pH 7.0
- cholesterol ester hydrolase
- cholesterol oxidase 
-perox idase  
-leuco dye
4. Support layer
5. Lower slide mount
HDL + n o n - H D L  * nuL
Em u lgen B-66
HDL --------------------------------► cholesterol + HDL cholesterol esters +
proteins
C ho lestero l ester hydrolase
HDL cholesterol esters + H20  --------------------------------► cholesterol + fa tty  acids
Cho lestero l oxidase
cholesterol + 0 2  ► cholestenone + H2 0 2
Perox idase
H2 0 2 + leuco dye --------------------------------► dye + 2H20
Figure 3.5; Direct HDL cholesterol measurement by the VITROS* chemistry system. The
VITROS dHDL slide is a m ultilayered, analytical e lem ent coated on a polyester support. 
The entire  in tegrated tes t environm ent, w ith  specific test reagents, is conta ined on a th in  
piece o f layered film  (A), where all reactions take place (B). The final measurable co lour 
change is p roportiona l to  the starting am ount o f HDL in the sample and is detected  by 
reflectance spectrophotom etry.
Sample
P TA /M gC I:
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Method
A 1% ORO solution was prepared fresh before each use by dissolving 500mg Oil Red 0  (Sigma- 
Aldrich, UK) in 50ml o f 60% triethyl phosphate (TEP) (Sigma-Aldrich, UK) and heating to 95- 
100°C for 5 minutes with constant stirring. The resulting solution was filtered, whilst still warm, 
through student grade filter paper (Whatman, UK) then left to settle and cool for a minimum 
o f lh  at room temperature. The ORO solution was filtered a second time before use.
Frozen sections, 5 per animal distributed evenly throughout the aortic root (approximately 
every 10th serial section) were air dried for 30 minutes at room temperature. The sections 
were fixed in cold 4% PFA for 45 minutes on the bench then rinsed with tap water. Sections 
were then rinsed in 60% TEP for 5 minutes and stained for 30 minutes with ORO. Slides were 
then briefly rinsed in 60% TEP until the non-lipid areas of the sections appeared colourless 
(approximately 5-10 seconds), and further washed in tap water. Slides were then slowly 
dipped 5 times in Harris's haematoxylin (20% v/v) (Sigma-Aldrich, UK) to counterstain the 
nuclei, and then washed well in tap water to blue the counterstain and remove any excess 
stain. Finally, slides were mounted using 60°C -heated glycerol gelatin (Sigma-Aldrich, UK).
Following ORO staining, the sections of aortic root were digitally photographed using an 
Olympus BX60 microscope w ith a CoolSNAP-Pro (Media Cybernetics) imaging system. 
Quantification of the lipid stained areas was performed with computer-assisted morphometry, 
using Image J software (National Institute of Health, USA). Analysis was performed by manually 
outlining the outer and inner medial areas of the aortic root, followed by outlining the lesions 
from the internal elastic lamina to the luminal edge. The lipid-stained areas were expressed as 
a percentage of the medial area (figure 3.6).
Measurements were taken from 5 sections per mouse and mean values calculated. Randomly 
selected annotated photographs were examined by a second investigator to confirm 
acceptable accuracy of area selection. As with the original analysis, both procedures were 
carried out with investigators blinded to the animal group.
3.2.10 Measurement of serum cytokines by Multiplex Bead 
Array Assay
Multiple soluble proteins in samples such as serum, plasma, other body fluids and cell culture 
supernatants can be measured simultaneously using multiplex bead array assay (MBAA) 
technology. MBAA combines the principles o f ELISA and flow cytometry. Different intensities 
of dyes are loaded into specific beads to create a range of spectrally distinct bead populations,
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_________ORO stained area (C)________  x 100%
Outer medial area (A) -  Inner medial area (B)
Figure 3.6; Quantification o f atherom a form ation in aortic root using oil red O 
staining and Im age J analysis software. By m anually outlin ing  the o u te r medial 
area (B) and subtracting the inner medial area (C) o f the  aortic roo t a to ta l area o f 
the vascular wall o f the aortic roo t was obta ined. The Oil red 0  stained areas (A) 
w ith in  the vessel wall were also outlined  (3-6), from  the in ternal elastic lamina to  
the lum inal edge, and used to  calculate the percentage o f the medial area stained, 
as shown.
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distinguishable by flow cytometric analysis (figure 3.7a&b) (Khan et al. 2004). These distinct 
bead populations can then be coated with antibodies directed against a particular soluble 
protein or target. The targets are captured to the beads and detected with a secondary 
fluorescent antibody against the analyte of interest, which forms a sandwich complex (figure 
3.7c). Using flow cytometry for excitation and subsequent detection of emission o f the 
fluorochromes conjugated to the detection antibody, which is different to the emission 
wavelength of the bead dye, analytes can be measured quantitatively against a range of 
standards with known concentration. Multiple distinct bead sets can be added to an individual 
sample to detect multiple targets simultaneously, allowing for small sample volumes to be 
analysed for multiple analytes.
In the present study the Becton Dickinson cytometric bead array (CBA) flex set kits, targeted 
against IL-ip, IL-6 , IL-10, CCL2 and TNFa, were used. These provide individual bead sets 
distinguishable on the red and near infrared (NIR) spectra that can be used in multiplex to 
measure serum concentrations of the cytokines (figure 3.2.8b).
Method
All reagents and 96-well assay plates were supplied by Becton Dickinson (BD, UK). All sample 
preparation and analysis was performed at the University of Sheffield core research facilities 
by Susan Newton.
The capture bead stock solutions provided were vortexed to resuspend the beads thoroughly, 
lp l of each of the different analyte-specific capture bead suspensions were pipetted into a 
tube for each sample or standard to be run (i.e. lp l per 2 0  samples and 8  standards would 
equal 28pl of bead suspension A, and 28pl of bead suspension B etc., added to the tube) 
followed by 0.5ml of wash buffer. The multi-bead suspension was centrifuged at 200 x g for 5 
minutes. The supernatant was carefully aspirated and discarded and the bead pellet was 
resuspended in capture bead diluent equal to 50pl per test (sample and standard). The bead 
suspension was incubated at room temperature for 15 minutes to block for non-specific 
binding.
A phycoerytherin (PE) detection reagent was made up w ith lp l of each analyte-specific 
detection reagent provided and detection reagent diluent added to create a final volume of 
25pl per well, or sample (i.e. 4 targets would equal 4pl of combined detection reagents and 
21pl o f diluent). These volumes were multiplied by the number of samples and standards (i.e. 
the number of separate assay wells) to generate one PE detection reagent working solution 
with the multiple PE-conjugated detection antibodies specific to the different analytes. All
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B ead antibody ‘sandw ich1 com p lex
Figure 3.7; M ultiplex bead analysis array. Beads are loaded w ith  d iffe ren t in tensities o f 
dyes (A) to  create spectrally d is tinct bead populations, distinguishable by flo w  cytom etric  
analysis. As varying intensities o f near in fra-red (NIR) and red fluorescent dye in a bead 
create a grouping o f particu lar bead populations by do t p lo t analysis, separate targets 
can be investigated (B). Each spectrally d iffe ren t bead population is coated w ith  specific 
capture antibodies against a ta rge t analyte. When the sample and the fluorescent 
detection antibody is added, a sandwich complex form s (C). By gating around a specific 
population on the do t p lo t separated by the d iffe ren t bead dye properties (B), a specific 
analyte can be analysed fo r fluorescence intensity, which is p roportiona l to  the  am ount 
o f antibody bound, and there fore  analyte, in a sample. M u ltip le  analytes can be analysed 
in a single sample by th is separation o f d is tinct bead populations w ith  d is tinct antibody.
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reagent working solutions were made up fresh on the day and were stored at 4°C until use. 
The serum samples were thawed at 4°C. A standard curve of known concentrations of each 
cytokine target was produced by serially diluting the standards provided in the flex set kit. 96 
well reaction plates were pre-wet by addition o f lOOpI o f wash buffer to each well, followed by 
immediate removal o f this volume. Capture bead working solution was vortexed directly 
before use and 50pl was added to each assay well. 50pl of sample or standard was added to 
each assay well. The plate was then mixed for 5 minutes on a shaker at 500rpm and then 
incubated at room temperature for lh . 50pl of PE detection reagent working solution was 
added to each assay well. The plates were then mixed on a shaker as before and incubated at 
room temperature for 2h. Assay wells were drained by vacuum and the beads were 
resuspended in 150pl o f wash buffer per well, followed by shaking for 5 minutes. The assay 
plate was measured on the BD FACS Array™ flow cytometer and analysed using FCAP Array™ 
software.
3.2.11 Measurement of CX3 CLI in mouse serum via ELISA
To measure the concentration of CX3CL1 in mouse serum the mouse CX3 CL1 ELISA 
development kit (R&D Systems, UK) was used, which employs the same methods and 
principles as the human CX3CL1 ELISA used in section 2.2.9.2. However, in this assay a rat anti­
mouse CX3CLI antibody and a biotinylated goat anti-mouse CX3CL1 antibody were used as the 
capture and detection antibody pair respectively.
3.2.12 Analysis of plaque composition by immunohistochemistry
Aortic root samples identified as containing atherosclerotic plaques from ORO lipid deposition 
analysis were further investigated by immunohistochem istry for a visual indication of lesion 
composition. Sections adjacent to, and as close as possible to, ORO stained sections were 
selected, single stained for targets, and plaque areas matched for comparison. Antibodies 
targeting vWF were used to identify the endothelial lining of the aorta and anti-M O M A2, a 
mouse-specific monocyte/macrophage marker, used to identify cells in the vessel wall. 
Antibodies for CX3CL1 and CX3CR1 were additionally used to investigate the ir presence in the 
lesions. Isotype controls directed against non-relevant targets were included where possible 
following the same procedure as target antibodies. A peptide block for CX3CR1 (AbCam, UK ) 
was used as an additional control by incubating the primary antibody with peptide for 30 
m inutes in an Eppendorf tube prior to tissue staining procedure. This would specifically block 
the antigenic sites o f the primary antibody. All steps subsequent to the block were as with 
target antibodies. The fixation method, blocking, antibody dilution, and incubation period was
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optimised to give the strongest specific antigen staining with the lowest non-specific binding 
for each antibody. Once this was established, the same procedure was repeatedly utilised for 
immunostaining (See Table 3.1).
M eth od
Sections were removed from -80°C storage and allowed to air dry for 30 min. During this time, 
sections were encircled with a wax hydrophobic pen (Vector Labs Inc, UK) to form a barrier 
around the sample. Sections were then fixed by submerging in ice-cold acetone for 5 min 
followed by 10 min air drying. Blocking with 5% serum of the secondary antibody host species 
for 30 min at room temperature in a humidified chamber was followed by incubation with 75pl 
(enough to completely cover the section) of pre-optimised concentrations of primary 
antibodies for lh  at humidified room temperature in the dark. Unbound antibody was then 
removed by 3 x 5 min washes in PBS. 75pl of pre-optimised concentrations of appropriate 
secondary antibody was applied to the sections and incubated for lh  at room temperature in 
the dark and in a hum idified chamber. The wash procedure was repeated and sections were 
completely covered with Sudan black solution for 10 min at room temperature. To make the 
Sudan black solution, 0.3g of Sudan black B powder was dissolved in 100ml of 70% ethanol 
with continuous stirring at room temperature in the dark for 2h. The resulting solution was 
filtered through student grade filter paper (Whatman, UK), and stored at 4°C until use.
Following Sudan black staining, sections were then washed briefly with PBS, 8  times in 
succession to remove excess Sudan black stain, and mounted in Vectashield mounting medium  
for fluorescence (Vector Labs Inc, UK) containing DAPI to stain the nuclei. Sections were 
covered with coverslips and were sealed at the edges with nail varnish to prevent tissue 
drying. Negative controls omitting the primary antibody were included to determ ine non­
specific binding of the secondary antibodies. Cells were exam ined and images captured using a 
Zeiss 510 laser scanning confocal microscope (Carl Zeiss Ltd, UK).
3.2.13 Statistical Analysis
Data is presented as mean ± SEM unless otherwise stated. Experimental groups were assessed 
for normality and equal variance as previously described (see section 2.2.12). Appropriate 
statistical analyses were selected to establish significant differences between groups as 
detailed previously. Significance was accepted at P<0.05.
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Antibody Company Isotype Dilution Secondary
CX3 CLI Abeam
(ab25088)
IgG (rb, 
polyclonal)
1 : 1 0 0
(1:50-1:800)
Gt x Rb 568
(1:400-1:800)
1:400
CX3 CRI Abeam
(ab8021)
IgG (rb, 
polyclonal)
1:400
(1:50-1:500)
Gt x Rb 568
(1:400-1:800)
1:800
M O M A2 Abeam
(ab33451)
lgG2b (rt, 
m onoclonal)
1:50
(1:25-1:200)
Rb x Rt FITC
1:400-1:800
1:400
vWF Abeam
(ab6994)
IgG (rb, 
polyclonal)
1:800
(1:500-
1 :1 0 0 0 )
Gt x Rb 568
(1:400-1:1000)
1 : 1 0 0 0
Isotype Abeam
(ab7260)
IgG (rb, 
polyclonal)
1 : 1 0 0 Gt x Rb 568
(1:400-1:800)
1:400
Isotype R&D
(MAB0061)
lgG2b (rt, 
m onoclonal)
1:50 Rb x Rt FITC 
1:400
Peptide
Block
Abeam
(ab8125)
C X 3C R I 
(C-term) 
peptide (ms)
1 : 1 0 0 Gt x Rb 568 
1:400
Table 3.1; Antibodies used fo r  immunohistochemistry. Summary o f the antibodies used fo r 
ta rge t pro te in  detection  in mouse aortic roo t sections fo llow ing  optim isa tion  o f m ethods. 
The block step and d ilu tions o f prim ary and secondary antibodies were selected to  produce 
the highest am ount o f specific staining w h ils t reducing, or p re fe ren tia lly  e lim inating, non­
specific binding and background fluorescence. The range o f antibody d ilu tions tested is 
shown, w ith  the  selected op tim um  d ilu tion  in bold. vWF, von W illebrand Factor; FITC 
fluorescein isothiocyanate; ms, mouse; rb, rabb it; rt, ra t; gt, goat.
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3.3 Results
3.3.1 Gender Determination
PCR confirmed the expression o f the Sry gene in all ear clip samples from Tfm mice at the 
expected product size of 340bp, indicating that all animals were genotypically males (figure 
3.8). The expression o f the reference gene was also confirmed in the extracted DNA, by 
observation of a band at 450bp. Two female samples utilised as negative controls showed no 
PCR product band at 340bp, but did display a band for the housekeeping gene (figure 3.8).
3.3.2 The effect of testicular feminization on atherosclerotic 
parameters
Tfm mice and XY littermates fed on a normal chow diet were compared across a range of 
parameters related to atherosclerosis.
3.3.2.1 Animal Body Weights
Animal body weights were compared over the treatm ent period between 8  weeks and 36 
weeks old. XY littermates were significantly heavier than Tfm mice at the beginning of the
study ( 8  weeks old), and this pattern was observed up to week 12 (figure 3.9A). Beyond week
12 body weights were similar between the two groups of animals, and by week 20 the Tfm 
mice were consistently heavier than XY littermates up to the end of the experimental period, 
although only significantly so at week 27.
The amount of weight gain over the experimental period was also calculated, in relation to 
starting weight (Figure 3.9B). Tfm mice demonstrated a significantly greater increase in weight 
from week 15 to the end of the study when compared to XY littermates (P<0.05, t test, n=16 
and n=10 respectively). The total weight gain over the experimental period was 12.85g for Tfm 
and 8.4g for XY littermates (P<0.05, t test).
3.3.2.2 Serum hormone measurements
Serum hormone measurements were taken at the end of the experimental period and 
compared between Tfm and XY littermates. Mean serum testosterone concentration in XY 
littermates was within the expected physiological range of (10-30nM), although variability, 
demonstrated by the error bars, was large w ithin this group. Serum testosterone was
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Figure 3.8; Agarose gel electrophoresis showing DNA samples from  ear clips o f 
Tfm mice am plified with Sry gene primers. A) The gel shows am plified  products fo r 
Sry and the reference gene. Lane 1 and 19 show the DNA base pair (bp) m arker 
ladders. Lane 2 is the negative contro l w ith  no DNA, and lane 3 is a positive contro l 
conta in ing sample known to  express the Sry gene. Lanes 4-16 are samples from  Tfm 
mice, showing expression o f Sry and the reference gene. Lane 17-18 show samples 
from  female mice am plified w ith  the same primers, and show ing expression o f only 
the  reference gene. B) The second gel was run in parallel to  the  previous gel. Lanes 
1 and 28 contain DNA bp m arker ladders. Lane 2 is the negative contro l w ith  no 
DNA, and lanes 3-27 are fu rth e r samples from  Tfm mice.
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Figure 3.9; Total body weight and weight gain o f Tfm mice and XY litterm ates on a 
norm al chow diet (ND). W eekly w eight measurements taken from  week 8  onwards 
were compared between Tfm (n=16) and XY litte rm ates  (n=10) fo r the  28 week 
study period. A) Mean weekly weights and B) mean w eight gains re lative  to  week 8 . 
Data is mean ± SEM (*P<0.05; **P<0.01; ***P <0 .001  versus XY ND. ).
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significantly reduced in Tfm mice compared to XY littermates (P<0.05, n=12 and n=10 
respectively) (figure 3.13). Serum estradiol concentrations in XY littermates were in the normal 
physiological range for male animals (figure 3.14). In comparison, serum estradiol 
concentration was significantly elevated in Tfm mice compared to littermate controls (P<0.01, 
Kruskal-Wallis, n=6 ).
3.3.23 Serum lipid measurements
Total cholesterol, HDL-C and LDL-C were all significantly elevated in the serum of Tfm mice fed 
a normal chow diet for 28 weeks (n=12) compared to XY littermate controls (n=10) (P<0.001, 
P<0.01, P<0.001 respectively; unpaired t test) (figure 3.15). Triglyceride levels were also raised 
in the serum of Tfm mice, but not significantly so. As serum LDL concentration was calculated 
from the total cholesterol, HDL and triglyceride measurements, inaccuracies may occur in 
samples with low total cholesterol and high HDL levels resulting in anomalous negative LDL 
values, as seen in XY mice. Statistical analyses were still performed on these negative values to 
accommodate group variability as opposed to zeroing the negatives.
3.3.2A Lipid deposition in the aortic root
ORO staining was distinguished from non-specific accumulation of the stain due to its cellular 
location identified by haemotoxylin counterstain compared to large droplets o f red dye, 
respectively. Very low levels o f ORO staining were detectable in the aortic root of Tfm mice fed 
a normal chow diet, when compared with XY littermate controls (figure 3.16a & c). Semi­
quantification of ORO staining revealed that lipid deposition was marginally increased in Tfm 
mice compared to littermates (figure 3.14), in which no staining was detected (n=6 ).
3.3.2.5 Serum cytokine measurements
All serum cytokines (IL-lp, IL-6 , IL-10, CCL2 and TNFa) were elevated in Tfm mice compared to 
XY littermates on normal chow diets (figure 3.17). IL- 6  and TNFa were both significantly 
elevated in Tfm mice relative to controls (P<0.05, unpaired t test, n=6 ), whereas the 
differences for the other cytokines were not significant due to reduced power of low sample 
numbers and variability o f the data.
3.3.2.6 Summary
In summary, testicular feminised mice demonstrated increased weight gain, elevated serum 
total cholesterol, HDL and LDL, occasional lipid deposition in the aortic root and elevated
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serum cytokines, in particular IL- 6  and TNFa, compared to XY littermate controls. In addition 
serum testosterone and estradiol concentrations were decreased and increased relative to XY 
littermate controls respectively.
3.3.3 The effect of high-cholesterol diet on atherosclerotic
parameters
To investigate the effect of diet on atherosclerotic parameters, Tfm mice and XY littermate 
controls were fed a high cholesterol diet ad libitum  for 28 weeks.
3.3.3.1 Animal body weights
Initially the body weights of Tfm mice fed a high-cholesterol diet (n=23) were similar to those 
on normal chow diet (n=13) (figure 3.10A). However, from week 8  of cholesterol feeding Tfm 
mice had consistently lower body weights than those on normal chow diet, significantly so 
from 14 weeks onwards (P<0.05-0.001, Mann Whitney). A similar pattern was seen when 
weight gain was calculated. Tfm mice on high cholesterol diet gained significantly less weight 
than those on normal chow diet (P<0.05-0.001, Mann Whitney) (figure 3.10B). Final weight 
gain over the 28 week feeding period was 8.06g for Tfm on high cholesterol diet, and 12.85g 
for Tfm on normal diet (P<0.01).
In XY littermates, a similar phenomenon was observed, with those on a high cholesterol diet 
(n=13) showing significantly lower body weights than XY littermates on normal diet (n=10), 
from week 9 of the regime onwards (figure 3.11A). Weight gain over the 28 week feeding 
period was significantly less in the XY littermates on high cholesterol diet than the XY 
littermates on normal diet (P<0.05-0.01, unpaired t test, n=13 and n=10 respectively) (figure 
3.11B).
When comparing the total body weights and weight gain of high-cholesterol fed Tfm mice 
(n=23) w ith high-cholesterol fed XY littermates (n=13), Tfm mice tended to show higher body 
weights and a greater weight gain over the 28 week feeding period (figure 3.12), however 
these differences reached significance only at limited time points.
3.3.3.2 Serum hormone measurements
Serum testosterone levels appeared reduced following feeding on a high cholesterol diet for 
both Tfm mice (n=12) and XY littermates (n=12) compared to normal diet controls (n=12 and 
n=10 respectively) (figure 3.13). However, this reduction was only significant in XY littermates
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Figure 3.10; Total body weight and weight gain o f Tfm mice fed  a norm al (ND) or 
high cholesterol diet (D). W eekly w eight m easurem ents were com pared between 
Tfm mice on norm al d ie t (n=13) and Tfm mice on h igh-cholesterol d ie t (n=23) fo r 
the 28 week study period. A) mean weekly weights and B) mean w e igh t gains 
relative to  week 8  s ta rt weights (*P<0.05; **P<0.01; ***P <0 .001  vs Tfm ND; Mann 
W hitney test).
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Figure 3.11; Total body weight and weight gain o fX Y  litterm ate mice fed  a norm al 
(ND) or high cholesterol diet (D). W eekly w eight m easurem ents were compared 
between litte rm a te  mice on normal d ie t (n= 1 0 ) and litte rm ates on high-cholesterol 
d ie t (n=13) fo r the 28 week study period. A) Mean weekly weights and B) mean 
w eight gains relative to  week 8  sta rt weights (*P<0.05; **P<0.01; ***P <0 .001  vs XY 
ND; Mann W hitney test).
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Figure 3.12; Total body weight and weight gain o f Tfm mice and XY litterm ate  
mice fed  a high cholesterol diet (D). W eekly w e igh t m easurem ents were compared 
between Tfm mice (n=23) and litte rm a te  mice (n=13) on h igh-cholesterol d ie t fo r 
the 28 week study period. A) Mean weekly weights and B) mean w e igh t gains 
relative to  week 8  starting  weights (*P<0.05; **P<0.01; ***P <0 .001  vs XY D; Mann 
W hitney test).
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(P<0.01, Mann Whitney test). Although reduced compared to normal diet controls, serum 
testosterone levels o f XY littermates on high-cholesterol diet remained higher than the ir Tfm 
counterparts.
28 weeks on a high cholesterol diet significantly reduced serum estradiol in Tfm mice 
compared to Tfm mice on normal diet (P<0.01, Mann-Wh itney test, n=6 ) (figure 3.14). The high 
cholesterol diet did not affect serum estradiol concentrations in XY littermates compared to XY 
littermates on normal diet.
Thus, Tfm mice on high-cholesterol diet had similar serum estradiol concentrations to XY 
littermates on high cholesterol diet.
3.3.33 Serum lipid measurements
Total serum cholesterol was significantly elevated (PcO.OOl, unpaired t test) as an effect of 
feeding on a high cholesterol diet in both Tfm mice (n=14) and XY littermates (n = ll)  compared 
to normal diet controls (n=12 and n=10 respectively) (figure 3.15A). Additionally, Tfm mice on 
high-cholesterol diet displayed significantly higher serum cholesterol levels than XY littermates 
on high-cholesterol diet (PcO.OOl, unpaired t test). High cholesterol feeding reduced serum 
HDL concentrations in Tfm mice and XY littermates relative to the ir normal diets controls 
(figure 3.15B), although this was significant only in Tfm mice (P<0.001, unpaired t test). Serum 
HDL concentrations were similar in high cholesterol fed Tfm mice and high cholesterol fed XY 
littermates. High cholesterol feeding appeared to reduce serum triglyceride concentrations in 
Tfm mice relative to Tfm mice on normal diet (figure 3.15C), however this was not statistically 
significant. Serum triglyceride levels were similar between Tfm and XY littermates on high 
cholesterol diet. The high cholesterol diet significantly elevated serum LDLs in both Tfm and XY 
littermate mice (PcO.OOl, unpaired t test) (figure 3.15D). The difference was more pronounced 
in Tfm mice, which had significantly higher serum LDL levels than XY litterm ate controls on 
high-cholesterol diet (PcO.OOl, unpaired t test).
3.33.4 Lipid deposition in the aortic root
ORO staining of aortic root sections revealed increased lipid deposition in both Tfm mice and 
XY littermates following high-cholesterol diet, w ith multiple lesions observed (figure 3.16). 
Lesions occurred primarily at the shoulders of the valve cusps in both Tfm and XY mice. 
Consistent w ith serum lipid measurements, sem i-quantification showed this increase in lipid 
deposition to be significant for Tfm mice when compared to normal diet Tfm controls (PcO.Ol
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Figure 3.13; Serum testosterone concentration o f Tfm mice and XY litterm ates  
fed  a norm al (ND) or high-cholesterol diet (D). Tfm mice on high cholesterol 
(n=12); Tfm mice on normal d ie t (n=12). XY litte rm ates on high cholesterol (n=12); 
and XY litte rm ates on normal d ie t (n=10) were compared fo r serum testosterone 
levels at the end o f the  28 week experim ental period. (*P<0.05; **P<0.01 vs XY 
litte rm ates on normal d iet, Mann W hitney test).
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Figure 3.14; Serum estradiol concentration o f Tfm mice and XY litterm ates fed  a 
normal (ND) or high-cholesterol diet (D). Tfm mice on high cholesterol (n=6 ); Tfm 
mice on normal d ie t (n=6 ); XY on high cholesterol d ie t (n= 6 ); and XY on normal 
d ie t (n=6 ) were compared fo r serum estradio l levels at the end o f the 28 weeks
experim ental period (**P<0.01 vs XY on normal d ie t 
d iet, Mann W h itney test).
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Figure 3.15; Serum lipid concentrations o f Tfm mice and XY litterm ates fed  a 
norm al (ND) or high-cholesterol diet (D). Data is mean ± SEM. Tfm mice on normal 
d ie t (n=12), XY litte rm a te  controls on normal d ie t (n=10), Tfm mice on high- 
cholesterol d ie t (n=14), XY litte rm a te  contro ls on high-cholesterol d ie t (n=12) were 
compared fo r serum lipid levels at the end o f the 28 week experim ental period. 
**P<0.01, ***P <0.001  vs XY litte rm a te  contro l on norm a l diet, r rP<0.001 vs Tfm on 
norm a l d ie t; unpaired t  test.
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Figure 3.16; Representative oil red O staining o f aortic root sections from  Tfm mice and XY  
litterm ate controls on a norm al chow diet (ND) and high-cholesterol diet (D). ORO stain was 
evident at low  levels in the aortae o f Tfm mice, but absent from  XY litte rm ates fed norm al d ie t 
(a and c respectively). Staining was apparent in the vascular wall o f aortae o f both Tfm and XY 
litte rm a te  mice fed high-cholesterol d ie t (b and d respectively). Lesions developed p rim arily  at 
the shoulders o f the aortic valve cusps. Sections were countersta ined w ith  haem otoxylin .
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Mann-Wh itney, n=6 ). In addition, lipid deposition was significantly greater in Tfm on high 
cholesterol diet than XY littermates on high cholesterol diet (figure 3.17).
3.3.3.5 Serum cytokine measurements
Serum CCL2 concentration was significantly elevated in Tfm mice fed high-cholesterol diet 
compared to Tfm mice on normal diet (P<0.05, unpaired t test, n=6 ) (figure 3.18D). All other 
serum cytokine concentrations were similar between Tfm mice on high cholesterol diet 
compared with Tfm on normal diet. However, although not statistically significant, IL-10 was 
reduced by high cholesterol diet in Tfm mice (figure 3.18C). In XY littermates high cholesterol 
feeding appeared to slightly elevate all serum cytokines, although only significantly so for CCL2 
(figure 3.18D) and TNFa (figure 3.18E). No significant differences in serum cytokine 
measurements were observed between Tfm mice and XY littermates fed high-cholesterol diet 
(figure 3.18).
3.3.3.6 Summary
In summary, the administration of a high cholesterol diet caused an elevation of total serum 
cholesterol and serum LDL concentrations, increased lipid deposition in the aortic root, 
increased serum CCL2 concentrations, and a reduction in testosterone and weight gain in both 
Tfm and XY littermate mice. Differences were generally more pronounced in Tfm mice, w ith 
tota l cholesterol, LDL and lipid deposition being significantly greater than in XY littermates. In 
addition, Tfm mice displayed reduced estradiol levels following high-cholesterol diet.
3.3.4 The effect of testosterone replacement on atherosclerotic 
parameters
To investigate the role of testosterone and AR on atherosclerotic parameters, Tfm mice on a 
high-cholesterol diet were supplemented with fortnightly injections o f Sustanon® 100, in order 
to restore testosterone to physiological levels. Atherosclerotic parameters were compared in 
placebo (saline)-injected Tfm and XY littermate mice also on high-cholesterol diet.
3.3.4.1 Animal body weights
No significant differences in total body weight or weight gain were seen between saline- 
injected Tfm mice (n=15), testosterone-injected Tfm mice (n=14) and saline injected littermate
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Figure 3.17; Percentage lipid deposition in aortic root sections from  Tfm mice and XY 
litterm ate controls on a norm al chow diet (ND) and high-cholesterol diet (D). Semi­
quantifica tion  o f lipid deposition in the aortic roo t (expressed as percentage o f medial 
area) was elevated in Tfm mice and XY litte rm ates fo llow ing  feeding on high cholesterol 
d iet. Tfm mice on high-cholesterol d ie t displayed sign ificantly elevated lipid deposition 
compared to  normal d ie t controls ("P<0.01, Mann W h itney test, n=6 ) and XY litte rm ates 
on high-cholesterol d ie t (***P <0.001, t  test, n=6 ).
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Figure 3.18; Serum cytokine concentrations o f Tfm mice and XY litterm ates fe d  a 
normal chow diet (ND) and high-cholesterol diet (D). Tfm mice on norm al (n=6 ) and 
high-cholesterol d ie t (n=6 ) and XY litte rm ates on norm al (n=6 ) and high-cholesterol 
d ie t (n=6 ) were compared fo r serum cytokine concentrations. *P<0.05, **P<0.01, i/s XY 
litte rm a te  con tro l on norm a l diet. 'P<0.05, i/s Tfm on norm a l d ie t; M ann-W hitney test, 
n=6.
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controls (n=14) (figure 3.19). Although not statistically significant, Tfm mice receiving 
testosterone replacement were heavier and gained more weight over the 28 week 
experimental period than saline-injected Tfm mice and XY littermates (figure 3.19).
3.3A.2 Serum hormone measurements
Fortnightly testosterone replacement was seen to be effective in elevating serum testosterone 
in Tfm mice on high-cholesterol diet (n=13) compared to saline-injected Tfm control mice on 
high-cholesterol diet (n=12) (P<0.01, Kruskal-Wallis) (figure 3.20). Testosterone replacement in 
this group increased serum Tfm levels to within the expected physiological range (10-30nM). 
However, surprisingly, when compared to saline-injected XY littermates (n=14), the 
testosterone-injected Tfm mice had significantly higher serum testosterone levels (P<0.01, 
Kruskal-Wallis) (figure 3.20). Serum testosterone concentrations in XY littermates were lower 
than physiologically predicted levels from previous investigations (Nettleship 2006), although 
still higher than saline-injected Tfm mice (figure 3.20). This was not statistically significant due 
to high levels of variability.
Serum estradiol concentrations were slightly, but non-significantly, raised in testosterone- 
injected Tfm mice compared to saline injected Tfm mice (figure 3.21), and although greater 
than saline-injected XY littermates, again this was not statistically significant (Kruskal-Wallis, 
n=6 ).
3.3A.3 Serum lipid measurements
Total serum cholesterol and LDL concentrations were similar in Tfm mice receiving 
testosterone replacement (n=13) compared to saline-injected Tfm controls (n=14), and both 
were still significantly higher than seen in XY littermates (n=12, PcO.OOl, ANOVA) (figure 3.22a 
& d). Serum HDL concentrations were similar in testosterone-injected Tfm mice, saline- 
injected Tfm mice and saline-injected XY littermates (figure 3.22b). Serum triglyceride levels 
were also similar in Tfm mice injected with testosterone compared to saline-injected Tfm mice, 
and higher in saline-injected XY littermate controls compared to both groups o f Tfm mice, 
although not significantly so (figure 3.22c).
3.3 A  A  Lipid deposition in the aortic root
Testosterone replacement in Tfm mice partially prevented the increase in lipid deposition in 
the aortic roots caused by high cholesterol feeding. Although ORO staining was detected in 
aortic root sections from Tfm mice injected with testosterone (figure 3.23), the degree of
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Figure 3.19; Total body weight and weight gain o f Tfm mice and XY litterm ate  
mice fed  a high cholesterol diet receiving testosterone (T) or saline (S) injections.
W eekly w eight measurements were compared between Tfm mice receiving 
testosterone replacem ent (n=14), Tfm mice receiving saline (n=15) and litte rm a te  
mice receiving saline (n=14) all on h igh-cholesterol d ie t fo r the 28 week study 
period. A) Mean weekly weights and B) mean w eight gains re lative  to  week 8  
starting weights.
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Figure 3.20; Serum testosterone concentration o f Tfm mice and XY litterm ates fed  
a high-cholesterol diet and receiving either testosterone (T) or saline (S) injections.
Testosterone concentrations compared between Tfm mice receiving saline 
injections (n=12); Tfm mice receiving testosterone injections (n=13), XY litte rm ates 
receiving saline in jections (n=14) all on high-cholesterol d ie t fo r the 28 week study 
period. (**P<0.01 vs XY S, and +tP<0.01 vs Tfm S, Mann W hitney).
oEQ .
■o
rz
18 0
16 0
14 0
S cs T
XY T fm T fm
Figure 3.21; Serum estradiol concentration o f Tfm mice and XY litterm ates fed  a 
high-cholesterol diet and receiving either testosterone (T) or saline (S) injections.
Estradiol concentra tions compared between Tfm mice receiving saline in jections 
(n=6 ); Tfm mice receiving testosterone injections (n=6 ), XY litte rm ates receiving 
saline injections (n=6 ) all on high-cholesterol d ie t fo r the 28 week study period.
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Figure 3.22; Serum lipid concentrations o f Tfm mice and XY litterm ates fe d  a  
high-cholesterol diet and receiving either testosterone (T) or saline (S) 
injections. Lipid concentrations compared between Tfm mice receiving 
testosterone replacem ent (n=13), Tfm mice receiving saline (n=14) and litte rm a te  
mice receiving saline (n=12) all on high-cholesterol d ie t fo r the 28 week study 
period. *P<0.05, **P<0.01, ***P<0.001  vs XY littermates receiving saline, Mann  
Whitney test.
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Figure 3.23; Representative oil red O staining of aortic root sections from Tfm mice and XY 
littermate controls on a high-cholesterol diet receiving either testosterone (T) or saline (S) 
injections. Staining was apparent in the vascular wall of aortae of both Tfm and XY littermate 
mice fed high-cholesterol diet and receiving saline injections and testosterone. Tfm mice 
receiving saline injections demonstrated much larger lesions (a). Lesions developed primarily 
at the shoulders of the aortic valve cusps in Tfm mice receiving testosterone (b) and XY 
littermates receiving saline (c). Sections were counterstained with haemotoxylin.
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staining was decreased significantly when measured semi-quantitatively compared to saline- 
injected Tfm mice (P<0.05, ANOVA, n=6 ) (figure 3.24). ORO staining in the aortic root of 
testosterone-injected Tfm mice was still greater than saline-injected XY littermates, although 
not significantly.
3.3A.5 Serum cytokine measurements
Concentrations of all serum cytokine (IL-ip, IL-6 , IL-10, CCL2 and TNFa) appeared marginally, 
but non-significantly reduced by testosterone replacement in Tfm mice compared to saline- 
injected Tfm mice (figure 3.25). The previously observed increase in serum CCL2 levels in Tfm 
mice on high cholesterol diet was partially, but not significantly prevented by testosterone 
replacement. Serum levels of IL- 6  and TNFa appeared to be reduced more markedly in Tfm 
mice injected with testosterone, although again not statistically so (n=6 ).
3.3.4.6 Immunohistochemistry
Aortic root sections known to contain lipid streaks from ORO staining were selected in 
sequence, where possible, or in the closest proximity to the detected lesion, for 
immunohistochemical analysis. Macrophage infiltration, detected by MOMA2 
immunofluorescence staining, was observed in all sections adjacent to lipid streaks and 
directly below the endothelial layer, identified by von Willebrand staining. CX3 CR1 staining was 
present in the plaque regions of the Tfm placebo-treated mouse and to a lesser extent in the 
XY littermate placebo-treated mouse aortic roots. No CX3 CR1 was detected in the aortic root of 
the Tfm mouse receiving testosterone replacement. CX3 CL1 staining was only detected at low 
levels in the aortic root lipid streak region of the Tfm mouse on placebo. No CX3 CL1 was 
detected in the Tfm mouse receiving testosterone replacement or the littermate placebo 
control (figure 3.26).
No staining was detected in negative controls, with the omission of the primary antibodies, for 
both secondary antibodies, Alexafluor 488 (green) and Alexfluor 568 (red), indicating no non­
specific binding of the secondary antibodies at the optimised conditions (figure 3.26). The 
positive control for the CX3 CR1 antibody was the cardiac tissue from a Tfm mouse which 
demonstrated specific staining throughout the myocardium. When this antibody was pre­
incubated with a specific peptide block, no staining occurred. Isotype controls for VWF, CX3 CL1 
and CX3 CR1 (which shared the same isotype) and MOMA2 demonstrated no staining following 
the same procedure as target antibodies, suggesting no non-specific binding of the primary 
antibodies (figure 3.27).
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Figure 3.24; Percentage lipid deposition in aortic root sections from Tfm mice and 
XY littermates fed a high-cholesterol diet and receiving either testosterone (T) or 
saline (S) injections. Semi-quantification of lipid deposition in the aortic root 
(expressed as percentage of medial area) was elevated in Tfm mice compared to 
XY littermates receiving saline. Lipid deposition was also reduced in Tfm mice 
receiving testosterone injections compared to saline-injected Tfm mice, though 
not to levels seen in XY littermates (**P<0.01, vs XY litte rm ates  receiving saline; 
P<0.05, vs Tfm mice receiving saline; Kruskal-Wallis, n=6 ).
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Figure 3.25; Serum cytokine concentrations of Tfm mice and XY littermates fed a high- 
cholesterol diet and receiving either testosterone (T) or saline (S) injections. XY littermates 
receiving fortnightly saline injections (n=6 ), Tfm mice receiving fortnightly saline injections 
(n=6) and Tfm mice receiving fortnightly testosterone injections (n=6 ) all on high- 
cholesterol diet were compared for serum cytokine concentrations, (unpaired t test).
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Figure 3.26; Immunohistochemical analysis of lipid streak composition in the aortic root 
of Tfm mice and XY littermates fed a high-cholesterol diet and receiving either 
testosterone or placebo treatment. Aortic root samples, identified as containing 
atherosclerotic plaques from oil red 0 (ORO) lipid deposition analysis, were selected. The 
endothelial layer was marked by von Willebrand factor (VWF, red) staining. Monocyte 
infiltration was detected locally adjacent to lipid streak areas (MOMA2, green). CX3CR1 
(red) was detected in the lipid streak areas of Tfm and littermate mice on placebo 
treatment, but not in Tfm mice receiving testosterone injections. Low level CX3CL1 
staining (red) was observed adjacent to lipid streaks in Tfm mice on placebo compared to 
littermates and Tfm mice on testosterone where no staining was seen. Negative controls 
with the omission of primary antibodies revealed no staining for both secondary 
antibodies labelled with AlexaFluor 488 (green) or AlexaFluor 568 (red). Cell nuclei were 
stained with DAPI (blue) and fluorescent images overlaid onto confocal images of the 
same area. Scale bar is 20(im
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Figure 3.27; Immunohistochemistry controls for testing the specificity of primary antibodies 
and validity o f immunostaining. Positive control tissues demonstrated clear staining for the 
target antigen with little non-specific staining following optimisation of the methods. Positive 
control tissues were; mouse cardiac tissue for CX3CR1, mouse aorta for vWF, and mouse 
aortic root atherosclerotic plaque for MOMA2. Isotype controls showed no staining in serial 
sections of the same control tissue with antibodies directed against non-relevant antigens. 
Peptide blockade of CX3CR1 primary antibody additionally revealed no staining.
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3.3.4.7 Serum CX3CLI measurements
CX3CLI concentrations in the serum of animals from all experimental groups were below the 
detection limit of the ELISA.
3.3.4.8 Summary
In summary, fortnightly testosterone injection significantly increased serum testosterone 
levels in Tfm mice, but did not significantly affect estradiol levels when compared to Tfm 
placebo controls. A significant reduction in the amount of lipid deposition in the aortic root 
was demonstrated following testosterone replacement in Tfm mice fed a high-cholesterol diet. 
Additionally, testosterone-injected Tfm mice displayed marginally reduced serum cytokines, 
total cholesterol and LDL compared to placebo-injected Tfm controls, though these changes 
did not return parameters to the same level as XY littermate mice or normal diet-fed Tfms.
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3.4 Discussion
3.4.1 Gender Determination
PCR confirmed the expression of the Sry gene in all ear clip samples from Tfm mice at the 
expected product size of 340bp, indicating that all animals were genotypically males. Thus it is 
possible to conclude that the breeding scheme was successful and that the Tfm strain was 
maintained throughout the process, based on the phenotypic expression of female 
characteristics by male mice. The conservation of the specific genetic manipulations of the Tfm 
strain was not investigated, but assumed to be maintained within the colony along with the 
inherent consequential symptoms of low endogenous testosterone and a non-functional 
androgen receptor. The low serum concentrations of testosterone observed in Tfm mice in this 
study further validate this assumption.
3.4.2 The effect of testicular feminization on atherosclerotic 
parameters
Tfm mice were shown to exhibit low endogenous serum testosterone levels compared to XY 
littermates. Serum levels of testosterone were approximately six-fold lower than that of XY 
littermates, and thus Tfm mice were overtly testosterone deficient, in addition to being unable 
to respond via the classical genomic signalling pathways mediated via AR activation. In a 
previous study using this mouse model, testosterone levels were found to be ten-fold lower 
than XY littermates (Nettleship et al. 2007a). The difference in magnitude of serum 
testosterone reduction between this and the present study may be explained by the timing of 
serum collection. Due to logistics and time limitations, all serum samples in the present study 
were collected mid-afternoon, when the diurnal rhythm of testosterone is declining toward 
the nadir of the cycle (Faiman and Winter 1971, Brambilla et al. 2009). In the previous study 
serum samples were taken closer to the morning peak in the cycle, when serum testosterone 
concentrations are considered more reliable and representative of the overall androgen status 
(Brambilla et al. 2009). Thus in future investigations samples would preferably be taken in the 
morning to investigate peak serum testosterone concentrations.
The low endogenous serum testosterone, along with a non-functional AR, were associated 
with a significant increase in weight gain over the course of the investigation in Tfm mice. 
Decreased levels of testosterone have been found in obese men, linking low levels of 
androgens with weight gain and fat accumulation (Zumoff et al. 1990, Derby et al. 2006,
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Goncharov et al. 2009). In the present study Tfm mice had inherent low serum testosterone 
and a non-functional AR, which would suggest that the increased weight gain was a 
consequence of androgen insensitivity rather than increased weight leading to low 
testosterone levels.
In contrast, serum estradiol levels in Tfm mice were unexpectedly and significantly elevated by 
almost three-fold compared to XY littermates. Although this was not observed by Nettleship et 
al. (2007a), this may be due to the use of different methods of analysis, with potential 
disparities in the sensitivity of the assays. The present study used an ELISA to directly detect 
hormone levels in serum samples, whereas Nettleship et al. (2007a) applied an extraction 
procedure to the samples prior to assaying. The elevated oestrogen levels in the Tfm group 
could also be related to increased adipose tissue, as this group also demonstrated the greatest 
weight gains, significantly greater than XY littermates. Adipose tissue contains a high 
concentration of aromatase, which is capable of converting testosterone to estradiol and/or 
androstenedione to oesterone, thus creating a more oestrogenic profile in males (Hammoud et 
al. 2006). In addition, adipose tissue has been shown to express several steroidogenic and 
steroid-inactivating enzymes (Blouin and Tchernof 2008). Although adipose tissue was not 
directly measured in this study, weight gain may be indicative of visceral fat accumulation. The 
elevated lipid status of Tfm mice compared to littermates in this study lends support to this 
theory. A low testosterone/high 17(3-estradiol serum profile has also previously been 
demonstrated in a male mouse model that has a partial deletion in the long arm of the Y 
chromosome, which contains a region of genes related to spermatogenesis and development 
of male characteristics (Kotula-Balak et al. 2004).
Several cross-sectional studies have reported that low endogenous serum testosterone is 
associated with high serum levels of either total and/or LDL-cholesterol in humans (Barrett- 
Conner et al. 1988, Barrett-Conner et al. 1992, Haffner et al. 1993, Simon et al. 1997, Barud et 
al. 2002) and animals (Jones et al. 2002). The present study supports this as total serum 
cholesterol and LDL cholesterol were shown to be significantly increased in Tfm mice 
compared to XY littermates. Elevated total cholesterol in the Tfm mice is consistent with 
previous reports (Nettleship et al. 2007a, Jones et al. 2003). As serum LDL concentration was 
calculated from the total cholesterol, HDL and triglyceride measurements, inaccuracies may 
occur in samples with low total cholesterol and high HDL levels, resulting in anomalous 
negative LDL values, as was seen in XY mice. Statistical analyses were still performed on these 
negative values to accommodate group variability as opposed to zeroing the negatives. 
However, the significance between the differences observed should be regarded with caution. 
Although higher than XY controls, the levels of serum LDL measured in the Tfm group were low
227
and therefore may not be significantly different from the XY littermate concentrations if the 
negative values were not included in analyses. Serum HDL was also elevated in Tfm mice, 
which would potentially counteract the negative effects associated with elevated LDL- 
cholesterol. On the other hand, due to the reported atheroprotective effects of HDLs 
(Reviewed in Murphy et al. 2009) and the multiple negative effects of non-HDL lipoproteins, it 
is often more pertinent to consider lipid profiles rather than individual lipid fractions 
(Tarchalski et al. 2003, Penalva et al. 2008, Okamura et al. 2009, Tamada et al. 2010). It is 
becoming more apparent, that HDL levels perse may not represent the whole story, as clinical 
studies have identified individuals with a significant atherosclerotic burden despite normal or 
elevated HDL cholesterol (reviewed in Ragbir and Farmer 2010). It has recently been proposed 
that the mechanism by which HDL-C levels are raised may influence their pro- or anti­
atherogenic effects (Leite and Fernandez 2010). Increased HDL as a result of increased 
synthesis appears to be protective against cardiovascular diseases, whereas an increase due to 
decreased catabolism has been associated with a greater number of cardiovascular-related 
deaths (reviewed in Leite and Fernandez 2010). In addition, the heightened oxidative status 
associated with vascular dysfunction and atherosclerosis is capable of oxidatively modifying 
HDL, generating dysfunctional HDL which is often incapable of reverse cholesterol transport 
(Heinecke et al. 2008, Li et al. 2009). Therefore, the functionality of HDL may be more 
indicative of negative cardiovascular outcomes.
The minimal lipid deposition found in the aortic root of Tfm mice in the present study 
however, would suggest that although these mice have elevated serum lipids and low 
endogenous testosterone, they remain relatively resistant to early atherosclerosis. It remains 
unknown from this investigation whether this is due to the elevated serum oestrogen, the 
moderately raised HDL levels or simply due to the fact that C57BL/6 mice are relatively 
resistant to spontaneous atheroma formation and require a high fat diet to induce 
atherosclerosis (Daugherty et al. 2002).
Serum IL- 6  and TNFa were significantly elevated in Tfm mice compared to XY littermates, 
suggesting that low endogenous testosterone and non-functional ARs may influence selective 
cytokines and, therefore, inflammatory status. As elevated IL- 6  levels have been shown to 
predict cardiovascular events in healthy men, and survival amongst patients with acute 
coronary syndromes, and TNFa has been associated with an elevated risk of M l and 
cardiovascular death (Ridker et al. 2000a), it may be postulated that elevated levels in the 
current model are predictive or indicative of early athero-inflammatory events. It has been 
suggested that plasma cytokine levels correlate negatively with androgen levels in men 
(Yesilova et al. 2000;) and women (Christodoulakos et al. 2007). Yang et al. (2005) confirmed a
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significant inverse correlation between serum testosterone levels and IL-6 , slCAM-1 and C- 
reactive protein (CRP) in elderly males. An inverse relationship was seen between serum IL-lp 
and endogenous testosterone in 69 male CAD patients diagnosed with ischaemic heart disease 
(Nettleship et al. 2007b). The increase in IL-ip was significantly related to disease severity in a 
stepwise manner, yet no association was observed for TNFa, IL- 6  and IL-10 (Nettleship et al. 
2007b). Although IL- 6  and TNFa were elevated in Tfm mice on normal chow diet in the present 
study, no association with lipid deposition in the aortic root was observed. This was due to a 
lack of lesion development, in line with previous suggestions in C57BL/6 mice on normal diet 
(Paigen et al. 1987). As this is a model of early atherogenesis, the elevated lipid and cytokine 
parameters observed in Tfm mice may be indicative of a pre-atherosclerotic state, preceding 
the development of lesions at an older age. Investigating lipid deposition in the aortic root of 
these animals on normal diet beyond the 36 weeks of age could help elucidate this.
3.4.3 The effect of high-cholesterol diet on atherosclerotic 
parameters
Animals were fed a diet containing 42% butterfat, 1.25% cholesterol and 0.5% cholate, a diet 
previously reported to induce atheroma formation in mice following feeding between 5 and 26 
weeks (Abramovitz et al. 1999, Calleja et al. 1999, Lichtman et al. 1999, Merat et al. 1999, 
Murakami et al. 1999, Tangirala et al. 1999, Tribble et al. 1999 Nathan et al. 2001). In these 
previous studies the animals had increased susceptibility to atherosclerosis through knockout 
of the LDLr. In addition to this, 28 weeks of feeding on this high-cholesterol diet has been 
previously shown to be sufficient to establish lipid streak formation in the Tfm mouse model 
(Nettleship et al. 2007a). This previous study reported a weight gain in Tfm mice compared to 
XY littermates over the feeding period, whereas the present study demonstrated inconsistent 
and only slightly elevated weights in Tfm mice, although they were significantly elevated by 
the end of the study period. When body weights were converted to weight gain, to account for 
variations in starting weights of animals, the differences were not statistically significant, 
although Tfm mice maintained the highest weight gains. Surprisingly, a decline in both body 
weight and weight gain following high-fat diet feeding compared to normal chow fed mice was 
seen in the current investigation in Tfm mice. The decrease in weight gain following high-fat 
diet consumption is inconsistent with previous studies using animal models, which report 
either weight gains (Nettleship et al. 2007a, Bourassa et al. 1999) or no change in body weight 
(Alexandersen et al. 1999). As XY littermates demonstrated similar decreases in total body 
weight and weight gain, it may be proposed that the palatability of the diet affected the 
amount of food consumed. Food intake was not monitored in the present study, but could be
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a useful additional parameter to monitor in future studies, to evaluate dietary habits in 
relation to weight.
The apparent decline in serum testosterone observed in XY littermates following 28 weeks 
high-cholesterol diet may be due to feedback mechanisms on steroidogenesis. Several 
enzymatic steps are involved in the biosynthesis of steroid hormones from cholesterol, the 
first one of which is the conversion of cholesterol to pregnenolone (see figure 1.9) in the 
mitochondria of steroid hormone producing cells (Stocco and Clark 1996). Sugawara et al
(2007) demonstrated that human adrenal carcinoma H295R cells displayed significantly 
decreased pregnenolone production when cultured with varying amounts of cholesterol 
sulphate. In addition, specific transport proteins are necessary to deliver cholesterol to the 
mitochondria for this enzymatic conversion (Strauss et al. 1999). Increased levels of 
cholesterol sulphate have been reported to inhibit cholesterol movement in the mitochondria 
from isolated rat adrenal cells, and thus decrease steroidogenesis (Lambeth et al. 1987). While 
this implicates a mechanism by which increased dietary cholesterol can result in reduced 
testosterone production, the effect of cholesterol on steroidogenesis remains unclear 
(Clemens et al. 2000).
Additionally, the concept of bioavailable testosterone, which comprises free testosterone and 
that loosely bound to albumin, may be considered a more accurate assessment of androgen 
status and may be of more use than total testosterone measures in future studies. In a report 
by Muller et al. (2004), free testosterone but not total testosterone, was associated with the 
progression of atherosclerosis in elderly men, although opposing results have also been shown 
(Svartberg et al. 2006). These conflicting results encourage the measurement of total and free 
testosterone in addition to SHBG and albumin levels as more encompassing parameters of 
testosterone assessment in future investigations.
17f3-estradiol was significantly reduced by high-cholesterol diet in Tfm mice, again potentially 
due to cholesterol feedback mechanisms acting upon the regulation of steroidogenesis. 
Estradiol levels were comparable between Tfm mice and XY littermates on high-cholesterol 
diet. This is important in the context of this investigation as it ensures that any differences in 
the atherosclerotic parameters may be attributable to the low testosterone concentrations 
and non-functional AR associated with the Tfm mouse, rather than any estradiol-mediated 
events.
As previously demonstrated (Barrett-Conner et al. 1988, Barrett-Conner et al. 1992, Haffner et
al. 1993, Simon et al. 1997, Barud et al. 2002), serum lipid measurements significantly favour
an atherogenic profile, following high-cholesterol diet feeding. Both Tfm mice and XY
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littermates displayed elevated total cholesterol and LDL-cholesterol after high-cholesterol 
feeding compared to normal diet. Additionally, HDL was decreased in Tfm mice, potentiating 
the atherogenic lipid balance. Despite the diet-induced increase in total cholesterol and LDL in 
XY littermates, Tfm mice displayed significantly higher concentrations of both, indicating that 
low testosterone and a non-functional AR negatively influence circulating lipids to favour 
dyslipidaemia. Simon et al. (1997) conducted a case-controlled study of 25 age- and ethnicity- 
matched males and demonstrated that low testosterone was significantly associated with 
higher total cholesterol, LDL cholesterol and lower HDL cholesterol. Laughlin et al. (2008) also 
reported an inverse relationship between endogenous testosterone and serum triglyceride, 
and a positive association with HDL cholesterol in a prospective population-based study of 794 
elderly men. Thus, the animal model demonstrated similar lipid profiles to patients with low 
testosterone, indicating that it is a good model in which to study atherosclerosis.
In agreement with these circulating serum lipid levels, significant fatty streak formation was 
detected within the aortic root of Tfm mice following 28 weeks feeding on the high-cholesterol 
diet. XY littermates also demonstrated increased lipid deposition compared to XY littermates 
on normal diet, though the lesions were fewer and significantly smaller than those in Tfm 
mice, when quantified. Comparable with these observations, several animal studies have 
reported a negative association between low endogenous testosterone levels in male animals 
and aortic atherosclerosis. Indeed, Alexandersen et al. (1999) examined the effects of natural 
androgen on lipids in sexually mature male rabbits. Following either bilateral castration or 
sham operation, 20 male rabbits per group were fed an atherogenic diet for 30 weeks to 
induce aortic atheroma formation. It was reported that aortic plaque formation was doubled 
in castrated rabbits compared to sham-operated controls (Alexandersen et al. 1999). 
Moreover, Nathan et al. (2001) demonstrated that sub-physiological testosterone levels in 
orchidectomised male LDL-receptor KO mice exacerbated aortic lesion formation compared to 
testes-intact controls, following 8  weeks cholesterol feeding. Such data provides further 
evidence that low serum testosterone is linked to atherosclerosis.
Many studies have investigated the association between serum levels of testosterone and CAD 
in men (Philips et al. 1994, Kabakci et al. 1999, English et al. 2000c, Pugh et al. 2004, Van den 
Beld et al. 2003, Rosano et al. 2007). Though these studies differ in the parameters used to 
measure atherosclerosis, consistent conclusions are reported that serum testosterone levels 
are not raised in men with CAD. Moreover, the majority of these studies conclude that serum 
testosterone is reduced in male CAD patients. Phillips et al. (1994) related the extent of CAD 
with declining levels of serum testosterone in men aged 39-89, and Van den Beld et al. (2003) 
similarly reported an inverse relationship between testosterone and carotid atherosclerosis. In
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addition, Pugh et al. (2004) reported a 24% prevalence of hypogonadism in a cohort of 831 
male subjects exhibiting >75% stenosis of at least one major coronary artery. In a study by 
Rosano et al. (2007), 129 male angina patients with symptoms suggestive of CAD were 
evaluated for plasma hormone levels. An inverse relationship between the degree of CAD and 
plasma testosterone levels was found. Premature CAD in men below the age of 45 was 
associated with lower concentrations of total and free testosterone compared to age matched 
controls (Turhan et al. 2007). In addition to CAD studies, Akishita et al. (2009) have recently 
reported that low testosterone is predictive of cardiovascular events in a Japanese population 
of 171 middle-aged male outpatients who initially had any coronary risk factor (hypertension, 
diabetes, dyslipidemia, smoking, and obesity) without a previous history of CV disease. IMT, as 
an indicator of general atherosclerosis, was also found to be associated with low total 
testosterone measures in a large male population-based study (Svartberg et al. 2006). Such 
studies provide strong evidence that negative cardiovascular events are associated with low 
testosterone, and the present study supports this.
Serum CCL2 levels were elevated in both Tfm mice and XY littermates following high- 
cholesterol diet feeding, suggesting that this diet influences inflammatory status regardless of 
serum androgen levels or AR functioning. Raised CCL2 levels have been associated with CVD. 
Elevated plasma CCL2 has been reported in patients with severe acute Ml (Parissis et al. 2002, 
Kobusiak-Prokopowicz et al. 2007). PBMCs from patients with CAD spontaneously secrete 
more CCL2 than PBMCs from healthy controls, and release greater amounts when stimulated 
with oxLDL (Breland et al. 2008, Oliveira et al. 2009). Additionally, increased serum CCL2 has 
been reported in rodent obesity as a direct result of high-fat diet feeding (Takahashi et al.
2003). Although CCL2 was not related to body mass in the present study, body composition 
may have been a more relevant parameter to measure as adipose tissue may increase without 
altering total body weight or weight gain, as fat distribution shifts. Increased circulating CCL2 
may be linked to monocytosis and a heightened inflammatory state associated with elevated 
monocytes in the blood. High-cholesterol diet feeding was additionally seen to significantly 
increase circulating TNFa concentrations in XY littermates. Adipocytes express TNFa (Fain et al.
2004) and, although circulating levels are low in comparison with local tissue concentrations, 
serum levels have been correlated with obesity (Fernandez-Real et al. 2003), an elevated risk 
of Ml and cardiovascular death (Ridker et al. 2000b), severity of PAD (Tedgui and Mallat 2006) 
and burden of atherosclerosis (Skoog et al. 2002). The lack of increase in serum TNFa in Tfm 
mice on high-cholesterol diet in the present study may be due to the high baseline levels 
observed compared to XY littermates.
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No significant differences were observed between Tfm mice and XY littermates on high- 
cholesterol diet for all serum cytokines measured, whereas earlier observations of mice on 
normal diet revealed differences between these groups for TNFa and IL-6 , potentially due to 
low testosterone and non-functional AR. This suggests that high-cholesterol diet may have a 
greater effect on cardiovascular-related systemic markers of inflammation than androgen 
status, masking any effects of testosterone in these groups. Measurement of circulating 
cytokines, however, may not be indicative of the local inflammatory state at the site of lipid 
streak formation observed in the animal groups. Following secretion from activated cells, 
cytokines are often rapidly bound to high affinity receptors on neighbouring cells. As the lipid 
streaks, which developed as a result of high-cholesterol diet feeding, were localised to the 
aortic root, any associated inflammation may have been insufficient to produce a systemic 
inflammatory response. Therefore, measuring circulating levels is not necessarily indicative of 
cytokine activity relevant to aortic atherosclerosis. Many cytokines, such as IL-ip, IL-6 , IL-10, 
IFNy and TNFa are highly expressed in atherosclerotic regions at multiple stages of disease 
progression (Tedgui and Mallat 2006), but may not reach detectable circulating levels, 
particularly in models of early atherogenesis, where lesions are local to specific areas of the 
vasculature. In addition, the use of cholate in the high-fat diet, to facilitate cholesterol 
absorption and promote the development of atherosclerosis in this murine model, could have 
influenced inflammatory processes through the induction of inflammatory response genes, as 
suggested by Vergnes et al. (2003).
Clearly the data presented in this section show that low endogenous testosterone leads to 
aortic fatty streak formation and a pro-atherogenic lipid profile following cholesterol feeding. 
However, whether it is the testosterone deficiency, or the effects of non-functional ARs, that 
cause fatty streak formation cannot be concluded from these data alone. Further experiments 
employing TRT were undertaken to investigate this.
3.4.4 The effect of testosterone replacement on 
atherosclerotic parameters
The present study confirmed previous findings that fortnightly injections of testosterone 
(Sustanon 100® (100mg/ml)) were capable of returning serum testosterone concentrations to 
within the physiological (10-30nmol/L) range in Tfm mice (Nettleship 2006). It has been shown 
previously that the fortnightly serum testosterone levels in Tfm mice following intramuscular 
injection of Sustanon 100® fluctuated from supraphysiological directly after injections, to 
subphysiological by day 14, due to metabolism and excretion. For the duration of this cycle, 
circulating testosterone levels mostly remained within the physiological range. In the present
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study, serum samples were collected at day 7 post-injection and correspond with the lower 
end of physiological (14.65±5.15 nmol/L) levels seen at this time point in the previous 
investigation. This highlights the robustness of the testosterone replacement protocol.
Serum testosterone levels in XY littermates were lower than previously described (Nettleship
2006), potentially due to the time of sample collection corresponding with the afternoon nadir 
of the diurnal testosterone cycle. Thus serum testosterone levels were significantly higher in 
Tfm mice receiving Sustanon 100® as supplemented testosterone does not display diurnal 
patterns. Tfm mice receiving placebo injections of saline demonstrated low endogenous 
testosterone levels, at levels similar to those of Tfm mice on high-cholesterol diet alone or 
normal chow diet. This further confirms that the Tfm mutation generates a phenotype with 
low circulating testosterone.
No significant differences were observed between the 17(3-estradiol levels of XY littermates on 
placebo injections, Tfm mice on placebo injections and Tfm mice receiving testosterone 
replacement and were comparable to mice on high-cholesterol diet alone. Although not 
significant, estradiol levels appeared elevated in Tfm mice receiving TRT. This increase may be 
due to increased expression of aromatase, as similarly noted in mice with partial deletion of 
the Y chromosome (Kotula-Balak et al. 2004;), or increased aromatase in adipose tissue 
resulting from high-cholesterol diet feeding (Hammoud et al. 2006). As testosterone is 
increased from TRT, amplified enzyme expression would therefore increase conversion to 
estradiol compared to Tfm placebo mice, where the substrate hormone is reduced.
No significant differences in body weight were observed between Tfm mice and XY littermates 
on high-cholesterol diet and receiving either testosterone or placebo. This observation 
demonstrates that changes in serum lipid parameters were independent of change in weight 
and suggests that they may arise from a direct modulation of metabolic processes by 
testosterone rather than a reduction in weight. TRT investigations have revealed that 
testosterone treatment can alter body composition (Snyder et al. 1999, Isidori et al. 2005, 
Allan et al. 2008). Snyder et al (1999) reported a decrease in fat mass and an increase of lean 
mass in testosterone treated elderly (>65 years) men compared to placebo-treated controls. 
Comparable to the present study, no significant differences were observed in overall body 
mass (Snyder et al. 1999). Similarly, transdermal testosterone therapy was shown to inhibit 
visceral fat accumulation and improve fat-free mass and muscle mass compared to placebo- 
treated controls in a population of men aged 55 years or older with low-normal testosterone 
(Allan et al. 2008). These studies suggest that body composition rather than body weight, may
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be influenced by testosterone, which may in turn be more relevant to metabolic syndrome and 
atherosclerosis.
Tfm mice on high-cholesterol diet had significantly higher total cholesterol and LDL serum 
concentrations compared to XY littermates. TRT in Tfm mice had no further modulatory effects 
on any of the lipid fractions measured. The lack of effect on the pro-atherogenic LDL and 
triglyceride fractions is in agreement with the study by Nettleship et al (2007a). Nettleship et 
al. (2007a) reported that physiological testosterone therapy had no lowering effect upon non- 
HDL-C in the Tfm mouse. These authors did show, however, an improvement in the serum 
concentrations of atheroprotective HDL-C in testosterone-treated Tfm mice compared to 
placebo-treated controls. These improvements brought HDL-C concentrations to levels 
comparable with XY littermates, suggesting that the beneficial effect of testosterone was not 
via AR activation. Moreover, blockade of ERa or aromatase inhibition abolished this increase in 
HDL-C, indicating that the effect of testosterone is dependent upon ERa activation and 
conversion of testosterone to estradiol (Nettleship et al. 2007a). Returning testosterone levels 
to low-normal by intramuscular injection in elderly men with subnormal levels was 
demonstrated to have no effect on circulating total cholesterol, LDL, HDL and triglyceride 
levels (Agledahl et al. 2008). Additionally, and similar to the present investigation, Allan et al.
(2008) concluded that transdermal testosterone treatment did not alter serum lipid 
measurements (total cholesterol, HDL-C, LDL-C and triglycerides) in a cohort of healthy but 
symptomatic, elderly men. Favourable body composition changes were observed in the 
testosterone-treated group compared to placebo-treated controls (Allan et al. 2008). In 
contrast, several other studies have reported beneficial modulatory effects of TRT on lipid 
profiles as shown in chapter one table 1.2 (See Jones and Saad 2009 for review).
Although serum LDL measurements remain an important predictor of atherosclerosis, 
evidence is emerging that the subclass of LDL may provide greater insight into cardiovascular 
risk. LDLs are heterogeneous particles and comprise at least four major subspecies that differ 
in size, density, physicochemical composition, metabolic and oxidative behaviour (Griffin et al. 
1990;). In particular, small dense LDLs express greater atherogenicity due to their increased 
long residence in the circulation, oxidative susceptibility, decreased receptor mediated uptake 
and increased endothelial penetration (Rizzo et al. 2009). In the present study, it is plausible 
that TRT may reduce the atherogenicity of the lipids by altering subclass, whilst not affecting 
the collective measurements of serum LDL and total cholesterol. This is supported by the 
protective effect of fortnightly sustanon 1 0 0 ® injections on lipid streak development in the 
aortic root of Tfm mice, in the absence of gross lipid changes, observed in the present study.
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The present study supports the findings of numerous animal studies that have shown 
beneficial effects of androgen supplementation in atherogenesis, as lipid deposition in the 
aortic root was significantly inhibited by testosterone therapy in Tfm mice on high-cholesterol 
diet. Larsen et al. (1993) showed a significant reduction in aortic cholesterol accumulation 
following testosterone supplementation in orchidectomised male rabbits fed a pro- 
atherogenic diet. Alexanderssen et al. (1999) published similar results. Castrated male rabbits 
and sham-operated controls were fed an atherogenic diet for 35 weeks to induce aortic 
atherosclerosis and additionally received either daily oral testosterone, twice weekly 
intramuscular injection or placebo. Both oral and intramuscular testosterone were associated 
with a reduction in plaque formation (Alexanderssen et al. 1999). Similar findings were 
reported by Bruck et al (1997). Moreover, a reduction in plaque development was also 
demonstrated in orchidectomised male LDLr KO mice receiving testosterone supplementation 
compared to controls (Nathan etal. 2001). Most pertinently, Nettleship etal. (2007a) revealed 
that physiological testosterone therapy virtually abolished the increased aortic root lipid 
deposition seen in Tfm mice fed a pro-atherogenic diet. As the present study showed that 
aortic root lipid streak formation was only partially retarded by testosterone therapy in Tfm 
mice, and not reduced to the level of deposition seen in XY littermates, it may be concluded 
that the protective effects of testosterone act via both AR-dependent and independent 
pathways. Interestingly, and contradictory to the majority of studies, Villablanca et al. (2004) 
reported the potentiating effects of testosterone on fatty streak development in high-fat, high 
cholesterol fed male mice. Castration of ERa knock-out mice and wild-type controls almost 
prevented lesion formation in the aorta. Compared to wild-type controls, intact ERa-deficient 
mice displayed reduced atherosclerosis leading the authors to conclude that the negative 
effects of testosterone act via local conversion to 17p-estradiol and subsequent ERa activation 
(Villablanca et al. 2004).
The role of the AR has previously been implicated in CAD. Naturally occurring truncations in 
the polymorphic CAG repeats, that encode a varying number of polyglutamine residues in the 
AR molecular structure, have been associated with CAD (Zitzmann et al. 2001, Alevizaki et al. 
2003). Shorter CAG repeats were associated with severity of CAD (Alevizaki et al. 2003). This 
may be, at least partly, due to effects on lipids, as lower HDL-C was reported in men with 
truncated CAG repeats (Zitzmann et al. 2001). The AR-independent mechanisms of 
testosterone's reported athero-protection are often considered to be mediated via a 
conversion to estradiol and subsequent activation of the ER. Nathan et al. (2001 described how 
the attenuating effects of testosterone on early atherogenesis, measured by aortic root lipid 
deposition in male LDLr KO mice, were not observed with simultaneous aromatase inhibition.
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Also, the treatment of male ApoE KO mice with 17(3-estradiol significantly reduced angiotensin 
ll-induced suprarenal aortic lesion formation by 75% compared to controls (Martin-McNulty et 
al. 2003). These findings reflect those observed in apoE mouse models of diet-induced fatty 
streak formation (Bourassa et al. 1996) and spontaneous lesion development (Elhage et al. 
1997), implicating a protective role for oestrogens. In contrast to these studies, Nettleship et 
al. (2007a) eloquently demonstrated that inhibition of aromatase and blockade of the ER only 
partially attenuated the protective effects of testosterone therapy in Tfm mice. This would 
suggest that testosterone additionally imparts beneficial effects on athero-development via 
non-classical non-genomic AR- and ER-independent mechanisms. The present study indicates 
both AR-dependent and independent protective functions of testosterone in athero- 
protection, although further investigation is required to elucidate the specific mechanisms 
involved.
No significant differences in serum cytokines were observed following testosterone treatment 
in Tfm mice on high-fat diet compared to littermates and placebo controls in the present 
study. Slight reductions in the diet-induced increases of IL-6 , CCL2 and TNFa as a result of TRT 
were noted. The lack of significance may be due to the variability of the data, compounded by 
the small sample size, thus reducing the power of the investigation. Beneficial effects of 
testosterone supplementation in reducing pro-inflammatory cytokine concentrations have 
been previously reported (Hatakeyama et al. 2002, Malkin et al. 2004a, Malkin et al. 2004b, 
Corrales et al. 2006, Zitzmann etal. 2005). TRT reduced circulating levels of TNFa and IL-1(3 in a 
cohort of 27 hypogonadal men of whom 80% had CHD (Malkin et al. 2004b). Similarly, male 
hypogonadal patients with ischaemic heart disease who received testosterone treatment for 1  
month demonstrated a significant decrease in serum TNFa (Malkin et al. 2004a). Interestingly, 
IL- 6  was significantly reduced in healthy male volunteers following 16 weeks of testosterone 
supplementation (Zitzmann et al. 2005).
Studies investigating the effects of androgen therapy on cytokine levels in animal models are 
limited. Testosterone replacement in castrated mice reduced the heightened TNFa respone to 
lipopolysaccharide (Spinedi et al. 1992). In addition, DHT treatment of mice with experimental 
autoimmune encephalomyelitis decreased IFNy concentrations, whilst elevating IL-10 (Dalai et 
al. 1997). Also, DHEA treatment reduced TNFa (Kimura et al. 1998) and IL-1 and LPS-induced 
TNFa (Ben-Nathan ef al. 1999) in obese rats and mice respectively. These data implicate that 
androgens can modulate inflammation, potentially conferring beneficial effects against the 
development of inflammatory diseases such as atherosclerosis.
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In the present study serum CX3 CL1 levels were below the detection range of the ELISA, 
potentially highlighting the local actions of these chemokines and indicating that localised 
inflammation may not be reflected in circulating markers. Similarly, Dougherty et al. (2005) 
found no change in serum levels of soluble ICAM-1 or VCAM-1 in 37 elderly hypogonadal men 
after normalising their testosterone levels, noting that circulating levels may not be indicative 
of local production. The circulating levels of both CCL2 and CX3 CL1 are associated with 
circulating monocyte number and subsequent accumulation in atherosclerotic plaques of 
ApoE-/- mice fed a high-fat diet (Combadiere et al. 2008). This may be partly due to chemokine 
control of monocyte emigration from the bone marrow to the circulation leading to a 
heightened immune response to local inflammatory stimuli. However, a reduction in 
atherosclerosis may not be indicative of a reduction in circulating monocytes or chemokines, 
as associations are not always observed (Rajavashisth et al. 1998;), and local cytokine activity 
may be more relevant to plaque progression.
To investigate local inflammatory activity, preliminary immunohistochemical staining of the 
fatty streak lesions in the aortic root of animals in the present study was undertaken, although 
due to the limited number of animals analysed, conclusions are tentative. As demonstrated in 
several other studies (Teupser et al. 2004), monocytes/macrophages were detected locally, 
adjacent to lipid streaks, indicating the presence of inflammatory leukocyte infiltration in 
atherosclerotic plaques. MOMA2 staining was consistent in the plaque areas of the different 
animal groups suggesting that monocytes and macrophages are present in the vessel wall at 
sites of atheroma, regardless of androgen influence. Monocyte/macrophages were located 
directly below the VWF-positive endothelial surface. As the size of the lipid streaks, analysed 
by ORO, were smaller and fewer in the aortic root of TRT treated Tfm mice and XY littermates, 
testosterone may not influence the proportion of monocytes/macrophages relative to lesion 
size, but may reduce overall immune reactivity and leukocyte entry to inhibit plaque 
formation. CX3 CR1 staining was present in the plaques of XY littermates and Tfm placebo mice, 
adjacent to ORO and MOMA2 staining. As dual staining was not carried out as part of this 
investigation, the localisation of CX3 CR1 could not be specifically designated to cell type. It's 
clear presence in the lipid streak area does, however, indicate a role for CX3 CL1 in early 
atherogenesis. Wong et al. (2002) reported CX3 CR1 staining in human atherosclerotic coronary 
arteries in the endothelium and immediate subendothelial cells. The authors localised the 
receptor to numerous infiltrating T cell and mononuclear cells seen within the adventitia. 
CX3 CRI positive cells in human atherosclerotic plaques were demonstrated to be SMCs in 
intimal regions of coronary artery segments from heart transplant recipients (Lucas et al.
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2003), suggesting a role for CX3 CL1 in vascular remodelling. A high amount of CX3 CR1 staining 
was present in the adventitia of AAA tissue (Patel et al. 2008).
CX3 CR1 staining in Tfm mice receiving TRT was not apparent in the lipid lesion. As XY 
littermates displayed lower levels of testosterone than anticipated and reduced 
concentrations compared to testosterone-treated Tfm mice, CX3 CR1 detection may be 
influenced by circulating testosterone levels. The staining apparent in XY littermates was of a 
relatively lower level than Tfm placebo, potentially supporting this idea, although this may 
have been simply reflective of lesion size. Reduced CX3 CR1 staining may be reflective of altered 
inflammatory cell phenotypes present in the fatty streak. Inflammatory monocytes are 
CX3 CRl'°, and monocytes that express high CX3 CR1 are non-classical monocytes destined to 
become resident macrophages (Geissmann et al. 2003). Although it is not known at which 
stages in atheroma formation these subsets predominate and the actions they elicit, it may be 
postulated that testosterone influences specific recruitment or subset switching, thus altering 
relative CX3 CR1 abundance in the lesion without affecting monocyte/macrophage numbers. 
This may ultimately affect the nature and progression of the plaque. However, this is purely 
speculative and, as previously suggested, the predominant cell type expressing CX3 CR1 in 
human plaques has been demonstrated to be SMC (Lucas et al. 2003). Again, this may be 
indicative of altered lesion composition.
CX3 CL1 staining was only detected in Tfm placebo animals, and therefore corresponded with 
the severity of lipid streak formation. A protective effect of testosterone was apparent through 
the lack of CX3 CL1 staining in XY littermates, an effect that was independent of the AR, as TRT 
in Tfm mice appeared to abolish CX3 CL1 expression in aortic root plaques. CX3 CL1 expression 
appeared to be within the lesion area rather than on the luminal endothelial surface. This is in 
support of previous studies investigating CX3 CL1 expression in human coronary artery plaques 
(Lucas et al. 2003) and carotid and femoral arteries (Bazan et al. 1997). Lucas et al. (2003) 
provided evidence for CX3 CL1 positive cells just below the luminal endothelium of coronary 
artery lesions and through colocalistion of immune cell markers, and suggested that these cells 
were recently transmigrated monocytes. The authors reported that SMCs also expressed 
CX3 CL1 in the plaque regions, but the most substantial staining was localised to macrophages.
This may be explained by an effect of testosterone in inhibiting atherogenesis and therefore 
altering the expression and activity of chemokines at distinct phases of plaque progression. 
Cheng and colleagues (2007) report that CX3 CL1 is highly expressed only in advanced lesions of 
apoE-/- mice fed a high-fat high-cholesterol diet, where carotid arteries were subjected to low 
or oscillatory shear stress to induce plaque progression. However, Lesnik et al (2003)
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demonstrate that CX3 CL1 is highly expressed in early aortic lesions of apoE-/- mice and plays an 
important role in atherogenesis. This, again, highlights the complexity of dissecting the role of 
a specific mediator in the multifaceted, dynamic and complex process of atherogenesis, which 
may be influenced by many other factors such as vascular territory and the initiating stimulus.
The direct mapping of multiple targets within the same lesion is difficult to achieve in the 
present study due to limitations in the sequential nature of the aortic root sections. Also, as 
sections are taken from different stages throughout the length of the lesion, plaque 
composition may alter. The upstream shoulder regions, or outer edges, of atherosclerotic 
lesions are considered to be subjected to increased shear stress and, although not sufficient to 
physically cause mechanical destruction of the plaque, rupture may be provoked via altered 
cellular and structural composition (Fukumoto et al. 2008). Macrophage-rich areas are more 
likely to form in these upstream shoulder regions than in downstream shoulders of the same 
lesion (Dirksen et al. 1998). As macrophages are the most abundant source of MMP 
production in lesions, it follows that these leukocytes accumulate at vulnerable regions (Galis 
et al. 1994a) and that plaque rupture is always colocalised with inflammatory cells 
(Pasterkamp et al. 1999). Therefore, it is possible that plaque composition may alter 
throughout the length of the lesion, potentially influencing cellular content and the expression 
of inflammatory markers, dependent upon the location of the section analysed. Therefore, a 
single section through a lesion at a particular point may not be representative of the entire 
fatty streak and its severity in terms of clinical consequence, and this highlights the importance 
of analysing multiple sections from an area of lesion and comparing representative data 
between different animals.
The major limitation of the immunohistochemical analysis in the present study is the lack of 
repetition. Only a single animal from each group was analysed due to time constraints, 
meaning no definitive conclusions can be drawn and suppositions are tentative. Additionally, 
the lack of complete sets of isotype controls and peptide blockade for all primary antibodies 
tested, brings into question the specificity of the staining and limits the reliability of the 
procedure. These limitations could be overcome in a continuation of the present investigation.
3.4.5 General considerations
As with all animal models of disease, the relevance to the pathophysiology of the human 
condition is always a consideration. In humans, the location and composition of the lesions are 
critical parameters that determine the severity and complication of the disease (Catanozi et al. 
2009). The mechanisms and location of atherosclerosis that are responsible for overt clinical
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symptoms in humans are often not those measured in mice, as it is often different areas that 
are prone to disease in animal models (Daugherty and Ratteri 2005). Although the lesions do 
not evolve into advanced fibrous plaques, this murine model mimics many of the features 
found in early lipid streak formation in humans. Feeding animals a high-cholesterol diet is a 
well established model for atheroma formation, although the dyslipidaemia induced differs 
compared to native human atherosclerosis. High LDL seen in humans and the associated 
mature plaques are replaced by high VLDL and cholesterol ester-enriched fatty streaks (Arad et 
al. 1989). These subtle differences may affect the delicate interplay between sex hormones 
and CVD, although fatty streaks as precursors of mature plaques appear to maintain similar 
morphology and cell behaviour in animal models as with human atheroma (Gordon et al. 
1988).
It has been noted that the high degree of variation inherent with animal models and the 
frequent lack of Gaussian distribution often requires reasonably large group sizes for robust 
statistical analysis (suggested as 20 per group) (Daugherty and Ratteri 2005). Due to practical 
limitations, respect for the reduction element in ethical considerations of animal work design, 
and based on power calculations from the previous study (Nettleship et al. 2007a), the present 
study utilised much lower group numbers than Daugherty and Rateri (2005) suggest. The 
variation within and between groups in the current study make it difficult to draw definitive 
conclusions from the data. It is possible that due to this variance, apparent patterns in the data 
of the present investigation are assessed to be non-significant with poor statistical value. A 
repeat of the present study may elucidate some of the smaller differences that may be 
important underlying mechanisms of lesion formation. However, as the present investigation 
repeated several parameters of an earlier study (Nettleship et al. 2007a), with inconsistencies 
in the some of the findings, the variability of animal experimentation is highlighted. Daugherty 
and Rateri (2005) also recognised considerable variance in the extent of atherosclerosis and 
parameters measured for the same model in different laboratories.
Measurement of circulating total testosterone and estradiol may not be reflective of their local 
tissue-specific actions and would therefore be imperfect parameters for extrapolating 
information regarding the hormonal influence on atherogenesis. In addition, a single point 
measurement of androgen/oestrogen status may be limited in its ability to indicate the 
preceding conditions as a determinant of the prevailing manifestations at the time of 
investigation. However, with the limited amount of collectable blood and the sample volume 
requirements for analysis, this issue was unavoidable in this study.
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Oil red 0  histological staining does not appear uniformly across the entire lesion, potentially 
due to regions of extracellular matrix and unesterified cholesterol that do not take up the 
neutral lipid stain (Daugherty and Ratteri 2005). This compromises the ability of image analysis 
software to quantitate lesion size and leads to potential investigator inaccuracies during 
manual assessment of area. This error should be consistent between samples however, and 
therefore can be accounted for when comparing groups. Although similar lipid staining may be 
seen in some animals from different groups, it is possible that differences in fatty acid 
composition may be present, and may result in different severity of lesion development in 
terms of clinical outcomes. In addition, Paigen et al. (1987) highlighted differences in plaques 
in the aortic wall and those on the valve cusps in C57BL/6 mice, and suggested that due to 
inconsistencies in reproducibility of each of these lesions, separate scoring or measurement of 
the different lesions should occur. The differences may be due to genetic factors, but it is 
considered that valve cusp lesions may not be as relevant to the human pathology, which 
involves arterial wall plaque formation. Due to the limited areas of ORO staining and taking 
into account details of previous studies (Nettleship et al. 2007a), all lesions were consistently 
quantified together in the present study. This may result in compositional variations being 
included. These factors may explain some of the within-group and between-experiment 
variance observed.
3.4.6 Summary
The data presented in this chapter demonstrate that testosterone has protective effects 
against diet-induced fatty streak development in early atherosclerosis. Decreased lipid 
deposition in aortic roots of Tfm mice following TRT suggest that these protective effects may 
be, at least in part, via mechanisms other than the AR. Both AR-dependent and independent 
actions appeared to offer atheroprotection. Slight beneficial actions of testosterone on 
inflammatory markers were apparent and these may translate locally to the lesion, where anti­
inflammatory functioning could be more pronounced and result in a reduced plaque. However, 
due to the variable nature of the data definitive conclusions cannot be drawn and therefore, 
further investigations are required to confirm these mechanisms.
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CHAPTER 4
______________ General Discussion
4.1 General discussion
The main aim of this study was to investigate the potential anti-inflammatory actions of 
testosterone, in order to explain its proposed anti-atherogenic effects. The study design was 
two-pronged, and used both in vitro and in vivo approaches. In the first part of the study an in 
vitro cell culture model of vascular inflammation was investigated, in order to specifically 
determine the effect of androgens on key regulators of the athero-inflammatory process, and 
to determine whether any such effects were mediated via the classical AR. In the second part 
of the study, an in vivo mouse model of early atherogenesis, combined with complete 
androgen insensitivity, was used to investigate the effects of TRT on atheroma formation. 
More specifically this model was used to determine whether the known beneficial effects of 
testosterone upon fatty streak formation in cholesterol-fed mice are due to anti-inflammatory 
actions, and if so, whether such effects occur independently of the classical signalling pathway 
mediated by the nuclear AR.
Early suggestions in the literature, based upon the higher male-to-female incidence of CAD 
mortality, proposed that testosterone exerts a detrimental influence on the cardiovascular 
system. However, there is now convincing evidence that testosterone deficiency is a marker 
for early death in men and is closely associated with cardiovascular risk factors and degree of 
atherosclerosis (Jones 2010). Furthermore, the fact that testosterone levels decline with age, 
whilst atherosclerosis increases, suggests that testosterone does not promote atheroma 
formation, but may protect against its development (English et al. 2000c, Channer and Jones 
2003). The aging male is characterised by a gradual reduction in total and free testosterone 
levels, the so called "andropause" (Vermeulen et al. 1999) and also decreased circulating levels 
of DHEA, the so called "adrenopause" (Herbert 1995). These low levels of testosterone are 
associated with multiple health consequences, and in particular, cardiovascular pathologies. 
Specifically, low serum levels of testosterone in elderly men are associated with aortic and 
carotid atherosclerosis (Hak et al. 2002, van den Beld et al. 2003) and also with CAD risk 
factors such as hypertension, obesity, hyperinsulinaemia and diabetes, and an adverse 
thrombotic profile (Malkin et al. 2003, Jones 2010). Although complicated by many conflicting
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reports, the majority of the evidence investigating hormone intervention in these patients 
suggests that TRT may be beneficial, exerting positive effects on several of the contributory 
factors that shape the pathophysiology of atherosclerosis (Lesser et al. 1946, Rosano et al. 
1999, Webb et al. 1999, English et al. 2000b, Pugh et al. 2004, Malkin et al. 2004a, Malkin et al. 
2006b, Zitzmann et al. 2008). Androgenic immunomodulation may be one such mechanism, 
although the evidence to support this is relatively scarce and findings have been conflicting. In 
addition, an anti-atherogenic action of testosterone has been previously shown in cholesterol- 
fed animal models (Bruck et al. 1997, Alexandersen et al. 1999, Jones et al. 2003, Nettleship et 
al. 2007). The exact mechanisms by which these anti-atherogenic actions take place remain 
controversial, with genomic and non-genomic actions, AR, ER, and non-classical receptor 
activation all attributed to the beneficial effects, dependent upon vascular territory and stage 
of disease progression.
The findings reported in this thesis suggest that inflammatory cytokines are certainly involved 
in vascular inflammation and a role for the novel chemokine CX3 CL1 is evident, although such 
pro-atherogenic mediators were not always seen to be modulated systemically. CX3 CL1 was 
found to be both dose- and time-dependently upregulated by pro-inflammatory cytokines in 
smooth muscle and endothelial cells of the aorta and was present, in addition to its cognate 
receptor, within the aortic lipid streaks of some, but not all, experimental mice in the present 
study, indicating its potential role in atherogenesis. However, the effects of testosterone on 
CX3 CL1 expression remain unclear. The pro-inflammatory cytokines, TNFa and IL-6 , were 
significantly elevated in the serum of Tfm mice on normal diet compared to XY littermates on 
normal diet, suggesting a heightened inflammatory state as a result of low testosterone levels 
and a non-functional AR. Although a measure at the systemic level, this may in itself represent 
susceptibility to inflammatory actions locally in the aorta, particularly since stimulation of 
HASMC and HAEC with TNFa in combination with IFNy induced an upregulation of CX3 CL1 and 
CCL2 in vitro. Previous studies have demonstrated similar actions of local cytokine levels on 
vascular chemokine and/or adhesion molecule expression in cultured cells (Rollins et al. 1990, 
Sica et al. 1990, Cybulsky et al. 1991, Taubman et al. 1992, Shyy et al. 1994, Bazan et al. 1997, 
Gimbrone et al. 1997, Imaizumi et al. 2000, Garcia et al. 2000, Ollivier et al. 2003, Ahn et al. 
2004, Lim et al. 2009). In the present study there was a lack of androgen modulation on this in 
vitro upregulation of cytokines. This may be due to testosterone having its effect upstream 
from CX3 CL1 expression. This is supported by the in vivo data, since TRT in the Tfm mouse 
marginally, but not significantly, reduced serum TNFa levels, and may potentially alter local 
concentrations at the aorta. Indeed, it has been noted in cell culture studies that testosterone 
reduced the expression of pro-inflammatory cytokines such as TNFa, IL-1 and IL- 6  (See Malkin
et al. 2004a). TRT has also been previously shown to reduce circulating levels of TNFa in 
hypogonadal men, an effect that was concurrent with decreased myocardial ischaemia and 
favourable lipid profiles (Malkin et al. 2004a, Malkin et al. 2004b). In addition, in the present 
study there was an apparent reduction of CX3 CL1 expression in aortic lipid streaks of Tfm mice 
receiving TRT and littermates on placebo, which may indicate that the protective effect of 
testosterone in atherogenesis is via local anti-inflammatory actions and at least partially via 
AR-independent mechanisms. This is also, weakly, supported by the in vitro cell culture data in 
this thesis, as testosterone treatment reduced cytokine-induced expression of CX3 CL1 at the 
molecular level in HASMC, an effect not prevented by blockade of the AR. Definite conclusions 
cannot be drawn, however, due to the limited power of the data and lack of statistical 
significance.
Serum CCL2 also appeared slightly, although not significantly, reduced in Tfm mice following 
TRT, an effect that could not be robustly demonstrated in cultured vascular cells. CCL2 mRNA 
in HAEC did appear physiologically, although not statistically, down-regulated by testosterone, 
potentially supporting the data from the animal model. This in vitro effect however, was 
prevented by AR blockade, contradicting the data from the mouse model, where the AR is non­
functional and therefore not involved in the observed effects. Monocyte infiltration in areas 
adjacent to lipid streak was consistent between the experimental animal groups, indicating 
that testosterone does not influence the extravasation of monocytes at the plaque site. Since 
the mean area of fatty streak was reduced by testosterone it may be that androgens reduce 
general aortic atherogenesis through mechanisms other than specifically influencing a 
particular local inflammatory process such as CCL2 or CX3 CL1 expression and subsequent 
leukocyte migration.
The work in this thesis demonstrates that the driving force behind atherosclerosis is a 
cholesterol-enriched diet, since both Tfm mice and littermates displayed increased lipid 
deposition in the aortic root following a period of high cholesterol feeding. This appears to be 
mediated through induction of a pro-atherogenic lipid profile, in particular, elevated 
circulating LDL and total cholesterol, although this was not related to obesity (body weight and 
weight gain) in this model. Although this has not been previously demonstrated in this Tfm 
mouse model, the concept of dietary influence on atherosclerosis is not novel (See Glueck 
1979, Kromhout 2001). Of particular interest, the INCAP study of atherosclerosis and CHD 
investigated 22,516 aortae and coronary vessels from a mainly Latin American population and 
demonstrated that the strongest correlation for the severity of lesions was the fat content of 
the diet (Guzman 2010).
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The present study has clearly reproduced previous findings that low endogenous testosterone 
is associated with fatty streak formation in the aortic root and a proatherogenic circulating 
lipid profile, after feeding on a cholesterol-enriched diet (Nettleship et al. 2007a). In fact, the 
elevated atherosclerotic parameters induced by high-cholesterol diet were significantly 
amplified as a result of low testosterone levels and a non-functional AR (Tfm mouse). The 
beneficial effects of testosterone on serum lipid concentrations appear to function through the 
AR, since TRT in Tfm mice did not significantly modulate lipid profiles, whereas LDL and total 
cholesterol were markedly lower in XY littermates. These findings are consistent with 
observations previously reported in this model, with no effect of TRT on total cholesterol and 
LDL-C in Tfm mice (Nettleship et al. 2007a). Clinical studies may indirectly support this idea as 
hypogonadal patients, with low serum testosterone and a functional AR, respond favourably to 
TRT. TRT is reported to induce significant reductions in total cholesterol and LDL-C in 
hypogonadal men (Tenover 1992, Zgliczynski et al. 1996, Tripathy et al. 1998, Howell et al. 
2001, Ly et al. 2001). Furthermore, total cholesterol levels are shown to fall following 
physiological testosterone replacement in hypogonadal men with CAD (Malkin et al. 2004b). 
No clinical data exists for AR-deficient males or co-administration of AR antagonists with TRT 
to establish modes of action in men.
Although TRT had no effect on circulating lipids in the present study, it did decrease lipid 
deposition in the aortic root. This may result from a specific local effect of testosterone at the 
vessel wall, with testosterone protecting against the detrimental effects of pro-atherogenic 
lipids on lesion-associated vascular and immune cells. Indeed, previous research has shown an 
in vitro upregulation of CX3CL1 and CCL2 in response to oxLDL exposure in vascular cells 
(Cushing et al. 1990, Yu et al. 1998, Dwivedi et al. 2001, Mackness et al. 2004, Barlic et al.
2007) and monocytes (Zhang et al. 2006). Therefore, it is reasonable to suggest that 
testosterone may be more likely to have an effect on oxLDL-induced CX3CL1 or CCL2 
upregulation in HASMC and HAEC in the present in vitro model (See future work). Additionally, 
testosterone may not exert anti-inflammatory effects on vascular cells, but may confer athero- 
protection within the plaque region through actions on immune cells. In particular, decreased 
cholesterol accumulation has been reported in cultured monocyte-derived macrphages 
through the reduction of LOX-1 expression and the upregulation of SR-BI following androgen 
treatment (Langer et al. 2002, Orekhov et al. 2009, Qui et al. 2010). Through these 
mechanisms of reduced foam cell formation and enhanced reverse cholesterol transport, 
testosterone may allow a protective effect on the inflammatory mechanisms of atheroma 
formation without influencing the immune recruitment directed by vascular cells, often 
considered a protective mechanism in early atherogenesis.
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From the combined findings that TRT had no significant effects on circulating lipids or 
cytokines in vivo, and that testosterone treatment did not significantly modulate the 
expression of chemokines in vitro, although lipid streaks were reduced in Tfm mice following 
TRT, it may be possible that the athero-protective effects of androgens are via a local action in 
the vessel. Testosterone is known to have beneficial effects on vascular tone, which may 
protect from shear stress-related vascular dysfunction and subsequent inflammation and lipid 
entry, thus reducing early atheroma formation (Webb et al. 1999, Kang et al. 2002, Jones et al. 
2003, Manolakou et al. 2009). Therefore, it is possible that the beneficial effects of TRT may 
not be seen systemically or in isolated cells.
The lack of convincing results regarding the effect of TRT on inflammatory mediators and 
circulating lipid profiles in this study, and the often contradictory reports from previous 
research, highlights the complexity of the relationship between testosterone and 
atherosclerosis and the difficulties in studying such mechanisms. Differences in study design, 
doses and formulations of androgens used, route of administration, animals or cell types used, 
vascular location studied, and/or methods of analysis may all influence the outcome of the 
experiments.
In addition, evidence suggests that the beneficial effects of testosterone may be gender- 
specific and may indicate a protective role of sex hormones in both genders, with regard to 
maintaining an anti-atherogenic gender-specific homeostasis. Potential opposing actions of sex 
hormones in men and women relating to atherosclerotic CVD and its risk factors have been 
noted previously (Phillips 2005;). Tomaszewski et al. (2009) repeated the findings of an earlier 
study implicating an association between increased oestrogen levels and unfavourable lipid 
profiles in young men (Wranicz et al. 2005). It is possible that the ratio between testosterone 
and oestrogen may prove to have a greater influence in athero-protection. However, these 
previous studies found no effect of TRT on lipid measurements. One cross-sectional study did 
demonstrate the link between low serum testosterone combined with elevated serum 
estradiol and peripheral arterial disease in elderly men (Tivesten et al. 2007;). The 
administration of anastrozole, an oral aromatase inhibitor, was able to normalise testosterone 
levels in hypogonadal men and reduce estradiol levels, thereby improving the sex hormone 
balance (Dougherty et al. 2005;). This however resulted in no significant changes to lipid 
profiles or markers of inflammation, contradicting previous work, although the study size was 
small and no direct measure of vessel atherosclerosis was investigated.
In support of a gender-specific hormone balance as an indicator of CV risk rather than simply 
androgen concentrations, post-menopausal women, whose oestrogen levels have declined,
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demonstrate an increased risk similar to that of age-related males, after a post-menopausal 
catch-up time of around 10 years (Malkin et al. 2003b). These data would therefore suggest 
that oestrogen replacement therapy may have beneficial cardiovascular effects in post­
menopausal women. However, this could not be confirmed by large randomised trials (Ouyang 
et al. 2006). This may in part be due to the timing of hormone therapy, as findings from the 
Women 's Health Initiative trial suggest that hormone therapy should be initiated within six 
years o f the menopause transition to achieve beneficial outcomes (Banks et al. 2009). 
Furthermore, the adverse effects of androgens in women is evident, w ith a correlation 
between both bioavailable and total testosterone levels and the degree of aortic 
atherosclerosis (Hak et al. 2002). These findings are strengthened by clinical case reports of 
fema le-to-ma le transsexuals who experience negative cardiovascular outcomes as a result of 
cross-gender hormone therapy (McCredie et al. 1998, Inoue et al. 2007). Inoue et al. (2007) 
described the sudden death of a female-toymale transsexual patient receiving cross-sex 
hormonal treatm ent. In this report the cause of death was concluded to be ischemic heart 
disease, influenced by high blood testosterone levels, as a result of bi-monthly intramuscular 
injections of testosterone for two years prior to death. Such reports are interesting, but may 
be limited in the ir clinical value as cardiovascular exam ination to determ ine systemic 
atherosclerotic state before hormone supplementation was not performed, and although 
elevated testosterone may have contributed to cause of death, a direct causality is difficult to 
delineate. Bruck et al (1997) eloquently demonstrated gender-specific effects of testosterone 
and oestrogen in castrated male and ovariectomised female cholesterol fed rabbits. IM T in the 
aortic arch was significantly reduced in castrated males receiving TRT, and reduced in 
ovariectomised females receiving oestrogen treatm ent. The reported differences were 
independent of changes in plasma lipid measurements. TRT in ovariectomised females 
resulted in a detrimental increase in IMT, whereas oestrogen treatm ent in males produced no 
significant effects. Interestingly, a combination of both testosterone and oestrogen treatm ent 
showed the greatest inhibition of intimal thickening in both genders.
To further complicate the androgen-oestrogen paradox, evidence exists for direct AR and ER 
interactions (Panet-Raymond et al. 2000), and the potential for androgens to interact w ith ER 
and oestrogens with AR reveals a complex interplay between sex hormone function 
(Kreitmann and Bayard 1979, Yeh et al. 1998). Additionally each hormone may affect the 
expression o f the receptor for the other hormone (See Philips et al. 2005), leading to a 
complex level o f control over local hormone-specific responses that may be atherogenic or 
atheroprotective depending upon cross-talk, receptor interactions and multiple other, largely 
as yet unknown, factors. Therefore, in depth molecular investigations, along with long-term
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prospective studies, are needed to provide further insight into the gender-specific role of 
androgens and oestrogens in the development of atherosclerosis.
4.1.1 Future work
Although conflicting reports exist, accumulating evidence strongly supports a role for 
testosterone as an immunomodulatory and atheroprotective hormone in men, and certainly 
warrants further scientific and clinical research. It is important that future research focuses on 
delineating the physiological and biochemical mechanisms underlying the protective role of 
testosterone in the development and progression of atherosclerosis.
4.1.1.1 In vitro investigations
Since the cell culture model used in this thesis demonstrated greatly elevated upregulation of 
CX3CLI and CCL2 expression upon stimulation of cells with cytokines, and the fact that 
previous investigations into steroid modulation of inflammatory molecules utilised single 
cytokine stimulations (see tables 2.1.1 and 2.1.2), repeating the present study with IFNy and 
TNFa alone may allow detection of androgen modulation o f these chemokines. However, 
another possibility is that, as the in vitro work in this thesis was unable to demonstrate 
reproducible androgen modulation of cytokine-induced CX3CL1 and CCL2 expression, this may 
indicate that these chemokines are in fact not modulated by testosterone. Thus a focussed 
gene expression profiling PCR array analysis of multiple inflammatory targets, simultaneously 
assessed for modulation by androgens under the same experimental conditions as in the 
present study, may be useful to highlight other potential inflammatory mediators to pursue.
The in vitro cell culture studies in this thesis were an attem pt to simulate the vascular 
inflammation that would be associated with atherosclerosis via cytokine stimulation o f cells, 
with subsequent investigation of the potential influences o f androgens on this. The in vivo 
studies revealed a protective effect of TRT on lipid deposition in the aortic root and 
demonstrated a negative influence of low endogenous testosterone and a non-functional AR 
on lipid profiles and deposition in the context of high-cholesterol feeding. Thus, the in vitro 
actions of androgens on lipid actions are of interest. Studying the effects o f native LDL and 
oxLDL on CX3CL1 expression in HASMC and HAEC, and the potential protective effects of 
androgens, may highlight a link between the beneficial effects o f testosterone on lipids within 
local aortic inflammation.
Implications from the present study and findings from recent reports suggesting that 
androgens influence macrophage behaviour in relation to atherosclerosis (Langer et al. 2002,
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Ng e ta l. 2003, Orekhov et al. 2009, Corcoran et al. 2010, Qui et al. 2010) direct future studies 
towards investigating the effects o f testosterone on monocyte/macrophage expression of 
CX3CL1, CCL2 and the ir cognate receptors under pro-inflammatory conditions.
4.1.1.2 In vivo investigation
From the preliminary findings of this thesis, it cannot be definitely concluded that TRT has a 
protective effect on inflammatory mediators associated with atherosclerosis. This may be due 
to the variability associated with animal work, and the low power of small sample numbers. 
Repeating the present study to increase sample numbers may address the lack of significance
observed in many of the parameters measured. Particularly, reproduction o f the
immunostaining seems essential for conclusive comparisons between the different 
experimental groups and for validating the staining observed. Additionally, dual staining of the 
current targets along with additional targets (such as T cell, macrophage, NK cell, dendritic cell 
markers) would enable co-localisation o f CX3 CL1 and CX3CR1 with specific cell types in the 
plaque region, thus providing further insight into the role of this chemokine in early 
atherogenesis.
4.1.1.3 New concepts
As the most pronounced effects o f testosterone treatm ent observed in this thesis were the 
effects on lipids, be it circulating profiles or aortic deposition, further investigation into the 
potential protective effects o f androgens on metabolic factors o f lipidomics may reveal 
important mechanisms o f atheroprotection. Lipases, the enzymes that hydrolyse ester bonds 
o f triglycerides, phospholipids and cholesterol esters, offer an interesting mechanism by which 
lipids are regulated (Wong and Scholtz 2002). In atherosclerotic lesions, lipoprotein lipase (LPL) 
is expressed by macrophages and SMC, and is involved in the lipolysis o f circulating VLDL and 
chylomicron remnants, leading to the accumulation o f cholesterol esters (Hasham and 
Pillarisetti 2006). Elevated expression of this enzyme is associated with susceptibility to 
atherosclerosis in experimental mouse models (Babaev et al. 2000), and macrophage-derived 
foam cells were found to be the major source of LPL in human lesions (O'Brien et al. 1992), 
suggesting that LPL may be involved in focal lipid activity and fatty streak development. In 
addition, endothelial lipase (EL) is considered to have pro-atherogenic properties through 
indirectly modifying circulating HDL concentrations via its catalytic effects facilitating clearance 
and therefore reducing antioxidant and reverse cholesterol transport activities of HDL (Huang 
et al. 2010). EL can be synthesised by endothelial cells with expression highly regulated by 
cytokines and physical forces such as shear stress (Choi et al. 2002), and has been shown in
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infiltrating SMC and macrophages o f human coronary artery plaques (Azumi et al. 2003). 
Therefore, a role for EL in plaque lipidomics may be apparent. Hepatic lipase (HP) is 
synthesised in hepatocytes and remains in the liver where it additionally influences circulating 
lipid profiles via metabolic activities (Hasham and Pillarisetti 2006), although the role of HP in 
modulating atherogenic risk remains controversial. Therefore, the potential modulation of 
lipase expression and activity may elucidate some of the local and systemic athero-protective 
effects of testosterone, and would represent an interesting focus o f research.
Recent evidence, that adipose tissue acts as an endocrine secretory organ, releasing numerous 
inflammatory factors, adipokines, highlights the importance of investigating the role of 
androgens in the regulation o f lipid metabolism and adipose tissue formation. This may lead to 
more definite conclusions on the influence of androgens on inflammation and obesity as major 
contributors to distal atherosclerosis.
In addition to the potential influence of oestrogens on the modulatory actions of androgens in 
atherosclerosis, the contribution of other steroids may also need to be investigated further. In 
particular, DHEA (the most abundant circulating adrenal steroid) levels in men have an inverse 
relationship with cardiovascular mortality (Alexandersen et al. 1996, Beer et al. 1996). While 
these findings may be due to a direct action of DHEA, the presence of the enzymes responsible 
for the conversion o f DHEA to androstenedione and subsequent reduction to testosterone, in 
addition to the previously mentioned aromatase, in peripheral tissues and perhaps the 
vasculature, implicate another potential source of androgen and oestrogen involvement 
(Ebeling and Koivisto 1994, Labrie et al. 1995). Additionally, the anti-inflammatory actions of 
glucocorticoids are well known, although the ir mechanisms are not fully understood. With the 
potential to reduce vascular inflammation, glucocorticoids may confer beneficial actions on 
specific mediators o f atheroma formation. In particular, CX3CL1 expression has been shown to 
be suppressed by glucocorticoid treatm ent in lung epithelial cells via reduction in gene 
promoter recruitment of NFkB (Bhavsar et al. 2008). Therefore, AR and glucocorticoid receptor 
actions may be coregulatory and influence inflammatory responses in conditions such as 
atherosclerosis. Furthermore, a high cortisol/testosterone ratio has been associated with 
incident ischemic heart disease (Araujo et al. 2007). When investigating androgenic 
parameters it may be necessary to include measures o f additional steroids, co-related enzymes 
and metabolites, and the ir signalling pathways, to dissect the specific role of testosterone in 
cardiovascular function.
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4.1.2 Conclusion
This thesis has investigated in detail the potentially beneficial effects o f androgens in the male 
cardiovascular system w ith particular focus on anti-inflammatory mechanisms. Evidence has 
been presented here which demonstrates that testosterone treatm ent, at physiological levels, 
does not have a detrimental effect on the cardiovascular system, but in fact may confer 
beneficial effects. Part of these effects may be via anti-inflammatory actions, shown by small 
physiological, but not statistically significant, modulations to inflammatory markers, whether 
detected locally or systemically. In addition, work in this thesis has confirmed that TRT can 
significantly inhibit fatty streak formation, a process known to involve immune interactions, 
and shown that this effect is only partially mediated through the AR. However, androgens 
exert a vast array of effects in vivo such that it may be misleading to extrapolate isolated 
experimental findings to the w ider clinical setting and generalise population specifics, or 
individual differences, to all. The complexities of androgen interactions and the often 
conflicting results in the research do not allow unequivocal conclusions to be made, and 
consequently, much remains unknown in the effort to delineate the actions o f testosterone for 
improved treatm ent of the aging male.
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Appendix 1
G ene N am e Assay ID Category G ene Group
B ACTIN ac tin , b e ta H s 9 9 9 9 9 9 0 3 _ m l C y to s k e le ta l
p ro te in
A ctin  fa m ily  
c y to s k e le ta l p ro te in
A D A M 1 7 A D A M
m e ta l lo p e p t id a s e  
d o m a in  10
H s 0 0 1 5 3 8 5 3 _ m l P ro tea se M e ta l lo p ro te a s e
A D A M 1 0 A D A M
m e ta l lo p e p t id a s e  
d o m a in  17
H s 0 1 0 4 1 9 1 5 _ m l P ro tea se M e ta l lo p ro te a s e
AR a n d ro g e n  re c e p to r H s 0 0 1 7 1 1 7 2 _ m l T ra n s c rip tio n
fa c to r
N u c le a r h o rm o n e  
re c e p to r
B 2M b e ta -2 -m ic ro g lo b u lin H s 0 0 1 8 7 8 4 2 _ m l D e fe n s e / im m u n it  
y p ro te in
M a jo r
h is to c o m p a tib ility  
c o m p le x  a n t ig e n
CX3CL1 c h e m o k in e  (C -X 3-C  
m o t if )  ligand 1
H s 0 0 1 7 1 0 8 6 _ m l S ignaling
m o le c u le
C h e m o k in e
CX3CR1 c h e m o k in e  (C -X 3-C  
m o t if )  re c e p to r  1
H s 0 0 3 6 5 8 4 2 _ m l R e c e p to r G -p ro te in  co u p led  
re c e p to r
GAPDH g ly c e ra ld e h y d e -3 -
p h o s p h a te
d e h y d ro g e n a s e
H s 9 9 9 9 9 9 0 5 _ m l O x id o re d u c ta s e D e h y d ro g e n a s e
HPRT h y p o x a n th in e  
p h o s p h o r ib o s y ltra n s fe r  
ase 1
H s 0 1 0 0 3 2 6 7 _ m l T ra n s fe ra s e G ly co s y ltran s fe ras e
RPL13A r ib o s o m a l p ro te in  
L1 3 a ;rib o s o m a l p ro te in  
L13a p s e u d o g e n e  5
H s 0 3 0 4 3 8 8 5 _ g l N uc le ic  acid  
b in d in g
R ib o so m al p ro te in
SDHA su cc in ate  
d e h y d ro g e n a s e  
co m p le x , s u b u n it A, 
f la v o p ro te in  (Fp)
H s 0 0 1 8 8 1 6 6 _ m l O x id o re d u c ta s e D e h y d ro g e n a s e
T IM P 1 T IM P  m e ta l lo p e p t id a s e  
in h ib ito r  1
H s 9 9 9 9 9 1 3 9 _ m l S e lec t re g u la to ry  
m o le c u le
P ro te a s e  in h ib ito r
T IM P 3 T IM P  m e ta l lo p e p t id a s e  
in h ib ito r  3
H s 0 0 1 6 5 9 4 9 _ m l S e lec t re g u la to ry  
m o le c u le
P ro te a s e  in h ib ito r
Appendix 1; Taqman® qRT-PCR prim er probe assays purchased from  Applied Biosystems
